

Specialist Medical Review Council

**Declaration and Reasons for Decisions**

*Section 196W  
Veterans’ Entitlements Act 1986*

**Re: Statements of Principles Nos. 53 and 54 of 2013**

**concerning fibrosing interstitial lung disease and**

**Statements of Principles Nos. 55 and 56 of 2013**

**concerning asbestosis**

Request for Review Declaration Nos. 27 and 28

1. In relation to the Repatriation Medical Authority (the RMA) Statement of Principles No. 53 of 2013 concerning fibrosing interstitial lung disease and death from fibrosing interstitial lung disease, made under subsections 196B (2) of the *Veterans’ Entitlements Act 1986* (the VEA), the Specialist Medical Review Council (the Council) under subsection 196W of the VEA:

DECLARES that the sound medical-scientific evidence available to the RMA is insufficient to justify an amendment to the Statement of Principles to existing factors, or to include a new factor or factors for;

asbestos bodies and pleural plaque; or

shorter periods of exposure to respirable asbestos fibres.

1. In relation to the RMA Statement of Principles No. 54 of 2013 concerning fibrosing interstitial lung disease and death from fibrosing interstitial lung disease, made under subsections 196B (3) of the VEA, the Council under subsection 196W of the VEA:

DECLARES that the sound medical-scientific evidence available to the RMA is insufficient to justify an amendment to the Statement of Principles to existing factors, or to include a new factor or factors for;

asbestos bodies and pleural plaque; or

shorter periods of exposure to respirable asbestos fibres.

1. In relation to the RMA Statement of Principles No. 55 of 2013 concerning asbestosis and death from asbestosis, made under subsections 196B (2) of the VEA, the Council under subsection 196W of the VEA:

DECLARES that the sound medical-scientific evidence available to the RMA is insufficient to justify an amendment to the Statement of Principles to existing factors, or to include a new factor or factors for;

asbestos bodies and pleural plaque; or

shorter periods of exposure to respirable asbestos fibres.

1. In relation to the RMA Statement of Principles No. 56 of 2013 concerning asbestosis and death from asbestosis, made under subsections 196B (3) of the VEA, the Council under subsection 196W of the VEA:

DECLARES that the sound medical-scientific evidence available to the RMA is insufficient to justify an amendment to the Statement of Principles to existing factors, or to include a new factor or factors for;

asbestos bodies and pleural plaque; or

shorter periods of exposure to respirable asbestos fibres.

1. In relation to the RMA Statements of Principles Nos. 53 and 54 of 2013 concerning fibrosing interstitial lung disease and death from fibrosing interstitial lung disease, and Nos. 55 and 56 of 2013 concerning asbestosis and death from asbestosis, made under subsections 196B (2) and 196B (3) of the VEA, the Council under subsection 196W of the VEA:

RECOMMENDS that the RMA, when it carries out any future investigation(s), considers whether there is relevant sound medical-scientific evidence concerning any direct measurements of asbestos fibre levels during tasks relevant to Australian Naval personnel or derived from the international literature, or alternative measures of exposure to asbestos and the required level of exposure used in the existing factors, for “inhaling respirable asbestos fibres in an enclosed space/open environment” (clinical onset) and for “inhaling respirable asbestos fibres” (clinical worsening) in the Statements of Principles.

**CONTENTS**

[REASONS FOR DECISION 6](#_Toc437343272)

[INTRODUCTION TO THE COUNCIL AND ITS FUNCTIONS 6](#_Toc437343273)

[SCOPE OF THIS REVIEW 7](#_Toc437343274)

[Council's Decision on the Scope of Review 7](#_Toc437343275)

[Written and Oral Submissions 8](#_Toc437343276)

[COUNCIL’S EVALUATION OF THE SOUND MEDICAL-SCIENTIFIC EVIDENCE 9](#_Toc437343277)

[Preliminary Comment on Fibrosing Interstitial Lung Disease and Asbestosis 10](#_Toc437343278)

[COUNCIL’S EVALUATION OF SOUND MEDICAL-SCIENTIFIC EVIDENCE RELEVANT TO THE APPLICANT’S CONTENTIONS 15](#_Toc437343279)

[The Relationship between Pleural Plaques and / or Asbestos Bodies and Fibrosing Interstitial Lung Disease and Asbestosis 15](#_Toc437343280)

[Summary of Council’s View 23](#_Toc437343281)

[New Information on the Relationship between Pleural Plaques and / or Asbestos Bodies and Fibrosing Interstitial Lung Disease and Asbestosis 23](#_Toc437343282)

[Comparison of the Statements of Principles, where Duration of Exposure is used as a Measure of Dose, with the Literature on a Threshold of Asbestos Concentrations 24](#_Toc437343283)

[The Levels of Asbestos Exposure Associated with Asbestosis in the Sound Medical-Scientific Evidence 30](#_Toc437343284)

[New Information on the Levels of Asbestos Exposure Associated with Asbestosis in the Sound Medical-Scientific Evidence 45](#_Toc437343285)

[Summary of Council’s View 45](#_Toc437343286)

[COUNCIL’S CONCLUSIONS ON THE SOUND MEDICAL-SCIENTIFIC EVIDENCE RELEVANT TO THE APPLICANT’S CONTENTIONS 47](#_Toc437343287)

[Pleural Plaques and Asbestos Bodies 48](#_Toc437343288)

[The Duration of Asbestos Exposure in the Statements of Principles 48](#_Toc437343289)

[Council’s View on Whether the Information Gathered by the Repatriation Medical Authority was Complete 49](#_Toc437343290)

[New Information 49](#_Toc437343291)

[New Information Submitted by the Applicant 50](#_Toc437343292)

[New Information Identified by the Council 51](#_Toc437343293)

**FIGURES/TABLES**

[Figure 1. Asbestos-related Disorders 14](#_Toc437343294)

[Figure 2. Diffuse Pleural Thickening 15](#_Toc437343295)

[Table 1. Asbestos Factors in the Current Statements of Principles For Fibrosing Interstitial Lung Disease and Asbestosis 29](#_Toc437343296)

**APPENDICES**

[APPENDIX A: TABLES OUTLINING THE SOUND MEDICAL EVIDENCE 59](#_Toc437343257)

[Table A1. Overview of 12 Papers Reporting Asbestos Cumulative Exposure Levels Associated with Producing Asbestosis (Ordered from Lowest to Highest Exposure Level) 59](#_Toc437343258)

[Table A2. Overview of 36 Papers Relevant to Low Level Exposure to Asbestos for Asbestosis (Ordered by Study Type and Date) 84](#_Toc437343259)

[Table A3. List of Medical Science Cited in the RMA Briefing Papers for Determining the Asbestos Factors in 1996, 2005, and 2013 106](#_Toc437343260)

[Table A4. New Information Identified by the Council and/ or the Applicant (Ordered by Date) 109](#_Toc437343261)

[Table A5. New Information Identified by the Council on Diffuse Pleural Thickening (Ordered by Date) 115](#_Toc437343262)

[APPENDIX B: THE CONSTITUTED COUNCIL AND LEGISLATIVE FRAMEWORK OF THE REVIEW 119](#_Toc437343263)

[The Specialist Medical Review Council 119](#_Toc437343264)

[APPENDIX C: WRITTEN AND ORAL SUBMISSIONS 121](#_Toc437343265)

[Applicant’s Submissions 121](#_Toc437343266)

[Commissions Submission 121](#_Toc437343267)

[APPENDIX D: INFORMATION BEFORE THE COUNCIL 123](#_Toc437343268)

[The Available Information, sent to the SMRC by the RMA under section 196K. 123](#_Toc437343269)

# REASONS FOR DECISION

## INTRODUCTION TO THE COUNCIL AND ITS FUNCTIONS

1. The Specialist Medical Review Council (the Council) is an independent statutory body established by the VEA. In general terms, upon receipt of a valid application the Council is to review as relevant:

* the contents of Statement/s of Principles in respect of a particular kind of injury, disease or death; or
* a decision of the RMA not to determine, not to amend, Statement/s of Principles in respect of a particular kind of injury, disease or death.

1. In conducting a review, the Council must review all of the information (and only that information) that was available to the RMA when it made the decision under review. This is information which was actually used by the RMA as opposed to information which was generally available but not accessed by the RMA. A list of the information that was available to the RMA is provided in **Appendix D**.
2. Fundamental to Statements of Principles (SoPs), and so to a Council review, is the concept of sound medical-scientific evidence (SMSE), as that term is defined in section 5AB(2) of the VEA[[1]](#footnote-1).
3. The information to which the Applicant referred, being information which the RMA advised was new information, that is, information which was not available to the RMA at the relevant times, and so was not considered by the Council in reaching its review decision is listed in **Table A3 of** **Appendix A**.
4. **Appendix B** sets out further details regarding the composition of the Council for this review and the legislation relating to the making of SoPs.

## SCOPE OF THIS REVIEW

1. In his application the Applicant sought review of the contents of SoPs Nos. 53 and 54 of 2013 for Fibrosing Interstitial Lung Disease and Nos. 55 and 56 of 2013 for Asbestosis.
2. The Council, when reviewing the SMSE, must determine whether or not there is SMSE which indicated a reasonable hypothesis connecting the particular injury, disease or death to the relevant service.
3. In a reasonable hypothesis, the evidence 'points to' as opposed to merely 'leaves open' a link between injury, disease or death and the relevant service. In a reasonable hypothesis, the link is not 'obviously fanciful, impossible, incredible or not tenable or too remote or too tenuous.[[2]](#footnote-2)
4. If Council is of the opinion that a reasonable hypothesis has been raised, the Council proceeds also to determine whether a connection exists to relevant service on the balance of probabilities,[[3]](#footnote-3) i.e. whether the connection is more probable than not.
5. In these Reasons the association for both the reasonable hypothesis test and the balance of probabilities test are respectively referred to as the 'relevant association'.
6. The Council exercises its scientific judgement in weighing the evidence about the relevant association.

### Council's Decision on the Scope of Review

1. The Council was asked to review the information that was available to the RMA at the relevant times to determine whether the evidence supports the possible inclusion of new factors, and / or the contents of the Fibrosing Interstitial Lung Disease (FILD)and Asbestosis SoPs in respect to asbestos bodies, pleural plaques, and the duration of asbestos exposure. The Council was also asked to form a view on whether the information gathered by the RMA included all the medical science relevant to the disease. The Applicant provided references to some new information, and contended that the Council should undertake a more extensive search of the published literature to determine the completeness of the information.
2. The Council determined that the scope of the review was as follows:

* whether the collection of information gathered by the RMA, on which it based its decisions, and sent to the Council as the information subject to review, is in some way incomplete; and
* the possible inclusion of a new factor(s) / amendment of an existing factor(s) in the above SoPs in the same or similar terms as:
* to have the presence of pleural plaques or asbestos bodies recognised as evidence that **asbestosis, fibrosing interstitial lung disease and pulmonary fibrosis** can be related to asbestos exposure, even without long asbestos exposure during service; and
* more generally, a reduction in the duration of the asbestos exposure requirements in the SoPs for both conditions.

1. The Council advised the Applicant and the Commissions of its decision on the proposed scope of review, at the Hearing of Oral Submissions. The Council invited the Applicant and the Commissions to comment on the proposed scope of review either at the hearing or afterwards as arranged with the Council’s Secretariat.
2. No comments were received on the proposed scope of the review.

### Written and Oral Submissions

1. The Council took into account all the submissions made to it, both written and oral. The Council's brief summaries of the respective submissions made by the Applicant and the Commissions are set out at **Appendix C.**

## COUNCIL’S EVALUATION OF THE SOUND MEDICAL-SCIENTIFIC EVIDENCE

1. In forming its decisions on the SMSE, the Council brings to bear its scientific expertise and judgement. The Bradford Hill criteria and other tools or criteria taken into account by epidemiologists were applied to the articles as the Council considered appropriate.
2. The Council also considered any methodological limitations or flaws (including such things as statistical power, control of confounders, bias, exposure assessment methods etc.) in the various articles.
3. For ease of reference, the Bradford Hill criteria (noting that these are not exhaustive) are:

* strength of association
* consistency across investigation
* specificity of the association
* temporal relationship of the association
* biological gradient
* biological plausibility
* coherence
* experiment
* analogy

1. The Council notes that these criteria are not necessary conditions of a cause and effect relationship. They act to provide some evidence of such a relationship.
2. While the Council considered, it did not focus its evaluation on those articles that did not provide data that the Council could draw conclusions on about the matters in scope (see [6]).
3. The Council took into account the submissions on the relevant SMSE made by both the Applicant and the Commissions.
4. The Council's decision on the relevant SMSE was that it should comprise the evidence, available to (before) the RMA, found in footnotes and endnotes in the Council's evaluation of the relevant SMSE in this document.
5. Information which the RMA advised was not available to it at the relevant times was not taken into account by the Council for the purposes of the review, as it could only be considered as 'new information’. The Council identified from its own knowledge new information that would likely be relevant SMSE concerning asbestos-related pulmonary diseases, including FILD and Asbestosis (see **Appendix A. Table A4**).
6. Therefore, the Council considered the SMSE concerning the Applicant’s contentions as set out by the Council in the scope of review (above), including SMSE relevant to the:
   1. Identical existing factors for clinical onset for both FILD and Asbestosis (see Table 1 below). That is “inhaling respirable asbestos fibres in”:
      * 1. an enclosed space; and
        2. an open environment.

Each of these factors provides different cumulative periods of hours (equivalent to cumulative duration) and different latency periods for the reasonable hypothesis (RH) SoPs and the balance of probabilities (BoP) SoPs; and

* 1. Existing clinical worsening factors for the Asbestosis[[4]](#footnote-4) SoPs only (see below) are also for “inhaling respirable asbestos fibres”, with different cumulative periods of hours and different latency periods for the RH SoPs and the BoP SoPs.

### Preliminary Comment on Fibrosing Interstitial Lung Disease and Asbestosis

1. The Council noted that in addition to FILD and Asbestosis, there are other SoPs, which include asbestos-related factors. These are the SoPs for Pleural Plaque, Mesothelioma, and Lung Cancer, and each have similar exposure factors.
2. In the FILD[[5]](#footnote-5) and Asbestosis[[6]](#footnote-6) SoPs the RMA defines the diseases as:

… "fibrosing interstitial lung disease" means one of a diverse group of lung diseases that are characterised by progressive fibrosis of the pulmonary interstitium with or without chronic inflammation. This definition excludes extrinsic allergic alveolitis, bronchiolitis obliterans organising pneumonia, desquamative interstitial pneumonia, respiratory bronchiolitis-associated interstitial lung disease and pulmonary manifestations of systemic diseases.[[7]](#footnote-7)(p.1)

… "asbestosis" means a form of lung disease caused by the deposition of asbestos fibres in the lung parenchyma, marked by bilateral interstitial fibrosis of the lung.[[8]](#footnote-8)(p.1)

1. FILD resulting from asbestos fibre inhalation is defined as asbestosis, which leads to the application of the Asbestosis SoPs. However, for those patients with extensive asbestos exposure and a high suspicion of asbestosis, who do not have the classical radiological and or pathological features despite numerous investigations and assessments, the FILD SoPs would likely apply.
2. The Commissions’ written submission[[9]](#footnote-9) provided the following explanation on the operational use of the two SoPs:

The current situation, with asbestos-related pulmonary fibrosis covered by both the asbestosis and FILD SoPs, is now one of the only exceptions to the one disease – one SoP principle.[[10]](#footnote-10)(p.5)

If a diagnosis of asbestosis can be established on the balance of probabilities, then the asbestosis SoP would be applied. If asbestosis cannot be so confirmed but fibrosing interstitial lung disease is present, then the FILD SoP would be applied (provided none of the conditions excluded by the SoP definition were present).[[11]](#footnote-11)(p.5)

1. Terms relating to asbestos-related diseases are set out below:

**Asbestosis** is the scarring of lung tissue (beginning around terminal bronchioles and alveolar ducts and extending into the alveolar walls) resulting from the inhalation of asbestos fibres. Asbestosis specifically refers to interstitial (parenchymal) fibrosis from asbestos, and not pleural fibrosis or pleural plaques.[[12]](#footnote-12) It is defined as diffuse interstitial pulmonary fibrosis secondary to asbestos exposure.[[13]](#footnote-13) Asbestosis is recognised as having a dose-response relationship.[[14]](#footnote-14), [[15]](#footnote-15)

**Pleural plaques** are localised areas of pleural thickening usually affecting the parietal pleura.[[16]](#footnote-16) They are related to the type of asbestos and dose.[[17]](#footnote-17) Pleural plaques become more radiologically evident with time, typically 20 years or more after the inhalation of asbestos fibres.[[18]](#footnote-18)

**Diffuse pleural thickening** is a different entity from pleural plaques, although it can co-exist with pleural plaques. Asbestos-related diffuse pleural thickening refers to extensive fibrosis of the visceral rather than the parietal pleura, with adherence to the parietal pleura and obliteration of the pleural space. It is more dose-related than pleural plaques and is probably also affected by individual susceptibilities.[[19]](#footnote-19) It may occur with higher asbestos exposure and may be accompanied by asbestosis itself. When present, it may be difficult to diagnose accompanying asbestosis in these cases because the diffuse pleural thickening obscures the lung parenchyma on plain chest radiology, and high resolution computed tomography (CT) scanning is needed.[[20]](#footnote-20) Clinically, diffuse pleural thickening decreases the audibility of the fine basal crackles. In this condition, there may also occur several features (e.g. parenchymal bands), which are easily confused with asbestosis.[[21]](#footnote-21)

**Benign asbestos pleural effusion** is an exudative pleural effusion (a build-up of fluid between the two pleural layers) following asbestos exposure.[[22]](#footnote-22) It is relatively uncommon and is usually the earliest manifestation of disease following asbestos exposure, typically occurring within 10 years from exposure.[[23]](#footnote-23) Effusions may be asymptomatic, or cause pain, fever, and breathlessness.[[24]](#footnote-24) Effusions usually last for 3-4 months and then resolve completely.[[25]](#footnote-25) They can also progress to diffuse pleural thickening.[[26]](#footnote-26) Diagnosis relies on a compatible history of asbestos exposure and exclusion of other probable causes.[[27]](#footnote-27)

1. The Council noted that there have been changes in the understanding and use of the terminology for asbestos-related diseases over time. This may account for some of the difficulties in classification between different diseases. “Pleural asbestosis” is an obsolete term used in early studies, and is not equivalent to asbestosis as understood in this document, but rather refers to pleural plaques and/or diffuse pleural thickening. Diffuse pleural thickening is well described as a separate entity in the medical literature, and should be considered distinct from multiple pleural plaques. In many studies in the epidemiological literature, the term “parenchymal fibrosis” is often used as a substitute for “asbestosis”.
2. The Council also notes that updated diagnostic criteria for the diagnosis of asbestosis were published in 2010 by the Asbestosis Committee of the College of American Pathologists and Pulmonary Pathology Society.[[28]](#footnote-28) One area of potential confusion is the acceptance of some pathologists of bronchiolar wall fibrosis in the absence of alveolar septal fibrosis as early asbestosis. The Asbestosis Committee believe that this bronchiolar wall fibrosis should not be referred to as asbestosis but as “asbestos airway disease”. This has also been called mineral dust airway disease. Similar fibrosis can be seen with a variety of dusts such as silica, iron, aluminium oxide and cigarette smoke as well as asbestosis. This area continues to be one of controversy and is relevant to the clinical diagnosis of asbestosis in that this type of fibrosis can produce small opacities visible on chest imaging, and may be one of the causes of false positive diagnoses.
3. An illustration of different types of asbestos-related pulmonary disease is shown in Figure 1.[[29]](#footnote-29) Figure 1A shows the location of the lungs, airways, pleura, and diaphragm and Figure 1B shows asbestos-related diseases, including pleural plaques, asbestosis, lung cancer, and mesothelioma.




Figure 1. Asbestos-related Disorders

1. In Figure 2[[30]](#footnote-30) diffuse pleural thickening is shown.




Figure 2. Diffuse Pleural Thickening

1. The Council noted a number of other issues about the medical science studies concerning the level of exposure to asbestos required to produce FILD and Asbestosis. Despite much published research where respirable fibre levels have been assessed, measurement of actual exposure is difficult. In the various studies, methodologies have differed, the types of asbestos inhaled have varied, and other factors may not have been considered such as smoking, and other dusts inhaled. Different measurement methods also make comparisons between levels of exposure difficult.
2. The Council notes that the SMSE usually refers to fibre/mL/years to quantify asbestos exposure rather than simply chronological exposure duration. The Council’s discussion regarding this is at [57].

## COUNCIL’S EVALUATION OF SOUND MEDICAL-SCIENTIFIC EVIDENCE RELEVANT TO THE APPLICANT’S CONTENTIONS

### The Relationship between Pleural Plaques and / or Asbestos Bodies and Fibrosing Interstitial Lung Disease and Asbestosis

1. Inhalation of asbestos fibres can cause fibrotic interstitial lung disease (asbestosis), pleural plaques, diffuse pleural thickening, malignant mesothelioma, and lung cancer.[[31]](#footnote-31) The interaction of asbestos fibres with alveolar macrophages in the lungs, in some instances, results in the formation of asbestos bodies, which are a marker of past exposure to asbestos fibres.[[32]](#footnote-32) The detection of asbestos fibres (or asbestos bodies) in lung tissue, sputum, or bronchial washings/ lavage fluid (BAL) are a definite indication of asbestos exposure. A histological diagnosis of asbestosis is regarded as the gold standard for diagnosis, for which the American College of Pathologists has recently published criteria.[[33]](#footnote-33) However, the uses of techniques such as surgically obtained lung biopsies are considered too invasive to be performed solely for compensation purposes. BAL is more available and less invasive, but laboratory expertise in identifying asbestos bodies is operator dependant and this skill is becoming rare.
2. Pleural plaques are the most common manifestation of the inhalation of asbestos fibres.[[34]](#footnote-34) The presence of pleural plaques is an indicator of exposure to asbestos fibres.[[35]](#footnote-35) Localised pleural plaques are usually asymptomatic, although diffuse pleural thickening is associated with decreased respiratory function.[[36]](#footnote-36)
3. Diffuse pleural thickening is another marker of asbestos exposure. Diffuse pleural thickening, or extensive fibrosis of the visceral pleura secondary to asbestos exposure, may coexist with pleural plaques but has a distinctly different pathology with a different natural history, radiology and prognosis.[[37]](#footnote-37) In contrast, pleural plaques primarily involve the parietal pleura.[[38]](#footnote-38) Diffuse pleural thickening can develop within a year from exposure to asbestos often following a benign asbestos related pleural effusion.[[39]](#footnote-39) Although symptoms are generally mild, severe restrictive lung disease with respiratory failure can rarely occur.[[40]](#footnote-40) The Council noted that the presence of diffuse pleural thickening rather than pleural plaques is more frequently associated with underlying asbestosis, but a history of substantial asbestos exposure is required before a diagnosis of asbestosis and or FILD can be made. Pleural plaques, diffuse pleural thickening and asbestosis can be distinguished from each other using internationally accepted evidence-based criteria.[[41]](#footnote-41), [[42]](#footnote-42), [[43]](#footnote-43)
4. The American Thoracic Society[[44]](#footnote-44) reported that for a diagnosis of non-malignant asbestos-related disease (asbestosis; pleural thickening or asbestos-related pleural fibrosis - plaques or diffuse fibrosis; non-malignant pleural effusion; and airflow obstruction) there must be:
5. evidence of structural pathology consistent with asbestos-related disease as documented by imaging or histology;
6. evidence of causation by asbestos as documented by the occupational and environmental history, markers of exposure (usually pleural plaques), recovery of asbestos bodies, or other means; and
7. exclusion of alternative plausible causes for the findings.[[45]](#footnote-45) (p.691)
8. Similarly, the International Expert Meeting on Asbestos, Asbestosis, and Cancer [[46]](#footnote-46) stated:

Asbestosis is defined as diffuse interstitial fibrosis of the lung as a consequence of exposure to asbestos dust. Neither the clinical features nor the architectural tissue abnormalities sufficiently differ from those of other causes of interstitial fibrosis to allow confident diagnosis without a history of significant exposure to asbestos dust in the past or the detection of asbestos fibers or bodies in the lung tissue greatly in excess of that commonly seen in the general population. Symptoms of asbestosis include dyspnea and cough. Common findings are inspiratory basilar crackles and, less commonly, clubbing of the fingers. Functional disturbances can include gas exchange abnormalities, a restrictive pattern, and obstructive features due to small airway disease.[[47]](#footnote-47) (p.312)

Asbestosis is generally associated with relatively high exposure levels with radiological signs of parenchymal fibrosis. However, it is possible that mild fibrosis may occur at lower exposure levels, and the radiological criteria need not always be fulfilled in cases of histologically detectable parenchymal fibrosis. The recognition of asbestosis by chest radiography is best guided by standardized methods such as the classification of the International Labour Organisation (ILO) and its modifications. Standard films must always be used. For research and screening purposes, radiological findings of small opacities, grade 1/0, are usually regarded as an early stage of asbestosis.[[48]](#footnote-48) (p.312)

1. Fischer et al[[49]](#footnote-49) reported that the concentration of asbestos fibres in lung tissue is the result of:

* the intensity and duration of exposure;
* geometry, type, and bio persistence of fibres;
* inhalation, elimination, and retention of fibres; and
* individual factors such as existing lesions, smoking, breathing frequency and volume, and work environment.

Light or electron microscopical lung-dust analysis with counts of asbestos bodies or asbestos fibres, are often conducted in order to quantify the actual pulmonary burden.[[50]](#footnote-50)

1. The concentrations of asbestos fibres in the air are often reported as fibres in a millilitre (mL) i.e. fibre/mL. Inhalation exposure is generally regarded as cumulative and is expressed as concentration of fibres over time i.e. fibre/mL-years, noting that some asbestos fibres may be removed by mucociliary clearance or macrophages, while others may be retained in the lungs for extended periods.[[51]](#footnote-51) Therefore, to calculate asbestos exposure as cumulative fibre exposure of fibre/mL-year, duration of exposure (measured in years) is multiplied by the average air concentration for the period of exposure (measured in fibre/mL).[[52]](#footnote-52)
2. The Agency for Toxic Substances and Disease Registry (ATSDR)[[53]](#footnote-53) reported that observations of asbestos-related diseases in groups of workers with cumulative exposures ranging from 5 to 1200 fibre/mL-years, resulting from 40 years of occupational exposure to air concentrations of 0.125 to 30 fibre/mL, have been shown. For the presence of pleural plaques, the ATSDR[[54]](#footnote-54) reported that an increased incidence of pleural plaques has been noted at relatively low cumulative exposure levels of approximately 0.12 fibre/mL-years.
3. Ehrlich et al[[55]](#footnote-55) studied the long-term radiological effects of short-term exposure to amosite[[56]](#footnote-56) asbestos among a subset of 386 factory workers from an original cohort of 820 (median exposure = 6 months; range = 0.01-13) and long-term follow-up (median exposure = 25 years). Asbestos dust concentrations were high (mean (*M*) = 51.8 fibre/mL, (standard deviation (*SD)* = 25)) and the asbestos exposure was accumulated rapidly, over months in most cases rather than years (median = 25.1 fibre/mL-years, range = 0.1-720). With as little as one month or less of employment, approximately 20% of the X-rays showed parenchymal abnormality (ILO profusion ≥1/0) and about a third showed pleural abnormality (any pleural thickening of the chest wall or diaphragm). Those in the lowest cumulative exposure group (≤5 fibre/mL-years) were found to have high rates of parenchymal and pleural abnormalities. The prevalence rate of parenchymal abnormality increased with increasing cumulative exposure; however, for pleural abnormalities there was no clear trend with increasing cumulative exposure.
4. The authors[[57]](#footnote-57) concluded that no cumulative exposure threshold for parenchymal and pleural abnormalities was detectable, and progression was still evident 20 years or more after the end of exposure. This finding showed that radiological abnormalities indicative of interstitial pulmonary fibrosis and pleural thickening can develop with as little as one month's exposure to high concentrations of amosite asbestos fibre. The authors stated “that under certain circumstances, a high dose of asbestos fibre inhaled in a short period of time is more potent than the same cumulative exposure inhaled over a longer interval”.[[58]](#footnote-58)(p.274)
5. Shepherd et al[[59]](#footnote-59) examined progression of pleural and parenchymal disease on chest X-rays of 887 workers exposed to amosite asbestos. The exposure was short-term (*M* = 8.0 months, *SD* = 14.9), but high (*M* = 638.9 fibre/mL-months, *SD* = 1460 *i.e. M* = 53.3 fibre/mL-years). The study showed parenchymal disease doubled over approximately 10 years between X-rays with only slightly less progression for pleural disease, and that an intense although short exposure to amosite asbestos can produce pleural and parenchymal changes on chest radiographs.
6. Koskinen et al[[60]](#footnote-60) screened 18 943 Finnish construction (*n* = 17 937), shipyard (*n* = 456), and asbestos industry (*n* = 550) workers for asbestos-related radiographic abnormalities. Of the screened workers, 4133 (22%) had asbestos-related radiographic abnormalities (22% construction; 16% shipyards; 24% asbestos industry). For all workers combined, the average duration of employment was 26 years, and the average duration of exposure was 9.0 years (construction *M* = 9.0 years; shipyards *M* = 7.8 years; and asbestos industry *M* = 9.7 years). The prevalence of positive findings increased with the duration of exposure (18% = <10 years; 27% = 10-30 years; and 43% = >30 years).
7. Of the 4133 workers with asbestos-related radiographic abnormalities present, 96% had abnormalities in the pleura and 4% had asbestosis. Pleural plaques were diagnosed in two-thirds of the workers with parenchymal fibrosis and they were observed in less than half of workers with small irregular opacities and less than 15 years of exposure. Additionally, after a period of exposure of more than 30 years, pleural plaques were present in 80% of cases. This study showed that parenchymal fibrosis developed after shorter and possibly greater asbestos exposure, whereas pleural plaques require a longer period to become detectable by chest X-ray.[[61]](#footnote-61)
8. Schaeffner et al[[62]](#footnote-62) assessed the association between asbestos exposure and pleural or parenchymal abnormalities on chest X-rays or CT scans of 103 asbestos-exposed patients with known lung cancer. Asbestos exposure was assessed using an asbestos exposure index that integrated time and intensity of reported exposure using a weighting score; low asbestos exposure index score = ≤10 and a high asbestos exposure index score = >10. There were 34 patients with a low exposure index score (≤10) and 69 had high exposure index score (>10) and a statistically significant correlation between exposure and chest CT scan changes in detecting asbestos-related abnormalities was shown. The group with the higher asbestos exposure index score were more likely to develop both pleural and parenchymal abnormalities (Odds ratio (OR) = 4.93; 95% confidence interval (CI): 1.05, 23.12). This study confirmed that chest CT scans were more sensitive in detecting pleural or parenchymal abnormalities than were standard chest X-rays and there was a significant correlation between higher asbestos exposure index scores and abnormalities on CT scans.
9. Rohs et al[[63]](#footnote-63) conducted a 25 year follow-up study of low-level fibre-induced radiographic changes caused by Libby Vermiculite[[64]](#footnote-64) of 280 participants. The average cumulative amphibole[[65]](#footnote-65) exposure was low (*M* = 2.48 fibre/mL-years (*SD* = 4.19); range = 0.01-19.03). A total of 80 participants had pleural changes (64 = localised pleural thickening only – pleural plaques; 10 = diffuse pleural thickening only; and 6 = both pleural thickening (4 = localised and 2 = diffuse) with interstitial changes) and 8 had interstitial changes (irregular opacities, profusion ≥1/0). Participants with any pleural changes (*n* = 80) had significantly greater cumulative fibre exposure compared with the 200 participants without pleural changes (*M* = 4.77 fibre/mL-years (*SD* = 5.72) and *M* = 1.56 (*SD* = 2.94); *p*< 0.001 respectively). Pleural changes were directly related to cumulative fibre exposure, with the greatest prevalence (54.3%) in the highest exposure quartile (range = 2.21-19.03 fibre/mL-years) of participants. The prevalence of pleural changes increased with age, including those workers with a lifetime cumulative fibre exposure of <1 fibre/mL-year. A significant increase in pleural changes overtime from 2.0% in the 1980 study to 28.7% in 2005 was shown.
10. In this study, interstitial changes (irregular opacities) were demonstrated in 2.9% of participants and were significantly related to cumulative fibre exposure. Participants with interstitial changes (*n* = 8) had significantly greater cumulative fibre exposure compared with the 198 participants without pleural changes (*M* = 11.86 fibre/mL-years (*SD* = 6.46); *p*< 0.001) and the 64 with only localised pleural changes (*p*< 0.001). A significant increase in interstitial changes over time from 0.2% in the 1980 study to 2.9% in 2005 was shown. This study demonstrated that exposure to asbestos fibres among users of Libby vermiculite ore caused pleural thickening and interstitial changes at low lifetime cumulative fibre exposure levels of <2.21 and 11.37 fibre/mL-years respectively. Rohs et al[[66]](#footnote-66) reported that a level of <2.21 fibre/mL-years is below the lifetime cumulative fibre exposure for a worker exposed to the current Occupational Safety and Health Administration permissible exposure level standard of 0.1 fibre/mL for regulated asbestos in general industry over a 45-year working life (4.5 fibre/mL-years).
11. Kishimoto et al[[67]](#footnote-67) examined the prevalence of pleural plaques and/or pulmonary changes, on chest X-rays and confirmed by chest CT, among construction workers in Japan. Among 2951 workers, 168 (5.7%) had significant findings for pleural plaques or pulmonary changes on chest X-ray, (74 = both pleural plaques and asbestosis; 85 = pleural plaques alone; and 9 = asbestosis alone). Pleural plaques were present in 5.4%, and fibrosis suggesting pulmonary asbestosis in 2.8% of chest CT images. Workers with pulmonary asbestosis accompanied by pleural plaques accounted for a considerably high percentage; there was no correlation between the lesions. More advanced age and a longer duration of asbestos exposure appeared to be associated with a higher percentage of workers with pulmonary and pleural lesions. The study demonstrated that pleural plaques develop even after exposure to a small amount of asbestos, but often do not develop until 20 years after the initial exposure.

### Summary of Council’s View

1. On the basis of its evaluation of the studies discussed above, the Council considered that the presence of either asbestos bodies or pleural plaques (and diffuse pleural thickening) were indicative of prior asbestos exposure. However, the Council did not find evidence that the presence of either of these markers alone, without a stated asbestos exposure level and duration, and suitable lag period, would indicate that the disease asbestosis was also present.
2. The Council recommends that the RMA considers whether diffuse pleural thickening should be specifically included in the SoPs regime as a compensable disease, possibly by recognising it as a separate disease.

### New Information on the Relationship between Pleural Plaques and / or Asbestos Bodies and Fibrosing Interstitial Lung Disease and Asbestosis

1. The Council noted there is new information available on the relationship between pleural plaques, asbestos bodies, and asbestosis (see **Appendix A. Table A4**) and in relation to diffuse pleural thickening (see **Appendix A. Table A5**).

### **Comparison of the Statements of Principles, where Duration of Exposure is used as a Measure of Dose, with the Literature on a Threshold of Asbestos Concentrations**

1. In previous RMA reviews in 1996[[68]](#footnote-68), [[69]](#footnote-69) and 2005[[70]](#footnote-70) the required levelof asbestos exposure associated with producing FILD or Asbestosis expressed as days was reduced, and exposure expressed as days changed to hours of exposure.
2. In the SoPs for Asbestosis for 1996[[71]](#footnote-71) the minimum period of exposure to asbestos fibres was changed from 500 days (RH and BoP) to 200 days (RH) and 365 days (BoP). The rationale for the change was the 500 days minimum period of exposure was derived from occupational studies (15 studies/reviews,[[72]](#footnote-72) particularly studies of Wittenoom mine workers and insulators by de Klerk et al[[73]](#footnote-73) and Cookson et al)[[74]](#footnote-74) and the dose was lowered to account for naval personnel who are often on board ship for 24 hours per day, seven days per week.[[75]](#footnote-75)
3. In the SoPs for Asbestosis for 2005[[76]](#footnote-76) the minimum period of exposure was changed from 200 days (RH) and 365 days (BoP) to 1000 hours (RH) and 1500 hours (BoP) in an enclosed environment and 3000 hours (RH) and 5000 hours (BoP) in an open environment. In making these changes the RMA evaluated its previous evidence,[[77]](#footnote-77) further relevant SMSE[[78]](#footnote-78) and responded to submissions contending:
4. an exposure of 200 days was excessive for naval personal exposed 24 hours, 7 days a week when at sea; and
5. exposure should be expressed in hours rather than days as is the case with passive smoking.
6. The RMA 2005 SoPs[[79]](#footnote-79) changed the minimum period of exposure from days to hours as an attempt “ to make up a time based dose “in a vacuum” as the actual or potential levels of exposure experienced by personnel is open to conjecture”.[[80]](#footnote-80)(p.44) The RMA took into account the previous 1996 studies and in 2005 an additional 13 studies/reviews - three review studies, seven cohort studies, two case series, and one case report, particularly studies by Wright et al[[81]](#footnote-81) and Fischer et al,[[82]](#footnote-82) a book chapter by Roggli,[[83]](#footnote-83) and reviews by ATSDR[[84]](#footnote-84) and Henderson et al.[[85]](#footnote-85)
7. The 2013 SoPs for Asbestosis[[86]](#footnote-86) retained the minimum period of exposure set out in the 2005 SoPs,[[87]](#footnote-87) after the RMA reviewed the 1996, 2005 studies and an additional 7 reviews/books and 14 studies.[[88]](#footnote-88)
8. In the SMSE, a cumulative asbestos exposure of 25 fibre/mL-years is commonly cited as a level of exposure associated with the induction of asbestosis. The RMA has also noted this threshold level in briefing papers (see [62]) used to determine asbestos factors in SoPs in 2005 and 2013.
9. Boffetta[[89]](#footnote-89) attributes a 25 fibre/mL-years exposure threshold to Doll & Peto.[[90]](#footnote-90) Boffetta[[91]](#footnote-91) states that:

In case of exposure to a low level of asbestos, radiological, pathological and clinical evidence of lung fibrosis is generally absent. This feature has suggested the existence of a threshold for lung fibrosis: a value commonly proposed for chronic cumulative exposure is 25 fibres/mL-years (fb/ml-yrs)…It has however been suggested that short exposure to very high levels of amphibole asbestos, resulting in a cumulative value below 25 fb/ml-yrs, might induce radiological asbestosis.[[92]](#footnote-92)(p.472)

1. In 1997, an expert group, which represented substantial consensus worldwide[[93]](#footnote-93) developed the ‘Helsinki diagnostic criteria’. These criteria have been reviewed in ways that do not affect the matters contended in this review. [[94]](#footnote-94) The 1997 paper states:

…a cumulative exposure of 25 fibre-years is estimated to increase the risk of lung cancer 2-fold. Clinical cases of asbestosis may occur at comparable cumulative exposures…Cumulative exposures below 25 fibre-years are also associated with an increased risk of lung cancer, but to a less extent. [[95]](#footnote-95)(p.314)

1. The ‘Helsinki diagnostic criteria[[96]](#footnote-96) have gained wide acceptance. To assess diagnosis and attribution of asbestos-related diseases in an Australian context, a number of Australian and International experts met in 2000. The Henderson et al[[97]](#footnote-97) report of the expert meeting provided the explanation for the ‘Helsinki diagnostic criteria’[[98]](#footnote-98) cumulative exposure of 25 fibre/mL-years associated with asbestosis. The report states:

…the 25 fibers/mL-year requirement in the Helsinki Criteria is based upon correlative multidisciplinary studies that include fiber burden studies of lung tissue, cohort studies, and case–referent studies, some of which include individualized estimates of exposures and which also include studies of those exposed at points of end-use of asbestos mixtures (representing the most common pattern of exposure)—for which cohort studies are unrealistic—and which may be more representative of the overall risk of asbestos-related lung cancer for an industrialized society than cohort studies restricted to special industries. The requirement of 25 fibers/mL-year of cumulative exposure set forth in the Helsinki Criteria represents a fair and reasonable approach for the attribution of lung cancer to asbestos for amphibole-only exposures (except for Wittenoom), mixed exposures, and asbestos textile exposures; the Helsinki Criteria did not specifically distinguish between fiber types of exposure for the purpose of attribution. Given an adequate period of latency, this cumulative exposure level has been widely used as a cumulative exposure index that makes it more likely than not that asbestos contributed to a particular lung cancer.[[99]](#footnote-99)(p.44)

A cumulative exposure of 25 fibers/mL-year delineates exposure of a character and magnitude sufficient to induce clinical/radiologic asbestosis in some individuals so exposed, whereas one study carried out on the South Carolina chrysotile textile cohort found that histologic evidence of asbestosis was usually present when cumulative exposures were in excess of 20 fibers/mL-year, but a few cases were encountered with exposures in the range of 10–20 fibers/mL-year.[[100]](#footnote-100)(p. 44)

1. The2005 RMA briefing paper for Asbestosis[[101]](#footnote-101) cited the cumulative exposure level of 25 fibre/mL-years stated by Henderson et al[[102]](#footnote-102) and acknowledged lower cumulative exposure levels for inducing clinical/radiologic asbestosis in some individuals as reported by Henderson et al[[103]](#footnote-103) and Fischer et al.[[104]](#footnote-104) The RMA reported that:

…This would support an option to focus dose on the levels used in assessments of occupational exposures, eg an assessment of fibers/mL-year (perhaps 25 fibers/mL-year cumulative exposure to asbestos fibres for BoP and 15 fibers/mL-year for Reasonable Hypothesis).[[105]](#footnote-105)(p.11)

1. The RMA’s methodology[[106]](#footnote-106) for the calculation of inhaling respirable asbestos fibres for a cumulative period of hours when making both sets of SoPs (for FILD[[107]](#footnote-107) and Asbestosis[[108]](#footnote-108)) in 2005 and 2013 is set out below:

The current (1996) RH asbestos factor required a minimum exposure for 200 days (about the number of working days in a calendar year after weekends, holidays and public holidays removed) which if working days is an exposure of 1600 hours. There are some cases which have low but intense exposures and the dose could be say 1000 hours (125 working/8 hour days) for the enclosed space exposures with some level of justification from the literature. Though the vast majority of those with asbestosis have had a history of heavy asbestos exposures. [[109]](#footnote-109)(p.11)

For exposures in an open space (drawing on evidence form shipyard and construction workers) exposures may still be significant and contribute to asbestosis. …Dose is again a low end estimate and should probably equate to several years working in that environment. For that I would suggest 3000 hours (approximately two working years). [[110]](#footnote-110)(p.11)

1. The cumulative periods of hours of exposure for both sets of SoPs[[111]](#footnote-111), [[112]](#footnote-112) are shown in Table 1.

Table 1. Asbestos Factors in the Current Statements of Principles For Fibrosing Interstitial Lung Disease and Asbestosis

|  |  |
| --- | --- |
| ***Reasonable Hypothesis*** - for FILD No. 53 of 2013 and for Asbestosis No. 55 of 2013 | |
| (b)&(a) inhaling respirable asbestos fibres in an **enclosed space**: | |
|  | (i) for a cumulative period of at least **1000 hours** before the clinical onset of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) the first inhalation of asbestos fibres commenced at least **five years** before the clinical onset of asbestosis; or |
| ***Balance of Probabilities*** - for FILD No. 54 of 2013 and for Asbestosis No. 56 of 2013 | |
| (b)&(a) inhaling respirable asbestos fibres in an **enclosed space**: | |
|  | (i) for a cumulative period of at least **1500 hours** before the clinical onset of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) the first inhalation of asbestos fibres commenced at least **ten years** before the clinical onset of asbestosis; or |
| ***Reasonable Hypothesis*** - for FILD No. 53 of 2013 and for Asbestosis No. 55 of 2013 | |
| (c)&(b) inhaling respirable asbestos fibres in an **open environment**: | |
|  | (i) for a cumulative period of at least **3000 hours** before the clinical onset of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) the first inhalation of asbestos fibres commenced at least **five years** before the clinical onset of asbestosis; |
| ***Balance of Probabilities*** - for FILD No. 54 of 2013 and for Asbestosis No. 56 of 2013 | |
| (c)&(b) inhaling respirable asbestos fibres in an **open environment**: | |
|  | (i) for a cumulative period of at least **5000 hours** before the clinical onset of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) the first inhalation of asbestos fibres commenced at least **ten years** before the clinical onset of asbestosis; |
| ***Reasonable Hypothesis*** - for Asbestosis No. 55 of 2013 only | |
| (c) inhaling respirable asbestos fibres: | |
|  | (i) for a cumulative period of at least **1000 hours** before the clinical worsening of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) within the **two years** before the **clinical worsening** of asbestosis |
| ***Balance of Probabilities*** - for Asbestosis No. 56 of 2013 only | |
| (c) inhaling respirable asbestos fibres: | |
|  | (i) for a cumulative period of at least **1500 hours** before the clinical worsening of asbestosis; and |
|  | (ii) at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled; and |
|  | (iii) within the **two years** before the **clinical worsening** of asbestosis |
|  | |

1. In relation to the existing asbestos factors above, the Council noted that assessment of the actual dose of asbestos that has been inhaled to produce asbestos-related diseases can only be, at best, a very rough estimate. Days of exposure give a limited evaluation of risk if concentration is not known. The cumulative periods indicated in the SoPs do not take account of other important determinants for the occurrence of disease, such as the type of asbestos fibres, ventilation, the presence of other dusts, smoking, and individual susceptibility.
2. In 2005, the RMA considered using a 25 fibre/mL-year cumulative exposure to asbestos fibres at the BoP level (see [62]), however, it decided to continue to use duration of exposure in the SoPs (1500 hours for an enclosed space and 5000 for an open environment at the BoP level). The medical science basis used to determine the level of cumulative exposure of asbestos in the SoPs was not totally clear to the Council.

### **The Levels of Asbestos Exposure Associated with Asbestosis in the Sound Medical-Scientific Evidence**

1. Forty eight studies were considered relevant SMSE to this review, of which twelve studies reported asbestos cumulative exposure levels significantly associated with producing asbestosis (see **Appendix A. Table A1**). The other thirty six studies (and an erratum) reported the relationship between the exposure to asbestos and asbestosis but did not report a cumulative fibre/mL-year exposure level or a significant association (see **Appendix A. Table A2**).
2. The twelve studies listed in **Appendix A. Table A1** reported asbestos cumulative exposure levels significantly associated with producing asbestosis and included analysis of asbestosis incidence and mortality. The methods for the determining and classifying asbestosis varied between the studies. In the five morbidity studies[[113]](#footnote-113), [[114]](#footnote-114), [[115]](#footnote-115), [[116]](#footnote-116), [[117]](#footnote-117) the ILO classification of Radiographs of Pneumoconioses[[118]](#footnote-118) was used. In the seven mortality studies [[119]](#footnote-119), [[120]](#footnote-120), [[121]](#footnote-121), [[122]](#footnote-122), [[123]](#footnote-123), [[124]](#footnote-124), [[125]](#footnote-125) asbestosis (or pneumoconiosis or non-malignant respiratory disease) was identified and determined using death certificates/databases, autopsy reports and/or recorded International Coding of Disease (ICD) codes, and in some an analysis of asbestos bodies and lung histology.
3. The twelve studies listed in **Appendix A. Table A1** reported exposure data from South Africa,[[126]](#footnote-126) USA,[[127]](#footnote-127), [[128]](#footnote-128), [[129]](#footnote-129), [[130]](#footnote-130), [[131]](#footnote-131), [[132]](#footnote-132), [[133]](#footnote-133) France,[[134]](#footnote-134) the UK,[[135]](#footnote-135) and Canada.[[136]](#footnote-136), [[137]](#footnote-137) The data included studies of workers exposed to: amphibole asbestos and serpentine asbestos from an amphibole mine;[[138]](#footnote-138) chrysotile asbestos textile plant;[[139]](#footnote-139), [[140]](#footnote-140) amosite asbestos factory;[[141]](#footnote-141), [[142]](#footnote-142) vermiculite mine/mill;[[143]](#footnote-143), [[144]](#footnote-144), [[145]](#footnote-145), [[146]](#footnote-146) asbestos textile and friction material factory, shipyards, fossil fuel power stations, and industrial insulation;[[147]](#footnote-147) chrysotile and crocidolite asbestos textile factory;[[148]](#footnote-148) and a chrysotile and crocidolite asbestos, silica, and cement factory.[[149]](#footnote-149) There were no studies reporting asbestos exposure data in the military or naval setting.
4. The twelve studies reported the collection of fibre concentrations using various air concentration estimation methods; konimeters; thermal precipitation; Optical Phase Contrast Microscopy; or the midget impinger collection method. From 1968 and later, seven studies[[150]](#footnote-150), [[151]](#footnote-151), [[152]](#footnote-152), [[153]](#footnote-153), [[154]](#footnote-154), [[155]](#footnote-155), [[156]](#footnote-156) reported the use of personal monitoring using membrane filter methods. While two studies[[157]](#footnote-157), [[158]](#footnote-158) reported the use of estimations of fibre concentrations extrapolated from fibre concentrations measured in other factories than those studied.
5. Eight studies[[159]](#footnote-159), [[160]](#footnote-160), [[161]](#footnote-161), [[162]](#footnote-162), [[163]](#footnote-163), [[164]](#footnote-164), [[165]](#footnote-165), [[166]](#footnote-166) calculated cumulative exposure using varied methods of individual’s duration of employment, weighing exposure by occupation using job matrices. Larson et al[[167]](#footnote-167) and Rohs et al[[168]](#footnote-168) both reported weighting the occupational exposure using the 8-hour time weighted average (TWA), multiplied by the number of years, summed over the total years. Seidman et al[[169]](#footnote-169) and Ehrlich et al[[170]](#footnote-170) calculated the average fibre counts for each job title estimated from measurements carried out at two other plants operated by the company and Green et al[[171]](#footnote-171) did not have individual exposure data available for each worker, therefore estimates of exposure by job category at the plant were conducted. Finkelstein and Vingilis[[172]](#footnote-172), [[173]](#footnote-173) calculated their cumulative exposure using a model that extrapolated measurements made by the personal membrane filter (a method that came into use 21 years after the plant was open) and individual work histories.
6. Duration of exposure was reported in the twelve studies with large variability, ranging from 1 day to 30 years, with the studies reporting duration exposure levels as either mean,[[174]](#footnote-174), [[175]](#footnote-175), [[176]](#footnote-176), [[177]](#footnote-177), [[178]](#footnote-178) median,[[179]](#footnote-179), [[180]](#footnote-180), [[181]](#footnote-181), [[182]](#footnote-182) range,[[183]](#footnote-183), [[184]](#footnote-184) not stated,[[185]](#footnote-185) or exact duration figures were not reported.[[186]](#footnote-186) The duration of exposure was most often calculated from the duration of employment: *M* = 4.0 (range = 1 day-43.1) years;[[187]](#footnote-187) *M* = 9 years;[[188]](#footnote-188) *M* = 20.1 years;[[189]](#footnote-189) *M* = 24.9 (*SD* = 9.1) years;[[190]](#footnote-190) *M* = 30.4 (*SD* = 14.0) years;[[191]](#footnote-191) median = 0.5; 6 months (range = 0.1-13) years;[[192]](#footnote-192) median = 0.8 (25th-75th percentile 0.1-4.1 years);[[193]](#footnote-193) median = 1.1 (range = 0.1-46.8) years;[[194]](#footnote-194) range = <1 month to 2-14 years;[[195]](#footnote-195) and 0.1- >27.3 years;[[196]](#footnote-196) and1 year.[[197]](#footnote-197)
7. Of the five morbidity studies, three studies[[198]](#footnote-198), [[199]](#footnote-199), [[200]](#footnote-200) demonstrated cumulative asbestos exposure levels of 25 fibre/mL-years or lower (at 5; 11.86; and 25 fibre/mL-years). Both Ehrlich et al[[201]](#footnote-201) and Rohs et al[[202]](#footnote-202) showed a significant association between cumulative asbestos exposure and asbestosis (ILO profusion ≥1/0) at <5 fibre/mL-years (*n* = 10) and 11.86 fibre/mL-years (*n* = 8) respectively. Paris et al[[203]](#footnote-203) showed a significant association between cumulative asbestos exposure and asbestosis (ILO profusion ≥1/1, HRCT grade 2 or 3) at 25 fibre/mL-years (*n* = 51). There were two studies[[204]](#footnote-204), [[205]](#footnote-205) that demonstrated cumulative asbestos levels greater than 25 fibre/mL-years, at 84 and 150 fibre/mL-years respectively.
8. Of the seven mortality studies, five studies[[206]](#footnote-206), [[207]](#footnote-207), [[208]](#footnote-208), [[209]](#footnote-209), [[210]](#footnote-210) demonstrated cumulative asbestos exposure levels below 25 fibre/mL-years (at 2; 3; 8.6; 10; and 11.7 fibre/mL-years). Sluis-Cremer et al[[211]](#footnote-211) found an increased risk of death from asbestosis at cumulative exposures of >2-5 fibre/mL-years (*n* = 4), Hein et al[[212]](#footnote-212) at 3-<16 fibre/mL-years (*n* = 42), Larson et al[[213]](#footnote-213) at 8.6 to <44.0 fibre/mL-years (*n* = 25), Green et al[[214]](#footnote-214) at 10-20 fibre/mL-years (*n* = 3), and McDonald et al[[215]](#footnote-215) found an increased risk of death from non-malignant respiratory disease at 11.7 fibre/mL-years (*n* = 51). There were two studies[[216]](#footnote-216), [[217]](#footnote-217) that reported levels above 25 fibre/mL-years at 50 and 100 fibre/mL-years respectively.
9. There were eight [[218]](#footnote-218), [[219]](#footnote-219), [[220]](#footnote-220), [[221]](#footnote-221), [[222]](#footnote-222), [[223]](#footnote-223), [[224]](#footnote-224), [[225]](#footnote-225) of the twelve studies that provided results of an association between a cumulative exposure between 2-25 fibre/mL-years and a diagnosis of asbestosis. The eight studies had cumulative exposure levels equivalent to or lower than the Helsinki diagnostic criterion[[226]](#footnote-226) of 25 fibre/mL-years associated with producing asbestosis.
10. It has been reported that asbestosis is more prevalent and more advanced for a given duration of exposure in cigarette smokers,[[227]](#footnote-227) however, only half of the twelve studies documented smoking histories[[228]](#footnote-228), [[229]](#footnote-229), [[230]](#footnote-230), [[231]](#footnote-231), [[232]](#footnote-232), [[233]](#footnote-233), [[234]](#footnote-234) while the other studies did not report or adjust for individuals smoking history.[[235]](#footnote-235), [[236]](#footnote-236), [[237]](#footnote-237), [[238]](#footnote-238), [[239]](#footnote-239), [[240]](#footnote-240), [[241]](#footnote-241)
11. Of the twelve studies, there were no data from Australia reporting cumulative exposure levels significantly associated with asbestosis. However, of the 36 studies there are data from Australia (see **Appendix A. Table A2**). The Wittenoom[[242]](#footnote-242) studies by Cookson et al[[243]](#footnote-243), [[244]](#footnote-244) and Reid et al[[245]](#footnote-245) (see [80]) were included in the review. These studies did include cumulative exposure data but the conditions of exposure were very different from those of the Australian military and showed also there was a significant incidence of asbestosis in non-cancer cases and at lower exposures than 25 fibre/mL-years. To the Council’s knowledge, there have been no reports regarding exposure levels in the Australian military. The Council acknowledges however that there are some reports from the military setting in the international literature. The Council noted that using data from the mining and manufacturing settings as exposure surrogates may not be appropriate for informing on military exposure levels.
12. The Council considered that the more reliable papers reporting asbestos exposure and threshold for development of asbestosis were the morbidity studies, while accepting that the radiological criteria for asbestosis are imperfect. The morbidity studies used a radiological definition for defining incidence of asbestosis rather than mortality studies that used autopsy reports and death certificates and/or databases. Morbidity studies reporting incidence analysis allow a more complete analysis of disease incidence in a non-fatal disease, which is more relevant to the Applicants contention.
13. The Council considered that studies using the membrane filter method for fibre collection and analysis are the most scientifically robust studies.[[246]](#footnote-246), [[247]](#footnote-247), [[248]](#footnote-248), [[249]](#footnote-249), [[250]](#footnote-250), [[251]](#footnote-251), [[252]](#footnote-252) Collection taking place in the job environment as close as possible to the area of respiration, at multiple collection points, and with data available across a number of years provide the most reliable exposure levels. All twelve studies reported various methods to calculate fibre concentration estimates, and many of the studies used exposure estimates derived from average airborne fibre concentrations that did not represent an assessment of individualised exposures. There were inconsistencies in measurement strategies and sampling techniques, which was further complicated by the use of retrospective exposure data. Retrospective data was often incomplete rendering the accuracy of the exposure, exposed mining and manufacturing workers prone to underestimation. However, the Council acknowledges the difficulties in collection of such data and the limitations inherent in assessing past exposures.
14. The Council considered that the most informative papers into lower dose exposure of the twelve studies that reported cumulative exposure levels were those of Rohs et al[[253]](#footnote-253) and Paris et al.[[254]](#footnote-254) The Council also acknowledged the Wittenoom studies conducted by Cookson et al[[255]](#footnote-255), [[256]](#footnote-256) and Reid et al[[257]](#footnote-257) reporting asbestos exposure in the Australia mining industry.
15. Rohs et al conducted a 25-year follow-up study of 280 Libby Vermiculite mine workers of the original 513 cohort, analysing incidence of asbestosis. There were eight cases of interstitial changes (ILO profusion of ≥1/0). From 1972, membrane filters method was used and prior to that air sampling was conducted by industrial hygienists who followed a worker with a sampling device. Each department was assigned two values of exposure (fibre exposures ≤1973 and >1973). Individuals were assigned a cumulative fibre exposure value, which was the summation of estimated fibre exposure by department, based on the years employed between 1963 and 1980. Cumulative fibre exposure was calculated by multiplying the 8-hour TWA exposure by the number of years. The authors demonstrated interstitial changes were significantly related to a mean cumulative fibre exposure of 11.37 fibre/mL-years. A limitation of the study is the potential misclassification of exposure due to limited industrial hygiene data at the facility and by not accounting for workers overtime. A second limitation is the potential for participation bias, as 30.9 % of cases were lost to follow-up, therefore several of those with advanced disease or illness may have been missed.
16. Paris et al[[258]](#footnote-258) screened 706 retired workers in the textile and friction material factory, shipyards, fossil fuel power stations, and industrial insulation industries for the incidence of early-stage asbestosis. There were 51 cases of pulmonary fibrosis diagnosed by HRCT (grade 2 or 3), of which only 38 could be diagnosed via chest X-ray (ILO profusion ≥1/1). A specific job-exposure matrix was used, based upon air-borne samples collected annually between 1959 and 1999 in the various workshops of the plant. From 1973 the membrane filter method was used. A cumulative-exposure index was calculated by summing the values for all job positions held, with reference to the occupational calendar established in the interview, the products of the job exposure level (in fibre/mL) by job duration (in years).The mean duration of exposure was 24.9 years. A significant association between HRCT fibrosis and cumulative asbestos exposure was apparent, with a clear dose-response relationship seen at 25-99.9 fibre/mL-years (OR = 3.4; 95% Cl: 0.8, 15.2; *p*>0.05) compared with an exposure of 25 fibre/mL-years or less. A limitation of the study was the potential for participation bias, as sufferers of established asbestosis were excluded from entry. This study demonstrated asbestosis was significantly associated with cumulative exposure >25 fibre/mL-years, and that the majority of cases occurred at much higher levels than 25 fibre/mL-years.
17. Cookson et al[[259]](#footnote-259) examined the prevalence of unrecognised pneumoconiosis in former crocidolite asbestos workers of Wittenoom who had never entered a compensation claim. Chest X-rays were available for 859 subjects, of which 541 had radiographs taken after the date of first employment, 52% of the original sample had post-employment radiographs that could be used to draw conclusions about the current prevalence of radiographic abnormality. The other 318 subjects with radiographs formed a comparison group with no known exposure to crocidolite at Wittenoom at the time of their radiographs. Prevalence of parenchymal abnormality (ILO profusion ≥1/0) of nearly 20% was calculated after adjusting for age, time since first exposure, and cumulative exposure level. A random selection of 74 men had a new radiographic examination, with 10 cases of parenchymal abnormality, and the predicted prevalence was confirmed. The total average cumulative exposure for 541 men was 9.6 fibre/mL-years; 318 men was 5.3 fibre/mL-years; and for 74 men followed-up was 8.1 fibre/mL-years. The average duration of exposure was less than 4 months. This study showed an increased relative risk for those workers exposed to <20 fibre/mL-years (RR = 1.227; 95%CI: 1.079, 1.396); 20-54.5 fibre/mL-years (RR = 1.289; 95%CI: 1.115, 1.49); and ≥55 fibre/mL-years (RR = 1.387; 95%CI: 1.20, 1.603). The results showed a prevalence of uncompensated radiographic abnormality consistent with pneumoconiosis in at least 16% of former Wittenoom workers and the data are consistent with there being no threshold dose of crocidolite exposure for the development of radiographic abnormality in this group. However, the authors were cautious in interpreting the results, stating that the study related only to the finding of radiographic changes of small irregular or small rounded opacities, and that the radiographic changes were not diagnostic of radiographic asbestosis and not necessarily indicative of clinical asbestosis in the participants.
18. Cookson et al[[260]](#footnote-260) examined 354 former crocidolite asbestos workers of Wittenoom who had applied for compensation for asbestosis. Chest X-rays were available for 280 men. Subjects were excluded if there was no definite radiographic evidence of pneumoconiosis, if they had a known other disease accounting for radiographic abnormality, or more than 5 years exposure to silica elsewhere in the mining industry. There were two radiograph readers, Reader 1 identified 136 subjects and Reader 2 identified 139 subjects who met the inclusion criteria. Subjects had an average of 10 or more radiographs each to document the onset and progression of asbestosis. For Reader 1, for the 136 men onset of definite radiographic asbestosis was observed in radiographs taken between 2 and 34 years after commencing employment (median = 14 years). No subjects developed asbestosis during the period of employment. The median cumulative exposure was 91 fibre/mL-years and median duration of exposure was 37 months. For Reader 2, for the 139 men there was a range between 1 to 33 years (median = 13 years) from the time of commencing employment to observed development of radiographic asbestosis. There were seven men diagnosed with asbestosis while they were still employed. The median cumulative exposure was 77 fibre/mL-years and median duration of exposure to onset of asbestosis was 33 months. Only the results of the analysis from Reader 1 were presented in the paper. Onset of asbestosis was most frequent between 10 and 20 year from first exposure, with no increased relative risk of progression for cumulative exposure of 0-54 fibre/mL-years. An increased relative rate of progression was seen for cumulative exposure of 55-148 fibre/mL-years (ILO category 1 to 2: RR = 1.6; 95%CI: 1.1, 2.3; ILO category 2 to 3: RR = 2.7, 95%CI: 0.9, 8.2) and cumulative exposure of >148 fibre/mL-years (ILO category 1 to 2: RR = 2.5; 95%CI: 1.2, 5.4; ILO category 2 to 3: RR = 7.1, 95%CI: 0.8, 66.5). Both onset of asbestosis and progression from ILO category 1 to 2 continued to occur throughout the follow-up period in workers exposed to crocidolite. There was no evidence of an effect of cumulative exposure to crocidolite on the time to onset of pneumoconiosis. However, there was some evidence of an effect of cumulative exposure for progression of pneumoconiosis. This study showed an increased relative rate of progression for cumulative exposure of ≥55 fibre/mL-years (ILO category 1 to 2 and 2 to 3). The authors concluded the rate of radiographic progression of established asbestosis increases with the accumulated exposure to crocidolite, and decreases with time from initial crocidolite exposure to the onset of definite radiographic abnormality.
19. Reid et al[[261]](#footnote-261) studied 1988 former workers and residents of Wittenoom with known crocidolite asbestos exposure participating in a cancer prevention program, to determine if the presence of asbestosis is a prerequisite for lung cancer. Over a 12 year period there were 58 cases of lung cancer, the cases had a greater intensity of asbestos exposure and greater cumulative exposure than the remaining cohort. For the 58 cases, 21 (36%) had radiographic evidence of asbestosis on chest X-rays (ILO profusion ≥1/0) compared to 220 (11%) non-cases (*n* = 1930), and 12% of total study participants (*n* = 1988). For the 58 cases the average cumulative exposure was 11 fibre/mL-years (*SD* = 2.6-46.5) with a duration of exposure of 330 days (interquartile range (IQR) = 118-1048). For the 1930 non-cases the average cumulative exposure was 5 fibre/mL-years (*SD* = 1.84-13.5) with a duration of exposure of 285 days (IQR = 106-868). Both radiographic asbestosis (OR = 1.94; 95%CI: 1.09, 3.46) and asbestos exposure (OR = 1.21 per fibre/mL-years; 95%CI: 1.02, 1.42) were significantly associated with an increased risk of lung cancer. There was an increased risk of lung cancer with increasing exposure in those without asbestosis. The authors concluded that the relative risk of lung cancer was higher in former Wittenoom workers and ex-residents with asbestosis than those without asbestosis, even after adjusting for the amount of asbestos exposure. This study showed the presence of asbestosis is not a necessary a precursor for lung cancer, and the presence of asbestosis is also associated with an increased risk of lung cancer which may be due to some action of the fibrosis itself, but in this study this excess risk may also be due to an underestimate of asbestos exposure.

### New Information on the Levels of Asbestos Exposure Associated with Asbestosis in the Sound Medical-Scientific Evidence

1. The Council noted there is new information available on the levels of asbestos exposure associated with asbestosis.
2. The Council considered that some of the most important relevant new studies are by Harries[[262]](#footnote-262), [[263]](#footnote-263) and van Oyen et al.[[264]](#footnote-264) An example of actual military data are studies by Harries[[265]](#footnote-265), [[266]](#footnote-266) which were conducted in the British Naval Dockyards and provide information regarding asbestos fibre concentrations and exposure of naval personnel in the UK. There are others from, for example, the USA.[[267]](#footnote-267) Furthermore, the study by van Oyen et al[[268]](#footnote-268) is an example of a job-exposure matrix using TWA for occupational asbestos exposure in Australia (see New Information section from [93] and **Appendix A. Table A4**).

### Summary of Council’s View

1. The Council’s attempt to compare a cumulative period of hours (from the SoPs) with fibre/mL-years (from the literature) did not reveal any relevant SMSE which could allow definite conclusions about the asbestos duration of exposure factors in Australian military personnel.
2. The relevant SMSE in the information available to the Council was sufficient to show a dose of 25 fibre/mL-years does cause FILD and Asbestosis [67]-[80]. However, there were also studies that demonstrated the development of asbestosis occurring below this level at between 2-15 fibre/mL-years. [[269]](#footnote-269), [[270]](#footnote-270), [[271]](#footnote-271), [[272]](#footnote-272) Additionally, the Council notes that fibre type should be considered along with estimates of the concentration of fibres, as there are data suggesting differences in rates of development of asbestosis depending on fibre type.
3. The Council believes that the SoPs should ideally use historical measurements from military work environments to determine the relevant dose as well as a cumulative period of time. If these data are not available, then those doses from comparable environments (for example the building of Royal Australian Navy ships) in the published literature should be used. If no data currently exist, the Council recommends that such asbestos exposures should be scientifically assessed as far as is practicable using optimal methods, before all naval vessels containing asbestos are retired. It concedes, that the measure of a cumulative period of hours may be the only practical measure currently available to the RMA to characterise dose, but considers this to be incomplete.
4. The assessment of exposures to asbestos experienced in the past is likely to continue to be estimated using the proxy measure of duration of employment in the SoPs until better methods become available.
5. The Council also considered those studies,[[273]](#footnote-273), [[274]](#footnote-274) that used accurate work histories to calculate a TWA of exposure for particular work roles, and concluded that these methods are likely to provide the most accurate representation of exposure data. Current methods using, for example, a job exposure matrix and an 8-hour TWA (rather than extrapolated exposure measurements or estimates of exposure by job category and time), are likely to be more accurate.
6. The Council noted a cumulative exposure involves the assumption that duration and intensity are equally important in determining the effective dose. If exposure estimates are inaccurate or inconsistently measured, a reported statistically significant association between cumulative exposure and asbestosis can misrepresent the actual exposure – response relationship.
7. The Council noted that the 12 studies reporting duration of exposure ranging from 1 day to 30 years (see [72]) and that eight of the twelve studies (see **Appendix A. Table A1**) demonstrated a significant association between lower cumulative asbestos exposure than 25 fibre/mL-years (see [75]) and asbestosis.
8. It is difficult to assess the applicability of the reported studies to the Australian military environment. The wide range (2-150 fibre/ml-years) of relevant asbestos exposure data in the 12 studies evaluated by Council (at [67] to [80]), and the imprecision of the measurement of dose in those studies and in practice generally, does not allow the Council to specify with confidence a duration of exposure that causes asbestosis.
9. Therefore, the Council was unable to recommend changes to the duration of employment as used for asbestos exposure in the SoPs, but suggests that the RMA considers the SMSE pertinent to current methods of optimally assessing occupational exposure to asbestos.
10. The Council discussed the possibility of obtaining concentrations of asbestos fibres in the air specific to Australian military work environments. Obtaining actual asbestos fibre measurements from past and current naval vessels and other military work environments may allow these measurements to be used in the future to build a job matrix specific to Australian conditions.

## COUNCIL’S CONCLUSIONS ON THE SOUND MEDICAL-SCIENTIFIC EVIDENCE RELEVANT TO THE APPLICANT’S CONTENTIONS

1. While the Council evaluated the SMSE relevant to the Applicant’s contentions. The Council placed particular weight on the articles discussed above (see **Appendix A. Table A1 and Table A2**) that provided specific results data for:
2. Pleural Plaques and Asbestos bodies;
3. The duration of asbestos exposure; and
4. The completeness of the information the RMA sent to the Council.

### Pleural Plaques and Asbestos Bodies

1. The Council’s summary of its consideration of relevant SMSE concerning pleural plaques and asbestos bodies is at [54]. Asbestos bodies or pleural plaques are markers of asbestos exposure, but do not equate to a diagnosis of asbestosis.
2. The Council considered all of the SMSE and its view was that the relevant SMSE fell short of indicating the existence of a reasonable hypothesis regarding the contended exposure to asbestos and the presence of pleural plaques and asbestos bodies alone as definite evidence of FILD or Asbestosis. That is, the SMSE was insufficient to justify an amendment to either of the reasonable hypothesis SoPs.
3. Accordingly, the Council’s view was that the SMSE was also insufficient to justify an amendment to either of the SoPs on the balance of probabilities.

### The Duration of Asbestos Exposure in the Statements of Principles

1. The Council’s summary of its consideration of the relevant SMSE concerning the duration of asbestos exposure is at [83] to [96].
2. A cumulative period of hours is not used in current SMSE as a measure of dose. In the absence of a job exposure matrix for military personnel it is difficult to accurately estimate cumulative fibre exposure. The Council recommends that a job exposure matrix for military personnel would be useful, based upon measured time weighted averages of exposure in actual settings, and accurate military records of jobs and tasks and their durations.
3. The Council, having considered all of the relevant SMSE formed the view that changing the duration of exposure to asbestos as expressed in the SoPs, to an alternative scientific measure or in any other way, was not justifiable for either the RH or BoP tests. That is, the SMSE was insufficient to justify an amendment to either of the reasonable hypothesis or balance of probabilities SoPs. Hence the Council made the declaration at [1] to [4].

### Council’s View on Whether the Information Gathered by the Repatriation Medical Authority was Complete

1. The Council’s summary of its consideration of the relevant SMSE concerning new information in relation to:
   * 1. pleural plaques is at [54] to [56];
     2. diffuse pleural thickening is at [54] to [56]; and
     3. duration of exposure is at [65] to [66].

and can be found in the following ‘New Information’.

### New Information

1. The status of the information discussed below is 'new information', that is, information that was not available to (not before) the RMA. Accordingly, it the Council did not take it into account for the purposes of the review.
2. Rather, the Council has considered the new information to determine whether, in the Council's view, it warrants the Council making any directions or recommendations to the RMA.
3. In the Council's view any such direction or recommendation should only be made by the Council if it formed the view that the new information:

* comprised sound medical-scientific evidence as defined in section 5AB(2) of the VEA being information which:
  + epidemiologists would consider appropriate to take into account; and
  + in the Council's view, 'touches on' (is relevant to) any contended factor and has been evaluated by the Council according to epidemiological criteria, including the Bradford Hill criteria; and
  + could potentially satisfy the reasonable hypothesis and/or balance of probabilities tests.

### New Information Submitted by the Applicant

1. The Council noted the Applicant’s references to and submissions concerning information not available to (not before) the RMA (see **Appendix A: Table A4**). The Council considered this information carefully. While some of the information may be considered relevant SMSE, this information did not allow a complete evaluation of the contended matters nor allow a practical method for amendment for the current SoPs on:
2. Pleural Plaques and Asbestos bodies being sufficient evidence of FILD or Asbestosis; and
3. Asbestos exposure duration in the current factors.

The Council noted and acknowledges that a number of the new information articles submitted by the Applicant concerned the process of inflammation and or wound healing as part of pulmonary healing and the development of fibrosis. The Council considered these papers, but they did not change its view about the role of pleural plaques and asbestos bodies, or asbestos exposure duration.

1. While the Council did not undertake a comprehensive analysis of any of the new information it noted the following study which was relied on by the Applicant.
   * + - 1. Gaensler et al [[275]](#footnote-275) studied lung tissue samples of 176 people exposed to asbestos. Nine had the clinical features of asbestosis but histologic sections failed to demonstrate the presence of asbestos bodies. These nine were compared by analytic electron microscopy with nine persons with idiopathic pulmonary fibrosis (Group 2), and with nine persons with all the criteria of asbestosis (Group 3). The authors concluded that it is sometimes difficult to define American Thoracic Society criterion of a reliable history of asbestos exposure. The authors also stated that:

… asbestos bodies are seen in tissue sections only when exposure has been reasonably high, and given the proper clinical setting, the presence of diffuse fibrosis and asbestos bodies in tissue sections are sensitive and specific criteria for a diagnosis of asbestosis.(at abstract)

The Council acknowledges the low sensitivity of asbestos bodies in histological sections of lung when examined by light microscopy. The finding of asbestos bodies alone is not sufficient for a histologic diagnosis of asbestosis and the Asbestos Committee recommends that such a diagnosis should only be made when there is an average rate of 2/cm2 of lung in conjunction with an acceptable pattern of alveolar septal fibrosis.[[276]](#footnote-276) Electron microscopic studies are reported to be more sensitive in this regard and also allow differentiation of fibre type. However, lung tissue samples are rarely available and the Council would not recommend that these be obtained solely for the purposes of compensation. High resolution CT scanning is a practical surrogate, and if performed using the recommended technique,[[277]](#footnote-277) is an adequate the recommended method for the diagnosis of asbestosis when taken in conjunction with the occupational exposure history.

### New Information Identified by the Council

1. The Council identified information not available to (not before) the RMA, which it considered was likely to be relevant SMSE (see **Appendix A: Table A4**).
2. While the Council did not undertake a comprehensive analysis of any of the new information it noted the following:

#### Diffuse Pleural Thickening

1. Selikoff et al[[278]](#footnote-278) examined insulation workers, where much of their work was in open air aboard ship, in tight quarters with poor ventilation. The study found 48.5% had asbestosis seen on X-ray, and a correlation between years of onset of exposure and increase in the development of asbestosis. Examination of lung tissue from 45 asbestos insulation workers, there were no case that the authors fail to find typical pulmonary asbestosis, with fibrosis and asbestos bodies present.
2. Miles et al[[279]](#footnote-279) conducted a comprehensive review of the clinical consequences of asbestos-related diffuse pleural thickening. This review has been used in the body of this document (see [39]).

#### Pleural Plaques

1. IACC Position Paper 23[[280]](#footnote-280) reported the evidence of pleural plaques, including prevalence, occupational causation, likelihood of disability, and if it should be a compensated disease. Based on the evidence, the IACC recommended against including pleural plaques as a compensated disease under the Industrial Injuries Disablement Benefit Scheme.

#### Asbestosis

1. Park et al[[281]](#footnote-281) studied lung function measurements in men with asbestosis; diffuse pleural thickening; asbestosis and diffuse pleural thickening; pleural plaques only; and healthy individuals with a history of asbestos exposure. The study showed the presence of asbestos-related diseases lowered lung function measurements compared to healthy individuals exposed to asbestos, with significant differences between asbestos-related diseases.
2. Harries[[282]](#footnote-282) conducted a comparison of mass and fibre concentrations of asbestos dust produced during shipbuilding and refitting in the British Naval Dockyards. This study shows that there is some correlation between mass and fibre concentrations in stripping processes with higher dust levels, but that there is no correlation between the dust indices at lower concentrations. Comparison of the results of measuring total dust, 'respirable' dust, and fibre concentration show that gravimetric measurements although simpler and quicker are not suitable for environmental monitoring in Naval Dockyards and the membrane filter technique is recommended for estimating fibre concentration. This study provided fibre concentration measurements and showed high concentration of asbestos fibre levels associated with removal of sprayed crocidolite asbestos, removal of pipe lagging in particular in brick stowage space, and the application of pipe lagging-boiler rooms in the Naval Dockyards. The fibre concentrations measured in this study are likely not relevant to current conditions including those in the Australian military setting.
3. Harries[[283]](#footnote-283) conducted a survey of asbestos fibres associated with working with asbestos insulating materials in ships being refitted in British Naval Dockyards. The membrane filter method of sampling and evaluation was used, and samples were also taken in other areas of the Dockyards. Very high concentrations of asbestos were recorded. This study showed there was widespread dispersion of high concentrations of asbestos dust throughout the ship, in particular, in areas of the ship which were not considered to be affected, unknowingly exposing men without respiratory protection to high concentrations of asbestos. The authors concluded that all processes involving work with asbestos insulating materials in Naval Dockyards give rise to asbestos dust concentrations of >2 fibre/mL, with many processes with dust concentrations of ≥50 fibre/mL. This study demonstrate that naval personnel working on the Dockyards were exposed to high concentration of asbestos, and in particular men working in small enclosed spaces were exposed to high levels of asbestos fibres.

#### Fibrosing Interstitial Lung Disease

1. Kawabata et al[[284]](#footnote-284) retrospectively examined 1718 cases (1202 men) who underwent lobectomy for resection of pleuro pulmonary tumours. The presence of malignant pleural mesothelioma, pleural plaques, and asbestos bodies in the histological specimen were used as objective markers for asbestos exposure. Two groups were studied. Group 1 = 183 cases with asbestos exposure had higher rates of positive occupational history and histological usual interstitial pneumonia (31%) than the remaining 1535, and a small numbers of asbestos bodies were found in histological specimens of 21 cases of histological usual interstitial pneumonia. Group 2 = 239 with histological usual interstitial pneumonia, pleural plaques and asbestos bodies were more frequent than the remaining 1479 of cases without histological usual interstitial pneumonia. The authors concluded asbestos exposure causes asbestosis and increases the incidence of histological usual interstitial pneumonia.
2. Copley et al[[285]](#footnote-285) studied the differences in thin-section CT features between asbestosis and idiopathic pulmonary fibrosis and tested the findings in a subset of histopathologically proved cases of usual interstitial pneumonia and nonspecific interstitial pneumonia. Consecutive patients with a diagnosis of idiopathic pulmonary fibrosis (*n* = 212) or asbestosis (*n* = 74) were included. The relationships derived from the initial comparison were tested in a separate group of biopsy-proved usual interstitial pneumonia (*n* = 30) and nonspecific interstitial pneumonia (*n* = 23) cases. The study showed those for the 212 people with idiopathic pulmonary fibrosis,fibrosis was present in all cases (*n* = 212); emphysema in 76 cases (36%); diffuse pleural thickening in 4 cases (2%) and pleural plaques were absent in all cases. For the 74 asbestosis cases, fibrosis was present in all cases (*n* = 74); emphysema in 25 cases (34%); pleural plaques in 58 cases (78%); and diffuse pleural thickening in 61 cases (82%). Both pleural thickening and pleural plaques were present for 49 cases (*n* = 49/74; 66%) and four patients (5%) had had no pleural disease. Fibrosis was more extensive in the idiopathic pulmonary fibrosis group (55%; range 5%–96%) than in the asbestosis group (26%; range 0.5%–90.5%) (*p*<.001). The study findings indicate that asbestosis closely resembles usual interstitial pneumonia but is strikingly different from nonspecific interstitial pneumonia. As patients with asbestosis had a coarser pattern of fibrosis than did the subgroup of patients with histopathologically proved nonspecific interstitial pneumonia. There was no statistically significant difference in coarseness between the asbestosis and biopsy-proved usual interstitial pneumonia groups.

#### Job Matrix

1. van Oyen et al[[286]](#footnote-286) developed a job-exposure matrix (JEM) to estimate occupational asbestos exposure levels in Australia (other than Wittenoom mine) since 1943 using all relevant and available data. The data included exposure measurements from 57 industries and 89 occupations from 1937 to 2007 in Australia, as well as records from overseas. Exposure measurements also included occupations within the armed forces.[[287]](#footnote-287) Intensity of exposure was assigned in five categories, based on the mid-point of five exposure ranges according to the Australian Standard for asbestos exposure 0.1 fibre/mL and expressed as a TWA for an 8 hour working day. Frequency of exposure was assigned over a working year of 240 days assuming 4 weeks holidays. A total of 537 combinations of 224 occupations and 60 industries with potential exposure to asbestos (mostly a mixture of asbestos varieties) were identified. The authors reported that asbestos workers, insulators, waterside workers (including shipyard, wharf, navy, and marine), carpenters/joiners, boilermakers / welders, power supply, and railway workers were estimated to have experienced the highest levels of occupational asbestos exposure. The JEM can provide a quantified estimate of asbestos exposure for any individual with a history of having worked in Australia, based on knowledge of the person’s occupation, the industry or location, year started working, and time spent (in months or years) or year finished. Thereby summing the exposure estimates for each year, an estimate of the cumulative asbestos exposure that an individual has experienced over their working life in Australia is calculated.Ideally, direct comparison of JEMs with lung asbestos fibre counts is required for validation of this matrix.
2. Hyland et al [[288]](#footnote-288) developed an asbestos specific task exposure matrix (ASTEM) based on quantitative measurements from historical workplace reports in NSW, using asbestos dust exposure measurements (fibre/mL) taken during workplace inspections in the 1970s and 1980s. Exposure was calculated by using the proportion of time spent on each task multiplied by the ASTEM value for each task and product combination. All resulting values were added to provide a cumulative asbestos exposure for a worker in fibre/mL-years. An asbestos task exposure matrix was created using 19 task-product combinations chosen for the matrix, the matrix was task-based rather than full shift TWA measurements primarily due to a lack of TWA data.
3. Macfarlane et al[[289]](#footnote-289) provided an overview of asbestos exposure in the Australian population, and described how the OccIDEAS exposure assessment tool is being adapted for use in the Australian Mesothelioma Registry to retrospectively assess asbestos exposure among mesothelioma cases. Within OccIDEAS a participant’s full job history is entered based on his job history, a job-specific questionnaires (known as job specific module) to jobs which potentially involve exposure to asbestos is assigned. A structured interview (usually by telephone) is conducted with the participant, and the interviewer records the answers to the job specific module questions in OccIDEAS. Twelve job specific modules have been developed specifically for assessing asbestos exposure, and have been developed to cover all job categories likely to be reported and which have possible asbestos exposure in the Australian context.
4. The Council’s view is that the above new information is likely to be relevant, should the RMA decide to conduct any future investigation concerning FILD and Asbestosis. The Council is of the view that the new information, particularly the job matrix papers by van Oyen et al, [[290]](#footnote-290) Hyland et al, [[291]](#footnote-291) and Macfarlane et al[[292]](#footnote-292) are valuable papers, especially as they refer specifically to the Australian context. Hence the Council made the declaration at [5].



Specialist Medical Review Council

**Declaration and Reasons for Decisions**

*Section 196W  
Veterans’ Entitlements Act 1986*

**Re: Statements of Principles Nos. 53 and 54 of 2013**

**concerning fibrosing interstitial lung disease and**

**Statements of Principles Nos. 55 and 56 of 2013**

**concerning asbestosis**

Request for Review Declaration Nos. 27 and 28

**APPENDICES**

|  |  |
| --- | --- |
| **Appendix A** | Tables Outlining the Sound Medical Scientific Evidence  Table A1. Overview of 12 Papers Reporting Asbestos Cumulative Exposure Levels  Table A2. Overview of 36 Papers Relevant to Low Level Exposure to Asbestos for Asbestosis  Table A3. List of Medical Science Cited in the RMA Briefing Papers  Table A4. New Information Identified by the Council and/ or the Applicant  Table A5. New Information Identified by the Council on Diffuse Pleural Thickening |
| **Appendix B** | The constituted council and legislative framework of the review |
| **Appendix C** | Written and oral submissions |
| **Appendix D** | The Available Information, sent to the Council by the RMA under section 196K. |

###### APPENDIX A: TABLES OUTLINING THE SOUND MEDICAL EVIDENCE

Table A1. Overview of 12 Papers Reporting Asbestos Cumulative Exposure Levels Associated with Producing Asbestosis (Ordered from Lowest to Highest Exposure Level)

| **Original Study Author (RMA ID)**  ***Or* Review of that Study** | **RMA  ID *Or* Review Author (RMA ID)** | **Title** | **Subjects** | **Type of  Exposure** | **Level of  Exposure  (fibre/mL-year)** | **Exposure Assessment Method** | **Duration of Exposure  (year)** | **Outcome: Study/Review with asbestos exposure producing Asbestosis; then Other Studies & Reviews** | **Comparison of the Studies Dose to that of the Asbestosis SoPs** |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Sluis-Cremer (1990)[[293]](#endnote-1) | Cited by: Sluis-Cremer (1991)[[294]](#endnote-2) RMA ID: 000440 | Evidence for an Amphibole Asbestos Threshold Exposure for Asbestosis Assessed by Autopsy in South African Asbestos Miners | 807 miners (100% men) who had autopsies to determine presence of pneumoconiosis  411= asbestosis deaths  No smoking history | Amphibole  mine (crocidolite; chrysotile workers excluded)  Also exposure to silica and gold in mines  Also likely environmental exposures near mills and mine dumps | Cumulative exposure: *N*=807; *M*=176.5 (*SD*=307.8) fibre/mL-year  ≤1 (*n*=33) >1-2 (*n*=29)  >2-5 (*n*=64)  >5-10 (*n*=73) >10-20 (*n*=68) >20-50 (*n*=105) >50-200 (*n*=125)  >200-300 (*n*=175)  >300 (*n*=135) fibre/mL-year | Fibre concentration methods used:  1940-1965 Konimeters  1965-1975 Thermal Precipitator  1975-current Membrane Filter Method.  Different fibre lengths and ratios for different time periods  Chronological exposure was calculated using mean mine graph for time exposed and weighing the exposure by occupation | Duration of exposure: *N*=807; *M*=30.4 (*SD*=14.0) years  ≤15 years  (*n*=111)  16-30 years  (*n*=338)  31-45 years  (*n*=232)  45+ years (*n*=126) | **Post-mortem study reporting asbestos exposure producing asbestosis**  Risk of asbestosis at cumulative exposures >2-5 fibre/mL-years (1 death at ≤15 years and 3 deaths at 16-30 years of exposure).  Asbestosis increased with cumulative exposures fibre/mL-year and number of years since the onset of exposure. Cumulative exposure >300 fibre/mL-years and ≥45 years since the onset of exposure 82% (*n*=64/78) of the workers had asbestosis  Author’s conclusion: incidence of asbestosis at increasing average fibre levels and increasing duration of exposure times. When exposure was expressed as fibre/mL-years no asbestosis was found at autopsy when exposure was <2 fibre/mL-years, even after 31-45 years of residence time. In the group exposed to >2-5 fibre/mL-years asbestosis was found (4 deaths). If a threshold dose for asbestosis does exist it is at approximately 2 fibre/mL if off-shift exposure is ignored. No threshold demonstrated. | Asbestos exposure producing asbestosis seen at >2-5 fibre/mL-years |
| Hein et al (2007)[[295]](#endnote-3) | RMA ID: 067597 | Follow-up Study of Chrysotile Textile Workers: Cohort Mortality and Exposure-Response | 3072 textile plant workers (59% men)  36=asbestosis deaths (1960- 2001)  No smoking history | South Carolina chrysotile asbestos textile plant  Small amounts of crocidolite from South Africa | Cumulative exposure: *N*=3072; Median=5.5 (range=0.1-699.8) fibre/mL-year | Fibre concentration method used: statistical modelling of nearly 6000 industrial hygiene samples taken over the period 1930-1975 and analysed using Phase Contrast Microscopy.  Specific job matrix used to calculate job exposure. Each day in the work history was assigned an exposure level based on the job exposure matrix and cumulative exposure was defined as the sum of the assigned exposure concentrations over all days worked. | Duration of employment: *N*=3072; median=1.1 (range=0.1–46.8) years | **Mortality study of chrysotile exposure and cause of death as indicated within the National Death Index**  36 asbestosis deaths (US expected deaths = 0.15; SMR=232.5; 95%CI: 162.8, 321.9; *p*<0.01) (South Carolina expected deaths =0.33; SMR=108.2, 95%CI: 75.8, 149.8). Mortality analysis (observed pneumoconiosis and other respiratory diseases deaths=85, asbestosis=42) showed increasing trends in pneumoconiosis SMRs with increasing cumulative exposure were observed overall from 3-<16 fibre/mL-years (SMR 2.43; (1.33-4.08). Asbestosis mortality (observed deaths=62) showed statistically significant interaction between cumulative exposure and age category was observed (*p*=0.026).  Author’s conclusion: association between estimated chrysotile exposure and mortality from asbestosis observed in previous updates of this cohort were confirmed with the addition of 11 years of follow-up. Cumulative exposure was positively and significantly associated with asbestosis mortality. Modelled exposure-response relationship showed no threshold for development of asbestosis. | Asbestos exposure producing pneumoconiosis seen at 3-<16 fibre/mL-years |
| Ehrlich et al (1992)[[296]](#endnote-4) | RMA ID: 034901 | Long Term Radiological Effects of Short Term Exposure to Amosite Asbestos Among Factory Workers | Subset of 386 factory workers (100% men) with less than one year of exposure and low cumulative exposure (<25 fibre/mL-year)  238 had serial X-rays  Smoking history available | Amosite asbestos factory  (Imported from South Africa; very small amounts of chrysotile used at one time)  Also residential exposure | 5 -120 fibre/mL (>5*µ*m long)  Cumulative exposure: *n*=386; Median=25.1 (range=0.1 -720) fibre/mL-year  Exposure concentration: *M*=51.8 (*SD*=25) fibre/mL | Fibre concentration method used: Membrane Filter Method (1968 and 1971).  Average fibre counts for each job title were estimated from measurements carried out at two other plants operated by the company after 1954; one in Tyler, Texas and another in Port Allegheny, Pennsylvania. | Duration of exposure: Median=0.5;6 months (range=0.1-13) years | **Radiological study reporting effect of short term amosite exposure producing parenchymal and pleural abnormalities.**  Parenchymal abnormality (profusion >1/0 ) >20 years from first employment by cumulative exposure (fibre/mL-year): <5 fibre/mL-year: *n*=85,10(12%)= abnormal  5.1-25 fibre/mL-year: *n*=87, 12(14%)= abnormal  25.1-125 fibre/mL-year: *n*=119, 30(25%)= abnormal  >125 fibre/mL-year: *n*=49,29(59%)= abnormal  Pleural abnormality (any pleural thickening of the cheat wall or diaphragm): Time from first employment (decade) by R1: OR=1.67 95%CI: 1.15, 2.42; *p*=0.007. R2: OR=1.85 95%CI: 1.24, 2.76; *p*=0.002  Cumulative exposure (≤ 5 fibre/mL-years) showed a significant rate of abnormality (R1: 23%; R2:17%) and the prevalence of abnormality increased with increasing cumulative exposure  Risk of developing small parenchymal opacities for an increment in cumulative exposure of 10 fibre/mL-years (R1: OR:1.06; 95% CI: 1 04, 1.09; *p*=0.000 and R2: OR:1 07; 95% CI: 1 04, 1.10; *p*=0.000)  Author’s conclusion: exposure to high concentrations of amosite with follow up for ≥20 years, no cumulative exposure threshold for parenchymal and pleural fibrosis detected, and parenchymal and pleural progression were still detectable >20 years after the end of exposure. Exposure for ≥1 month was sufficient to produce radiological signs of parenchymal and pleural fibrosis. Those in the lowest cumulative exposure stratum <5 fibre/mL-years were found to have high rates of abnormality. Increase in risk of parenchymal abnormality of 6-7% for each fibre/ml-years. | Asbestos exposure producing parenchymal abnormality seen at <5 fibre/mL-years |
| Larson et al (2010)[[297]](#endnote-5) | RMA ID: 067598 | Vermiculite Worker Mortality: Estimated Effects of Occupational Exposure  to Libby Amphibole | 1862 mine and process workers  69=asbestosis deaths  No smoking history | Vermiculite mining and processing operation  (tremolite and actinolite, winchite and richterite) | Cumulative exposure: *N*=1862; Median=4.3  (range=0.8-22.5) fibre/mL-year  Cumulative exposure -asbestosis: *n*=69; Median=39.0 (25th-75th percentile =14.6-283.2) fibre/mL-year | Fibre concentration method used:  Historical air sampling data were used to estimate the 8-hour time-weighted average (TWA) fibre exposure. The proportion of each day spent at each location was calculated for each job title, and an 8-hour TWA exposure was estimated for each job at a given time. The lifetime cumulative fibre exposure for each worker was obtained by summing the cumulative fibre exposure for each job that worker held.  Before 1967 samples collected using midget impinger and later samples using a membrane filter. Conversion factors used to convert between the two and 8 hr TWAs calculated. | Duration of exposure: *N*=1862; Median=0.8  (25th-75th percentile 0.1-4.1 years)  Duration of exposure -asbestosis: *n*=69; Median=10.4 (25th-75th percentile 1.2–19.5) years | **Retrospective cohort mortality study**  Significantly elevated SMR for deaths from asbestosis =69 (expected=0.5; SMR=142.8; 95%CI:111.1,180.8)  Workers who died from asbestosis had a much greater median lifetime cumulative fibre exposure (39.0 fibre/mL-year compared with 2.4 fibre/mL-year for censored (or alive) workers) and median length of employment (10.4 years compared to 0.8 years for censored (alive) workers)  Cox models for death from asbestosis were statistically significant (with no lag and 20-year lag) for increase in the hazard of mortality, indicating <1% increase in the hazard of mortality with each additional fibre/mL-years of exposure (i.e. 1 fibre/mL-years) Relative risks (RRs) showed an increased RR with cumulative exposure, which did not become statistically significant for asbestosis until the 3rd quartile. Cumulative fibre exposure (20 year lag) showed statistically significant risk from 8.6 to <44.0 fibre/mL-year (*n*=25; RR=8.0, 95%CI: 3.2, 19.5) and ≥44.0 fibre/mL-year (*n*= 32, RR= 11.8, 95%CI: 4.9, 28.7)  Authors conclusion: statistically significant association from 8.6 fibre/mL- year for deaths from asbestosis with significantly elevated SMR=142.8 for asbestosis. | Asbestos exposure producing asbestosis seen at 8.6 to <44.0 fibre/mL- years |
| Green et al (1997)[[298]](#endnote-6) | RMA ID: 026469 | Exposure and Mineralogical Correlates of Pulmonary Fibrosis in Chrysotile Asbestos Workers | 54 asbestos workers necropsy reports (lung tissue for 39 workers) (44=men, 10=women)  34 controls necropsy reports (lung tissue for 31 workers) (22=men, 12=women)  Fibre counts performed on 39 former textile workers and 31 controls.  NB: small numbers  Incomplete smoking history available | Chrysotile asbestos textile plant  Raw asbestos predominantly from Quebec with small amounts from BC and Zimbabwe; small amounts of crocidolite yarn woven but never carded, spun or twisted. | Cumulative exposure: *N*=54; Median=30.2 (range=0.1-370.0) fibre/mL-year  Men had larger cumulative exposures than women 34.6 and 25.6 median fibre/mL-year respectively | Exposure assessment method used (published previously): Linear statistical models for reconstructing historic dust exposure levels, taking into account textile processes, dust control measures, and job were developed. Estimates used 5,952 industrial hygiene samples from 1930-1975. Individual exposure data were not available for each worker in the cohort; estimates of exposure by job category at the plant were required. Both the exposure zone concept and the uniform task concept were used to develop exposure models which used historic plant production, control, and exposure data to estimate exposure by job and calendar period. Cumulative lifetime TWA exposure for each worker was calculated by multiplying estimates of exposure for each job held by the time spent in each job and was expressed as fibre-year. | Duration of employment: *N*=54; range=0.1- >27.3 years  Latency: Median=30.0 (range=17-44) years | **Case- control study examining relationship between chrysotile exposure and pulmonary fibrosis in a South Carolina textile plant**  Asbestosis was usually present in asbestos textile workers with >20 fibre/mL-year cumulative exposure  Median fibrosis scores were greater in the asbestos workers than in the control population for **all** levels of exposure significant (*p*< 0.001) for exposure 7.2-36.5 fibre/mL-year- Chrysotile median 37.6 & tremolite median 5.0 asbestos fibre x106 dry lung *p*<0.05  36.6-109.5 fibre/mL-year Chrysotile median 30.8 & Tremolite median 6.4 asbestos fibre x106 dry lung *p*<0.05  109.5-370 fibre/mL-year Chrysotile median 104.5 & Tremolite median 27.8 asbestos fibre x106 dry lung *p*<0.05  Not significant for 0.1-7.1 fibre-years.  Author’s conclusion: Both cumulative exposures to asbestos and lung fibre burden were strongly correlated with severity of asbestosis. Lack of statistical power in the study was largely due to the small number of cases with low and intermediate levels of exposure, making it not possible to detect a threshold dose for the development of asbestosis. Asbestosis of grade 2 severity or more was consistently found in workers with lifetime cumulative exposures in excess of 20 fibre/mL-year and in three cases with exposures ranging from 10-20 fibre/mL-year  Authors’ conclusion: histologic asbestosis was usually detectable with exposures of >20 fibre/mL-year and a few cases were found with estimated cumulative exposures of 10-20 fibre/mL-year. | Asbestos exposure producing asbestosis seen at 10-20 fibre/mL-years |
| McDonald et al (2004)[[299]](#endnote-7) | Cited by: Antao et al (2012)[[300]](#endnote-8) RMA ID: 068460 | Mortality in a Cohort of Vermiculite Miners Exposed to Fibrous Amphibole in Libby, Montana | 406 mine workers (100% men) with net service of at least 1 year before 1.1.63  285=deaths  51=non-malignant respiratory disease deaths  No smoking history | Vermiculite mine/mill | Exposure Concentration: *M*=18 fibre/mL | Fibre concentration method used:  Standard Optical Microscope Measurements were scanty and, until about 1970, by Midget Impinger method only. After 1970 Membrane Filter Method was used.  Estimating cumulative exposures was to take the maximum advantage of existing air measurements and to concentrate efforts on the past dry mill period (before 1975) when substantial exposures occurred. Altogether, results of 1363 air measurements were available for the period before1975.  Used job descriptions to estimate for each job the duration and the number of hours spent by workers in different operation locations; the cumulative exposure was  then calculated | Duration of exposure: *M*=9 years | **Cohort mortality study reporting deaths in vermiculite miners from Libby, Montana**  Non-malignant respiratory disease associated with cumulative exposure: SMR=3.09 (95% Cl: 2.30, 4.06). Non-malignant respiratory disease (*n*=51): Cumulative exposure of 11.7- (16.7) fibre/mL-year (deaths=13, expected death =3.7; RR=2.53; 95%CI: 0.88, 7.24)  Cumulative exposure at 25.2- (53.2) fibre/mL-year (deaths=14, expected deaths=3.8; RR=2.62 (95%CI: 0.93, 7.27). Cumulative exposure at 113.8- (393.8) fibre/mL-year (deaths=19, expected deaths=4.1; RR=3.11; 95% CI: 1.15, 8.44). Linear model (per 100 fibre/mL-year) RR=0.38 (95%CI: 0.12, 0.96; *p*=0.0001)  Author’s conclusion: a statistically significant linear trend between exposure and deaths from non-malignant respiratory disease. The all-cause linear model would imply a 14% increase in mortality for mine workers exposed occupationally to 100 fibre/mL-year or about 3.2% for a general population exposed for 50 years to an ambient concentration of 0.1 fibre/mL – not insignificant impact. | Asbestos exposure producing non-malignant respiratory disease seen at 11.7 fibre/mL-year |
| Rohs et al (2008)[[301]](#endnote-9) | RMA ID: 067995 | Low-Level Fiber-Induced Radiographic Changes Caused by Libby Vermiculite. A 25-Year Follow-up Study  (Chest radiographic changes only) | 280 mine workers of the original 513 cohort (94.3% men)  80=pleural changes (68=localised pleural plaques 12=diffuse pleural thickening, 28.7%)  8=Interstitial changes (irregular opacities, profusion of ≥1/0; 2.9%)  NB. Small numbers of workers with interstitial changes (*n*=8)  Smoking history available | Vermiculite mine/mill | Cumulative exposure: *N*=280 *M*=2.48 (*SD*=4.19; range=0.01-19.03) fibre/mL-year  Cumulative exposure - Interstitial changes (*n*=8): *M*= 11.86 (*SD*=6.46) fibre/mL-year  All 8 with interstitial changes occurred at the 72% or greater maximum cumulative fibre exposure range, 6 occurring at the 90% or greater range. | Fibre concentration method used:  Membrane filters method since 1972.  Cumulative fibre exposure was calculated using the 8-hour TWA by the number of years at the TWA summed overall years according to department. Due to new environmental controls, there was a decrease in fibre exposure after 1973. Therefore, each department was assigned two values, fibre exposures through 1973 and exposures after 1973. Individuals were assigned a cumulative fibre exposure value, which was the summation of estimated fibre exposure by department, based on the years employed between 1963 and 1980. | Duration of exposure: N=280 based on hire date  Hired on or before 1973  *n* =186  Hired after 1973  *n*= 94 | **Radiographic study reporting vermiculite - induced interstitial change and pleural changes in a cohort of vermiculite workers**  Significant increase seen in the follow-up in pleural changes: 2.0% in the 1980 study to 28.7% in 2005. Interstitial changes: 0.2% in 1980 to 2.9% in 2005  Pleural changes directly related to cumulative fibre exposure, greatest prevalence (54.3%) in the highest exposure quartile (range=2.21-19.03 fibre/mL-year) of workers  Pleural changes can occur at low lifetime cumulative fibre exposure levels as demonstrated by the 12% prevalence within participants and living non participants with <1.92 fibre/ mL-years cumulative fibre exposure, and 20% prevalence within participants with <2.21 fibre/mL-year cumulative exposure  2.9% of participants had interstitial changes and were significantly related to cumulative fibre exposure mean exposure of 11.37 fibre/mL-year  Author’s conclusion: exposures to asbestos among users of Libby vermiculite ore within an industrial process cause pleural thickening at low lifetime cumulative fibre exposure levels of <2.21 fibre/mL-year. | Asbestos exposure producing interstitial changes seen at 11.37 fibre/mL-year |
| Paris et al (2004)[[302]](#endnote-10) | RMA ID: 067600 | Factors Associated with Early-Stage Pulmonary Fibrosis as Determined by High-Resolution Computed Tomography Among Persons Occupationally Exposed to Asbestos | 706 retired workers exposed to asbestos (89% men)  51=pulmonary fibrosis (grade 2- bilateral interstitial abnormalities limited in extent but consistent with asbestos-related pulmonary fibrosis or grade 3-profuse bilateral interstitial abnormalities visible on several slices) diagnosed by HRCT (only 38 diagnosed asbestosis - small opacity profusion of ≥1/1 according to American Thoracic Society criteriab)  Excluded those with known asbestos-related diseases  Aims of study were to clarify group suitable for screening by HRCT  Variable asbestos exposure although the main exposure types unclear  Smoking history available | Asbestos textile and friction material factory, shipyards, fossil fuel power stations, and industrial insulation | Cumulative exposure: *N=706; M*=137.9 (*SD* =136.4) fibre/mL-year  112 participants (16%)=<25 fibre/mL-year Only 2 subjects with HRCT pulmonary fibrosis exposed to <25 fibre/mL-year (9.3 and 15 fibre/mL-year respectively)  52 participants with <25 fibre/mL-year had no symptoms or abnormal examinations no case of HRCT asbestosis detected. 60 participants with <25 fibre/mL-year, 2 cases were detected, both having basilar crackles and one having small irregular opacities on X-ray | Fibre concentration method used: For the participants who had worked in the asbestos textile and friction material plant a specific job-exposure matrix determined from air-borne samples collected annually between 1959 and 1999 in the various workshops of the plant.  For all the other participants, the asbestos exposure level associated with each job was assessed using published airborne measurements available in the French database  Cumulative-exposure index was then calculated by summing the values for all job positions held, with reference to the occupational calendar established in the interview, the products of the job exposure level (in fibre/mL) by job duration (in years).  Dust measurements performed in numerous points of the workshops: Membrane Filter Method since 1973: phase-contrast light microscopy counts of fibres performed by an accredited laboratory between 1960–1974, samples were collected on Soluble Filters by an AvyRaille`re-Martin (ARM) type of apparatus, and the light microscopy fibre counts  Measurements were performed by a specialised independent laboratory as no atmospheric measurements were available for the period before 1960. | Duration of exposure: *N=706; M*=24.9 (*SD*=9.1) years | **Radiological study reporting relationship between asbestos exposure and HRCT findings**  There were 51 pulmonary fibrosis (grade 2 or 3; different scoring system to ILO) diagnosed by HRCT. Only 38 diagnosed with pulmonary fibrosis according to American Thoracic Society criteriab, 9 which were diagnosed by HRCT  For 112 participants the cumulative exposure level was <25 fibre/mL-year of which 2 subjects had HRCT asbestosis  Significant association between HRCT fibrosis and cumulative asbestos exposure, with a clear dose-response relationship for 25-99.9 fibre/mL-year (OR=3.4; 95% Cl: 0.8, 15.2; *p*>0.05) and≥100 fibre/mL-year (OR=6.1; 95% Cl: 1.5, 25.9) in comparison with ≤25 fibre/mL-year (Trend test *p* =0.002) but not with duration of exposure (Trend test *p*=0.791).  Author’s conclusions: significant association between HRCT fibrosis and cumulative asbestos exposure, with a clear dose-response relationship. Only 2 cases of HRCT pulmonary fibrosis (2%) among the 112 patients with a cumulative fibre exposure of <25 fibre/mL -years. HRCT can detect early-stage asbestosis in people who have been highly exposed to asbestos and whose X-ray can be considered normal. HRCT screening does not seem warranted for people with low occupational exposure such as cumulative exposure level <25 fibre/mL-year, especially in the absence of other asbestosis-related alterations. | Asbestos exposure producing asbestosis seen at 25-99.9 fibre/mL-year |
| Sullivan (2007)[[303]](#endnote-11) | RMA ID: 045641 | Vermiculite, Respiratory Disease, and Asbestos Exposure In Libby, Montana: Update of a Cohort Mortality Study | 1672 mine and mill workers (all men)  40=asbestosis deaths 22=asbestosis deaths  Followed May 1982-Dec 2002  No smoking history | Vermiculite mine/mill  Miners, millers and processors | Cumulative exposure: *N*=1672; Median=8.7 fibre/mL-year  All deaths: *n*=767; Median= 21.0 fibre/mL-year  Asbestosis: *n*=40; Median=228.4 fibre/mL-year (worked <1year =36.2 fibre/mL-year and worked ≥1 year =244.8 fibre/mL-year | Fibre concentration method used: Job-exposure matrix exposure index available for this and previous studies of Libby workers is based on fibre count data obtained using Optical Phase Contrast Microscopy of all asbestiform fibres, of which 6% were estimated to be tremolite | Duration of exposure: *N*=1672; *M*=4.0 (range=1day -43.1) years  Asbestosis deaths: *n*=40 (5.3% of cohort); mean duration of employment in those with asbestosis *M*=14.6 years | **Historical cohort mortality study reporting vermiculite exposure**  Based on 22 asbestosis deaths SMR increased with increasing cumulative exposure: <0-49.9 fibre/mL-year exposure (SMR=37.3; 95% Cl:7.5, 122.3); SMR for non-malignant respiratory death was 1.9 for CFE < 3.5 fibre/mL-year 50.0-249.9 fibre/mL-year  (SMR =212.6; 95%CI: 91.6, 433.2) and ≥250 fibre/mL-year (SMR=749.1; 95% Cl: 373.0, 1367.8) allowing for a 15-year exposure lag  More likely than expected to die from asbestosis with employment duration <15 months (SMR=38.2; 95% Cl: 7.7, 125.1),  15 months to 9.9 years (SMR=236.0; 95%CI: 107.8, 461.1) and employment duration ≥10 years (SMR=628.6; 95%CI: 301.1, 1185.1)  Author’s conclusion: SRR was statistically significant asbestosis increased across categories of exposure duration (≥15 months) and over increasing categories of cumulative exposure from ≥50 fibre/mL-year asbestosis. Note levels of likely exposure were high in this mill. | Asbestos exposure producing asbestosis seen at ≥50 fibre/mL-year |
| Berry et al (1979)[[304]](#endnote-12) | Cited by: Becklake (1991)[[305]](#endnote-13) RMA ID: 000429 | Asbestosis: a study of dose-response relationships in an asbestos textile factory | 379 textile factory workers (100% men) with >10 years’ service  58 =possible asbestosis (34 = certified as asbestosis)  Diagnosis and examination by Pneumoconiosis Medical Panel  82=crepitation’s  Smoking history available | Chrysotile and crocidolite asbestos  textile factory | Group first employed after 1950 cumulative exposure: (*n*=197) *M*=84 fibre/mL-year  Concentration of exposure: *M*=5.0 fibre/mL | Fibre concentration method used: For each job description a dust level was calculated for each year by taking the average of the levels measured at the static dust sampling locations in the area where the job was carried out.  Fibre counts were not available for 1951-60, but Thermal Precipitator particle counts were available for 1952 and 1960. The fibre counts for 1951-1955 were taken as those of 1961 multiplied by the ratio of the 1952 to the 1960 thermal precipitator measurement.  The counts for 1956-1960 were taken to be the same as 1961-1965. Before 1950 no dust measurements  For 1933-45 the concentrations were taken to be 1.5 times those in 1951 and for 1946-1950 as 1-25 times the 1951 values. | Duration of exposure*: M*=20.1 years  Group first employed after 1950 (*n*=197) the average follow-up since first exposure: *M*=16 years | **Morbidity study reporting asbestos exposure producing asbestosis and crepitation’s**  For possible and certified asbestosis the 1% prevalence are estimated at 55 fibre/mL-year and 72 fibre/mL-year. Prevalence of small irregular opacities graded 1/0 or more = 21.2% pleural changes = 7%. 4/36 subjects with exposures < 50 fibre/mL-year had signs of asbestosis.  Author’s conclusion: For possible and certified asbestosis the 1% prevalence’s estimated at 55 and 72 fibre/mL-year respectively. The most reliable data relate to men first employed after 1950 the average cumulative exposure was 84 fibre/mL-year, the average follow-up since first exposure was 16 years, and the prevalence of possible asbestosis was 6.6 %. Higher prevalence of crepitation’s at any dose than previously observed. No room for complacency regarding the 2 fibre/cm3 standard of the British Occupational Hygiene Society. | Asbestos exposure producing asbestosis seen 84 fibre/mL-year |
| Seidman et al (1986)[[306]](#endnote-14) | RMA ID: 020152 | Mortality Experience of Amosite Asbestos Factory Workers:  Dose-Response Relationships 5 to 40 Years After Onset of Short-Term Work Exposures | 820 asbestos factory workers (100% men)  31=asbestosis deaths  No smoking history | Amosite asbestos factory | Concentration of exposure: Median=50 (range=5-120) fibre/mL | Fibre concentration method used: There were no direct fibre count measurements or exposures in this plant. Average fibre counts for each job title were estimated from measurements carried out at two other plants operated by the company after 1954; one in Tyler, Texas and another in Port Allegheny, Pennsylvania. | Duration of exposure: *N*=820; range=<1 month to 2-14 years  *n*=384:<6  *n*=241:6-24  *n*=195:24+ months | **Mortality study after short-term work exposure**  The lower the cumulative exposure dose, the longer it took for adverse mortality experience to become evident and also the smaller the magnitude of that adverse mortality. Workers exposure to <25 fibre/mL-year cumulative exposure observed and expected deaths from 5 to 40 elapsed years since onset work were:  109 men exposed to 6.0 -11.9 fibre/mL-year (asbestosis deaths=1; seen at 5-24 years since onset of work, SMR not reported if both observed and expected deaths are <5)  139 men exposed to 12.0-24.9 fibre/mL-year (asbestosis deaths=1; see at 5-19 years since onset of work, SMR not reported)  57 men exposed to 100.0-149.9 fibre/mL-year (asbestosis deaths=5; significant increase seen from 5-24 years (*n*=4) since onset of work, SMR = 15.63; *p*<0.001)  58 men exposed to 150.0-249.9 fibre/mL-year (asbestosis deaths=7; significant increase seen from 5-29 years (*n*=6) since onset of work, SMR = 13.04; *p*<0.001)  53 men exposed to ≥250 fibre/mL-year (asbestosis deaths=13; significant increase seen from 5-19 years (*n*=6) since onset of work, SMR = 36.84; *p*<0.001)  Dose response relationship observed at all durations of employment  Authors conclusion: with lighter (and/or shorter) direct exposure, as time goes on, the longer the time after onset of work, the more pronounced the excesses in mortality | Asbestos exposure producing asbestosis seen at 100 fibre/mL-year |
| Finkelstein & Vingilis (1984)[[307]](#endnote-15) | RMA ID: 000454 | Radiographic Abnormalities Among Asbestos-Cement Workers: an Exposure-Response Study | 181 asbestos cement workers (100% men)  51(28%)=small irregular opacities 1/1 or more  40 (22%)= pleural thickening of category A or more  Excluded 5 men who had died of unstated cause.  Smoking history available | Chrysotile and crocidolite asbestos, silica, and cement factory | 18 year cumulative exposures: *N*=181; *n* =32:0-49.9  *n* =68: 50-99.9  *n* =41: 100-149.9  *n* =25: 150-199.9  *n* =15: >200 fibre/mL-year | Fibre concentration method used: Cumulative exposures to asbestos were calculated using a model that extrapolated measurements made by the personal Membrane Filter. Exposures were estimated to be accurate to a factor of 3-5. Eighteen-year cumulative exposures were calculated by summing annual exposures during the 18 year from first exposure  Silica exposure not assessed (also can produce interstitial opacities on chest radiographs) | Duration of exposure: ≥1 year | **Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques**  Risk of small irregular opacities category >1/0 was seen at >200 fibre/mL-year (All men *n*=60; RR=2.24;Trend test (*X*2) =27.9; *p*<0.001)  Risk of small irregular opacities category >1/1 was seen at >200 fibre/mL-year (All men *n*=50; RR=2.57;Trend test (*X*2) =24.4; *p*<0.001)  Risk of small irregular opacities category >1/2 was seen 150-199.9 fibre/mL-year (All men *n*=11; RR=2.19;Trend test (*X*2) =18.0; *p*<0.001)  Risk of bilateral pleural thickening (grade A) was seen at >200 fibre/mL-year (All men *n* =40; RR=1.44;Trend test (*X*2) =4.34; *p*=0.04)  Risk of bilateral pleural thickening (grade B) was seen at >200 fibre/mL-year (All men *n* =23; RR=1.38;Trend test (*X*2) =2.36; *p*=0.12)  Author’s conclusion: 20 years from 1st exposure mortality rates were elevated. Men leaving asbestos exposure had a risk of radiographic progression similar to men continuing in exposure and men with abnormal radiographs had a higher mortality rate than men with normal chest X-rays. Increased risk of cancer with interstitial opacities and bilateral pleural changes. | Asbestos exposure producing small irregular opacities 1/1 or more seen at 150-199.9 fibre/mL-year |
| a Participants with small opacity ILO profusion of grade 1/1 on X-rays were considered to have asbestosis according to the American Thoracic Society criteria, whether or not they were found to have inspiratory crackles, restrictive pattern impairment, or a low TLCO. Pleural abnormalities were defined by the presence of the ILO- criteria for circumscribed pleural plaques or diffuse pleural thickening. Abbreviations: TWA= time weighted average; SMR= standardised mortality rate; SRR = standardised rate ratio; *M* = mean; *SD* = standard deviation; OR = odds ratio; RR = relative risk; NS = non-significant | | | | | | | | | |

Table A2. Overview of 36 Papers Relevant to Low Level Exposure to Asbestos for Asbestosis (Ordered by Study Type and Date)

| **Original Study Author (RMA ID) o*r* Review of that Study** | **RMA ID *Or* Review Author (RMA ID)** | **Title** | **Subjects** | **Type of  Exposure** | **Level of  Exposure  (fibre/mL)** | **Duration of Exposure (year)** | **Outcome: Study/Review with asbestos exposure (but with no exposure data that could be compared to the levels in the SoPs), producing Asbestosis; then Other Studies & Reviews** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Mortality Studies | | | | | | | |
| Paris et al (2009)[[308]](#endnote-16) | RMA ID: 067601 | Pleural Plaques and Asbestosis: Dose- and Time-Response Relationships Based on HRCT Data | 5545 retired workers exposure to asbestos (100% men)  882=pleural plaques  375=asbestosis | Metal, construction and repairs industry | Cumulative Exposure Indexa: *M*=49.6 (Estimated 80% had high level of exposure)  Concentration of exposure (fibre/mL) not reported | Duration of exposure: *M*=27.4 (*SD*=11.1) years  Time since 1st exposure: *M*=41.9 (*SD*=8.1) years | Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques. Pleural plaques: Overall (*n*=882) Trend test *p*<0.0001. High exposure (*n*=777; 17.5%) OR significant (OR=2.89; 95%CI: 1.51, 5.52; *p*<0.0001). Asbestosis: Overall (*n*=375) Trend test *p*=0.01. High exposure (*n*=322; 7.3%) OR significant (OR=1.20; 95%CI: 0.62, 2.30; *p*=0.02). Only cumulative exposure (*p*<0.0001) or level of exposure (*p*=0.02) were significantly associated with asbestosis. Both time and dose-response relationships were demonstrated for pleural plaques. Only dose-response relationships were shown for asbestosis. Author’s conclusion: Both time-response and dose-response relationships were demonstrated for pleural plaques, while only dose-response relationships were demonstrated for asbestosis. |
| Reid et al (2005)[[309]](#endnote-17) | RMA ID: 037507 | The Effect of Asbestosis on Lung Cancer Risk Beyond the Dose Related Effect of Asbestos Alone | 1988 (1196 former Wittenoom workers; 792 residents of Wittenoom) cancer prevention program participants  58=lung cancer cases(21= asbestosis)  1930=non-cases (220=asbestosis) | Crocidolite mine/mill | Cumulative exposure: Cases (*n*=58 lung cancer): *M*=11 (range=2.6-46.5) fibre/mL-year  Controls (*n*=1930 non-cases): *M*=5 (range=1.8-13.5) fibre/mL-year  Concentration of exposure: Cases (*n*=58 lung cancer): *M*=12 (range=6.2-40.3) fibre/mL  Controls: (*n*=1930 non-cases): *M*=6 (range=2.1-20.3) fibre/mL | Duration of exposure (days): Cases (*n*=58 lung cancer): *M*=330 (range=118-1048) days Controls(*n*=1930 non-cases): *M*=285 (range=106-854) days | Morbidity study reporting asbestos exposure producing asbestosis in lung cancer patients. 58 lung cancer cases 21; 36% had radiographic asbestosis compared to 220 (11%) of participants. Radiographic asbestosis (OR=1.94, 95% Cl: 1.09, 3.46) and asbestos exposure (OR=1.21 per fibre/mL-year, 95% Cl: 1.02, 1.42) significantly associated with an increased risk of lung cancer. Intensity of exposure and cumulative exposure were both statistically significant. The interaction between cumulative asbestos exposure and asbestosis was not significant (Hazard Ratio = 0.82, 95% CI: 0.59, 1.13, *p* = 0.23). Author’s conclusion: asbestos fibres cause lung cancer in persons exposed to asbestos. The presence of asbestosis is also associated with an increased risk of lung cancer which may be due to some action of the fibrosis itself, but the excess risk may also be due to an underestimate of asbestos exposure. |
| Peipins et al (2003)[[310]](#endnote-18) RMA ID: 046972 | RMA ID: 046972 | Radiographic Abnormalities and Exposure to Asbestos-Contaminated Vermiculite in the Community of Libby, Montana, USA | 7307 participants of a Community based medical screening program (6668 chest X-rays)  Nearly 18%= radiographic pleural abnormalities and asbestos exposure  1%= interstitial abnormalities (opacities profusion ≥1/0) | Occupational and/or community exposure from Libby, Montana | Not reported | Duration of exposure: ≥6 months | Morbidity study reporting asbestos exposure producing asbestosis, pleural changes and pleural thickening. There were 29 occupational, recreational, household, and other exposure pathway examined and the prevalence of pleural abnormalities increased with the increasing number of exposures. Ranging from 6.7% for those without exposure to 34.6% for those ≥12 pathways. Pleural abnormalities in 51% of the 365 and interstitial abnormalities in 3.8% workers at the mine and associated facilities. Authors conclusion: the factors most strongly associated with pleural abnormalities were being; a former Libby mine worker; older, a household contact of a Libby mine worker; and male |
| Fischer et al (2002)[[[311]](#endnote-19)](#_ENREF_13) | RMA ID: 026590 | Fibre-Years, Pulmonary Asbestos Burden and Asbestosis | 366 patients on the German Mesothelioma Register  64=asbestosis cases  193=without elevated pulmonary burden | German Industry exposure | Exposure: range=0.094-314 fibre/mL-year | Not reported | Morbidity study reporting asbestos exposure producing asbestosis. Without elevated pulmonary burden (*n*=193): 19.6%=cumulative asbestos exposure of ≥25 fibre/mL-year. Asbestosis cases (*n*=64): 58% = cumulative asbestos exposure of ≥25 fibre/mL-year and 42% = cumulative asbestos exposure of <25 fibre-year. In contrast 24% of the patients with >25 fibre-year showed no elevated levels of pulmonary asbestos burden and no asbestos-associated lung fibroses. Using the criterion of asbestos fibre concentration of 25 fibre/mL-year showed 42% false-negative and 24% false-positive result. Author conclusion: the criterion of 25 fibre/mL-year alone is an insufficient parameter for the industrial disease adjudication procedure in the sector of asbestos associated lung fibroses. |
| Koskinen et al (1998)[[[312]](#endnote-20)](#_ENREF_16) | RMA ID: 026513 | Radiographic Abnormalities Among Finnish Construction, Shipyard and Asbestos Industry Workers | 18 943 workers screened (96%=men)  4133 (22%)= positive radiological finding (96% abnormalities in the pleura)  4%=asbestosis | Finnish construction, shipyard, and asbestos industry workers | Not reported | Duration exposure: Construction: *M*=9.0 years Shipyards: *M*= 7.8 years Asbestos industry: *M*= 9.7 years | Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques. Pleural plaques were diagnosed for two-thirds of the workers with small irregular lung opacities (at least ILO 1/0), 52% were found to have bilateral pleural plaques, 20% unilateral plaques, and 28% no plaque change. Pleural plaques were observed in < half of workers with small irregular opacities and <15 years of exposure, but after a long period of exposure (>30 years) pleural plaques were present in 80% of cases. Prevalence of positive findings increased with duration of exposure, 18% among those who had been exposed to asbestos for <10 years (*n*=12 507), 27% among those exposed for 10-30 years (*n*=5542), and 43% among those exposed for > 30 years (*n*=914). Author’s conclusion: parenchymal fibrosis may have developed after shorter and possibly larger asbestos exposure, whereas pleural plaques require a longer period to become detectable by chest X-ray. |
| Klaas (1993)[[313]](#endnote-21) | RMA ID: 000435 | A Diagnostic Approach to Asbestosis, Utilizing Clinical Criteria, High Resolution Computed Tomography (HRCT), and Gallium Scanning | 75 previous workers (100% men)  16=asbestosis cases | Shipyard welders,  riggers, pipe fitters, longshoremen boilermakers,  machinists, janitors insulation strippers,  and labourers | Not reported | Duration of exposure: *N*=75;*M*=22.7 (range=2-42) years  Asbestosis cases: *n*=16; *M*=23.3 (latency *M*=35.9) years | Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques. Of 75 men, 16 (21%) met the clinical asbestosis diagnosis criteria, 59 (75%) had both a positive HRCT and a positive gallium scan for asbestosis. The 16 men with asbestosis, 14 (87%) had asbestosis and 10 (62%) had pleural plaques on chest X-ray. Control group (*n*=59): 43 (73%) had pleural plaques on chest X-ray. Author’s conclusions: 21% of the subjects satisfied commonly accepted criteria for the diagnosis of asbestosis, 75% had evidence of disease by both HRCT and gallium scanning. Therefore the current six-criterion approach may underestimate the presence of asbestos-related pulmonary disease in asbestos workers. HRCT and gallium scanning detect lesser degrees of asbestos-related pulmonary disease. |
| Jarvholm (1992)[[314]](#endnote-22) | RMA ID: 035335 | Pleural Plaques and Exposure to Asbestos: A Mathematical Model | 2423 Swedish shipyard workers (100% men) | Shipyard workers exposed to asbestos Göteborg, Sweden | Not reported | Not reported | Morbidity study reporting asbestos exposure producing pleural plaques. Increase in prevalence beginning at about 10-14 years after onset of exposure. Incidence of pleural plaques had a latency period around 13 years.  Authors conclusion: the incidence of pleural plaques attributable to asbestos exposure in humans can be modelled as:  *1(t) = K(t-w)a for t>w* where *K* is a constant depending on intensity of asbestos exposure, *a* constant around 0.4 and *w* a minimum latency period of around 13 years. |
| Lilis et al (1991)[[315]](#endnote-23) | RMA ID: 046916 | Radiographic Abnormalities in Asbestos Insulators: Effects of Duration from Onset of Exposure and Smoking. Relationships of Dyspnea with Parenchymal and Pleural Fibrosis | 2790 asbestos insulators  439 (15.7%)= normal chest X-ray  668 (23.9%)= pleural changes  325 (11.6%)= parenchymal changes  1358 (48.7%)= both parenchymal and pleural changes | Asbestos insulation workers | Not reported | Duration of exposure: *n*=368;<30 years  *n*=1712;30-39 years  *n*=710;≥40 years | Morbidity study reporting asbestos exposure producing parenchymal and pleural changes. Prevalence of radiographic parenchymal abnormalities changes increased significantly (*p*<0.001) from 38.6% duration from onset of exposure (<30 years) to 69.7% (≥40 years). Pleural abnormalities changes the comparative prevalence’s were 55.4% and 82.4%.Author conclusion: each of the three categories of duration from onset of exposure prevalence of interstitial pulmonary fibrosis was consistently higher in persons with a history of cigarette smoking than workers who had never smoked. |
| Selikoff & Lilis (1991)[[316]](#endnote-24) | RMA ID: 035756 | Radiological Abnormalities Among Sheet-Metal Workers in the Construction Industry in the United States and Canada: Relationship to Asbestos Exposure | 1330 sheet metal workers (100% men) | Sheet metal | Not reported | Duration from onset of exposure: *M*=39.51 (*SD*=7.41) years  For 76.4% (1016/1330) men employed as sheet-metal workers for ≥35 years | Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques. As the number of years exposed increased, so did the prevalence of radiologic abnormalities and breathing difficulties. Radiologic changes were seen in 58.9% of the 1330 men. These changes occurred more frequently in the subgroup of 1016 workers who had been exposed ≥35 years (63.3%). Author’s conclusion: majority of individuals who have been employed ≥30 years now have abnormal chest X-rays that resulted from exposure, and the less experienced men face the likelihood of developing similar changes over time. |
| Selikoff et al (1990)[[317]](#endnote-25) | RMA ID: 035792 | Asbestotic Radiological Abnormalities Among United States Merchant Marine Seamen | 3324 seamen (100% men) 1157 (34.8%)= pneumoconiosis 329 (9.9%) (profusion ≥1/0) 227 (6.8%) (pleural thickening, pleural plaques, with or without calcification) 601 (18.1%) (only radiological change) | Merchant marine seamen | Not reported | Duration of exposure: *M*=>20 years | Morbidity study reporting asbestos exposure producing pneumoconiosis and pleural plaques. Prevalence rate for all radiological asbestos related abnormalities (pleural or parenchymal or both) highest level (38.5%) >40 years from onset of exposure. Authors conclusion: prevalence of asbestotic changes was greater among seamen who had served in the engine department (391/420; 425%) compared with seamen in other departments, including deck (301/820; 36.6%), steward (278/ 981; 28.4%), or with service in multiple departments (167/541; 30.9%) |
| Sluis-Cremer (1989)[[318]](#endnote-26) | RMA ID: 035796 | Progression of Irregular Opacities in Asbestos Miners | 1454 South African asbestos mine and mill workers (100% men)  (661 discontinued work; 793 continued work) | Amphibole  mine/mill | *Mining exposure up to 1st X-ray: e*xposure after 1st X-Ray: Yes=793; *M*=38.4 fibre/mL-year No=661; *M*=23.2 fibre/mL-year  *Mining exposure between the 1st and 2nd X-ray: e*xposure after 1st X-Ray Yes=793;*M*=6.2 fibre/mL-year | *Mining exposure up to* 1st *X-ray: e*xposure after 1st X-Ray Yes=793; *M*=6.7 years No=661; *M*=4.2 years  *Mining exposure between the* 1st *and 2nd X-ray: e*xposure after 1st X-Ray  Yes=793; *M*=4.5 years | Morbidity study reporting asbestos exposure producing asbestosis and pleural plaques. No difference in the frequency of disease incidence or rate of progression between those who discontinued work (discontinued asbestos exposure) and continued work (asbestos exposure) <5 years of asbestos exposure and in those with <5 fibre/mL-year cumulative exposure a progression of irregular opacities. Authors conclusion: relatively short period of follow up means that the group who continued exposure had only a mean of 4.5 years of exposure and 6.2 fibre-years after the first radiograph and that the time may have been too short for the additional exposure to take effect and the dose too low. Non-significant. |
| Cookson et al (1986)[[319]](#endnote-27) | RMA ID: 000444 | Prevalence of Radiographic Asbestosis in Crocidolite Miners and Millers at Wittenoom, Western Australia | 859 mine and mill workers (100% men)  541 = X-ray from 1st date of employment  318 = comparison group with no known exposure to crocidolite at the time of X-ray  74 = men randomly selected from those known to be alive for a new radiographic examination (10 abnormal) | Crocidolite  mine/mill | Cumulative exposure: 541 men=9.6 fibre/mL-year  318 men=5.3 fibre/mL-year  74 men followed up: 8.1 fibre/mL-year | Total days worked:541 men=126 days  318 men=65 days  74 men=101 days  Average duration of stay = <4 months | Morbidity study reporting asbestos exposure producing radiographic changes of small irregular or small rounded opacities. 299 men = no exposure, 5 = abnormal X-ray and 432 men =exposed had 45 abnormal X-ray. Increases in prevalence of radiographic abnormality both with age at the time of the radiograph from (0% at age 15-24 to 22.2% at age ≥65) and years since first exposed (from 1.6% with no exposure to 26.6% more than 20 years after first exposure. Linear increase in log odds of the log of days (364 days) since starting work after the first year for each of the three defined cumulative exposure groups:<20 fibre/mL-year (RR=1.227; 95%CI: 1.079, 1.396). 20-54.5 fibre/mL-year (RR=1.289; 95%CI: 1.115, 1.492) ≥55 fibre/mL-year (RR=1.387; 95%CI: 1.20, 1.603) (significance was not reported). Even with short periods of work, 5% of the workforce were exposed to at least 100 fibre/mL-year and 11% of the workforce to at least 50 fibre/mL-year. For 74 men there was 10 agreed "cases" in the current radiographs total estimated exposure ranged from 0.5-120 fibre-mL-year, with 3 men having total exposures <5 fibre-mL-year. Author’s conclusion: study relates only to the finding of radiographic changes of small irregular or small rounded opacities (ILO classification of the pneumoconiosis). These changes are not diagnostic of radiographic asbestosis and not necessarily indicative of clinical asbestosis in the participants. The results clearly show a prevalence of uncompensated radiographic abnormality consistent with pneumoconiosis in at least 16% of former Wittenoom workers. Data are consistent with there being no threshold dose of crocidolite exposure for the development of radiographic abnormality. |
| Cookson et al (1986)[[320]](#endnote-28) | RMA ID: 000445 | The Natural History of Asbestosis in Former Crocidolite Workers of Wittenoom Gorge | 136 mine and mill workers (100% men)  (R1: radiographic evidence of pneumoconiosis)  139 subjects (R2: radiographic evidence of pneumoconiosis) | Crocidolite  mine/mill | (R1) Onset of asbestosis 2-34 years after starting work (median=14 years)  Cumulative exposure=91 fibre/mL-year  (R2) Onset of asbestosis 1-33 years after starting work (median=13 years)  Cumulative exposure: Median=77 fibre/mL-year | (R1) duration of exposure: median=3 years approx. (37 months)  (R2) duration of exposure: median = 2.75 years approx. (33 months) | Morbidity study reporting asbestos exposure producing pneumoconiosis. In 136 men had a median exposure duration of 37 months, radiographic asbestosis appeared between 1 and 34 years after initial exposure and then progressed continuously. Onset of asbestosis was most frequent between 10 and 20 year from first exposure, No increased RR of progression for cumulative exposure of 0-54 fibre/mL-year. Increase RR of progression was seen for cumulative exposure of 55-148 fibre/mL-year (ILO category 1 to 2: RR=1.6; 95%CI: 1.1, 2.3; category 2 to 3: RR=2.7, 95%CI: 0.9, 8.2) and cumulative exposure of >148 fibre/mL-year (category 1 to 2: RR=2.5; 95%CI: 1.2, 5.4; category 2 to 3: RR=7.1, 95%CI: 0.8, 66.5) *p* values were not provided. Both onset of asbestosis and progression from Category 1 to Category 2 continued to occur throughout the follow-up period in workers exposed to crocidolite. No evidence of an effect of cumulative exposure to crocidolite on the time to onset of pneumoconiosis. However, progression of pneumoconiosis there was some evidence of effect of cumulative exposure. Authors conclusion: rate of radiographic progression of established asbestosis increases with the accumulated exposure to crocidolite and decreases with time from initial crocidolite exposure to the onset of definite radiographic abnormality |
| Irwig et al (1979)[[321]](#endnote-29),[[322]](#endnote-30) | Cited by Becklake (1991)[[323]](#endnote-31)  RMA ID: 000429 | Risk of Asbestosis in Crocidolite and Amosite Mines in South Africa. (And an erratum) | 1692 mine and mill workers (100% men)  76=pleural thickening  123 =small opacities (profusion of ≥1/0) | Crocidolite and Amosite mines/mills | Concentration exposure ≤20 fibre/mL *n*=668  20.01-50 fibre/mL *n*=521  >50 fibre/mL *n*=274 | Duration of exposure: *N*=1692  ≤ 1 year: *n*=569  1.01-3 year: *n*=348  3.01-7 years: *n*=348  7.01-15 years: *n*=281  >15 years: *n*=146 | Morbidity study reporting asbestos exposure producing irregular opacities and pleural thickening. Prevalence small irregular opacities = 7.3%; and any pleural changes = 7.6%. Prevalence of irregular opacities increased from 2.3% in men exposure for ≤1 year to 26.7% in men >15 years of exposure. Authors conclusion: prevalence of pleural abnormality (pleural thickening, calcification, or obliteration of the costophrenic angle) were related to both age and the duration of asbestos exposure. Pleural and parenchymal abnormalities significantly predicted by fibre concentration, after adjusting for age and duration of exposure |
| Mortality Studies | | | | | | | |
| Deng et al (2012)[[324]](#endnote-32) | RMA ID: 067596 | Exposure-Response Relationship Between Chrysotile Exposure and Mortality from Lung Cancer and Asbestosis | 586 Chinese textile factory workers  226= deaths  37=asbestosis deaths | Asbestos chrysotile textile factory | Cumulative exposure: *N*=586;  *M*=126.1 (*SD* =181.1) fibre/mL-year  Concentration of exposure: *M*=13.8 (*SD*=17.3) fibre/mL | Duration of exposure: *N*=586; *M*=25.4 (*SD*=8.3) years | Mortality study reporting asbestos exposure producing asbestosis. 37=asbestosis deaths 2.39 per 1000 person-years. Cumulative asbestos exposure was significantly associated with mortality from asbestosis in all models (*p*<0.001), except for the additive relative risk model. High estimated cumulative exposures were due to high dust/fibre concentrations in the workplace and the longer duration of employment. Estimated risk of asbestosis mortality increased with asbestos cumulative exposure in a convex curve, which tended to be steeper at a low exposure level (<50 fibre/mL-year) than a higher exposure level (>50 fibre/mL-year). Risk of asbestosis mortality rose more sharply than lung cancer mortality at higher exposure levels (>150 fibre/mL-year). Author’s conclusion: study confirmed strong associations between exposure to chrysotile asbestos and lung cancer and asbestosis, in which clear exposure-response relationships were observed. |
| Moolgavkar et al (2010)[[325]](#endnote-33) | Cited by Antao et al (2012)[[326]](#endnote-34) RMA ID 068460 | Potency Factors for Risk Assessment at Libby, Montana | 1662 Libby vermiculite workers (100% men)  117=non-malignant respiratory disease | Vermiculite mine/mill | Cumulative exposure: *N*=1662 *M*=91.4 fibre/mL-year; Worked <1 year: *M*=8.5 fibre/mL-year Worked ≥1 year: *M*=178 fibre/mL-year  117 non-malignant respiratory disease cumulative exposure: *M*=270 fibre/mL-year; Worked <1 year: *M*=16.1 fibre/mL-year Worked ≥1 year: *M*=447 fibre/mL-year | Employment duration: *N*=1662 *M*= 3.6 years; Worked <1 year(*n*=850): 0.27 years. Worked ≥1 year (*n*=812): *M*=7.1 years 117 non-malignant respiratory disease employment duration: 91.4 *M*= 5.9 years; Worked <1 year (*n*=48): 0.30 years Worked ≥1 year (*n*=69): *M*=9.8 years | Mortality study reporting asbestos exposure producing non-malignant respiratory disease. Risk for non-malignant respiratory disease cumulative exposure of 100 fibre/mL-year: RR=1.14 (95% CI: 1.09, 1.18). Non-malignant respiratory disease (*n*=117): SMR=2.29 (95% Cl: 1.89, 2.74). Non-malignant respiratory disease for those worked ≥1 year (*n*=69): SMR=2.62 (95% Cl: 2.04, 3.31). Author’s conclusion: SMRs for non-malignant respiratory disease are significantly elevated in the entire cohort and also in the sub-cohort of workers employed for ≥ 1 year. Detailed comparison by exposure categories was not possible for non-malignant respiratory disease. |
| Agency for Toxic Substances and Disease Registry (ATSDR) (2002)[[327]](#endnote-35) | Cited by US Department of Health & Human Services, ATSDR & Disease Registry Division  of Health Assessment & Consultation (2008)[[328]](#endnote-36) RMA ID:067997 | Health consultation: mortality in Libby, Montana (1979-1998) | 542 subjects  12=asbestosis deaths (1=household contact, 11=former mine employees) | Libby, Montana community | Not reported | Duration of exposure: Former employees died from asbestosis: *n*=11; *M*=24.5 (*SD*=10.7; range=3-38) years | Mortality due to asbestosis was significantly elevated over the 20-year period. All asbestosis deaths were associated with the mining and milling facility through either previous employment or as a household contact of a former worker. Author’s conclusion: SMR were all statistically significant for asbestosis in all areas of analysis. A mortality for the Libby community revealed significantly elevated SMR for asbestosis (40 to 80 times higher than expected) and lung cancer (20% to 30% higher than expected) |
| Liddell et al (1997)[[329]](#endnote-37) | RMA ID: 026465 | The 1891-1920 Birth Cohort of Quebec Chrysotile Miners and Millers: Development from 1904 and Mortality to 1992 | 9780 workers (100% men)  8009=deaths  108= pneumoconiosis deaths | Chrysotile mine/mill and asbestos factory | Level of exposure: Exposure 300 million particles per cubic foot (mppcf)  British Occupational Hygiene Society [[330]](#endnote-38) (1968) suggested an asbestos air concentration of 1 mppcf = 3 fibre/ml (detected by phase contrast microscopy). Therefor the concentration of exposure approximately 300 mppcf = 900 fibre/mL | Duration of employment: >1 month (0.1 years) | Mortality study reporting asbestos exposure producing pneumoconiosis. Pneumoconiosis death rates per  100 000 subject-years clearly associated with exposure at the asbestos mine/mill (23=deaths) and Thetford mine-company 3 (53=deaths). Men whose exposures were <300mpcf.y accounted for 30 pneumoconiosis deaths. Exposure <300 mpcf.y has been essentially mild, although there was a small risk of pneumoconiosis mortality. Author’s conclusion: Higher exposures have, led to excesses, increasing with degree of exposure, of mortality from all causes, but such exposures, of at least 300 mpcf.y. |
| Albin et al (1994)[[331]](#endnote-39) | RMA ID: 034864 | Retention patterns of asbestos fibres in lung tissue among asbestos cement workers | 165 Lung tissue analysis (69 Swedish asbestos-cement workers and 96 controls)  2=pulmonary fibrosis deaths | Asbestos-cement chrysotile, tremolite, and crocidolite | Concentration of exposure: M=1.7 (median=1.2, range=00-7-3) fibre/mL. For workers performing milling, mixing, sawing, and polishing operations, or sweeping asbestos barn M=>2 fibre/mL | Duration of employment: M=18 (median=15) years | Mortality study reporting asbestos exposure producing pulmonary fibrosis. Chrysotile relatively rapid removal in lungs, whereas amphiboles (tremolite and crocidolite) displayed a slower removal patterns. Author’s conclusion: Chrysotile retention may be dependent on dose rate, chrysotile and crocidolite retention may be increased by smoking, and chrysotile and tremolite retention may be enhanced by the presence of lung fibrosis. |
| Amandus et al (1987)[[332]](#endnote-40) | Antao et al [[333]](#endnote-41) |  |  |  |  |  | Study reporting asbestos exposure producing non-malignant respiratory disease. Non-malignant respiratory disease (n=20): SMR=2.43 (95% CI: 1.48, 3.75; p<0.05). Non-malignant respiratory disease: <50 fibre/mL-year (n=8; SMR=2.20; p<0.05). 50-99 fibre/mL-year (n=2; SMR=1.70; NS)100-399 fibre/mL-year (n=3; SMR=1.79;NS) >399 fibre/mL-year (n=7; SMR=2.20; p<0.01). Author’s conclusion: an association between cumulative fibre exposure and non-malignant respiratory disease mortality was not found, and conclusions as to the exposure-response association are unclear. For >20 years latency, an inverse relationship is suggested. There were also too few deaths due to asbestos-related respiratory disease, 10 of 20 non-malignant respiratory disease. |
| McDonald et al (1986)[[334]](#endnote-42) | Cited by: Antao et al [[335]](#endnote-43) RMA ID: 068460 | Cohort Study of Mortality of Vermiculite Miners Exposed to Tremolite | 406 Libby vermiculite workers employed (100% men)  165=total deaths  21=non-malignant respiratory disease (8=pneumoconiosis) |  |  |  | Mortality study reporting asbestos exposure producing pneumoconiosis. Non-malignant respiratory disease: SMR=2.55 (95% CI not presented) for among mine workers employed for at least 1 year. Non-malignant respiratory disease associated with exposure: SMR=3.36 (10-19 years) and SMR=5.30 (>20 years) since first employment. Pneumoconiosis: linear increase in relative risk is estimated at 0.3% per fibre year (95% CI: 0.0, 4.1; NS). Author’s conclusion: although positive relations with cumulative exposure were observed with pneumoconiosis numbers were small, confidence intervals wide, and conventional levels of statistical significance were not reached. |
| Review/Reports | | | | | | | |
| Antao et al[[336]](#endnote-44) | RMA ID: 068460 | Libby Vermiculite Exposure & Risk of Developing Asbestos Related Lung & Pleural Diseases | Not reported | Vermiculite mine/mill | Not reported | Not reported | Review**.** Author’s conclusion: excessive mortality attributed to non-malignant respiratory disease among sub-cohorts of Libby mine and mill workers. Association of asbestosis mortality with levels of cumulative exposure and duration of exposure |
| Mossman et al (2011)[[337]](#endnote-45) | RMA ID: 067547 | Pulmonary Endpoints (Lung Carcinomas and Asbestosis) Following Inhalation Exposure to Asbestos | Not reported | Not reported | Not reported | Not reported | Review. Authors conclusion: Fibre toxicity studies suggests that human exposure to respirable fibre that are bio persistent in the lung may induce significant and persistent pulmonary inflammation, cell proliferation, or fibrosis, and inhalation exposure to such fibre needs to be viewed with concern. Despite the fact that most chrysotile fibre are cleared rapidly, some small proportion of these fibre remains in the lung, and all of the asbestos types were noted in animal models and in epidemiological studies to induce asbestosis and lung cancer, especially in smokers. |
| Roggli et al (2010)[[338]](#endnote-46) | RMA ID: 067548 | Pathology of Asbestosis - An Update of the Diagnostic Criteria. | Not reported | Not reported | Not reported | Not reported | Report Authors conclusion: Probability of exposure is evidence of direct exposure to asbestos ≥5.0 fibre/mL for >1 year is enough for "ascertainment" of asbestosis (i.e. >5.0 fibre/mL-year). Estimates of cumulative asbestos exposures required for induction of asbestosis have diminished during the years. The threshold cumulative dose of asbestos necessary for clinical manifestations of asbestosis 20-200 fibre/mL-year with a few cases of 2-20 fibre/mL-year. |
| US Department of Health and Human Services, ATSDR & Disease Registry Division of Health Assessment & Consultation (2008)[[339]](#endnote-47) | RMA ID: 067997 | Summary Report. Exposure to Asbestos-Containing Vermiculite From Libby, Montana, at 28 Processing Sites in the United States | 28 sites - 3 groups who experienced the most significant exposure to asbestos former employees at exfoliation facilities, household contacts of these former employees, and some community members | sites that exfoliated Vermiculite from Libby: | Not reported | Not reported | Report. Author’s conclusion: Fibre levels inside the exfoliation facilities ranged from below detection levels -139 fibre/mL. Before 1980, measured fibre levels ranged from 1-10 fibre/mL, which is above the current acceptable level of 0.1 fibre/mL for occupational exposure to asbestos. Libby indicated airborne fibre levels were as high as 245 fibre/mL in an unloading area. Short-duration sampling results indicated airborne fibre levels of 3.9-23.3 fibre/mL, with a corresponding 8-hour TWA calculated as 5.7 fibre/mL. Significantly elevated SMR for asbestosis in the Libby Montana community were 40 to 80 times higher than expected |
| American Thoracic Society (2004)[[340]](#endnote-48) | RMA ID: 067594 | Diagnosis & Initial Management of Non-malignant Diseases Related to Asbestos | Not reported | Asbestos | Not reported | Not reported | Report. Author’s conclusion: asbestosis is commonly associated with prolonged exposure, usually over 10 to 20 years. Short, intense exposures to asbestos, from several months to ≥1 year, can be sufficient to cause asbestosis. |
| Henderson et al (2004)[[341]](#endnote-49) | RMA ID: 035222 | The Diagnosis and Attribution of Asbestos Related diseases in an Australian Context. | Not reported | Not reported | Not reported | Not reported | Report. Author’s conclusion: cumulative exposure of 25 fibre/mL-year delineated exposure of a character and magnitude sufficient to induce asbestosis. In some individuals. Asbestosis in chrysotile workers with cumulative exposure of >20 fibre/mL-year and in some cases 10-20 fibre/mL-year. |
| Agency for Toxic (2001)[[342]](#endnote-50) | RMA ID: 035227 | Toxicological Profile for Asbestos | Not reported | Not reported | Level of exposure: 10 fibre are typically in a cubic metre (fibre/m3) of rural outdoor air. There is 1 million cm3 (or 1 million mL) in a cubic metre so there would be 0.00001 fibre/mL of asbestos in rural air. Air in the city is 10 fold higher. Close to asbestos mines or factories levels reach 10,000 fibre/m3 i.e. 0.01 fibre/mL. | Not reported | Report. Author’s conclusion: asbestosis at prolonged exposures of 5-20 fibre/mL corresponds to cumulative exposures of 50-200 fibre/mL-year for a 10 year exposure. Chronic exposure significantly increases asbestosis mortality rates in exposed workers with cumulative exposure of 32-1271 fibre/mL-year. Cases of asbestosis with very high asbestos air fibre and shorter latent periods (5-6 years) compared with latency of 10-20 years from studies of workers more recently exposed to lower fibre concentrations. Exposure durations (median 6-12 months) at 5-100 fibre/mL associated with pulmonary fibrosis. |
| Burdorf & Swuste (1999)[[343]](#endnote-51) | Roggli et al (2010)[[344]](#endnote-52) RMA ID: 067548 | An Expert System for the Evaluation Of Historical Asbestos Exposure as Diagnostic Criterion in Asbestos Related Diseases | Not reported | Not reported | Not reported | Not reported | Historical Review. Author’s conclusion: a life time risk of asbestosis of 2 per 1000 cases at 4.5 fibre/mL-year. Evidence of direct exposure to asbestos amounting to, or in excess of 5.0 fibre/mL for more than 1 year is enough for “ascertainment” of asbestosis. The 1st step in the decision tree distinguishes between jobs in which it is most likely blue collar worker is exposed and jobs where asbestos exposure is limited to those workers who handle asbestos. For the latter group proof of asbestos exposure is required at individual level. The 2nd and 3rd steps provide the qualitative cut-off points for the decision as to the attribution of asbestosis to occupational exposure. The cut-off point roughly reflects the minimum cumulative exposure of 5 fibre/mL-year to induce asbestosis. |
| Roggli (1998)[[345]](#endnote-53) | RMA ID: 033719 | Fiber analysis | Not reported | Not reported | Fibre per gram of wet or dry lung or cubic centimetre of lung i.e. 1 fibre/g wet lung = 1 fibre/cm3 =10 fibre/g dry lung | Not reported | Review. Asbestos body counts exceed 1700 per gram of wet lung in 90% in a series of 148 asbestosis cases. 59 insulators workers (59 asbestosis cases) median 20 400 bodies/gram of wet lung. 60 shipyard workers (19 asbestosis cases) median 3600 asbestos bodies/gram wet lung. 10 rail workers (1 asbestosis case) median 55 bodies/ gram of wet lung. 8 brake line workers (no cases) 50 bodies/gram wet lung. 24 other asbestos workers (6 asbestosis cases) 2360 bodies/gram wet lung. 16 household content workers (2 asbestosis cases) 410 bodies/gram of wet lung. 4 building occupants workers (no cases) 1.9 bodies/gram wet lung. |
| Rom (1998)[[346]](#endnote-54) | RMA ID: 033719 | Asbestos related disease | Not reported | Not reported | Number of asbestos bodies per gram in general population ~>500 but twice as many are found in the lungs of blue collar workers | Exposure duration depends on intensity | Report. Author’s conclusion: people with pleural plaques have 10000 to 20000 asbestos bodies per gram of dry lung compared to people with asbestosis have >100 000 and often > 1 million. Short term high exposure in contained area – short exposures of 1 to 2 years would be sufficient to induce asbestos-related disease. |
| Anonymous (1997)[[347]](#endnote-55) | RMA ID: 026517 | Asbestos, Asbestosis, and Cancer: the Helsinki Criteria for Diagnosis and Attribution | Not reported | Not reported | For clinical purposes, the following guide-lines are recommended to identify persons with a high probability of exposure to asbestos dust at work: > 0.1 million amphibole fibres (>5 μm) per gram of dry lung tissue or over I million amphibole fibres (>1 μm ) per gram of dry lung tissue; or over 1000 asbestos bodies per gram of dry tissue (100 asbestos bodies per gram of wet tissue) or over 1 asbestos body per mL of bronchoalveolar lavage fluid, as measured by light microscopy | Not reported | Report.Author’s conclusion: asbestosis generally associated high exposure levels with radiological signs of parenchymal fibrosis. Mild fibrosis may occur at lower exposure levels, and detectable parenchymal fibrosis may not been seen on X-rays. HRCT can confirm radiological findings of asbestosis and show early changes not seen on chest X-rays. Cumulative exposure, on a probability basis, should be considered the main criterion for the attribution of a substantial contribution by asbestos to lung cancer risk. RR is roughly doubled for cohorts exposed to asbestos fibres at a cumulative exposure of 25 fibre-years or with an equivalent occupational history, at which level asbestosis may or may not be present or detectable. Heavy exposure, in the absence of radiological diagnosed asbestosis, is sufficient to increase the risk of lung cancer. Cumulative exposures <25 fibre-years are also associated with an increased risk of lung cancer, but to a less extent. The relative risk of lung cancer is estimated to increase 0.5-4% for each fibre per cc per year (fibre-years) of cumulative exposure. With the use of the upper boundary of this range, a cumulative expo-sure of 25 fibre-years is estimated to increase the risk of lung cancer 2-fold. Clinical cases of asbestosis may occur at comparable cumulative exposures. |
| Becklake & Case (1994)[[348]](#endnote-56) | RMA ID: 000430 | Fiber Burden And Asbestos-Related Lung Disease: Determinants of Dose Response Relationships | Not reported | Mine/mill workers, insulators, & tradesmen | Not reported | Not reported | Editorial. Author’s conclusion: There are major differences in the relationship of fibre concentrations and disease for chrysotile and tremolite, and amosite and crocidolite. Heaviest burdens for asbestosis and airway fibrosis with lower burdens for pleural plaques and lung cancer. Differences between fibre types and doses responses. |
| Churg (1994)[[349]](#endnote-57) | Mossman et al (2011)[[350]](#endnote-58) RMA ID: 067547 | Deposition and Clearance of Chrysotile Asbestos | Lung tissue analysis of 94 chrysotile asbestos miners and millers from Thetford –Quebec Canada | Chrysotile asbestos mill/mine | Not reported | Not reported | Review. Author’s conclusion: The retained chrysotile and exposure atmosphere contained small percentage of tremolite, yet the lungs contained more tremolite than chrysotile, and the tremolite content increased rapidly with the duration of exposure. Most inhaled chrysotile was rapidity cleared by the lungs a small fraction was retained indefinitely. After exposure ended there was little or no clearance of either fibres from the lung. |
| Becklake (1991)[[351]](#endnote-59) | RMA ID: 000429 | Asbestos and other fiber-related disease of the lungs and Pleura. Distribution & determinants in exposed populations. | Not reported | Not reported | Not reported | Not reported | Review. Author conclusion: men exposure to low level of fibre/mL over a short duration (5 -20 years) had small irregular opacities and pleural changes |
| Sluis-Cremer (1991)[[352]](#endnote-60) | RMA ID: 000440 | Asbestos Disease at Low Exposures After Long Residence Times | Not reported | Not reported | A risk of asbestosis at cumulative exposure of 2-5 fibre/mL-year | Not reported | Review. Author conclusion: No difference in the frequency of disease incidence or rate of progression of irregular opacities between workers with discontinued asbestos exposure compared to workers with continued asbestos exposure |

Table A3. List of Medical Science Cited in the RMA Briefing Papers for Determining the Asbestos Factors in 1996, 2005, and 2013

|  |  |
| --- | --- |
| RMA ID | Title |
| RMA Briefing Papers for Determining the Asbestos Factors in 1996 | |
| 046975 | Speizer FE. Asbestosis. Harrison's Principles of Internal Medicine: "Part 9, Section 2, 2005. |
| 033719 | Roggli VL. Fiber Analysis. In: Rom WN, editor. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p. 335-45. |
| 033719 | Rom WN. Chapter 24: Asbestos related diseases. In: Rom WN, editor. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p. 349-75. |
| 000430 | Becklake MR, Case BW. Fiber burden and asbestos-related lung disease: Determinants of dose-response relationships. Am J Respir Crit Care Med. 1994;150(6 Pt 1):1488-92. |
| 000431 | Churg A, Vedal S. Fiber burden and patterns of asbestos-related disease in workers with heavy mixed amosite and chrysotile exposure. Am J Respir Crit Care Med. 1994;150(3):663-739. |
| 000437 | Murai Y, Kitagawa M, Yasuda M, Okada E, Koizumi F. Asbestos fiber analysis in seven asbestosis cases. Arch Environ Health. 1994;49(1):67-72. |
| 000435 | Klaas VE. A diagnostic approach to asbestosis, utilizing clinical criteria, high resolution computed tomography, and gallium scanning. Am J Ind Med. 1993;23(5):801-9. |
| 000434 | Gaensler EA. Asbestos exposure in buildings. Clin Chest Med. 1992;13(2):231-42. |
| 000429 | Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. |
| 000432 | de Klerk NH, Musk AW, Armstrong BK, Hobbs MS. Smoking, exposure to crocidolite, and the incidence of lung cancer and asbestosis. Br J Ind Med. 1991;48(6):412-7. |
| 000440 | Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. |
| 035796 | Sluis-Cremer GK, Hnizdo E. Progression of irregular opacities in asbestos miners. Br J Ind Med. 1989;46:846-52. |
| 000445 | Cookson WO, De Klerk N, Musk W, Glancy JJ. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-8. |
| 000454 | Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. |
| Cited by: Gaensler 000434 | Murphy RLH, Ferris BG, Burgess WA, Worcester J, Gaensler EA. Effects of Low Concentrations of Asbestos. NE J Med.1971. p. 1271-8. Cited by: Gaensler EA. Asbestos exposure in buildings. Clin Chest Med. 1992;13(2):231-42. |
| RMA Briefing Papers for Determining the Asbestos Factors in 2005 | |
| 035222 | Henderson DW, Jones ML, De Lerk N, leigh J, Musk AW, Shilkin KB, et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide Workshop on Asbestos-related Diseases October 6-7, 2000. Int J Hyg Environ Health. 2004;10(1):40-6. |
| 035752 | Burdorf A, Dahhan M, Swuste P. Occupational characteristics of cases with asbestos-related diseases in the Netherlands. Ann Occup Hyg. 2003;47(6):485-92. |
| 026590 | Fischer M, Günther S, Müller KM. Fibre-years, pulmonary asbestos burden and asbestosis. Int J Hyg Environ Health. 2002;205(3):245-48. |
| 028160 | Szeszenia-Dabrowska N, Urszula W, Szymczak W, Strzelecka A. Mortality study of workers compensated for asbestosis in Poland, 1970-1997. Int J Occup Environ Health. 2002;15(3):267-78. |
| 026507 | Wright RS, Abraham J, Harber P, Burnett BR, Morris P, West P. Fatal asbestosis 50 years after brief high intensity exposure in a Vermiculite expansion plant. Am J Respir Crit Care Med. 2002;165(8):1145-9. |
| 035227 | Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service -ATSDR, 2001. |
| 026602 | Schaeffner ES, Miller DP, Wain JC, Christiani DC. Use of an asbestos exposure score and the presence of pleural and parenchymal abnormalities in a lung cancer case series. Int J Occup Environ Health. 2001;7(1):14-8. |
| 026552 | Kurumatani N, Natori Y, Mizutani R. A historical cohort mortality study of workers exposed to asbestos in a refitting shipyard. Ind Health. 1999;37(1):41899. |
| 026600 | Boffetta P. Health effects of asbestos exposure in humans: a quantitative assessment. Medicina del Lavoro. 1998;89(6):471-80. |
| 026470 | Levin JL, McLarty JW, Hurst GA, Smith AN, Frank Al. Tyler asbestos workers: mortality experience in a cohort exposed to amosite. Occup Environ Med. 1998;55:155-60. |
| 035757 | Shepherd JR, Hillerdal G, McLarty J. Progression of pleural and parenchymal disease on chest radiographs of workers exposed to amosite asbestos. J Occup Environl Med. 1997;54(6):410-15. |
| 034901 | Ehrlich R, Lilis R, Chan E, Nicholson WJ, Selikoff IJ. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. |
| 035792 | Selikoff IJ, Lilis R, Levin G. Asbestotic radiological abnormalities among United States merchant marine seamen. Br J Ind Med. 1990;47(5):292-7. |
| RMA Briefing Papers for Determining the Asbestos Factors in 2013 | |
| 067565 | Balmes JR, Speizer FE. Occupational and environmental lung disease. Occupational exposures and pulmonary disease. Harrison's Principles of Internal Medicine 2013. p. 2122-8. |
| 067504 | Popper HH. Interstitial lung diseases - can pathologists arrive at an etiology-based diagnosis? A critical update. Virchows Arch. 2013;462(1):1-26. |
| 073946 | Varkey B, Varkey AB, Mosenifar Z, Sharma S. Asbestosis. Medscape. 2013. |
| 068770 | Webb WR, Higgins CB. Chapter 18: Asbestosis and asbestos-related disease. Thoracic Imaging: Pulmonary and Cardiovascular Radiology. 2nd ed: Lippincot; 2011. p. 505-11. |
| 067598 | Larson TC, Antao VC, Bove FJ. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. Occup Environ Med. 2010;52(5):555-60. |
| 067548 | Roggli VL, Gibbs AR, Attanoos R, Chung A, Popper H, Cagle P, et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| 067601 | Paris C, Thierry S, Brochard P, Letourneux M, Schorle E, Stoufflet A, et al. Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J. 2009;34(1):72-9. |
| 067995 | Rohs AM, Lockey JE, Dunning KK, Shukla R, Fan H, Hilbert T, et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-7. |
| 067997 | U.S. Department of Health and Human Services, ATSDR, Disease Registry Division of Health Assessment and Consultation. Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United States. 2008. |
| 045641 | Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspectives. 2007;115(4): 579-85. |
| 067594 | American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. |
| Cited by: Roggli  et al 067548 | Fischer et al. (2002) Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol & Lab Med. 2010;134(3):462-80. |
| 026507 | Wright RS, Abraham J, Harber P, Burnett BR, Morris P, West P. Fatal asbestosis 50 years after brief high intensity exposure in a Vermiculite expansion plant. Am J Respir Crit Care Med. 2002;165(8):1145-9. |
| Cited by: Roggli  et al 067548 | Browne (2001). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Burdorf & Swuste. (1999). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Churg. (1998). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Gibbs et al. (1997). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Green et al. (1997). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Sluis-Creamer (1991). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Dement et al. (1983). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med 2010;134(3):462-80. |
| Cited by: Roggli  et al 067548 | Browne (1986). Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med 2010;134(3):462-80. |

Table A4. New Information Identified by the Council and/ or the Applicant (Ordered by Date)

| **Title** |
| --- |
| Kawabata Y, Shimizu Y, Hoshi E, Murai K, Kanauchi T, Kurashima K, et al. Asbestos exposure increases the incidence of histologically confirmed usual interstitial pneumonia. Histopathology. 2015; Published Online 22 July 2015. |
| van Oyen SC, Peters S, Alfonso H, Fritschi L, de Klerk NH, Reid A, et al. Development of a job matrix (AsbJEM) to estimate occupational exposure to asbestos in Australia. Ann Ocup Hyg. 2015;59(6):737-48 and supplement tables S1 & S2 pp1-9. |
| Asbestos Victim Advice. Pleural Thickening. Asbestos related pleural thickening. [Internet]. WE Solicitors LLP - Asbestos compensation and claim lawyers and Mesothelioma compensations and claims [cited 2015]. [Figure 1]. Available from: http://asbestosvictimadvice.com/pleural-thickening/ |
| Australian Idiopathic Pulmonary Fibrosis Registry 2014. Participant Information & Consent Form. |
| Bernstein DM. The health risk of chrysotile asbestos. Curr Opin Pulm Med. 2014;20(4):366-70. |
| Eisenhawer C, Felten MK, Tamm M, Das M, Kraus T. Radiological surveillance of formerly asbestos-exposed power industry workers: rates and risk factors of benign changes on chest x-ray and MDCT. J Occu Med Toxicol. 2014;9:18. |
| Asbestos Related Lung Diseases [Internet]. National Heart Lung and Blood Institute, NIH (US) 2014 [cited 2015]. Available from: http://www.nhlbi.nih.gov/health-topics/topics/asb/ |
| Finnish Institute of Occupational Health. Asbestos, Asbestosis, and Cancer. Helsinki Criteria for Diagnosis and Attribution 2014. Helsinki. |
| Park EK, Yates DH, Wilson, D. Lung function profiles among subjects with non-malignant asbestos-related disorders. Saf Health Work. 2014 Dec;5(4):234-7. |
| Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: an update. Clin Respir J. 2014;8(1):1-10. |
| Kukkonen MK, Vehmas T, Piirila P, Hirvonen A. Genes involved in innate immunity associated with asbestos-related fibrotic changes. Occup Environ Med. 2013;71(1):48-54. |
| Srikantha S, Hibbert M. How to treat: occupational lung disease: Asbestos related lung conditions. Australian Doctor. 2013. 8th March. |
| MacFarlane E, Benke G, Sim MR, Fritschi L. OccIDEAS: An innovative tool to assess past asbestos exposure in the Australian Mesothelioma Registry. Saf Health Work. 2012:3(1):71-76. |
| Macneal K, Schwartz DA. The genetic and environmental causes of pulmonary fibrosis. Proc Am Throrac Soc. 2012;9(3):120-25. |
| Azaria MR, Nasermoaddeli A, Movahadi M, Mehrabi Y, Hatami H, Soori H, et al. Risk assessment of lung cancer and asbestosis in workers exposed to asbestos fibers in brake shoe factory in Iran. Ind Health. 2010;40(1):38-42. |
| Felten MK, Knoll L, Eisenhawer C, Ackermann D, Khatab K, Hudepohl J, et al. Retrospective exposure assessment to airborne asbestos among power industry workers. J Occu Med Toxicol. 2010;5:15 |
| Hyland RA, Yates DH, Benke G, Sim M, Johnson AR. Occupational exposure to asbestos in New South Wales, Australia (1970-1989): development of an asbestos task exposure matrix. Occup Environ Med. 2010;67(3):201-06. |
| Wang X, Wang M, Qiu H, Yu I, Yano E. Longitudinal changes in pulmonary function in asbestos workers. J Occup Health. 2010; 52(5):272-77. |
| Mastrangleo G, Ballarin MN, Bellini E, Bicciato F, Zannol F, Gioffre F, et al. Asbestos exposure and benign asbestos disease in 772 formerly exposure workers: dose response relationships. Am J Ind Med. 2009;52(8):596-602. |
| Industrial Injuries Advisory Council (IIAC). Pleural plaques: position paper. 2009: 1-58. |
| Wilson MS, Wynn TA. Pulmonary fibrosis: pathogenesis, etiology and regulation. Muscosal Immunol. 2009;2(2):103-21. |
| Miles SE, Sandrini A, Johnson AR, Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: A review. J Occup Med Toxicol. 2008;3:20 |
| Murbach DM, Madi AK, Unice KM, Knutsen JS, Chapman PS, Brown JL, Paustenbach DJ. Airborne concentrations of asbestos onboard maritime shipping vessels (1978-1992). Ann Occup Hyg. 2008;52(4):267-79. |
| Paris C, Martin A, Letourneux M, Wild P. Modelling prevalence and incidence of fibrosis and pleural plaques in asbestos-exposed populations for screening and follow-up: a cross-sectional study. Environ health. 2008; 7:1-8. |
| Wilson R, McConnell EE, Ross M, Axten CW, Nolan RP. Risk assessment due to environmental exposures to fibrous particulates associated with taconite ore. Reg Toxicol Pharmacol. 2008;52(Supp 1):S232-45. |
| Wilson JW, du Bois RM, King TEJ. Challenges in pulmonary fibrosis: 8 -The need for an international registry for idiopathic pulmonary fibrosis. Thorax. 2008;63(3):285-87. |
| Das M, Muhlenbruch G, Maknken AH, Hering KG, Sirbu H, Zschiesche W, et al. Asbestos Surveillance Program Aachen (ASPA): Initial results from baseline screening for lung cancer in asbestos- exposure high risk individuals using low dose multidetector-row CT. Eur Radiol. 2007;17(5):1193-99. |
| Khalil N, Churg A, Muller N, O’Connor R. Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicol Pathol. 2007;35(1):86-96. |
| Tsuchiya K, Inase N, Ichinose S, Usui Y, Miyazaki Y, Ohtani T. et al. Elemental analysis of inorganic dusts in lung tissues of interstitial pneumonias. J Med Dent Sci. 2007;54(1):9-16. |
| Clark CC, Mowat FS, Kelsh MA, Roberts MA. Pleural plaques: a review of diagnostic issues and possible non asbestos factors. Arch Environ Occup Health. 2006;61(4):183-92. |
| Misumi S, Lynch DA. Idiopathic pulmonary fibrosis/usual interstitial pneumonia: imaging diagnosis, spectrum of abnormalities, the temporal progression. Proc Am Thorac Soc. 2006;3(4):307-14. |
| Raghu G. Idiopathic pulmonary fibrosis: treatment options in pursuit of evidence-based approaches (Editorial). Eur Respir J. 2006;28(3):463-65. |
| Ghio AJ, Roggli VL. Diagnosis and initial management of non-malignant diseases related to asbestos (Letter to the Editor). AM J Respir Crit Care Med. 2005;171(5):527. |
| Metintas M, Metintas S, Hillerdral G, Ucgun I, Erginel S, Atatas F, Yildirim H. Non-malignant pleural lesions due to environmental exposure to asbestos: a field based, cross sectional study. Eur Respir J. 2005;26(5):875-80. |
| National Occupational Health & Safety Commission. Guidance note on the membrane filter method for estimating airborne asbestos fibres. Canberra, Australia: NOHSC: 3003; 2005. |
| Matrat M, Pairon JC, Paolillio AG, Joly N, Iwatsubo Y, Orlowski E, et al. Asbestos exposure and radiological abnormalities among maintenance and custodian workers in buildings with friable asbestos-containing materials. Int Arch Occup Environ Health. 2004;77(5):307-12. |
| Selman M, Thannickal VJ, Pardo A, Zisman DA, Martinez FJ, Lynch JP. Idiopathic pulmonary fibrosis: pathogenesis and therapeutic approaches. Drugs. 2004;64(4):405-30. |
| Akira M, Yamamoto S, Inoue Y, Sakatani M. High-resolution CT of asbestosis and idiopathic pulmonary fibrosis. Am J Roentgenol. 2003; 181(1):163-69 |
| Chapman SJ, Cookson WOC, Musk AW, Lee YCG. Benign asbestos pleural diseases. Curr Opin Pulm Med. 2003;9(4):1-5. |
| Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Lee YC, Desai SR, et al. Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT feature. Radiol. 2003;229(3):731-36. |
| Holland P, Smith DD. III. Environmental Toxicology. Chapter 59: Asbestos. In: Greenberg MI, Hamilton RJ, Phillips SD, McCluskey G, editors. Occupational, Industrial and Environmental Toxicology. 2nd ed: Elsevier Health Sciences; 2003. p. 1-864. |
| Hunninghake GW, Lynch DA, Gavin JR, Gross BH, Muller N, Schwartz DA, et al. Radiologic findings are strongly associated with a pathologic diagnosis of usual interstitial pneumonia. Chest. 2003;124(4):125-23. |
| Brown PK, Jones AD, Miller BG. Development in the RICE asbestos fibre counting scheme 1992-2000. Am Occup Hyg. 2002;46(3):329-39. |
| Gauldie J, Kolb M, Sime PJ. A new direction in the pathogenesis of idiopathic pulmonary fibrosis? Respir Res. 2002;3(1):1-3. |
| Strieter L. Inflammatory mechanisms are not a minor component of the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med. 2002;165(9):1207-08. |
| Pardo A, Selman M. Idiopathic pulmonary fibrosis: new insights in its pathogenesis. Int J Biochem Cell Biol. 2002;34(12):1532-38. |
| Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S. Asbestos: when the dust settles an imaging review of asbestos-related disease. RadioGraphics. 2002;22(Suppl 1):S167-84. |
| Gross TJ, Hunninghake GW. Idiopathic pulmonary fibrosis. N Engl J Med. 2001;345(7):517-25. |
| Lui Y, Zhang P, Yi F. Asbestos fibre burdens in lung tissues of Hong Kong Chinese with and without lung cancer. Lung Cancer. 2001;32(2):113-16. |
| Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med. 2001;134(2):136-51. |
| De Vuyst P, Camus P. The past and present of pneumoconiosis. Curr Opin Pulm Med. 2000;6(2):151-56. |
| Tossavainen A. Consensus report. International expert meeting on new advances in the radiology and screening of asbestos-related diseases. Scand J Work Environ Health. 2000;26(5):449-54. |
| Harrison PT, Levy LS, Patrick G, Pigott GH, Smith LL. Comparative hazards of chrysotile asbestos and its substitutes: A European perspective. Environ Health Perspect. 1999;107(8):607-11. |
| Gevenois PA, de Maertelaer V, Madani A, Winant C, Sergent G, de Vuyst P. Asbestosis, plural plaques and diffuse plural thickening: three distinct benign responses to asbestos exposure. Eur Respir J. 1998;11:1021-27. |
| Mossman BT, Churg A. Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med. 1998;157(5):1660-80. |
| Gardi C, Calzoni P, Ferrali M, Comporti M. Iron mobilization from crocidolite as enhancer of collagen content in rat lung fibroblasts. BioChem Pharmacol. 1997;53(11):1659-65. |
| Stayner L, Smith R, Bailer J, Gilbert S, Steenland K, Dement J, et al. Exposure-response analysis of risk of respiratory diseases associated with occupational exposure to chrysotile asbestos. Occup Environ Med. 1997;54(7):646-52. |
| Jones RN, Hughes JM, Weill H. Asbestos exposure, asbestosis and asbestos-attributable lung cancer. Thorax. 1996;51(Suppl 2):S9-15. |
| Maple DW, Samet JM, Coultas DB. Corticosteroids and the treatment idiopathic pulmonary fibrosis: Past, present and Future. Chest. 1996;110(4):1058-67. |
| Jakobsson K, Stromberg U, Albin M, Welinder H, Hagmar L. Radiological changes in asbestos cement workers. Occup Environ Med. 1995;52(1):20-27. |
| de Vuyst P, Dumortier P, Jacobovitz D, Emri S, Coplu L, Baris YI. Environmental asbestosis complicated by lung cancer. Chest. 1994;105(5):1593-95. |
| Churg A. Asbestos-related disease in the workplace and the environment: controversial issues. Monogr Pathol. 1993;(36):54-77. |
| Cullen MR, Lopez-Carrillo L, Alli B, Pace PE, Shalat SL, Baloyi RS. Chrysotile asbestos and health in Zimbabwe: II. Health status survey of active miners and millers. Am J Ind Med. 1991;19(2):771-82. |
| Enfield JD. Report of the Independent review of asbestos in Defence, Directorate of Department of Publications. Canberra, Australia: HR&M Division, 1991. |
| Gaensler EA, Jederlinic PJ, Churg A. Idiopathic pulmonary fibrosis in asbestos-exposed workers. Am Rev Respir Dis. 1991;144(3 PT 1):689-96. |
| Monso E, Tura JM, Pujadas J, Morell F, Ruiz J, Morera J. Lung dust content in idiopathic pulmonary fibrosis: a study with scanning electron microscopy and energy dispersive x-ray analysis. Br J Ind Med. 1991;48(5):327-31. |
| Gaensler E, Goff AM. Asbestos related disease in Crocidolite and chrysotile filter paper plants. 1990. Hazard Evaluation/Clinical Studies. |
| Mossman BT, Bignon J, Corn M, Seaton A, Gee JB. Asbestos: scientific developments and implications for public policy. Science. 1990;247(4940):294-301. |
| Sluis-Cremer GK, Hnizdo E, du Toit RS. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51 |
| Barbers R, Abraham JL. Asbestosis occurring after brief inhalational exposure: usefulness of bronchoalveolar lavage in diagnosis. Br J Ind Med. 1989;46(2):106-10. |
| Johansson LG, Albin MP, Jakobsson KM, Welinder H, Ranstam PJ, Attewell RG. Ferruginous bodies and pulmonary fibrosis in dead low to moderately exposed asbestos cement workers: histological examinations. Br J Ind Med. 1987;44(8):550-58. |
| Kipen HM, Lilis R, Suzuki Y, Valciukas JA, Selikoff IJ. Pulmonary fibrosis in asbestos insulation workers with lung cancer: a radiological and histopathological evaluation. Br J Ind Med. 1987;44(2):96-100. |
| Lundorf E, Aagaard MT, Andresen J, Silberschmid M, Sabro S, Coutte A, Bolvig L. Radiological evaluation of early pleural and pulmonary changes in light asbestos exposure. Eur J Respir Dis. 1987;70(3):145-49. |
| Begin R, Masse S, Sebastien P,Bosse J, Rola-Pleszczynski M, Boctor M, et al. Asbestos exposure and retention as determinants of airway disease and asbestos alveolitis. Am Rev Respir Dis. 1986;134(6):1176-81. |
| Browne K. A threshold for asbestos related lung cancer. Br Ind Med. 1986;43(8):556-58. |
| Hughes JM, Weill H. Asbestos exposure-quantitative assessment of risk. Am Rev Respir Dis. 1986;133(1):5-13. |
| Altree-Williams S, Preston JS. Asbestos and other fibre levels in buildings. Ann Occup Hyg. 1985; 29(3):357-63 |
| Greene R, Boggis C, Jantsch H. Asbestos-related plural thickening: effect of threshold criteria on interpretation. Radiol. 1984;152(3):569-73. |
| Begin R, Rola-Pleszczynski M, Masse S, Nadeau D, Drapeau G. Assessment of progression of asbestosis in sheep model by bronchoalveolar lavage and pulmonary function tests. Thorax. 1983;38(6):449-57. |
| Cadieux A, Masse S, Sirois P. Effects of asbestos on the metabolism of vasoactive substances in isolated perfused guinea pigs lungs. Environ Health Perspect. 1983;51:287-91. |
| Lemaire I, Rola-Pleszczynski M, Begin R. Asbestos exposure enhances the release of fibroblast growth factor in sheep alveolar macrophages. J Reticuloendothel Soc. 1983;33(4):275-85. |
| Sirois P, Drapeau G, Begin R. Biochemical components of bronchoalveolar lavage in early experimental asbestosis of sheep; phospholipase A2 activity, prostaglandin E2 and proteins. Environ Health Perspect. 1983;51:293-98. |
| Burilkov T, Mikhailova L, Lukanova R, Dobreva M, Tocheva V. Occupational risk of asbestos injuries among workers in asbestos cement industry. Probl Khig. 1980;5:125-32. |
| Lacquet LM, van der Linden L, Lepoutre J. Roentgenographic lung changes, asbestosis and mortality in a Belgian asbestos-cement factory. IARC Scientific Publications. 1980;(30):783-93. |
| McDonald JC, Liddell FD, Gibbs GW, Eyssen GE, McDonald AD. Dust exposure and mortality in chrysotile mining, 1910-75. Br J Ind Med. 1980;37(1):11-24. |
| Roggli VL, Greenberg SD, Seitzman LH, McGavran MH, Hurst GA, Spivey CG, et al. Pulmonary fibrosis, carcinoma, and ferruginous body counts in amosite asbestos workers: A study of six cases. Am J Clin Pathol. 1980;73(4):496-503. |
| Rossiter CE, Heath JR, Harries PG. Royal Naval dockyards asbestosis research project: nine year follow-up study of men exposed to asbestos in Devonport dockyard. J R Soc Med. 1980;73(5):337-44. |
| Peto J. Lung cancer mortality in relation to measured dust levels in an asbestos textile factory. IARC Scientific Publications. 1980(30):829-36. |
| Berry G, Gilson JC, Holmes S, Lewinsohn HC, Roach SA. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br Ind Med. 1979;36(2): 98-112. |
| Hammad YY, Diem J, Weill H. Evaluation of dust exposure in asbestos cement manufacturing operations. Am Ind Hyg Assoc J. 1979;40(6):490-95. |
| Rossiter CE, Harries PG. UK Naval dockyards asbestosis study: a survey of the sample population aged 50-59 years. Br J Ind Med. 1979;36(4):281-91. |
| Hiett DM. Experimental asbestosis: an investigation of functional and pathological disturbances. I Methods, control animals and exposure conditions. Br J Ind Med. 1978;35(2):129-34. |
| Peto J. The Hygiene standard for chrysotile asbestos. Lancet. 1978; 1(8062):484-89. |
| Harries PG, Lumley KP. Royal Naval Dockyards Asbestosis Research Project- Survey of registered asbestos workers. J R Nav Med Serv. 1977;63(1):133-48. |
| Harries PG. Experience with asbestos disease and its control in Great Britain’s naval dockyards. Environ Res. 1976;11:261-67. |
| Weill H, Ziskind MM, Waggenspack C, Rossiter CE. Lung function consequences of dust exposure in asbestos cement manufacturing plants. Arch Environ health. 1975;30(2):88-97. |
| Wagner JC, Berry G, Sidmore JW, Timbrell V. The effects of the inhalation of asbestos in rats. Br J Cancer. 1974;29(3):252-69. |
| Harries PG, Mackenzie FA, Sheers G, Kemp JH, Oliver TP, Wright DS. Radiological survey of men exposed to asbestos in naval dockyards. Br J Ind Med. 1972;29(1):274-79. |
| Goff AM, Gaensler EA. Asbestosis following brief exposure in cigarette filter manufacture. Respir. 1972;29(1):83-93. |
| Harries PG. A comparison of mass and fibre concentrations of asbestos dust in shipyards insulation processes. Ann Occup Hyg. 1971;14(3):235-40. |
| Harries PG. Asbestos dust concentrations in ship repairing: a practical approach to improving asbestos hygiene in naval dockyards. Ann Occup Hyg. 1971:14(3):241-54. |
| Lumley KPS, Harries PG, O’Kelly FJ. Buildings insulated with sprayed asbestos: A potential hazard. Ann Occup Hyg. 1971;14(3):255-57. |
| Roberts GH. The pathology of parietal pleural plaques. J Clin Pathol. 1971;24(4):348-53. |
| Harries PG. Protection of dockyard workers against asbestosis. Proc R Soc Med. 1970;63(10):1015. |
| Mackenzie FA, Harries PG. Changing attitudes to the diagnosis of asbestos disease. J R Nav Med Serv. 1970;56(1):116-23. |
| Harries PG. Asbestos hazards in the naval dockyards. Ann Ocup Hyg. 1968;11(2):135-45. |
| Lange JH, Lange R, Reinhard TK, Thomulka KW. A study of personal and area airborne asbestos concentrations during asbestos abatement: a statistical evaluation of fibre concentration data. Am Occup Hyg. 1966;40(4):449-66. |
| Schall EL. Present threshold limit value in the USA for asbestos dust: a critique. Ann NY Acad Sci. 1965;132(1):316-21. |
| Selikoff IJ, Churg J, Hammond EC. The occurrence of asbestosis among insulation workers in the United State. Ann N Y Acad Sci.1965;132(1):139-55. |
| Merewether EPA, Price CW. Report on effects of asbestos dust on the lung and dust suppression in the asbestos industry. HMSO. 1930:1-34. |
| Queensland Asbestos Related Disease Support Society. Undated. Mesothelioma and other asbestos related diseases: pleural Plaque. |
| Asbestos Disease Foundation of Australia (ADFA) Undated. Medical Information: Asbestosis. |
| International ban Asbestos Secretariat. Undated. Fact Sheet on Pleural Plaque. |
| Wikipedia undated. Idiopathic, http://en.wikipeadia.org |

Table A5. New Information Identified by the Council on Diffuse Pleural Thickening (Ordered by Date)

| **Title** |
| --- |
| Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: an update. Clin Respir J. 2014; 8: 1-10. |
| Chapman E, Thomas PS, Yates DH. Breath analysis in asbestos-related disorders: a review of the literature and potential future applications. J Breath Res. 2010; 4: 1-11. |
| Johnson A, Hannaford-Turner K, Little A, Yates D, Sim M, Elder D, Abramson M. The surveillance of Australian Workplace-based Respiratory Events (SABRE) scheme in three states [abstract]. Respirology.2007;12 (Suppl 1):A30-78. |
| Baram D, Degene A, Amin M, Bilfinger T, Smaldone G. A case of hypercapnic respiratory failure. Chest. 2004;126:1994-9. |
| Cugell DW, Kamp DW. Asbestos and the pleura: a review. Chest. 2004;125:1103-17. |
| Huggins JT, Sahn SA. Causes and management of pleural fibrosis. Respirology. 2004;9:441-7. |
| Mutsaers SE, Prele CM, Brody AR, Idell S. Pathogenesis of pleural fibrosis. Respirology. 2004;9:428-40. |
| Remy-Jardin M, Sobaszek A, Duhamel A, Mastora I, Zanetti C, Remy J. Asbestos-related pleuropulmonary diseases: evaluation with low-dose four-detector row spiral CT. Radiology 2004;233:182-90. |
| Weber MA, Bock M, Plathow C, Wasser K, Fink C, Zuna I, et al. Asbestos-related pleural disease: value of dedicated magnetic resonance imaging techniques. Invest Radiol. 2004;39:554-64. |
| Weill D, Weill H. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170:691-715. |
| Smith KA, Sykes LJ, McGavin CR. Diffuse pleural fibrosis-an unreliable indicator of heavy asbestos exposure? Scand J Work Environ Health. 2003;29:60-3. |
| International Labor Office International Classification of Radiographs of Pneumoconioses. Geneva, Switzerland: International Labour Organization; 2003. |
| Luo S, Liu X, Mu S, Tsai SP, Wen CP. Asbestos related diseases from environmental exposure to crocidolite in Da-yao, China. I. Review of exposure and epidemiological data. Occup Environ Med. 2003;60:35-41; discussion 41-2. |
| Tiitola M, Kivisaari L, Zitting A, Huuskonen MS, Kaleva S, Tossavainen A, Vehmas T. Computed tomogrpahy of asbestos-related pleural abnormalities. Int Arch Occup Environ Health. 2002;75:224-28. |
| Copley SJ, Wells AU, Rubens MB, Chabat F, Sheehan RE, Musk AW, Hansell DM. Functional consequences of pleural disease evaluated with chest radiography and CT. Radiology. 2001;220:237-43. |
| Gary Lee YC, Teixeira LR, Devin CJ, Vaz MA, Vargas FS, Thompson PJ, et al. Transforming growth factor-beta2 induces pleurodesis significantly faster than talc. Am J Respir Crit Care Med. 2001;163:640-4. |
| Korhola O, Hiltunen A, Karjalainen A, Martikainen R, Riihimaki H. Association between pleural plaques and coronary heart disease. Scand J Work Environ Health. 2001;27:154-5. |
| Luo L, Hierholzer J, Bittner RC, Chen J, Huang L. Magnetic resonance imaging in distinguishing malignant from benign pleural disease. Chin Med J (Engl). 2001;114:645-9. |
| Munoz X, Roger A, Pallisa E, Marti S, Ferrer J. Ventilatory insufficiency due to asbestos-related diffuse pleural fibrosis successfully treated with non invasive home mechanical ventilation. Respiration. 2001;68:533-6. |
| Hierholzer J, Luo L, Bittner RC, Stroszczynski C, Schroder RJ, Schoenfeld N, et al. MRI and CT in the differential diagnosis of pleural disease. Chest. 2000;118:604-9. |
| Light RW, Cheng DS, Lee YC, Rogers J, Davidson J, Lane KB. A single intrapleural injection of transforming growth factor-beta(2) produces an excellent pleurodesis in rabbits. Am J Respir Crit Care Med. 2000;162:98-104. |
| Mukherjee S, de Klerk N, Palmer LJ, Olsen NJ, Pang SC, William Musk A. Chest pain in asbestos-exposed individuals with benign pleural and parenchymal disease. Am J Respir Crit Care Med 2000;162:1807-11. |
| Peacock C, Copley SJ, Hansell DM. Asbestos-related benign pleural disease. Clin Radiol. 2000;55:422-32. |
| Kamp DW, Weitzman SA. The molecular basis of asbestos induced lung injury. Thorax. 1999;54:638-52. |
| Singh B, Eastwood PR, Finucane KE, Panizza JA, Musk AW. Effect of asbestos-related pleural fibrosis on excursion of the lower chest wall and diaphragm. Am J Respir Crit Care Med. 1999;160:1507-15. |
| Gevenois PA, de Maertelaer V, Madani A, Winant C, Sergent G, De Vuyst P. Asbestosis, pleural plaques and diffuse pleural thickening: three distinct benign responses to asbestos exposure. Eur Respir J. 1998;11:1021-7. |
| Nishimura SL, Broaddus VC. Asbestos-induced pleural disease. Clin Chest Med. 1998;19:311-29. |
| Tanaka S, Choe N, Hemenway DR, Zhu S, Matalon S, Kagan E. Asbestos inhalation induces reactive nitrogen species and nitrotyrosine formation in the lungs and pleura of the rat. J Clin Invest. 1998;102:445-54. |
| Brody AR. Asbestos. New York: Elsevier Science; 1997. |
| Koskinen K, Rinne JP, Zitting A, Tossavainen A, Kivekas J, Reijula K, et al. Screening for asbestos-induced diseases in Finland. Am J Ind Med. 1996;30:241-51. |
| Rudd RM. New developments in asbestos-related pleural disease. Thorax. 1996;51:210-6. |
| Yates DH, Browne K, Stidolph PN, Neville E. Asbestos-related bilateral diffuse pleural thickening: natural history of radiographic and lung function abnormalities. Am J Respir Crit Care Med. 1996;153:301-6. |
| Karjalainen A, Karhunen PJ, Lalu K, Penttila A, Vanhala E, Kyyronen P, Tossavainen A. Pleural plaques and exposure to mineral fibres in a male urban necropsy population. Occup Environ Med. 1994;51:456-60. |
| Vargas FS, Cukier A, Hueb W, Teixeira LR, Light RW. Relationship between pleural effusion and pericardial involvement after myocardial revascularization. Chest. 1994;105:1748-52. |
| de Klerk NH, Musk AW, Cookson WO, Glancy JJ, Hobbs MS. Radiographic abnormalities and mortality in subjects with exposure to crocidolite. Br J Ind Med. 1993;50:902-6. |
| Rey F, Boutin C, Steinbauer J, Viallat JR, Alessandroni P, Jutisz P, et al. Environmental pleural plaques in an asbestos exposed population of northeast Corsica. Eur Respir J. 1993;6:978-82 |
| Gibbs AR, Stephens M, Griffiths DM, Blight BJ, Pooley FD. Fibre distribution in the lungs and pleura of subjects with asbestos related diffuse pleural fibrosis. Br J Ind Med. 1991;48:762-70. |
| Rom WN, Travis WD, Brody AR. Cellular and molecular basis of the asbestos-related diseases. Am Rev Respir Dis. 1991;143:408-22. |
| Bourbeau J, Ernst P, Chrome J, Armstrong B, Becklake MR. The relationship between respiratory impairment and asbestos-related pleural abnormality in an active work force. Am Rev Respir Dis. 1990;142:837-42. |
| Hillerdal G. Pleural and parenchymal fibrosis mainly affecting the upper lung lobes in persons exposed to asbestos. Respir Med. 1990;84:129-34. |
| Leung AN, Muller NL, Miller RR. CT in differential diagnosis of diffuse pleural disease. Am J Roentgenol. 1990;154:487-92. |
| Lynch DA, Gamsu G, Aberle DR. Conventional and high resolution computed tomography in the diagnosis of asbestos-related diseases. Radiographics. 1989;9:523-51. |
| Aberle DR, Gamsu G, Ray CS. High-resolution CT of benign asbestos-related diseases: clinical and radiographic correlation. Am J Roentgenol. 1988;151:883-91. |
| Lilis R, Lerman Y, Selikoff IJ. Symptomatic benign pleural effusions among asbestos insulation workers: residual radiographic abnormalities. Br J Ind Med. 1988;45:443-9. |
| Hillerdal G, Ozesmi M. Benign asbestos pleural effusion: 73 exudates in 60 patients. Eur J Respir Dis. 1987;71:113-21. |
| Rom WN, Bitterman PB, Rennard SI, Cantin A, Crystal RG. Characterization of the lower respiratory tract inflammation of nonsmoking individuals with interstitial lung disease associated with chronic inhalation of inorganic dusts. Am Rev Respir Dis. 1987;136:1429-34. |
| Rosenstock L, Hudson LD. The pleural manifestations of asbestos exposure. Occup Med 1987;2:383-407. |
| McLoud TC, Woods BO, Carrington CB, Epler GR, Gaensler EA. Diffuse pleural thickening in an asbestos-exposed population: prevalence and causes. Am J Roentgenol. 1985;144:9-18 |
| Peto J, Doll R, Hermon C, Binns W, Clayton R, Goffe T. Relationship of mortality to measures of environmental asbestos pollution in an asbestos textile factory. Ann Occup Hyg. 1985;29:305-55. |
| Rogers AJ. Determination of mineral fibre in human lung tissue by light microscopy and transmission electron microscopy. Ann Occup Hyg. 1984;28:1-12. |
| Sahn SA, Antony VB. Pathogenesis of pleural plaques. Relationship of early cellular response and pathology. Am Rev Respir Dis. 1984;130:884-7. |
| Miller A, Teirstein AS, Selikoff IJ. Ventilatory failure due to asbestos pleurisy. Am J Med 1983;75:911-9. |
| Hillerdal G. The pathogenesis of pleural plaques and pulmonary asbestosis: possibilities and impossibilities. Eur J Respir Dis. 1980;61:129-38. |
| Sebastien P, Janson X, Gaudichet A, Hirsch A, Bignon J. Asbestos retention in human respiratory tissues: comparative measurements in lung parenchyma and in parietal pleura. IARC Sci Publ. 1980:237-46. |
| Wright PH, Hanson A, Kreel L, Capel LH. Respiratory function changes after asbestos pleurisy. Thorax. 1980;35:31-6. |
| Yazicioglu S, Ilcayto R, Balci K, Sayli BS, Yorulmaz B. Pleural calcification, pleural mesotheliomas, and bronchial cancers caused by tremolite dust. Thorax. 1980;35:564-9 |
| Taskinen E, Ahlamn K, Wukeri M. A current hypothesis of the lymphatic transport of inspired dust to the parietal pleura. Chest. 1973;64:193-6. |
| Blesovsky A. The folded lung. Br J Dis Chest. 1966;60:19-22. |
| Selikoff IJ. The occurrence of pleural calcification among asbestos insulation workers. Ann N Y Acad Sci. 1965; 132:351-67. |
| Merewether ERA, Price CW. Report on effects of asbestos on the lungs and dust suppression in the asbestos industry. London:1930 |

###### APPENDIX B: THE CONSTITUTED COUNCIL AND LEGISLATIVE FRAMEWORK OF THE REVIEW

The Specialist Medical Review Council

1. The composition of each Review Council changes from review to review depending on the issues relevant to the particular Statement/s of Principles under review. When a review is undertaken three to five Councillors selected by the Convener constitute the Council.
2. The Minister must appoint one of the Councillors to be the Convener. If the Council does not include the Convener, the Convener must appoint one of the Councillors selected for the review to preside at all meetings as Presiding Councillor.
3. Professor Charles Guest, Convener of the Council, was the Presiding Councillor for this review. He is a public health physician with ACT Health and the Australian National University, and a Past-President of the Australasian Faculty of Public Health Medicine.
4. The other members of the Council were:

– Associate Professor Deborah Yates, Senior Staff Specialist in Thoracic Medicine, St Vincent’s Hospital, Sydney, and conjoint Associate Professor, UNSW. Former alternate Chairperson of Medical Authority, Dust Diseases Board of NSW, and of the Central Pneumoconiosis Panel, London, UK. Leads a research program into occupational and obstructive lung diseases, including mesothelioma, asbestos-related disease and occupational asthma. Current member of the National Centre for Asbestos Related Diseases (NCARD).

– Professor John Wilson, Respiratory Physician and Head, Cystic Fibrosis Service, Department of Allergy, Immunology & Respiratory Medicine, Alfred Hospital, Melbourne. Professor, Faculty of Medicine, Nursing and Health Sciences, Monash University.

– Associate Professor Ian Glaspole, Visiting Medical Officer, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital, Melbourne. Head of Interstitial Lung Disease Clinic. Co-chair, Australian Idiopathic Pulmonary Fibrosis Registry. Adjunct Clinical Associate Professor, Monash University, Central and Eastern Clinical School, Alfred Hospital. The Legislation

1. The legislative scheme for the making of Statements of Principles is set out in Parts XIA and XIB of the VEA. Statements of Principles operate as templates. They are determined by the RMA, and set out those criteria (conditions or exposures), known as factors, that must as a minimum exist before it can be said that an injury, disease or death can be connected with service, on either or both of the two statutory tests, the reasonable hypothesis test [[353]](#footnote-293) and the balance of probabilities test.[[354]](#footnote-294) Statements of Principles are ultimately applied by decision-makers in determining individual claims for benefits under the VEA and the Military Rehabilitation and Compensation Act 2004 (the MRCA).[[355]](#footnote-295)

###### APPENDIX C: WRITTEN AND ORAL SUBMISSIONS

Applicant’s Submissions

1. The Applicant, made written and oral submissions. In them he raised concerns with both the duration of exposure required in the SoPs, and the means of exposure. He contended that the medical consensus that conditions such as asbestosis are usually associated with heavy long term exposure appears to be shifting to the view that low levels of asbestos fibres in the air can also be dangerous.
2. The Applicant also contended that the American Thoracic Society has proposed that the presence of asbestos bodies or pleural plaques can be used as an “…alternative to duration of exposure in attributing non-malignant diseases to asbestos exposure”.
3. The Applicant regarded the American Thoracic Society criteria and the parties that developed the Helsinki criteria as expert bodies.[[356]](#footnote-296) He contended that the current requirement in the SoPs for exposure to be experienced, “at the time material containing respirable asbestos fibres was being applied, removed, dislodged, cut or drilled…”, is not supported by the findings of these expert bodies.
4. The Applicant considered that the Greenberg article also supported his contentions that low exposures to asbestos can potentially create disease.
5. The Applicant proposed that what he referred to as the ‘…long exposure requirements and the heavy exposure requirement’ in the current SoPs could be amended in accordance with the 2004 American Thoracic Society criteria.

Commissions Submission

1. The Commissions’ representative made written and oral submissions. Essentially the Commissions contended that pleural plaques and asbestos bodies are markers of exposure at some time to asbestos, but not to how much asbestos exposure is required to develop asbestosis or pulmonary fibrosis.
2. The Commissions contended that there was sound medical scientific evidence[[357]](#footnote-297) from studies of people who had worked in asbestos handling industries, asbestos product manufacture and miners, shipbuilders that related to long term occupational exposure generally measured in years.
3. The Commissions also noted the evidence in non-occupationally exposed persons such as wives of shipbuilders or from people who lived in proximity to asbestos industrial plants, with quite low level exposures.
4. The Commissions contended there was other evidence where authors advocated exposures between 25 fibre/mL/years as a bench mark level sufficient to induce fibrosis, but that other evidence supported lower levels of around 5 fibre/mL-years, although there was also evidence that it was possible to have quite a high exposure and not get asbestosis.
5. In the Commissions’ view the evidence in respect of Merchant Mariners (Selikoff et al[[358]](#footnote-298)) relate to the sort of low exposures likely for Australian NAVY veterans, but asbestos exposure may have occurred in the other services for example related to mechanical situations such as with asbestos brake linings.
6. In conclusion the Commissions submitted that lower minimum exposure durations than contained in the existing SoP factors were not warranted by the available evidence. The Commissions re-affirmed their view that the existence of either pleural plaques or asbestos bodies were markers of asbestos exposure, but did not reduce the minimum amount of asbestos exposure necessary to cause asbestosis.

The Commissions’ view was that amendments to factors in the SoP to lower minimum exposure durations were not warranted on the available evidence.

###### APPENDIX D: INFORMATION BEFORE THE COUNCIL

The Available Information, sent to the SMRC by the RMA under section 196K.

 **ASBESTOSIS**

|  |  |
| --- | --- |
| RMA ID Number | Reference List for # 48 as at 7 August 2013 |

|  |  |
| --- | --- |
| 429 | Becklake MR (1991). Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest, 100(1): 248-54. |
| 430 | Becklake MR, Case BW (1994). Fiber burden and asbestos-related lung disease: Determinants of dose-response relationships. Am J Respir Crit Care Med, 150(6 Pt 1): 1488-92. |
| 431 | Churg A, Vedal S (1994). Fiber burden and patterns of asbestos-related disease in workers with heavy mixed amosite and chrysotile exposure. Am J Respir Crit Care Med, 150(3): 663-9. |
| 432 | de Klerk NH, Musk AW, Armstrong BK, Hobbs MST (1991). Smoking, exposure to crocidolite, and the incidence of lung cancer and asbestosis. Br J Ind Med, 48(6): 412-7. |
| 433 | Anderson DM, Keith J, Novak PD (Lexicographers) (1994). Asbestosis. Dorland's Illustrated Medical Dictionary, 28th Edition,: 146. WB Saunders, Philadelphia. |
| 434 | Gasensler EA (1992). Asbestos exposure in buildings. Clinics in Chest Medicine, 13(2): 231-42. |
| 435 | Klaas VE (1993). A diagnostic approach to asbestosis, utilizing clinical criteria, high resolution computed tomography, and gallium scanning. Am J Ind Med, 23(5): 801-9. |
| 436 | Lordi GM, Reichman LB (1993). Pulmonary complications of asbestos exposure. Am Family Physician, 48(8): 1471-7. |
| 437 | Murai Y, Kitagawa M, Yasuda M, Okada E, et al (1994). Asbestos fiber analysis in seven asbestosis cases. Arch Environ Health, 49(1): 67-72. |
| 438 | National Occupational Health and Safety Commission (1988). Asbestos: Code of practice and guidance notes. Guide to the control of asbestos hazards in buildings and structures, : 3-7. Australian Government Publishing Service. |
| 439 | International Labour Organisation (1981). L Parmeggiani (Ed). Encyclopaedia of Occupational Health and Safety, 3rd Edition, Vol (A-K): 857-9. International Labour Office Publication, Geneva. |
| 440 | Sluis-Cremer GK (1991). Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci, : 182-93. |
| 441 | Mossman BT, Gee JBL (1989). Asbestos-related diseases. NEJM, 320(26): 1721-30. |
| 442 | Matos E, Boffetta P (1994). Other Diseases. Occupational Cancer in Developing Countries, 1st Edition, Chapter 8: 129-39. Stylus Publishing LLC , Sterling, VA. |
| 443 | Joseph MR (1994). Asbestos-related diseases. MJA, 161(3): 228-9. |
| 444 | Cookson WO, De Klerk NH, Musk AW, Armstrong BK, et al (1986). Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med, 43(7): 450-7. |
| 445 | Cookson WO, De Klerk N, Musk W, Glancy JJ, et al (1986). The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis, 133(6): 994-8. |
| 454 | Finkelstein MM, Vingilis JJ (1984). Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis, 129(1): 17-22. |
| 4296 | Enterline PE, et al (1987). Asbestos and cancer: a cohort followed up to death. British Journal of Industrial Medicine, 44: 396-401. |
| 6733 | Selikoff IJ, Hammond EC, Seidman H (Eds) (1979). Mortality experience of insulation workers in the United States and Canada, 1943-1976. Health Hazards of Asbestos Exposure, 330: 91-116. Annals of the New York Academy of Sciences. |
| 6902 | Giaroli C, Belli S, Bruno C, Candella S, et al (1994). Mortality study of asbestos cement workers. Int Arch Occup Environ Health, 66: 7-11. |
| 7020 | Rosler JA, Woitowitz HJ, Lange HJ, et al (1994). Mortality rates in a female cohort following asbestos exposure in Germany. JOM, 36(5): 889-93. |
| 7162 | Huncharek M (1994). Asbestos and cancer: epidemiological and public health controversies. Cancer Investigation, 12(2): 214-22. |
| 7176 | Cheng W, Kong J (1992). A retrospective mortality cohort study of chrysolite asbestos products workers in Tianjin 1972-1987. Environ Res, 59: 271-8. |
| 10438 | Andersen A, Glattre E, Johansen BV (1993). Incidence of cancer among lighthouse keepers exposed to asbestos in drinking water. Am J Epidemiol, 138(9): 682-7. |
| 14774 | Selikoff IJ, Seidman H (1991). Asbestos-associated deaths among insulation workers in the United States and Canada, 1967-1987. Annals New York Academy of Sciences, 643: 1-14. |
| 19882 | Camus M, Siemiatycki J, Meek B (1998). Nonoccupational exposure to chrysotile asbestos and the risk of lung cancer. NEJM, 338(22): 1565-71. |
| 20152 | Seidman H, Selikoff IJ, Gelb SK (1986). Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. American Journal of Industrial Medicine, 10: 479-514. |
| 26458 | Dumortier P, Coplu L, de Maertelaer V, Emri S, Baris I, De Vuyst P (1998). Assessment of environmental asbestos exposure in Turkey by bronchoaloveolar lavage. American Journal of Respiratory Critical Care Medicine, 158: 1815-24. |
| 26459 | Markowitz SB, Morabia A, Lilis R, Miller A, Nicholson WJ, Levin S (1997). Clinical predictors of mortality from asbestosis in the North American Insulator Cohort, 1981 to 1991. American Journal of Respiratory Critical Care Medicine, 156: 101-8. |
| 26460 | Jagielo PJ, Watt JL, Quinn TJ, Knapp HR, Schwartz DA (1997). Occupational and environmental lung disease. Pentoxifylline does not alter the response to inhaled grain dust. Chest, 111: 1429-35. |
| 26461 | Beckett WS (1997). Diagnosis of asbestosis. Primum non nocere. Chest, 111: 1427-8. |
| 26462 | Rosenberg DM (1997). Debate in print. Asbestos-related disorders. A realistic perspective. Chest, 111: 1424-26. |
| 26463 | Rosenberg DM (1997). Debate in print. Asbestos-related disorders. A realistic perspective. Chest, 111: 1424-26. |
| 26464 | Wagner GR (1997). Asbestosis and silicosis. Lancet, 349: 1311-15. |
| 26465 | Liddell FD, McDonald AD, McDonald JC (1997). The 1891-1920 birth cohort of Quebec chrysotile miners and millers: development from 1904 and mortality to 1992. Annuals of Occupational Hygiene, 41(1): 13-36. |
| 26466 | Borron SW, Forman SA, Lockey JE, et al (1997). An early study of pulmonary asbestosis among manufacturing workers: original data and reconstruction of the 1932 cohort. American Journal of Industrial Medicine, 31: 324-34. |
| 26468 | Wang X, Yano E, Nonaka K, Wang M, Wang Z (1997). Respiratory impairments due to dust exposure: a comparative study among workers exposed to Silica, asbestos, and coalmine dust. American Journal of Industrial Medicine, 31: 495-502. |
| 26469 | Green FH, Harley R, Althouse R, et al (1997). Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. Occupational & Environmental Medicine, 54: 549-59. |
| 26470 | Levin JL, McLarty JW, Hurst GA, Smith AN, Frank Al (1998). Tyler asbestos workers: mortality experience in a cohort exposed to amosite. Occupational & Environmental Medicine, 55: 155-60. |
| 26481 | Magnani C, Mollo F, Paoletti L, et al (1998). Asbestos lung burden and asbestosis after occupational and environmental exposure in an asbestos cement manufacturing area: a necropsy study. Occupational & Environmental Medicine, 55: 840-6. |
| 26482 | Wang XR, Christiani DC (2000). Respiratory symptoms and functional status in workers exposed to silica, asbestos, and coal mine dusts. Journal of Occupational & Environmental Medicine, 42: 1076-84. |
| 26483 | Wang XR, Yano E, Wang M, Wang Z, Christiani DC (2001). Pulmonary function in long-term asbestos workers in China. Journal of Occupational & Environmental Medicine, 43: 623-9. |
| 26484 | Kilburn KH (2000). Prevalence and features of advanced asbestosis (ILO Profusion scores above 2/2). Archives of Environmental Health, 55(2): 104-8. |
| 26485 | Murai Y, Kitagawa M (2000). Autopsy cases of asbestosis in Japan: a statistical analysis on registered cases. Archives of Environmental Health, 55(6): 447-52. |
| 26486 | Nayebzadeh A, Dufresne A, Case B, Vali H, Williams-Jones AE, Normand C, Martin R, Clark J (2001). Lung mineral fibers of former miners and millers from Thetford-Mines and asbestos regions: a comparative study of fiber concentration and dimension. Archives of Environmental Health, 56(1): 65-76. |
| 26487 | Manning CB, Vallyathan V, Mossman BT (2002). Diseases caused by asbestos: mechanisms of injury and disease development. International Immunopharmacology, 2: 191-200. |
| 26488 | Hirvonen A, Tuimala J, Ollikainen T, Linnainmaa K, Kinnula V (2002). Manganese superoxide dismutase genotypes and asbestos-associated pulmonary disorders. Cancer Letters, 178: 71-4. |
| 26489 | Lafuente MJ, Casterad X, Laso N, et al (2002). Pi S and Pi Z alpha 1 antitrysin polymorphism and the risk for asbestosis in occupational exposure to asbestos. Toxicology Letters, 136: 9-17. |
| 26490 | Rosenman KD, Reilly MJ (1998). Asbestos-related x-ray changes in foundry workers. American Journal of Industrial Medicine, 34: 197-201. |
| 26491 | Mattioli S, Nini D, Mancini G, Violante FS (2002). Past asbestos exposure levels in foundries and cement-asbestos factories. American Journal of Industrial Medicine, 42: 363. |
| 26492 | Puntoni R, Merlo F, Borsa L, Reggiardo G, et al (2001). A historical cohort mortality study among shipyard workers in Genoa, Italy. American Journal of Industrial Medicine, 40: 363-70. |
| 26493 | Algranti E, Mendonca EM, DeCapitani EM, et al (2001). Non-malignant asbestos-related diseases in Brazilian asbestos-cement workers. American Journal of Industrial Medicine, 40: 240-54. |
| 26494 | Kishimoto T, Morinaga K, Kira S (2000). The prevalence of pleural plagues and/or pulmonary changes among construction workers in Okayama, Japan. American Journal of Industrial Medicine, 37: 291-5. |
| 26495 | Germani D, Belli S, Bruno C, Grignoli M, Nesti M, Pirastu R, Comba P (1999). Cohort mortality study of women compensated for asbestosis in Italy. American Journal of Industrial Medicine, 36: 129-34. |
| 26496 | Glencross PM, Weinberg JM, Ibrahim JG, Christiani DC (1997). Loss of lung function among sheet metal workers: ten-year study. American Journal of Industrial Medicine, 32: 460-6. |
| 26497 | Finkelstein MM (1997). Radiographic asbestosis is not a prerequisite for asbestos-associated lung cancer in Ontario asbestos-cement workers. American Journal of Industrial Medicine, 32: 341-8. |
| 26507 | Wright RS, Abraham JL, Harber P, Burnett BR, Morris P, West P (2002). Fatal asbestosis 50 years after brief high intensity exposure in a Vermiculite expansion plant. American Journal of Respiratory Care Medicine, 165: 1145-9. |
| 26508 | Cagle PT (2002). Criteria for attributing lung cancer to asbestos exposure. American Journal of Clinical Pathology, 117: 9-15. |
| 26509 | Mollo F, Magnani C, Bo P, Burlo P, Cravello M (2002). The attribution of lung cancers to asbestos exposure. American Journal of Clinical Pathology, 117: 90-5. |
| 26510 | Tossavainen A (2000). Consensus report. International expert meeting on new advances in the radiology and screening of asbestos-related diseases. Scandinavian Journal of Work, Environment & Health, 26(5): 449-54. |
| 26511 | O'Reilly D, Reid J, Middleton R, Gavin AT (1999). Asbestos related mortality in Northern Ireland: 1985-1994. Journal of Public Health Medicine, 21(1): 95-101. |
| 26512 | Kamp DW, Weitzman SA (1997). Asbestosis: clinical spectrum and pathogenic mechanisms. Proceedings of the Society for Experimental Biology & Medicine, 214(1): 12-26. |
| 26513 | Koskinen K, Zitting A, Tossavainen A, et al (1998). Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scandinavian Journal of Work, Environment & Health, 24(2): 109-17. |
| 26514 | Miller A (1998). Sherlock Holmes, Albrecht Durer, and Socrates: The International Labour Office Radiographic Classification of pneumoconioses reassessed for asbestosis. Chest, 113(6): 1439-42. |
| 26515 | Oksa P, Klockars M, Karjalainen A, et al (1998). Progression of asbestosis predicts lung cancer. Chest, 113: 1517-21. |
| 26516 | Morgan WK (1999). On perception, perspicuity, and precision. Chest, 115(1): 303-5. |
| 26517 | Anonymous (1997). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scandinavian Journal of Work, Environment & Health, 23(4): 311-6. |
| 26539 | Merler E (1996). Asbestos-related mortality among Italian migrants to Western Australia. Epidemiology, 7(5): 556-7. |
| 26548 | Kuku O, Parker DL (2000). Diagnosis and management of asbestosis. Minnesota Medicine, 83: 47-9. |
| 26549 | Osinubi OY, Gochfeld M, Kipen HM (2000). Health effects of asbestos and nonasbestos fibers. Environmental Health Perspectives, Vol 108(Suppl 4): 665-74. |
| 26550 | Tsai W, Morgan WK (1996). The pneumoconioses. Current Opinion in Pulmonary Medicine, 2(2): 116-20. |
| 26551 | Landrigan PJ, Nicholson WJ, Suzuki Y, Ladou J (1999). The hazards of chrysotile asbestos: a critical review. Industrial Health, 37(3): 271-80. |
| 26552 | Kurumatani N, Natori Y, Mizutani R, et al (1999). A historical cohort mortality study of workers exposed to asbestos in a refitting shipyard. Industrial Health, 37(1): 9-17. |
| 26585 | Wells C, Mannino DM (1996). Pulmonary fibrosis and lung cancer in the United States: analysis of the multiple cause of death mortality data, 1979 through 1991. Southern Medical Association Journal, 89(5): 505-10. |
| 26586 | Bang KM, Althouse RB, Kim JH, Game SR (1999). Recent trends of age-specific pneumoconiosis mortality rates in the United States, 1985-1996: coal workers' pneumoconiosis, asbestosis, and silicosis. International Journal of Occupational & Environmental Health, 5(4): 251-5. |
| 26587 | Case BW, Dufresne A (1997). Asbestos, asbestosis, and lung cancer: observations in Quebec chrysotile workers. Environmental Health Perspectives, 105(Suppl 5): 113-9. |
| 26588 | Neri S, Boraschi P, Antonelli A, Falaschi F, Baschieri L (1996). Pulmonary function, smoking habits, and high resolution computed tomography (HRCT) early abnormalities of lung and pleural fibrosis in shipyard workers exposed to asbestos. American Journal of Industrial Medicine, 30(5): 588-95. |
| 26589 | Robinson CF, Petersen M, Sieber WK, Palu S, Halperin WE (1996). Mortality of Carpenters' Union members employed in the US construction or wood products industries, 1987-1990. American Journal of Industrial Medicine, 30(6): 674-94; Erratum: (1997): 31(1):126. |
| 26590 | Fischer M, Gunther S, Muller KM (2002). Fibre-years, pulmonary asbestos burden and asbestosis. International Journal of Hygiene Environmental Health, 205: 245-8. |
| 26600 | Boffetta P (1998). Health effects of asbestos exposure in humans: a quantitative assessment. Medicina del Lavoro, 89(6): 471-80. |
| 26601 | Szeszenia-Dabrowska N, Urszula W, Szymzak W, Stzelecka A (2002). Mortality study of workers compensated for asbestosis in Poland, 1970-1997. International Journal of Occupational & Environmental Health, 15(3): 267-78. |
| 26602 | Schaeffner ES, Miller DP, Wain JC, Christiani DC (2001). Use of an asbestos exposure score and the presence of pleural and parenchymal abnormalities in a lung cancer case series. International Journal of Occupational & Environmental Health, 7(1): 14-8. |
| 26723 | Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S (2002). Asbestos: when the dust settles - an imaging review of asbestos-related disease. Radiographics, 22: S167-S84. |
| 26724 | Bekkelund SI, Aasebo U, Pierre-Jerome C, Holmboe J (1998). Magnetic resonance imaging of the thorax in the evaluation of asbestosis. European Respiratory Journal, 11: 194-7. |
| 26734 | Meel BL (2002). Patterns of lung diseases in former mine workers of the former Republic of the Transkei: an x-ray-based study. International Journal of Occupational & Environmental Health, Vol 8(2): 105-10. |
| 27243 | Battista G, Belli S, Comba P, et al (1999). Mortality due to asbestos-related causes among railway carriage construction and repair workers. Occup Med, 49: 536-9. |
| 28698 | McMillan GH, Pethybridge RJ, Sheers G (1980). Effect of smoking on attack rates of pulmonary and pleural lesions related to exposure to asbestos dust. British Journal of Industrial Medicine, 37: 268-72. |
| 29566 | Omenn GS, Goodman GE, Thornquist MD, et al (1993). The carotene and retinol efficacy trial (CARET) to prevent lung cancer in high-risk populations: pilot study with asbestos-exposed workers. Cancer Epidemiology Biomarkers & Prevention, 2: 381-7. |
| 33719 | Rom WN (Ed) (1998). Environmental and Occupational Medicine, Third Edition,. Lippincott-Raven, Philadelphia. |
| 34864 | Albin M, Pooley FD, Stromberg U, et al (1994). Retention patterns of asbestos fibres in lung tissue among asbestos cement workers. Occupational and Environmental Medicine, 51(3): 205-11. |
| 34865 | Greenberg M (2004). The British approach to asbestos standard setting: 1898-2000. American Journal of Industrial Medicine, 46: 534-41. |
| 34901 | Ehrlich R, Lilis R, Chan E, Nicholson WJ, Selikoff IJ (1992). Long term radiological effects of short term exposure to amosite asbestos among factory workers. British Journal of Industrial Medicine, 49: 268-75. |
| 34902 | Quinlan TR, Marsh JP, Jannssen YM, et al (1994). Dose-responsive increases in pulmonary fibrosis after inhalation of asbestos. Am J Respir Crit Care Med, 150: 200-6. |
| 34903 | Hillerdal G, Henderson DW (1997). Asbestos, asbestosis, pleural plaques and lung cancer. Scand J Work Environ Health, 23: 93-103. |
| 34904 | Quinlan TR, Berube KA, Marsh JP, Janssen YMW, Taishi P, Leslie KO, Hemenway D, O'shaughnessy PT, Vacek P, Mossman BT (1995). Patterns of inflammation, cell proliferation, and related gene expression in lung after inhalation of chrysotile asbestos. Am J Pathol, 147(3): 728-39. |
| 34905 | Corn JK, Corn M (1995). Approaches to assessment of environmental inhalation risk: A case study. The Milbank Memorial Fund, 73(1): 97-119. |
| 34906 | Rodelsperger K, Woitowitz HJ, Bruckel B, Arhelger R, Pohlabeln H, Jockel KH (1999). Dose-response relationship between amphibole fiber lung burden and mesothelioma. Cancer Detection and Prevention, 23(3): 183-93. |
| 35222 | Henderson DW, Jones ML, De Lerk N, et al (2004). The diagnosis and attribution of asbestos-related diseases in an Australian context. Int J Occup Environ Health, 10: 40-6. |
| 35223 | Levin JL, McLarty JW, Hurst GA, Smith AN, Frank AL (1998). Tyler asbestos workers: mortality experience in a cohort exposed to amosite. Occup Environ Med, 55: 155-60. |
| 35224 | Attfield MD, Wood JM, Pinheiro GA (2004). Changing patterns of pneumoconiosis mortality in United States, 1968-2000. MMWR Weekly, 53(28): 627-32. |
| 35225 | Markowitz SB, Morabia A, Lilis R, Miller A, Nicholoson WJ, Levin S (1997). Clinical predictors of mortality from asbestosis in the North American insulator cohort, 1981 to 1991. AM J Respir Crit Care Med, 156: 101-8. |
| 35226 | Faust RA (1995). Toxicity Summary For Asbestos. Oak Ridge Reservation Environmental Restoration Program, . Oak Ridge National Laboratory, Oak Ridge, Tennessee. |
| 35227 | Agency for Toxic Substances and Disease Registry (ATSDR) (2001). Toxicological Profile for Asbestos, . Department of Human Services, Public Health Service, Atlanta, GA. |
| 35331 | Lebovit AH, Strain JJ (1990). The asbestos worker who smokes: adding insult to injury. Health Psychology, 9(4): 405-17. |
| 35332 | Churg A, Wright JL, Hobson J, Stevens B (1992). Effects of cigarette smoke on the clearance of short asbestos fibres from the lung and a comparison with the clearance of long asbestos fibres. Int J Exp Path, 73: 287-97. |
| 35333 | Kilburn KH, Warshaw RH (1993). Total lung capacity in asbestosis: A comparison of radiographic and body plethysmographic methods. Am J Med Sci, 305(2): 84-7. |
| 35334 | McDonald JC, Liddell FDK, Dufresne A, McDonald AD (1993). The 1891-1920 birth cohort of Quebec chrysotile miners and millers: mortality 1976-88. Br J Ind Med, 50(12): 1073-81. |
| 35335 | Jarvholm B (1992). Pleural plaques and exposure to asbestos: A mathematical model. International Journal of Epidemiology, 21(6): 1180-4. |
| 35752 | Burdorf A, Dahhan M, Swuste P (2003). Occupational characteristics of cases with asbestos-related diseases in the Netherlands. Ann Occup Hyg, 47(6): 485-92. |
| 35753 | Churg A, Wiggs B (1985). Mineral particles, mineral fibers, and lung cancer. Environmental Research, 37(2): 364-72. |
| 35754 | Kilburn KH, Lilis R, Anderson HA, Miller A, Warshaw RH (1986). Interaction of asbestos, age, and cigarette smoking in producing radiographic evidence of diffuse pulmonary fibrosis. The American Journal of Medicine, 80(3): 377-81. |
| 35755 | Kilburn KH, Warshaw RH (1994). Airways obstruction from asbestos exposure: effects of asbestosis and smoking. Chest, 106(4): 1061-70. |
| 35756 | Selikoff IJ, Lilis R (1991). Radiological abnormalities among sheet-metal workers in the construction industry in the United States and Canada: relationship to asbestos exposure. Archives of Environmental Health, 46(1): 30-6. |
| 35757 | Shepherd JR, Hillerdal G, McLarty J (1997). Progression of pleural and parenchymal disease on chest radiographs of workers exposed to amosite asbestos. Occupational & Environmental Medicine, 54(6): 410-5. |
| 35758 | World Health Organization (2000). Air quality guidelines. Asbestos. 2nd Edition, Chapter 6.2. Retrieved 9 May 2005, from http://www.euro.who.int/\_\_data/assets/pdf\_file/0015/123072/AQG2ndEd\_6\_2\_asbestos.PDF  http://www.euro.who.int/\_\_data/assets/pdf\_file/0015/123072/AQG2ndEd\_6\_2\_asbestos.PDF |
| 35759 | MMWR US CDC (2004). Changing patterns of pneumoconiosis mortality - United States, 1968-2000. 53 (28): 627-632. Retrieved 12 May 2005, from http://www.cdc.gov/mmwr/preview/mmwrhtml/mm5328a1.htm |
| 35768 | Varkey B, Varkey AB (2004). Asbestosis. . Retrieved 12 May 2005, from http://www.emedicine.com/med/topic171.htm |
| 35769 | Lerman Y, Selikoff IJ, Lilis R, Seidman H, Gelb SK (1986). Clinical findings among asbestos workers in U.S.: influence of cigarette smoking. Am J Ind Med, 10(5-6): 449-58. |
| 35770 | Lilis R, Selikoff IJ, Lerman Y, Seidman H, Gelb SK (1986). Asbestosis: interstitial pulmonary fibrosis and pleural fibrosis in a cohort of asbestos insulation workers: influence of cigarette smoking. Am J Ind Med, 10(5-6): 459-70. |
| 35792 | Selikoff IJ, Lilis R, Levin G (1990). Asbestotic radiological abnormalities among United States merchant marine seamen. Br J Ind Med, 47(5) pp 292-7. |
| 35793 | Schwartz DA, Davis CS, Merchant JA, Bunn WB, Galvin JR, Van Fossen DS, Dayton CS, Hunninghake GW (1994). Longitudinal changes in lung function among asbestos-exposed workers. Am J Respir Crit Care Med, 150(5 Pt 1): 1243-9. |
| 35794 | McFadden D, Wright J, Wiggs B, Churg A (1986). Cigarette smoke increases the penetration of asbestos fibers into airway walls. Am J Pathol, 123(1): 95-9. |
| 35795 | Miller A, Lilis R, Godbold J, Chan E, Wu X, Selikoff IJ (1994). Spirometric impairments in long-term insulators. Relationships to duration of exposure, smoking, and radiographic abnormalities. Chest, 105(1): 175-82. |
| 35796 | Sluis-Cremer GK, Hnizdo E (1989). Progression of irregular opacities in asbestos miners. British Journal of Industrial Medicine, 46: 846-52. |
| 37668 | Maron CR (2005). [Comment] Email regarding exposure to asbestos in Navy. chris.maron@defence.gov.au, : . |
| 41104 | Googe A (2005). [E-mail]. Asbestos Exposure, : . |
| 41105 | Shilkin, K (2005). [Comment] [E-mail]. Asbestosis, : . |
| 41106 | Gardner I (2005). [E-mail]. Asbestos exposure - RMA review of SoP's etc, : . |
| 45641 | Sullivan PA (2007). Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect, 115(4): 579-85. |
| 46916 | Lilis R, Miller A, Godbold J, Chan E, Selikoff IJ (1991). Radiographic abnormalities in asbestos insulators: effects of duration from onset of exposure and smoking. Relationships of dyspnea with parenchymal and pleural fibrosis. American Journal of Industrial Medicine, 20: 1-15. |
| 46917 | Kilburn KH, Warshaw RH (1992). Severity of pulmonary asbestosis as classified by International Labour Organisation profusion of irregular opacities in 8749 asbestos-exposed American workers. Arch Intern Med, 152: 325-7. |
| 46918 | Churg A, Stevens B (1995). Enhanced retention of asbestos fibers in the airways of human smokers. Am J Respir Crit Care Med, 151: 1409-13. |
| 46972 | Peipins LA, Lewin M, Campolucci S, Lybarger JA, et al (2003). Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA. Environmental Health Perspectives, 111(14): 1753-59. |
| 46973 | Price B; Peipins LA, et al; Flynn JJ, et al; Peipins LA, et al (2004). [Comments] Radiographic abnormalities and asbestos exposure: Libby, Montana. Environmental Health Perspectives, 112(2): a82-a85. |
| 46974 | Burdorf A, Dahhan M, Swuste P (2003). Occupational characteristics of cases with asbestos-related diseases in the Netherlands. Ann Occup Hyg, 47(6): 485-92. |
| 46975 | Speizer (2005). Asbestosis. Harrison's Internal Medicine. Part 9, Section 2, Chapter 238. Retrieved 22 January 2008, from http://proxy14.use.hcn.com.au/popup.aspx?aID=84212&print=yes |
| 46976 | Copley SJ, Lee YC, Hansell DM, Sivakumaran P, et al (2007). Asbestos-induced and smoking-related disease: apportioning pulmonary function deficit by using thing-section CT. Radiology, 242(1): 258-66. |
| 46996 | Franko A, Dolzan V, Arneric N, Dodic-Fikfak M (2008). The influence of genetic polymorphisms of GSTP1 on the development of asbestosis. JOEM, 50(1): 7-12. |
| 46997 | Howard TP (2003). Pneumoconiosis in a vermiculite end-product user. American Journal of Industrial Medicine, 44: 214-7. |
| 47043 | Al-Ghimlas F, Hoffstein V (2007). Pleuroparenchymal lung disease secondary to nonoccupational exposure to vermiculite. Can Respir J, 14(3): 164-6. |
| 67504 | Popper HH (2013). Interstitial lung diseases - can pathologists arrive at an etiology-based diagnosis? A critical update. Virchows Arch, 462: 1-26. |
| 67546 | Kamp DW (2009). Asbestos-induced lung diseases: an update. Transl Res, 153(4): 143-52. |
| 67547 | Mossman BT, Lippmann M, Hesterberg TW, Kelsey KT et al (2011). Pulmonary endpoints (lung carcinomas and asbestosis) following inhalation exposure to asbestos. J Toxicol Environ Health Part B, 14: 76-121. |
| 67548 | Roggli VL, Gibbs AR, Attanoos R, Chung A et al (2010). Pathology of asbestosis - An update of the diagnostic criteria. Arch Path Lab Med, 134: 462-80. |
| 67549 | Yang HY, Shie RH, Chen PA (2013). Pulmonary fibrosis in workers exposed to non-asbestiform tremolite asbestos minerals. Epidemiol, 24: 143-9. |
| 67565 | Balmes JR, Speizer FE (2013). Occupational and environmental lung disease. Occupational exposures and pulmonary disease. Harrison's Principles of Internal Medicine, 18th Edition, Chapter 256: 2122-8. . |
| 67594 | American Thoracic society documents (2004). Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med, 170: 691-715. |
| 67595 | Bernstein D, Dunnigan J, Hesterberg T et al (2013). Health risk of chrysotile revisited. Crit Rev Toxicol, 43(2): 154-83. |
| 67596 | Deng Q, Wang X, Wang M, Lan Y (2011). Exposure-response relationship between chryostile exposure and mortality from lung cancer and asbestosis. Occup Environ Med, 69: 81-6. |
| 67597 | Hein MJ, Stayner LT, Lehman E, Dement JM (2007). Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. Occup Environ Med, 64: 616-25. |
| 67598 | Larson TC, Antao VC, Bove FJ (2010). Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. JOEM, 52(5): 555-60. |
| 67599 | O'Reilly KM, McLaughlin AM, Beckett WS, Sime PJ (2007). Asbestos-related lung disease. Am Fam Physician, 75: 683-8. |
| 67600 | Paris C, Benichou J, Raffaelli C, Genevois A, et al (2004). Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health, 30(3): 206-14. |
| 67601 | Paris C, Thierry S, Brochard P, Letourneux M, et al (2009). Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J, 34: 72-9. |
| 67602 | Price B (2008). Exposure to airborne amphibole structures and health risks: Libby, Montana. Regulatory Toxicology & Pharmacology, 52: S97-109. |
| 67995 | Rohs AM, Lockey JE, Dunning KK et al (2008). Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med, 177: 630-7. |
| 67997 | U.S. Department of Health and Human Services, ATSDR and Disease Registry Division of Health Assessment and Consultation (2008). Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United States. . |
| 68460 | Antao VC, Larson TC, Horton DK (2012). Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med, 18(2): 161-7. |
| 68770 | Webb WR, Higgins CB (2011). Asbestosis and asbestos-related disease. Thoracic Imaging: Pulmonary and Cardiovascular Radiology, 2nd Edition, Chapter 18: 505-11. Lippincott-Williams & Wilkins. |

**FIBROSING INTERSTITIAL LUNG DISEASE**

|  |  |
| --- | --- |
| RMA ID Number | Reference List for # 285 as at 7 August 2013 |
| 9483 | McKee AL, Rajapaksa A, Kalish PE, Pitchumoni CS (1983). Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am J Gastroenterology, 78(2): 86-9. |
| 9810 | Cugell DW, Morgan WKC, Perkins DG, Rubin A (1990). The respiratory effects of cobalt. Arch Intern Med, 150: 177-183. |
| 9815 | Liipo KK, Anttila SL, Taikina-Aho O, Ruokonen E-L, Toivonen ST, Tuomi T (1993). Hypersensitivity pneumonitis and exposure to zirconium silicate in a young ceramic tile worker. Am Rev Respir Dis, 148: 1089-92. |
| 11682 | Roscoe RJ, Deddens JA, Salvan A, & Schnorr TM (1995). Mortality among Navajo uranium miners. American Journal of Public Health, 85: 535-40. |
| 11751 | Vergon JM, De TH, Weynants P, Vincent M, Mornex JF and Brune J (1984). Cryptogenic fibrosing fibreolitis and Epstein-Barr virus: an association? The Lancet, Oct 6: 768-771. |
| 11752 | Turner-Warwick M, Burrows B and Johnson A (1980). Cryptogenic fibrosing alveolitis: clinical features and their influence on survival. Thorax, 35: 171-80. |
| 11753 | Staton FW Jr and Ingram RH Jr (1996). Chronic Diffuse Infiltrative Lung Disease Scientific American Medicine Dale DC and Federman DD (Eds). Scientific American Inc. New York, 14, VB: 15-18. . |
| 11754 | Scott J, Johnston I and Britton J (1990). What causes cryptogenic fibrosing alveolitis? A case-control study of environmental exposure to dust. BMJ, 301(6759): 1015-7. |
| 11755 | Reynolds HY (1994). Interstitial Lung Diseases. Harrison's Principles of Internal Medicine, 13th Edition, 224: 1206-9. McGraw Hill . New York. |
| 11756 | Ramage JE, Roggli VL, Bell DY and Piantodosi CA (1988). Interstitial lung disease and domestic wood burning. Am Rev Resp Dis, 137: 1229-32. |
| 11757 | Marshall RP, McAnulty RJ, Laurent GJ (1997). The pathogenesis of pulmonary fibrosis: is there a fibrosis gene? International Journal of Biochemistry & Cell Biology, 29(1): 107-20. |
| 11758 | Hubbard R, Lewis S, Richards K, Johnston I and Britton J (1996). Occupational exposure to metal or wood dust and aetiology of cryptogenic fibrosing alveolitis [see comments]. Lancet, 347(8997): 284-9. |
| 11759 | Iwai K, Mori T, Yamada N, Yamaguchi M and Hosoda Y (1994). Idiopathic pulmonary fibrosis. Epidemiologic approaches to occupational exposure. American Journal of Respiratory & Critical Care Medicine, 150(3): 670-5. |
| 11760 | Kaelin RM, Kapanci Y and Teshopp JM (1988). Diffuse interstitial lung disease associated with hydrogen peroxide in a dairy worker. Am Rev Resp Dis, 137: 1233-5. |
| 11761 | Marsh P, Johnston I and Britton J (1994). Atopy as a risk factor for cryptogenic fibrosing alveolitis. Respiratory Medicine, 88(5): 369-71. |
| 11762 | Hansell DM and Wells AU (1996). CT evaluation of fibrosing alveolitis-applications and insights. Journal of Thoracic Imaging, 11(4): 231-49. |
| 11763 | Egan JJ, Stewart JP, Hasleton PS, Arrand JR, Carroll KB and Woodcock AA (1995). Epstein-Barr virus replication within pulmonary epithelial cells in cryptogenic fibrosing alveolitis. Thorax, 50: 1234-9. |
| 11764 | Crystal RG (1994). Impact of Cell and Molecular Biology on Pulmonary Disease. Harrison's Principles of Internal Medicine, 13th Edition, 213: 1147-8. McGraw Hill. New York. |
| 11765 | Crystal RG (1988). Interstitial Lung Disease in Cecil's Textbook of Medicine. Wyngaarden JB, Smith LH (Eds). ., 19th Edition, 63: 421-9. WB Saunders Company, Philadelphia. |
| 11766 | Cherniak RM, Crystal RG and Kalica AR (1991). Current concepts in idiopathic pulmonary fibrosis: a road map for the future. Am Rev Resp Dis, 143: 680-3. |
| 11767 | Baumgartner KB, Samet JM, Stidley CA, Colby TV and Waldron JA (1997). Cigarette smoking: a risk factor for idiopathic pulmonary fibrosis. American Journal of Respiratory & Critical Care Medicine, 155(1): 242-8. |
| 11870 | Weiss W (1988). Smoking and pulmonary fibrosis. Journal of Occupational Medicine, 30(1): 33-9. |
| 11871 | Johnston I, Britton J, Kinnear W & Logan R (1990). Rising mortality from crytogenic fibrosing alveolitis. BMJ, 301(3): 1017-1021. |
| 11872 | Pratt DS, Schwartz MI, May JJ & Dreisin RB (1979). Rapidly fatal pulmonary fibrosis: the accelerated variant of interstitial pneumonitis. Thorax, 34: 587-93. |
| 11873 | Warren CPW (1977). Extrinsic allergic alveolitis: a disease commoner in non-smokers. Thorax, 32: 567-9. |
| 11874 | Martin WJ & McDougall JC (1983). Cytomegalovirus infection with idiopathic pulmonary fibrosis. Diagnosis suggested by bronchoalveolar lavage. Chest, 84(4): 500-2. |
| 11875 | Anonymous (1994). New insights into the pathogenesis of interstitial pulmonary fibrosis. Thorax, 49: 193-5. |
| 11876 | Myers JL, Veal CF, Shin MS, & Katzenstein A-L A (1987). Respiratory bronchiolitis causing interstitial lung disease. A clinicopathologic study of six cases. American Review Respiratory Disease, 135: 880-4. |
| 11877 | Foxman B, Higgins ITT & Oh MS (1986). The effects of occupation and smoking on respiratory disease mortality. American Review Respiratory Disease, 134: 649-52. |
| 11878 | Marinelli WA (1995). Idiopathic pulmonary fibrosis. Progress and challenge. Chest, 108(2): 297-8. |
| 11879 | Mays EE, Dubois JJ, Hamilton GB (1976). Pulmonary fibrosis associated with tracheobronchial aspiration. A study of the frequency of hiatal hernia and gastroesophageal reflux in interstitial pulmonary fibrosis of obscure etiology. Chest, 69(4): 512.5. |
| 11880 | de Cremoux H, Bernaudin J-F, Laurent P, Brochard P, & Bignon J (1990). interactions between cigarette smoking and the natural history of idiopathic pulmonary fibrosis. Chest, 98(1): 71-6. |
| 11881 | Monso E, Tura JM, Marsal M, Morell F, Pujadas J, Morera J (1990). Mineralogical microanalysis of idiopathic pulmonary fibrosis. Archives of Environmental Health, 45(3): 185-8. |
| 11882 | Schwartz DA, Van Fossen DS, Davis CS, Helmers RA, Dayton CS, Burmeister LF, Hunninghake GW (1994). Determinants of progression in idiopathic pulmonary fibrosis. American Journal of Respiratory Critical Care Medicine, 149: 444-9. |
| 11901 | Ueda T, Ohta K, Suzuki N, Yamaguchi M, Hirai K, Horiuchi T, Watanabe J, Miyamoto T, & Ito K (1992). Idiopathic pulmonary fibrosis and high prevalence of serum antibodies to hepatitis C virus. American Review Respiratory Disease, 146: 266-8. |
| 11902 | Irving WL, Day S, & Johnston IDA (1993). Idiopathic pulmonary fibrosis and hepatitis C virus infection. American Review Respiratory Disease, 148: 1683-4. |
| 11903 | Cherniack RM, Colby TV, Flint A, Thurbeck WM, Waldron J, Ackerson L, King TE and the BAL cooperative group steering committee (1991). Quantitive assessment of lung pathology in idiopathic pulmonary fibrosis. American Review Respiratory Disease, 144: 892-900. |
| 11904 | Billings CG, Howard P (1994). Hypothesis: exposure to solvents may cause fibrosing alveolitis. European Respiratory Journal, 7: 1172-6. |
| 11905 | Anonymous (1972). Blackfat tobacco smoker's lung. BMJ, 1(797): 393. |
| 11906 | Miller GJ, Beadnell HMSG, Ashcroft MT (1968). Diffuse pulmonary fibrosis and blackfat-tobacco smoking in Guyana. The Lancet, 2(562): 259-60. |
| 11907 | Costabel U, Donner CF, Haslam PL, Rizzato HG, Teschler H, Velluti G, Wallaert B (1990). Clinical guidelines and indications for bronchoalveolar lavage (BAL) : occupational lung diseases due to inhalation of inorganic dust. European Respiratory Journal, 3(8): 946-9, 961-9. |
| 11967 | Schwartz DA, Helmers RA, Dayton CS, Merchant RK, Hunninghake GW (1991). Determinants of bronchoalveolar lavage cellularity in idiopathic pulmonary fibrosis. Journal of Applied Physiology, 7(5): 1688-93. |
| 11968 | Crystal RG, Bitterman PB, Rennard SI, Hance AJ, et al (1984). Interstitial lung diseases of unknown causes. Disorders characterized by chronic inflammation of the lower respiratory tract (second of two parts). NEJM, 310(4): 235-44. |
| 11969 | Kerenyi T, Voss B, Goeckenjan G & Muller K-M (1992). Cellular autofluorescent pigment and interstitial fibrosis in smoker's lung. Path Res Pract, 188: 925 -30. |
| 11970 | Smith SD, Cho CT, Brahmacupta N, Lenahan MF (1977). Pulmonary involvement with cytomegalovirus infections in children. Archives of Disease in Childhood, 52: 1441-6.1. |
| 12118 | Carrington CB, Gaensler EA, Coutu RE, FitzGerald MX, & Gupta RG (1978). Natural history and treated course of usual and desquamative interstitial pneumonia. NEJM, 298(15): 801-9. |
| 12126 | Michaels L (1967). Lung changes in woodworkers. Canadian Medical Association Journal, 96(16): 1150-5. |
| 12127 | Smith C, Feldman C, Levy H, Kallenbach JM, Zwi S (1990). Cryptogenic fibrosing alveolitis. A study of an indigenous African population. Respiration, 57(6): 364-71. |
| 12128 | Deepe GS, & Eagleton LE (1980). Resolution of influenzal pneumonia. Illinois Medical Journal, 158(2): 76-8. |
| 12129 | Kilburn KH (1981). Cigarette smoking does not produce or enhance the radiologic appearance of pulmonary fibrosis. American Journal of Industrial Medicine, 2(3): 305-8. |
| 12130 | Weiss W (1984). Presentation of data on pulmonary fibrosis and cigarette smoking. American Journal of Industrial Medicine, 5(5): 417-21. |
| 12131 | Belsey R (1979). Complications of gastro-oesophageal reflux, and surgical management. Acta. Gastroenterologica Belgia, 42(5-6): 200-6. |
| 12132 | Winterbauer RH, Ludwig WR, Hammar SP (1977). Clinical course, management, and long-term sequelae of respiratory failure due to influenza viral pneumonia. Johns Hopkins Medical Journal, 141(3): 148-55. |
| 12133 | O'Shea PA & Yardley JH (1970). The human-rich syndrome in infancy: report of a case with virus-like particles by electron microscopy. Johns Hopkins Medical Journal, 126(6): 320-36. |
| 12134 | Moallem S, Gross A, Gluck M, Kaplan S, Sanoudos GM, Ray JF, Clauss RH (1973). Pulmonary complications of gastroesophageal reflux. New York State Journal of Medicine, 73(2): 279-83. |
| 12135 | Laraya-Cuasay LR, DeForest A, Huff D, Lischner H, & Huang NN (1977). Chronic pulmonary complications of early influenza virus infection in children. American Review of Respiratory Disease, 116(4): 617-25. |
| 12136 | Schwartz HJ, Chester EH, Fink JN, Payne CB, & Baum GL (1978). On respirable organic antigens, mattresses and some idiopathic lung diseases. Annals of Allergy, 40(6): 385-6. |
| 12139 | Tatrai E, Adamis Z, Bohm U, Meretey K & Ungvary G (1995). Role of cellulose in wood dust-induced fibrosing alveo-bronchiolitis in rat. Journal of Applied Toxicology, 15: 45-8. |
| 12143 | Turner-Warwick M (1991). Interstitial lung disease of unknown etiology. Chest, 100(1): 232-3. |
| 12148 | Stack BHR, Choo-Kang FJ, Heard BE (1972). The prognosis of cryptogenic fibrosing alveolitis. Thorax, 27(27): 535-42. |
| 12155 | Smith C, Feldman C, Levy H, Kallenbach JM, Zwi S (1990). Cryptogenic fibrosing alveolitis. A study of an indegenous African population. Respiration, 57: 364-71. |
| 12157 | Weiss W (1969). Cigarette smoking and diffuse pulmonary fibrosis. American Review of Respiratory Disease, 99: 67-72. |
| 12178 | Kennedy S, Chan-Yeung M (1996). Taking "cryptogenic" out of fibrosing alveolitis. The Lancet, 347(8997): 276-7. |
| 12179 | Hodges NG, Beer We (1996). Implication of flowers and weeds in fibrosing alveolitis. The Lancet, 347(9006): 966. |
| 13755 | Katzenstein AL, Myers JL (1998). Idiopathic pulmonary fibrosis. Clinical relevance of pathologic classification. American Journal of Respiratory & Critical Care Medicine, 157: 1301-15. |
| 17197 | Wong FL, Yamada M, Sasaki H, Kodama K, Akiba S, et al (1993). Noncancer disease incidence in the atomic bomb survivors: 1958-1986. Radiation Research, 135: 418-30. |
| 20351 | Archer VE, Renzetti AD, Doggett RS, Jarvis JQ, Colby TV (1998). Chronic diffuse interstitial fibrosis of the lung in uranium miners. J Occup Environ Med, 40(5): 460-74. |
| 20446 | Tomasek L, Swerdlow AJ, Darby SC, Placek V, Kunz E (1994). Mortality in uranium miners in West Bohemia: a long term cohort study. Occupational & Environmental Medicine, 51(5): 308-15. |
| 20923 | el-Serag HB, Sonnenberg A (1997). Comorbid occurrence of laryngeal or pulmonary disease with esophagitis in United States Military Veterans. Gastroenterology, 113(3): 755-60. |
| 21785 | Agency for Toxic Substances and Disease Registry (ATSDR) (1999). Toxicological profile for uranium. ., . US Department of Health and Human Services, Public Health Service, Atlanta, GA. |
| 26464 | Wagner GR (1997). Asbestosis and silicosis. Lancet, 349: 1311-15. |
| 26519 | American Lung Association (2001). Interstitial Lung disease. . Retrieved 14 February 2003, from http://www.cheshire-med.com/programs/pulrehab/ipt.html |
| 27668 | Al-Adsani A, Dahniya MH, Al-Adsani N (2001). Loss of weight in a female heavy smoker with diffuse interstitial pulmonary fibrosis. Postgraduate Medical Journal, 77(904): 137-8. |
| 27670 | Britton J, Hubbard R (2000). Recent advances in the aetiology of crypyogenic fibrosing alveolitis. Histopathology, 37: 387-92. |
| 27672 | Murin S, Smith Bilello K, Matthay R (2000). Other smoking-affected pulmonary diseases. Clinics in Chest Medicine, 21(1): 121-37. |
| 27747 | Ryu JH, Colby TV, Hartman TE, Vassallo R (2001). Smoking-related interstitial lung diseases: a concise review. European Respiratory Journal, 17(1): 122-32. |
| 29907 | Partanen T, Jaakkola J, Tossavainen A (1995). Silica, silicosis and cancer in Finland. Scandinavian Journal of Work and Environmental Health, 21(2): 84-86. |
| 32231 | Ruediger HW (2000). Hard metal particles and lung disease: coincidence or causality? Respiration, 67: 137-8. |
| 33820 | Welch L, Ringen K, Bingham E, Dement J, Takaro T, McGowan W, Chen A, Quinn P (2004). Screening for beryllium disease among construction trade workers at Department of Energy nuclear sites. Am J Ind Med, 46(3): 207-18. |
| 33825 | Infante PF, Newman LS (2004). Beryllium exposure and chronic beryllium disease. Lancet, 363(9407): 415-6. |
| 33918 | Williams WJ (1996). United Kingdom Beryllium Registry: Mortality and Autopsy Study. Environmental Health Perspectives, 104(5): 949 - 51. |
| 33927 | Willis HH, Florig HK (2002). Potential Exposures and risks from Beryllium-Containing Products. Risk Analysis, 22(5): 1019-33. |
| 34125 | Kent MS, Robins TG, Madl AK (2001). Is total mass or mass of alveolar-deposited airborne particles of beryllium a better predictor of the prevalence of disease? A preliminary study of a beryllium processing facility. App Occup Environ Hyg, 16(5): 539-58. |
| 34127 | Maier LA (2002). Clinical approach to chronic beryllium disease and other nonpneumoconiotic interstitial lung diseases. J Thorac Imaging, 17(4): 273-84. |
| 34147 | Johnson JS, Foote K, McClean M, Cogbill G (2001). Beryllium Exposure Control Program at the Cardiff Atomic Weapons Establishment in the United Kingdom. Appl Occup Environ Hyg, 16(5): 619-30. |
| 35768 | Varkey B, Varkey AB (2004). Asbestosis. . Retrieved 12 May 2005, from http://www.emedicine.com/med/topic171.htm |
| 36148 | Preston DL, Shimizu Y, Pierce DA, Suyama A, Mabuchi K (2003). Studies of mortality of atomic bomb survivors. Report 13: Solid cancer and noncancer disease mortality: 1950-1997. Radiation Research, 160: 381-407. |
| 38566 | Ross MH, Murray J (2004). Occupational respiratory disease in mining. In-Depth Review. Occupational Medicine, 54(5): 304-10. |
| 38567 | Scarisbrick DA, Quinlan RM (2005). Occupational respiratory disease in mining [Comment]. Occupational Medicine, 55(1): 72-3. |
| 39742 | Pulmonary Fibrosis Foundation (2004). Patient Information Handbook. ., : . |
| 40734 | Highland KB, Silver RM (2005). Clinical aspects of lung involvement: lessons from idiopathic pulmonary fibrosis and the scleroderma lung study. Curr Rheum Reports, 7: 135-141. |
| 40735 | Selman M, King TE Jr, Pardo A (2001). Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med, 134: 136-151. |
| 40736 | Noble PW (2003). Idiopathic pulmonary fibrosis. New insights into classification and pathogenesis usher in a new era in therapeutic approaches. Am J Respir Cell Molecular Biol, 29(3): S27-S31. |
| 40737 | du Bois RM, Wells AU (2001). Cryptogenic fibrosing alveolitis/idiopathic pulmonary fibrosis. Eur Respir J, 18(32): 43s-55s. |
| 40738 | Hubbard R (2001). Occupational dust exposure and the aetiology of cryptogenic fibrosing alveolitis. Eur Respir J, 18(32): 119s-21s. |
| 40739 | Kamp DW (2003). Idiopathic pulmonary fibrosis: the inflammation hypothesis revisited. Chest, 124(4): 1187-90. |
| 40740 | Khalil N, O'Connor R (2004). Idiopathic pulmonary fibrosis: current understanding of the pathogenesis and the status of treatment. CMAJ, 171(2): 153-60. |
| 40741 | Fellrath JM, du Bois RM (2003). Idiopathic pulmonary fibrosis/cryptogenic fibrosing alveolitis. Clin Exp Med, 3: 65-83. |
| 40742 | Miyake Y, Sasaki S, Yokoyama T, Chida K, et al (2005). Occupational and environmental factors and idiopathic pulmonary fibrosis in Japan. Ann Occup Hyg, 49(3): 259-65. |
| 40743 | Keane MP, Strieter RM, Belperio JA (2005). Mechanisms and mediators of pulmonary fibrosis. Critical Reviews in Immunology, 25(6): 429-63. |
| 40744 | Lok SS, Egan JJ (2000). Viruses and idiopathic pulmonary fibrosis. Monaldi Arch Chest Dis, 55(2): 146-50. |
| 40745 | Grubstein A, Bendayan D, Schactman I, Cohen M, et al (2005). Concomitant upper-lobe bullous emphysema, lower-lobe interstitial fibrosis and pulmonary hypertension in heavy smokers: report of eight cases and review of the literature. Respiratory Medicine, 99: 948-54. |
| 40746 | Gochuico BR (2001). Potential pathogenesis and clinical aspects of pulmonary fibrosis associated with rheumatoid arthritis. Am J Med Sci, 321(1): 83-8. |
| 40747 | Newman LE, Mroz MM, Ruttenber AJ (2005). Lung fibrosis in plutonium workers. Radiation Research, 164: 123-31. |
| 40748 | Brautbar N, Wu MP, Richter ED (2003). Chronic ammonia inhalation and interstitial pulmonary fibrosis: a case report and review of the literature. Arch Environ Health, 58(9): 592-6. |
| 40749 | Doran P, Egan JJ (2005). Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, 289: 709-10. |
| 40750 | Tajima S, Oshikawa K, Tominaga S-I, Sugiyama Y (2003). The increase in serum soluble ST2 protein upon acute exacerbation of idiopathic pulmonary fibrosis. Chest, 124: 1206-14. |
| 40755 | Abid SH, Malhotra V, Perry MC (2001). Radiation-induced and chemotherapy-induced pulmonary injury. Current Opinion in Oncology, 13(4): 242-8. |
| 40756 | Yuksel M, Ozyurtkan MO, Bostanci K, Ahiskali R, Kodalli N (2006). Acute exacerbation of interstitial fibrosis after pulmonary resection. Ann Thorac Surg, 82: 336-8. |
| 40810 | Daba MH, El-Tahir KE, Al-Arifi MN, Gubara OA (2004). Drug-induced pulmonary fibrosis. Saudi Med J, 25(6): 700-6. |
| 40864 | Daniil Z, Koutsokera, Gourgoulianis K (2006). [Letter] Combined pulmonary fibrosis and emphysema in patients exposed to agrochemical compounds. Eur Respir J, 27: 434-9. |
| 40865 | Cottin V, Nunes H, Brillet PY, et al (2005). Combined pulmonary fibrosis and emphysema: a distinct underrecognised entity. Eur Respir J, 26: 586-93. |
| 40866 | White B (2003). Interstitial lung disease in scleroderma. Rheum Dis Clin N Am, 29: 371-90. |
| 41065 | Steen VD (2005). The lung in systemic sclerosis. J Clin Rheumatol, 11(1): 40-6. |
| 41473 | Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S (2003). Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest, 123(6): 2007-11. |
| 41474 | Gosney (JR (2001). [Letter] Terminology and clinicopathological correlation in the idiopathic interstitial pneumonias. Histopathology, 39: 540-1. |
| 41475 | Kuwano K, Nomoto Y, Kunitake R, Hagimoto N, et al (1997). Detection of adenovirus E1A DNA in pulmonary fibrosis using nested polymerase chain reaction. Eur Respir J, 10: 1445-9. |
| 41476 | Egan JJ, Woodcock AA, Stewart JP (1997). Viruses and idiopathic pulmonary fibrosis. Eur Respir J, 10: 1433-7. |
| 41477 | Yang SC, Yang SP (2003). Ventilatory function of progressive massive fibrosis among bituminous coal miners in Taiwan. Arch Environ Health, 58(5): 290-7. |
| 41478 | Movsas B, Raffin TA, Epstein AH, Link CJ Jr (1997). Pulmonary radiation injury. Chest, 11: 1061-76. |
| 41914 | Agostini C, Albera C, Bariffi F, De Palma M, et al (2001). First report of the Italian register for diffuse infiltrative lung disorders (RIPID). Monaldi Arch Chest Dis, 56(4): 364-8. |
| 41958 | von Plessen C, Grinde O, Gulsvik A (2003). Incidence and prevalence of cryptogenic fibrosing alveolitis in a Norwegian community. Respiratory Medicine, 97: 428-35. |
| 41961 | Desai SR, Ryan SM, Colby TV (2003). Smoking-related interstitial lung diseases: histopathological and imaging perspectives. Clinical Radiology, 58: 259-68. |
| 41994 | Nadrous HF, Myers JL, Decker PA, Ryu JH (2005). Idiopathic pulmonary fibrosis in patients younger than 50 years. Mayo Clin Proc, 80(1): 37-40. |
| 41995 | Descatha A, Mompoint D, Ameille J (2006). Occupational paraffin-induced pulmonary fibrosis: a 25-year follow-up. Occupational Medicine, 56: 504-6. |
| 41996 | Zisman DA, Keane MP, Belperio JA, Strieter RM, Lynch JP (2005). Pulmonary fibrosis. Methods Mol Med, 117: 3-44. |
| 42061 | Enomoto T, Usuki J, Azuma A, Nakagawa T, Kudoh S (2003). Diabetes mellitus may increase risk for idiopathic pulmonary fibrosis. Chest, 123(6): 2007-11. |
| 42062 | Honda Y, Beall C, Delzell E, Oestenstad K, Brill I, Matthews R (2002). Mortality among workers at a talc mining and milling facility. Ann Occup Hyg, 46(7): 575-85. |
| 42063 | American Thoracic Society/European Respiratory Society (2002). International multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med, 165: 277-304. |
| 42064 | Taskar VS, Coultas DB (2006). Is idiopathic pulmonary fibrosis an environmental disease? Proc Am Thorac Soc, 3: 293-8. |
| 42065 | Baumgartner KB, Samet JM, Coultas DB, Stidley CA, et al (2000). Occupational and environmental risk factors for idiopathic pulmonary fibrosis: a multicenter case-control study. Am J Epidemiol, 152(4): 307-15. |
| 42066 | Araki T, Katsura H, Sawabe M, Kida K (2003). A clinical study of idiopathic pulmonary fibrosis based on autopsy studies in elderly patients. Internal Medicine, 42(6): 483-9. |
| 43303 | Quismorio FP Jr (2006). Pulmonary involvement in ankylosing spondylitis. Current Opinion in Pulmonary Medicine, 12(5): 342-5. |
| 43304 | Camus P, Fanton A, Bonniaud P, Camus C, Foucher P (2004). Interstitial lung disease induced by drugs and radiation. Respiration, 71(4): 301-26. |
| 43305 | Harari S, Caminati A (2005). Idiopathic pulmonary fibrosis. Allergy, 60(4): 421-35. |
| 43392 | Garantziotis S, Steele MP, Schwartz DA (2004). Pulmonary fibrosis: thinking outside the lung. J Clin Invest, 114(3): 319-21. |
| 43393 | Burns SM (2006). What causes idiopathic pulmonary fibrosis (IPF) and how do we manage patients admitted to the intensive care unit (ICU) with this disease? Critical Care Nurse, 26(6): 65-6, 74. |
| 43394 | Abratt RP, Onc FR, Morgan GW, Silvestri G, Willcox P (2004). Pulmonary complications of radiation therapy. Clin Chest Med, 25: 167-77. |
| 43395 | Allanore Y, Devos-Francois G, Caramella C, Boumier P, et al (2006). Fatal exacerbation of fibrosing alveolitis associated with systemic sclerosis in a patient treated with adalimumab. Ann Rheum Dis, 65: 834-5. |
| 43396 | Calabrese F, Giacometti C, Rea F, Loy M, Valente M (2005). Idiopathic interstitial pneumonias. Primum movens: epithelial, endothelial or whatever. Sarcoidosis Vasc Diffuse Lung Dis, 22: s15-s23. |
| 43397 | Ing AJ (2001). Interstitial lung disease and gastroesophageal reflux. Am J Med, 111(8A): 41s-4s. |
| 43410 | Dempsey OJ (2006). Clinical review: idiopathic pulmonary fibrosis-past, present and future. Respiratory Medicine, 100: 1871-85. |
| 43536 | Yamada M, Wong FL, Fujiwara S et al (2004). Noncancer disease incidence in atomic bomb survivors, 1958-1998. Radiat Res, 161(6): 622-32. |
| 43547 | Raghu G (2003). The role of gastroesophageal reflux in idiopathic pulmonary fibrosis. Am J Med, 115(3A): 60S-4S. |
| 43821 | King TE (2005). Interstitial lung diseases. Chapter 243. . Retrieved 7 March 2007, from http://www.accessmedicine.com/popup.aspx?aID=85023&print=yes\_chapter |
| 43822 | Staton GW Jr, Ingram RH Jr (2003). Chronic diffuse infiltrative lung disease. Section 14 Chapter V. http://www.acpmedicine.com/acpmedicine/chapters/ch1405.htm, : . |
| 43823 | Unknown (2007). Hermansky-Pudlak syndrome. Wikipedia, : . Retrieved 1 March 2007, from http://en.wikipedia.org/wiki/Hermansky-Pudlak\_syndrome |
| 43824 | Schmitz N, Diehl V (1997). Carmustine and the lungs. The Lancet, 349(9067): 1712-3. |
| 43825 | Dirix LY, Schrijvers D, Druwe P, Van Den Brande J, Verhoeven D, Van Oosterom AT (1994). Pulmonary toxicity and bleomycin. The Lancet, 344(8914): 56. |
| 43826 | Harris L, McKenna WJ, Rowland E, Holt DW, Storey GCA, Krikler DM (1983). Side effects of long-term amiodarone therapy. Circulation, 67(1): 45-51. |
| 43827 | Camus PH, Foucher P, Bonniaud PH, Ask K (2001). Drug-induced infiltrative lung disease. Eur Respir J, 18(32): 93S-100S. |
| 43828 | Bourke SC, Clague H (2000). Review of cryptogenic fibrosing alveolitis, including current treatment guidelines. Postgrad Med J, 76(900): 618-24. |
| 43829 | Konen E, Weisbrod GL, Pakhale S, Chung T, Paul NS, Hutcheon MA (2003). Fibrosis of the upper lobes: a newly identified late-onset complication after lung transplantation? AJR, 181(6): 1539-43. |
| 43830 | Unknown (2007). Diffuse interstitial pulmonary fibrosis. , : . Retrieved 1 March 2007, from http://www.medhelp.org/glossary2/new/GLS\_1665.HTM |
| 43831 | Turesson C, O'Fallon WM, Crowson CS, Gabriel SE, Matteson EL (2003). Extra-articular disease manifestations in rheumatoid arthritis: incidence trends and risk factors over 46 years. Ann Rheum Dis, 62(8): 722-7. |
| 43837 | Eddleston M, Wilks MF, Buckley NA (2003). Prospects for treatment of paraquat-induced lung fibrosis with immunosuppressive drugs and the need for better prediction of outcome: a systemic review. Q J Med, 96(11): 809-24. |
| 43838 | Doran P, Egan JJ (2005). Herpesviruses: a cofactor in the pathogenesis of idiopathic pulmonary fibrosis? Am J Physiol Lung Cell Mol Physiol, 289: 709-10. |
| 43839 | Lee H-L, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, Limper AH (2005). Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest, 127(6): 2034-41. |
| 43840 | Ng JM (2005). Yet another cause for drug-induced pulmonary fibrosis. J Postgrad Med, 51(1): 76-7. |
| 43841 | Algranti E, Handar AM, Dumortier P, Mendonca EMC, Rodrigues GL, et al (2005). Pneumoconiosis after sericite inhalation. Occup Environ Med, 62(3): e2. |
| 43842 | Ostor AJK, Crisp AJ, Somerville MF, Scott DGI (2004). Fatal exacerbation of rheumatoid arthritis associated fibrosing alveolitis in patients given infliximab. BMJ, 329(7477): 1266. |
| 43843 | Schenker MB, Stoecklin M, Lee K, Lupercio R, Zeballos RJ, et al (2004). Pulmonary function and exercise-associated changes with chronic low-level paraquat exposure. Am J Respir Crit Care Med, 170: 773-9. |
| 43844 | Bargagli E, Galeazzi M, Rottoli P (2004). [Comment] Infliximab treatment in a patient with rheumatoid arthritis pulmonary fibrosis. Eur Respir J, 24(4): 708. |
| 43845 | Atis S, Tutluoglu B, Levent E, et al (2005). The respiratory effects of occupational polypropylene flock exposure. Eur Respir J, 25(1): 110-7. |
| 43846 | Homma S, Miyamoto A, Sakamoto S, Kishi K, Motoi N, Yoshimura K (2005). Pulmonary fibrosis in an individual occupationally exposed to inhaled indium-tin oxide. Eur Respir J, 25(1): 200-4. |
| 43853 | Noble PW, Homer RJ (2005). Back to the future. Historical perspective on the pathogenesis of idiopathic pulmonary fibrosis. Am J Respir Cell Mol Biol, 33: 113-20. |
| 44382 | Mullen J, Hodgson MJ, DeGraff CA, Godar T (1998). Case-control study of idiopathic pulmonary fibrosis and environmental exposures. JOEM, 40(4): 363-7. |
| 44498 | Mogulkoc N, Veral A, Bishop PW, Bayindir U, Pickering CA, Egan JJ (1999). Pulmonary Langerhans' cell histiocytosis: radiologic resolution following smoking cessation. Chest, 115(5): 1452-5. |
| 44499 | Heyneman LE, Ward S, Lynch DA, Remy-Jardin M, Johkoh T, Muller NL (1999). Respiratory bronchiolitis, respiratory bronchiolitis-associated interstitial lung disease, and desquamative interstitial pneumonia: different entities or part of the spectrum of the same disease process? AJR, 173(6): 1617-22. |
| 44500 | Lee HK, Kim DS, Yoo B, et al (2005). Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest, 127(6): 2019-27. |
| 44509 | Craig PJ, Wells AU, Doffman S, Rassl D, et al (2004). Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology, 45(3): 275-82. |
| 44510 | Yousem SA, Colby TV, Gaensler EA (1989). Respiratory bronchiolitis-associated interstitial lung disease and its relationship to desquamative interstitial pneumonia. Mayo Clin Proceedings, 64(11): 1373-80. |
| 44511 | Vassallo R, Ryu JH (2004). Pulmonary Langerhans' cell histiocytosis. Clinics in Chest Medicine, 25(3): 561-71. |
| 44512 | Fraig M, Shreesha U, Savici D, Katzenstein A-L A (2002). Respiratory Bronchiolitis. A clinicopathologic study in current smokers, ex-smokers, and never-smokers. The American Journal of Surgical Pathology, 26(5): 647-53. |
| 44513 | Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH (2002). Clinical Outcomes of Pulmonary Langerhans'-Cell Histiocytosis in Adults. NEJM, 346(7): 484-490. |
| 44514 | Tazi A (2006). Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J, 27(6): 1272-85. |
| 44515 | Bernstrand C, Cederlund K, Sandstedt B, Ahstrom L, et al (2001). Pulmonary abnormalities at long-term follow-up of patients with Langerhans Cell Histiocytosis. Medical and Pediatric Oncology, 36(4): 459-68. |
| 44552 | Caminati A, Harari S (2006). Smoking-related interstitial pneumonia and pulmonary langerhans cell histiocytosis. Proc Am Thorac Soc, 3: 299-306. |
| 44553 | Unknown (2007). Idiopathic pulmonary fibrosis. . |
| 44554 | Riha RL, Duhig EE, Clarke BE, Steele RH, et al (2002). Survival of patients with biopsy-proven usual interstitial pneumonia and nonspecific interstitial pneumonia. Eur Respir J, 19: 1114-8. |
| 44555 | Ryu JH, Myers JL, Capizzi SA, Douglas WW, et al (2005). Dequamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial lung disease. Chest, 127: 178-84. |
| 44556 | Lynch DA, Travis WD, Muller NL, Galvin JR, et al (2005). Idiopathic interstitial pneumonias: CT features. Radiology, 236: 10-21. |
| 44557 | Demedts M, Costabel U (2002). ATS/ERS international multidisciplinary consensus classification of the idiopathic interstitial pneumonias. Eur Respir J, 19: 794-6. |
| 44558 | unknown (2007). Eosinophilic Pneumonia. . |
| 44559 | Abbott GF, Rosado-de-Christenson ML, Franks JF, Frazier AA, Galvin JR (2004). From the archives of the AFIP. Pulmonary langerhans cell histiocytosis. Radiographics, 24(3): 821-41. |
| 44652 | Moorman J, Saad M, Kosseifi S, Krishnaswamy G (2005). Hepatitis C virus and the lung. Implications for therapy. Chest, 128: 2882-92. |
| 44726 | Nagai S, Hoshino Y, Hayashi M, Ito I (2000). Smoking-related interstitial lung diseases. Current Opinion in Pulmonary Medicine, 6(5): 415-9. |
| 44727 | Watanabe R, Tatsumi R, Hashimoto K, Tamakoshi S, Kuriyama A (2001). Clinico-epidemiological features of pulmonary histiocytosis X. I. Internal Medicine, 40(10): 998-1003. |
| 44728 | Gotz G, Fichter J (2004). Langerhans'-cell histiocytosis in 58 adults. Eur J Med Res, 9(11): 510-4. |
| 44729 | Arico M (2004). Langerhans cell histiocytosis in adults: more questions than answers? Eur J Cancer, 40(10): 1467-673. |
| 44730 | Westerlaan HE, van der Valk, PDLPM (2002). Clinical and radiological evolution in patients with pulmonary Langerhans' cell histiocytosis. Netherlands Journal of Medicine, 60(8): 320-6. |
| 44774 | Peno-Green L, Lluberas G, Kingsley T, Brantly S (2002). [Letters] Lung injury linked to etanercept therapy. Chest, 122(5): 1858-60. |
| 44791 | Arico M, Girschikofsky M, Genereau T, Klersy C, McClain K, et al (2003). Langerhans cell histiocytosis in adults. Report from the International Registry of the Histiocyte Society. Eur J Cancer, 39(16): 2341-8. |
| 45500 | Enriquez-Matas A, Quirce S, Hernandez E, Vereda A, et al (2007). Hypersensitivity pneumonitis caused by domestic exposures to molds. J Investig Allergol Clin Immunol, 17(2): 126-8. |
| 45501 | Hoy RF, Pretto JJ, van Gelderen D, McDonald CF (2007). Mushroom worker's lung: organic dust exposure in the spawning shed. MJA, 186(9): 472-4. |
| 45502 | Volkman KK, Merrick JG, Zacharisen MC (2006). Yacht-maker's lung: a case of hypersensitivity pneumonitis in yacht manufacturing. Wisconsin Medical Journal, 105(7): 47-50. |
| 45503 | Gross TJ, Hunninghake GW (2001). Idiopathic pulmonary fibrosis. NEJM, 345(7): 517-25. |
| 45504 | Hubbard R, Venn A, Smith C, Cooper M (1998). Exposure to commonly prescribed drugs and the etiology of cryptogenic fibrosing alveolitis. A case-control study. Am J Respir Crit Care Med, 157: 743-7. |
| 45505 | Hoppin JA, Umbach DM, Kullman GJ, Henneberger PK, et al (2007). Pesticides and other Agricultural Factors Associated with Self-reported Farmer's Lung among Farm Residents in the Agricultural. Health Study. Occup Environ Med, 64(5): 334-341. |
| 45506 | Sood A, Sreedhar R, Kulkarni P, Nawoor AR (2007). Hypersensitivity pneumonitis-like granulomatous lung disease with nontuberculous mycobacteria from exposure to hot water aerosols. Environ Health Perspect, 115(2): 262-6. |
| 45507 | Ishiguro T, Yasui M, Nakade Y, Kimura H, et al (2007). Extrinsic allergic alveolitis with eosinophil infiltration induced by 1,1,1,2-tetrafluoroethane (HFC-134a): a case report. Internal Medicine, 46(17): 1455-7. |
| 45508 | Beckett W, Kallay M, Sood A, Zuo Z, Milton D (2005). Hypersensitivity pneumonitis associated with environmental mycobacteria. Environmental Health Perspect, 113(6): 767-70. |
| 45509 | Steele MP, Speer MC, Loyd JE, Brown KK, et al (2005). Clinical and pathologic features of familial interstitial pneumonia. Am J Respir Crit Care Med, 172: 1146-52. |
| 45524 | Thornburg A, et al (2007). [Letters] Hypersensitivity pneumonitis-like syndrome associated with the use of Lenalidomide. Chest, 131(5): 1572-4. |
| 45525 | Hanak V, Golbin JM, Ryu JH (2007). Causes and presenting features in 85 consecutive patients with hypersensitivity pneumonitis. Mayo Clin Proc, 82(7): 812-6. |
| 45526 | Chew GYJ, et al (2006). Roxithromycin induced hypersensitivity pneumonitis. Pathology, 38(5): 475-7. |
| 45527 | Patel AM, Ryu JH, Reed CE (2001). Hypersensitivity pneumonitis: current concepts and future questions. J Allergy Clin Immunol, 108: 661-70. |
| 45528 | Lipworth BJ (2002). Combined mediator blockade or topical corticosteroids for seasonal allergic rhinitis. J Allergy Clin Immunol, 110(6): 939. |
| 45529 | Giles GJ, Smith MP, Goldstone AH (1990). Chlorambucil Lung Toxicity. Acta Haematol, 183: 156-8. |
| 45530 | Churg A, Muller NL, Silva IS, Wright JL (2007). Acute exacerbation (acute lung injury of unknown cause) in UIP and other forms of fibrotic interstitial pneumonias. Am J Surg Pathol, 31(2): 277-84. |
| 45531 | Vassallo R (2003). Viral-induced inflammation in interstitial lung diseases. Seminars in Respiratory Infections, 18(1): 55-60. |
| 45532 | Dawkins P, Robertson A, Robertson W, Moore V, et al (2006). An outbreak of extrinsic alveolitis at a car engine plant. Occupational Medicine, 56: 559-65. |
| 45533 | Adamson YR (1984). Drug-induced pulmonary fibrosis. Environmental Health Perspectives, 55: 25-36. |
| 45534 | Turner-Warwick M (1998). In search of a cause of cryptogenic fibrosing alveolitis (CFA)\*: one initiating factor or many? Thorax, 53(S): S3-S9. |
| 45535 | Hamada K, Nagai S, Kitaichi M, Jin G, et al (2003). Cyclophosphamide-induced late-onset lung disease. Internal Medicine, 42(1): 82-7. |
| 45536 | Slavin RG (2007). What the allergist should know about hypersensitivity pneumonitis. Allergy Asthma Proc, 28(1): 25-7. |
| 45537 | Azambuja E, Fleck JF, Batista RG, Menna Barreto SS (2005). Bleomycin lung toxicity: who are the patients with increased risk? Pulmonary Pharmacology & Therapeutics, 18: 363-6. |
| 45538 | Sene D, Limal N, Cacoub P (2004). Hepatitis Brain Disease. Metabolic Brain Disease, 19(314): 357-381. |
| 45539 | Zignego AL, Ferri C, Pileri SA, Caini P, Bianchi FB (2007). Extrahepatic manifestations of Hepatitis C Virus infection: A general overview and guidelines for a clinical approach. Digestive and Liver Disease, 39: 2-17. |
| 45540 | Beinert T, Binder D, Stuschke M, Jorres RA, et al (1999). Oxidant-induced lung injury in anticancer therapy. European Journal of Medical Research, 4(2): 43-53. |
| 45541 | Kim DS, Collard HR, King TE Jr (2006). Classification and natural history of the idiopathic interstitial pneumonias. Proc Am Thorac Soc, 3(4): 285-92. |
| 45542 | Khalil N, Churg A, Muller N, O'Connor R (2007). Environmental, inhaled and ingested causes of pulmonary fibrosis. Toxicologic Pathology, 35(1): 86-96. |
| 45543 | Veillette M, Cormier Y, Israel-Assayaq E, Meriaux A, Duchaine C (2006). Hypersensitivity pneumonitis in a hardwood processing plant related to heavy mold exposure. Journal of Occupational and Environmental Hygiene, 3: 301-7. |
| 45544 | Weiss RB, Muggia FM (1980). Cytotoxic drug-induced pulmonary disease: update 1980. The American Journal of Medicine, 68: 259-66. |
| 45545 | Lam C-W, James JT, McCluskey R, Arepalli S, Hunter RL (2006). A review of carbon nanotube toxicity and assessment of potential occupational and environmental health risks. Critical Reviews in Toxicology, 36(3): 189-217. |
| 45546 | Mohr LC (2004). Hypersensitivity pneumonitis. Curr Opin Pulm Med, 10: 401-11. |
| 45630 | Garantziotis S, Schwartz DA (2006). Host-environment interactions in pulmonary fibrosis. Semin Respir Crit Care Med, 27(6): 574-80. |
| 45631 | Waller EA, Kaplan J (2006). Pergolide-associated valvular heart disease. Comp Ther, 32(2): 94-101. |
| 45632 | Ismail T, McSharry C, Boyd G (2006). Extrinsic allergic alveolitis. Respirology, 11(3): 262-8. |
| 45633 | Ghanei M, Harandi AA (2007). Long term consequences from exposure to sulfur mustard: a review. Inhalation Toxicology, 19(5): 451-6. |
| 45634 | Abramson MJ, Wlodarczyk JH, Saunders NA, Hensley MJ (1989). Does aluminium smelting cause lung disease? Am Rev Respir Dis, 139(4): 1042-57. |
| 45635 | Feinberg L, Travis WD, Ferrans V, Sato N, Bernton HF (1990). Pulmonary fibrosis associated with tocainide: report of a case with literature review. Am Rev Respir Dis, 141(2): 505-8. |
| 45636 | Haley PJ (1991). Pulmonary toxicity of stable and radioactive lanthanides. Health Physics, 61(6): 809-20. |
| 45637 | Dweik RA (2007). Berylliosis. . Retrieved 29 October 2007, from Obtained from: http://www.emedicine.com/med/topic222.htm |
| 45638 | Sharma S (2006). Hypersensitivity pneumonitis. , : . Retrieved 29 October 2007, from Obtained from: http://www.emedicine.com/med/topic1103.htm |
| 45639 | Hubbard R, Cooper M, Antoniak M, Venn A, Khan S, Johnston I, Lewis S, Britton J (2000). Risk of cryptogenic fibrosing alveolitis in metal workers. The Lancet, 355(9202): 466-7. |
| 45640 | Chong S, Lee KS, Chung MJ, Han J, Kwon OJ, Kim TS (2006). Pneumoconiosis: comparison of imaging and pathologic findings. Radiographics, 26(1): 59-77. |
| 45641 | Sullivan PA (2007). Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect, 115(4): 579-85. |
| 45642 | Ghio AJ, Funkhouser W, Pugh CB, Winters S, Stonehuerner JG, Mahar AM, Roggli VL (2006). Pulmonary fibrosis and ferruginous bodies associated with exposure to synthetic fibers. Toxicologic Pathology, 34(6): 723-9. |
| 45643 | Malik SW, Myers JL, DeRemee RA, Specks U (1996). Lung toxicity associated with cyclophosphamide use. Two distinct patterns. Am J Respir Crit Care Med, 154: 1851-6. |
| 45802 | Yucesoy B, Luster MI (2007). Genetic susceptibility in pneumonconiosis. Toxicol Lett, 168(3): 249-54. |
| 45803 | Menon B, Sharma A, Kripalani J, Jain S (2006). Giant cell interstitial pneumonia in a 60-year-old female without hard metal exposure. Respiration, 73: 833-5. |
| 45804 | Berge SR, Skyberg K (2003). Radiographic evidence of pulmonary fibrosis and possible etiologic factors at a nickel refinery in Norway. J Environ Monit, 5: 681-8. |
| 45805 | Bourke SJ (2007). Respiratory Medicine. Lecture Notes. Occupational Lung Disease, 7th Edition, 15: 161-70. Malden, MA. Blackwell Publishing. |
| 45806 | Bourke SJ (2007). Respiratory Medicine. Lecture Notes. 7th Ed. Chapter 16. Interstitial Lung Disease. Malden, 7th Edition, 16: 150-60. A. Blackwell Publishing. |
| 45807 | Bartter T, Irwin RS, Abraham JL, Dascal A, et al (1991). Zirconium compound-induced pulmonary fibrosis. Arch Intern Med, 151: 1197-201. |
| 45808 | Barceloux DG (1999). Cobalt. Clinical Toxicology, 37(2): 201-16. |
| 45809 | Twohig KJ, Matthay RA (1990). Pulmonary effects of cytotoxic agents other than bleomycin. Clinics in Chest Medicine, 11(1): 31-54. |
| 45810 | Jules-Elysee K, White DA (1990). Bleomycin-induced pulmonary toxicity. Clinics in Chest Medicine, 11(1): 1-20. |
| 45811 | van der Veen MJ, Dekker JJ, Dinant HJ, et al (1995). Fatal pulmonary fibrosis complicating low dose methotrexate therapy for rheumatoid arthritis. The Journal of Rheumatology, 22(9): 1766-8. |
| 45812 | Israel-Biet D, Labrune S, Huchon GJ (1991). Drug-induced lung disease: 1990 review. Eur Respir J, 4: 465-78. |
| 45813 | Warheit DB, Hart GA, Hesterberg TW, Collins JJ, et al (2001). Potential pulmonary effects of man-made organic fiber (MMOF) dusts. Critical Reviews in Toxicology, 31(6): 697-736. |
| 45814 | Nemery B (1990). Metal toxicity and the respiratory tract. Eur Respir J, 3: 202-19. |
| 45815 | McDonald JW, Ghio A, Sheehan CE, Bernhardt PF, Roggli VL (1995). Rare earth (cerium oxide) pneumoconiosis: analytical scanning electron microscopy and literature review. Modern Pathology, 8(8): 859-65. |
| 45816 | Tan KL, Lee HS, Poh WT, Ren MQ, et al (2000). Hard metal lung disease--the first case in Singapore. Ann Acad Med Singapore, 29(4): 521-7. |
| 45817 | Ryu JH, Daniels CE, Hartman TE, Yi ES (2007). Diagnosis of interstitial lung diseases. Mayo Clinic Proceedings, 82(8): 976-86. |
| 45886 | De Vuyst P, Camus P (2000). The past and present of pneumonioses. Current Opinion in Pulmonary Medicine, 6: 151-6. |
| 45895 | Vallyathan V, Bergeron WN, Robichaux PA, Craighead JE (1982). Pulmonary fibrosis in an aluminium arc welder. Chest, 81(3): 372-4. |
| 45896 | Akira M (1995). Uncommon pneumoconioses: CT and pathologic findings. Radiology, 197: 403-9. |
| 45897 | Zou S, Zou T, Ma F (1995). An epidemiologic study on pulmonary fibrosis caused by hard alloy dust [Article in Chinese]. Zhonghua Yu Fang Yi Xue Za Zhi, 29(2): 70-2. [Abstract] |
| 45898 | Selden A, Sahle W, Johansson L, Sorenson S, Persson B (1996). Three cases of dental technician's pneumoconiosis related to cobalt-chromium-molybdenum dust exposure. Chest, 109(3): 837-42. |
| 46040 | Wittram C, Mark EJ, McLoud TC (2003). CT-Histologic correlation of the ATS/ERS 2002 classification of idiopathic interstitial pneumonias. RadioGraphics, 23: 1057-71. |
| 46041 | Rossi SE, Erasmus JJ, McAdams HP, Sporn TA, Goodman PC (2000). Pulmonary drug toxicity: radiologic and pathologic manifestations. Radiographics, 20: 1245-59. |
| 46042 | Ray DE, Richards PG (2001). The potential for toxic effects of chronic, low-dose exposure to organophosphates. Toxicology Letters, 120: 343-51. |
| 46043 | Rosenman K, Hertzberg V, Rice C, Reilly MJ, et al (2005). Chronic beryllium disease and sensitization at a beryllium processing facility. Environ Health Perspect, 113(10): 1366-72; Erratum: (2006): 114(4); A214. |
| 46044 | Kolanz M; Rosenman K, et al (2006). Beryllium exposure data. Environ Health Perspectives, 114(4): A213-5. |
| 46045 | Verma DK, Ritchie AC, Shaw ML (2003). Measurement of beryllium in lung tissue of a chronic beryllium disease case and cases with sarcoidosis. Occupational Medicine, 53: 223-7. |
| 46046 | Peng JJ, Zhou ZS, Wang FY, Shen X (2005). Clinical analysis on 75 cases of aluminosis caused by black fused alumina [article in Chinese]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi, 23(4): 286-9. [Abstract] |
| 46047 | Merck (2005). Aspiration pneumonitis and pneumonia. . Retrieved 4 December 2007, from http://www.merck.com/mmpe/sec05/ch052/ch052f.html |
| 46048 | Amanullah S, et al (2007). Chemical Worker's Lung. . Retrieved 4 December 2007, from http://www.emedicine.com/med/topic334.htm |
| 46049 | Gysbrechts C, Michiels E, Verbeken E, Verschakelen J, et al (1998). Interstitial lung disease more than 40 years after a 5 year occupational exposure to talc. Eur Respir J, 11: 1412-5. |
| 46050 | Kim K-I, Kim CW, Lee MK, Lee KS, et al (2001). Imaging of occupational lung disease. RadioGraphics, 21: 1371-91. |
| 46051 | O'Donnell AE, Mappin G, Sebo TJ, Tazelaar H (1991). Interstitial pneumonitis associated with "crack" cocaine abuse. Chest, 100(4): 1155-7. |
| 46052 | Castranova V, Vallyathan V (2000). Silicosis and coal workers' pneumoconiosis. Environ Health Perspect., 108(4): 675-84. |
| 46053 | Rappaport SM, Goldberg M, Susi P, Herrick RF (2003). Excessive exposure to silica in the US construction industry. Ann Occup Hyg, 47(2): 111-22. |
| 46054 | Crummy F, Carl I, Cameron CHS, Heaney LG (2004). A possible case of pneumoconiosis in a limestone quarry worker. Occupational Medicine, 54: 497-9. |
| 46055 | Ulvestad B, Bakke B, Eduard W, Kongerud J, Lund MB (2001). Cumulative exposure to dust causes accelerated decline in lung function in tunnel workers. Occup Environ Med, 58: 663-9. |
| 46056 | Demedts M, Gyselen A (1989). The cobalt lung in diamond cutters: a new disease. Verh K Acad Geneeskd Belg, 51(6): 559-81 [article in Dutch]. [Abstract] |
| 46057 | Ott G, Mikuz G (1982). Hard metal pulmonary fibrosis [article in German]. Dtsch Med Wochenschr, 107(37): 1396-9. [Abstract] |
| 46058 | Sung JH, Choi B-G, Maeng S-H, Kim S-J, et al (2004). Recovery from welding-fume-exposure-induced lung fibrosis and pulmonary function changes in Sprague Dawley rats. Toxicological Sciences, 82: 608-13. |
| 46059 | Ferreira AS, Moreira VB, Ricardo HM, Coutinho R, et al (2006). Progressive massive fibrosis in silica-exposed workers. High-resolution computed tomography findings. J Bras Pneumol, 32(6): 523-8. |
| 46060 | De Capitani EM (2006). Silicosis (still) among us. J Bras Pneumol, 32(6): xxxiii-xxxv. |
| 46061 | Kuschner WG (2000). What exactly is flock worker's lung? Chest, 117(10): 10-3. |
| 46062 | Kern DG, Kuhn C III, Ely WE, Prannsky GS, et al (2000). Flock worker's lung: broadening the spectrum of clinicopathology, narrowing the spectrum of suspected etiologies. Chest, 117(1): 251-9. |
| 46063 | Kern DG, Crausman RS, Durand KTH, Nayer A, Kuhn C III (1998). Flock worker's lung: chronic interstitial lung disease in the nylon flocking industry. Annals of Internal Medicine, 129(4): 261-72. |
| 46064 | Mangum JB, Turpin EA, Antao-Menezes A, Cesta MF, et al (2006). Single-walled carbon nanotube (SWCNT)-induced interstitial fibrosis in the lungs of rats is associated with increased levels of PDGF mRNA and the formation of unique intercellular carbon structures that bridge alveolar macrophages in situ. Particle and Fibre Toxicology, 3: 15. |
| 46065 | Anto JM, Cullinan P (2001). Clusters, classification and epidemiology of interstitial lung diseases: concepts, methods and critical reflections. Eur Respir J, 32: 101s-6s. |
| 46066 | King TE, Costabel U, Cordier J-F, et al (2000). Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement.. American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med, 161(161): 646-64. |
| 46067 | Lynch DA, Newell JD, Logan PM, King TE Jr, Muller NL (1995). Can CT distinguish hypersensitivity pneumonitis from idiopathic pulmonary fibrosis? AJR, 165: 807-11. |
| 46068 | Nemery B, Verbeken EK, Demedts M (2001). Giant cell interstitial pneumonia (hard metal lung disease, cobalt lung). Seminars in Respiratory and Critical Care Medicine, 22(4): 435-47. |
| 46069 | Buerke U, Schneider J, Rosler J, Woitowitz HJ (2001). Interstitial pulmonary fibrosis after severe exposure to welding fumes. American Journal of Industrial Medicine, 41: 259-68. |
| 46070 | Love RG, Miller BG, Groat SK, Hagen S, et al (1997). Respiratory health effects of opencast coalmining: a cross sectional study of current workers. Occupational and Environmental Medicine, 54: 416-23. |
| 46071 | Nemery B, Abraham JL (2007). [Editorial] Hard metal lung disease: Still hard to understand. American Journal of Respiratory and Critical Care Medicine, 176: 2-3. |
| 46072 | Moriyama H, Kobayashi M, Takada T, Shimizu T, et al (2007). Two-dimensional analysis of elements and mononuclear cells in hard metal lung disease. Am J Respir Crit Care Med, 176: 70-7. |
| 46073 | Lasfargues G, Lardot C, Delos M, Lauwerys R, Lison D (1995). The delayed lung responses to single and repeated intratracheal administration of pure cobalt and hard metal powder in the rat. Environmental Research, 69: 108-21. |
| 46074 | Sabbioni E, Minoia C, Pietra R, Mosconi G, et al (1994). Metal determinations in biological specimens of diseased and non-diseased hard metal workers. The Science of the Total Environment, 150: 41-54. |
| 46075 | Mariano A, Sartorelli P, Innocenti A (1994). Evolution of hard metal pulmonary fibrosis in two artisan grinders of woodworking tools. The Science of the Total Environment, 150: 219-21. |
| 46076 | Henneberger PK, Cumro D, Deubner DD, Kent MS, et al (2001). Beryllium sensitization and disease among long-term and short-term workers in a beryllium ceramics plant. Int Arch Occup Environ Health, 74: 167-76. |
| 46077 | Madl AK, Unice K, Brown JL, Kolanz ME, Kent MS (2007). Exposure-response analysis for beryllium sensitization and chronic beryllium disease among workers in a beryllium metal machining plant. Journal of Occupational and Environmental Hygiene, 4(6): 448-66. |
| 46078 | Hull MJ, Abraham JL (2002). Aluminium welding fume-induced pneumoconiosis. Human Pathology, 33(8): 819-25. |
| 46079 | Schuler CR, Kent MS, Deubner DC, Berakis MT, et al (2005). Process-related risk of beryllium sensitization and disease in a copper-beryllium alloy facility. American Journal of Industrial Medicine, 47: 195-205. |
| 46080 | Maier LA (2001). Beryllium health effects in the era of the beryllium lymphocyte proliferation test. Applied Occupational and Environmental Hygiene, 16(5): 514-20. |
| 46081 | Dufresne A, Loosereewanich P, Begin R, Dion C, et al (1998). Tentative explanatory variable of lung dust concentration in gold miners exposed to crystalline silica. Journal of Exposure Analysis and Environmental Epidemiology, 8(3): 375-98. |
| 46082 | Lim HE, Shim JJ, Lee SY, Lee SH, et al (1998). Mercury inhalation poisoning and acute lung injury. The Korean Journal of Internal Medicine, 13(2): 127-30. |
| 46083 | Ezri T, Kunichezky S, Eliraz A, Soroker D, et al (1994). Bronchiolitis obliterans - current concepts. Quarterly Journal of Medicine, 87: 1-10. |
| 46084 | Kraus T, Heinz Schaller K, Angerer J, Hilgers R-D, Letzel S (2006). Aluminosis - detection of an almost forgotten disease with HRCT. Journal of Occupational Medicine and Toxicology, 1: 4. |
| 46085 | Stover DE, Milite F, Zakowski M (2001). A newly recognized syndrome - radiation-related bronchiolitis obliterans and organizing pneumonia. A case report and literature review. Respiration, 68: 540-4. |
| 46086 | Mosiewicz J, Myslinski W, Zlomaniec G, Czabak-Garbacz R, et al (2004). Diagnostic value of high resolution computed tomography in the assessment of nodular changes in pneumoconiosis in foundry workers in Lublin. Ann Agric Environ Med, 11: 279-84. |
| 46087 | Silva CIS, Muller NL, Fujimoto K, Kato S, et al (2007). Acute exacerbation of chronic interstitial pneumonia. High-resolution computed tomography and pathologic findings. J Thorac Imaging, 22: 221-9. |
| 46088 | Hubbs A, Greskevitch M, Kuempel E, Suarez F, Toraason M (2005). Abrasive blasting agents: designing studies to evaluate relative risk. Journal of Toxicology and Environmental Health, 68: 999-1016. |
| 46089 | Stanton ML, Henneberger PK, Kent MS, Deubner DC, et al (2006). Sensitization and chronic beryllium disease among workers in copper-beryllium distribution centres. J Occup Environ Med, 48: 204-11. |
| 46090 | Mueller-Mang C, Grosse C, Schmid K, Stiebellehner L, Bankier AA (2007). What every radiologist should know about idiopathic interstitial pneumonias. RadioGraphics, 27: 595-615. |
| 46091 | Restrepo CS, Carrillo JA, Martinez S, Ojeda P, Rivera AL, Hatta A (2007). Pulmonary complications from cocaine and cocaine-based substances: imaging manifestations. RadioGraphics, 27: 941-56. |
| 46092 | Churg A, Muller NL, Flint J, Wright JL (2006). Chronic hypersensitivity pneumonitis. Am J Surg Pathol, 30(2): 201-8. |
| 46093 | Sahin H, Brown KK, Curran-Everett D, Hale V, et al (2007). Chronic hypersensitivity pneumonitis: CT features - comparison with pathologic evidence of fibrosis and survival. Radiology, 244(2): 591-8. |
| 46094 | Hainer BL, White AA (1981). Nitrofurantoin pulmonary toxicity. The Journal of Family Practice, 13(6): 817-23. |
| 46095 | Gong H Jr, Tashkin DP (1979). Silicosis due to intentional inhalation of abrasive scouring powder. Case report with long-term survival and vasculitic sequelae. The American Journal of Medicine, 67: 358-62. |
| 46096 | Barroso-Moguel R, Villeda-Hernandez J, Mendez-Armenta M, Santamaria A, Galvan-Arzate S (1999). Alveolar lesions induced by systemic administration of cocaine to rats. Toxicology Letters, 110: 113-8. |
| 46097 | Bailey ME, Fraire AE, Greenberg SD, Barnard J, Cagle PT (1994). Pulmonary histiopathology in cocaine abusers. Human Pathology, 25: 203-7. |
| 46098 | Emad A, Emad Y (2007). Levels of cytokine in bronchoalveolar lavage (BAL) fluid in patients with pulmonary fibrosis due to sulfur mustard gas inhalation. Journal of Interferon & Cytokine Research, 27(1): 38-43. |
| 46099 | Emad A, Emad Y (2007). Increased in CD8 T lymphocytes in the BAL fluid of patients with sulfer mustard gas-induced pulmonary fibrosis. Respiratory Medicine, 101(4): 786-92. |
| 46100 | Kitamura H, Ichinose S, Hosoya T, Ando T, et al (2007). Inhalation of inorganic particles as a risk factor for idiopathic pulmonary fibrosis - elemental microanalysis of pulmonary lymph nodes obtained at autopsy cases. Pathology - Research and Practice, 203: 575-85. |
| 46101 | Zinman C, Richards GA, Murray J, Phillips JI, et al (2002). Mica dust as a cause of severe pneumoconiosis. American Journal of Industrial Medicine, 41: 139-44. |
| 46102 | Guber A, Lerman S, Lerman Y, Ganor E, et al (2006). Pulmonary fibrosis in a patient with exposure to glass wool fibers. American Journal of Industrial Medicine, 49: 1066-9. |
| 46103 | Takahashi T, Munakata M, Takekawa H, Homma Y, Kawakami Y (1996). Pulmonary fibrosis in a carpenter with long-lasting exposure to fiberglass. American Journal of Industrial Medicine, 30: 596-600. |
| 46104 | Kraus T, Schaller KH, Angerer J, Letzel S (2000). Aluminium dust-induced lung disease in the pyro-powder-producing industry: detection by high-resolution computed tomography. Int Arch Occup Environ Health, 73: 61-4. |
| 46105 | Wittram C (2004). The idiopathic interstitial pneumonias. Curr Probl Diagn Radiol, 33(5): 189-99. |
| 46106 | Maitland ML, Wilcox R, Hogarth DK, Desai AA, et al (2006). Diffuse alveolar damage after a single dose of topotecan in a patient with pulmonary fibrosis and small cell lung cancer. Lung Cancer, 54: 243-5. |
| 46107 | Kriess K, Mroz MM, Newman LS, Martyny J, Zhen B (1996). Machining risk of beryllium disease and sensitization with median exposures below 2ug/m3. American Journal of Industrial Medicine, 30: 16-25. |
| 46108 | Brancaleone P, Weynand B, De Vuyst P, Stanescu D, Pieters T (1998). Lung granulomatosis in a dental technician. American Journal of Industrial Medicine, 34: 628-31. |
| 46109 | Sjogren B, Ljunggren KG, Almkvist O, Frech W, Basun H (1996). A follow-up study of five cases of aluminosis. Int Arch Occup Environ Health, 68: 161-4. |
| 46110 | Richeldi L, Kreiss K, Mroz MM, Zhen B, et al (1997). Interaction of genetic and exposure factors in the prevalence of berylliosis. American Journal of Industrial Medicine, 32: 337-40. |
| 46111 | Niewoehner DE, Hoidal JR (1982). Lung fibrosis and emphysema: divergent responses to a common injury? Science, 217: 359-60. |
| 46112 | Zanelli R, Barbic F, Migliori M, Michetti G (1994). Uncommon evolution of fibrosing alveolitis in a hard metal grinder exposed to cobalt dusts. The Science of the total Environment, 150: 225-9. |
| 46113 | Segura A, Yuste A, Cercos A, Lopez-Tendero P, et al (2001). Pulmonary fibrosis induced by cyclophosphamide. The Annals of Pharmacotherapy, 35: 894-7. |
| 46114 | Dumontet C, Biron F, Vitrey D, Guerin J-C, et al (1991). Acute silicosis due to inhalation of a domestic product. Am Rev Respir Dis, 143: 880-2. |
| 46115 | Cohen C, Fireman E, Ganor E, Man A, et al (1999). Accelerated silicosis with mixed-dust pneumoconiosis in a hard-metal grinder. J Occup Environ Med, 41(6): 480-5. |
| 46116 | Demedts M, Gheysens B, Nagels J, Verbeken E, et al (1984). Cobalt lung in diamond polishers. Am Rev Respir Dis, 130: 130-5. |
| 46117 | Funahashi A, Schlueter DP, Pintar K, Siegesmund KA, et al (1984). Pneumoconiosis in workers exposed to silicon carbide. Am Rev Respir Dis, 129: 635-40. |
| 46118 | Landas SK, Schwartz DA (1991). Mica-associated pulmonary interstitial fibrosis. Am Rev Respir Dis, 144: 718-21. |
| 46119 | Dumontet C, Vincent M, Laennec E, Girodet B, et al (1991). [Letter] Silicosis due to inhalation of domestic cleaning powder. The Lancet, 338: 1085. |
| 46120 | Boag AH, Colby TV, Fraire AE, Kuhn C III, et al (1999). The pathology of interstitial lung disease in nylon flock workers. The American Journal of Surgical Pathology, 23(12): 1539-45. |
| 46121 | Lapenas DJ, Davis GS, Gale PN, Brody AR (1982). Mineral dusts as etiologic agents in pulmonary fibrosis: the diagnostic role of analytical scanning electron microscopy. Am J Clin Pathol, 78: 701-6. |
| 46122 | Nemery B, Bast A, Behr J, Borm PJA, et al (2001). Report of Working Group 3. Interstitial lung disease induced by exogenous agents: factors governing susceptibility. Eur Respir J, 18(Suppl 32): 30s-42s. |
| 46123 | Jederlinic PJ, Abraham JL, Churg A, Himmelstein JS, et al (1990). Pulmonary fibrosis in aluminium oxide workers. Investigation of nine workers, with pathologic examination and microanalysis in three of them. Am Rev Respir Dis, 142: 1179-84. |
| 46124 | Kreiss K, Mroz MM, Zhen B, Martyny JW, Newman LS (1993). Epidemiology of beryllium sensitization and disease in nuclear workers. Am Rev Respir Dis, 148: 985-91. |
| 46125 | Kreiss K, Wasserman S, Mroz MM, Newman LS (1993). Beryllium disease screening in the ceramics industry. Blood lymphcyte test performance and exposure-disease relations. JOM, 35(3): 267-74. |
| 46126 | Sherson D, Maltbaek N, Heydorn K (1990). A dental technician with pulmonary fibrosis: a case of chromium-cobalt alloy pneumoconiosis? Eur Respir J, 3: 1227-9. |
| 46127 | De Vuyst P, Dumortier P, Schandene L, Estenne M, et al (1987). Sarcoidlike lung granulomatosis induced by aluminium dusts. Am Rev Respir Dis, 135: 493-7. |
| 46128 | Funahashi A, Schlueter DP, Pintar K, Bemis EL, Siegesmund KA (1988). Welders' pneumoconiosis: tissue elemental microanalysis by energy dispersive x ray analysis. British Journal of Industrial Medicine, 45: 14-18. |
| 46129 | Sjogren B, Ulfvarson U (1985). Respiratory symptoms and pulmonary function among welders working with aluminium, stainless steel and railroad tracks. Scand J Work Environ Health, 11: 27-32. |
| 46130 | Sorahan T, Lister A, Filthorpe MS, Harrington JM (1995). Mortality of copper cadmium alloy workers with special reference to lung cancer and non-malignant diseases of the respiratory system, 1946-92. Occupational and Environmental Medicine, 52: 804-12. |
| 46132 | Townshend RH (1982). Acute cadmium pneumonitis: a 17-year follow-up. British Journal of Industrial Medicine, 39: 411-2. |
| 46133 | Nasr MR, Savici D, Tudor L, Abou Abdallah D, et al (2006). Inorganic dust exposure causes pulmonary fibrosis in smokers: analysis using light microscopy, scanning electron microscopy, and energy dispersive x-ray spectroscopy. Archives of Environmental & Occupational Health, 61(2): 53-60. |
| 46134 | Ruttner JR, Spycher MA, Stolkin I (1987). Inorganic particulates in pneumoconiotic lungs of hard metal grinders. British Journal of Industrial Medicine, 44: 657-60. |
| 46135 | Swennen B, Buchet J-P, Stanescu D, Lison D, Lauwerys R (1993). Epidemiological survey of workers exposed to cobalt oxides, cobalt salts, and cobalt metal. British Journal of Industrial Medicine, 50: 835-42. |
| 46136 | Auchincloss JH, Anraham JL, Gilbert R, Lax M, et al (1992). Health hazard of poorly regulated exposure during manufacture of cemented tungsten carbides and cobalt. British Journal of Industrial Medicine, 49: 832-6. |
| 46138 | Fischbein A, Luo J-CJ, Solomon SJ, Horowitz S, et al (1992). Clinical findings among hard metal workers. British Journal of Industrial Medicine, 49: 17-24. |
| 46139 | Hesterberg TW, Hart GA (2001). Synthetic vitreous fibers: a review of toxicology research and its impact on hazard classification. Critical Reviews in Toxicology, 31(1): 1-53. |
| 46140 | Al Kassimi FA, et al (1991). [Letter] Silicosis in a Himalayan village population: role of environmental dust. Thorax, 46: 861-2. |
| 46141 | Norboo T, Angchuk PT, Yahya M, Kamat SR, et al (1991). Silicosis in a Himalayan village population: role of environmental dust. Thorax, 46: 341-3, 544. |
| 46142 | Lohr RH, Boland BJ, Douglas WW, Dockrell DH, et al (1997). Organizing pneumonia. Features and prognosis of cryptogenic, secondary, and focal variants. Arch Intern Med, 157: 1323-9. |
| 46143 | Arbetter KR, Prakash UB, Tazelaar HD, Douglas WW (1999). Radiation-induced pneumonitis in the "nonirradiated" lung. Mayo Clin Proc, 74: 27-36. |
| 46144 | Ghanei M, Harandi AA (2007). Long term consequences from exposure to sulfer mustard: a review. Inhalation. Toxicology, 19: 451-6. |
| 46145 | US Department of Health and Human Services (2001). NTP Technical Report on the Toxicology and Carcinogenesis Studies of Indium Phosphide (Cas No. 22398-80-7) in F344/N rats and B6C3F1 Mice (inhalation studies). . Retrieved 6 December 2007, from http://ntp.niehs.nih.gov/ntp/htdocs/LT\_rpts/tr499.pdf |
| 46248 | Kelleher P, Pacheco K, Newman LS (2000). Inorganic dust pneumonias: the metal-related parenchymal disorders. Environmental Health Perspectives, 108(Suppl 4): 685-96. |
| 46249 | Rosenstock L, Cullen MR (2005). Occupational medicine. ACP Medicine, Clinical Essentials, Chapter VI. |
| 46250 | Turner-Warwick M (1974). A perspective view on widespread pulmonary fibrosis. Br Med J, Vol 2:371-6. |
| 46251 | Schenker M (2000). Exposures and health effects from inorganic agricultural dusts. Environmental Health Perspectives, 108(Suppl 4):661-4. |
| 46252 | Terra Filho M, Yen CC, Santos Ude P, Muñoz DR (2004). Pulmonary alterations in cocaine users. Sao Paulo Med J, 122(1): 26-31. |
| 46253 | Vu VT, Lai DY (1997). Approaches to characterizing human health risks of exposure to fibers. Environmental Health Perspectives, 105(Suppl 5):1329-36. |
| 46254 | Davis JM, Cowie HA (1990). The relationship between fibrosis and cancer in experimental animals exposed to asbestos and other fibers. Environmental Health Perspectives, 88: 305-9. |
| 46309 | Lilis R (1981). Review of pulmonary effects of poly (vinyl chloride) and vinyl chloride exposure. Environmental Perspectives, 41: 167-9. |
| 46310 | Sprince NL, Oliver LC, Eisen EA, Greene RE, Chamberlin RI (1988). Cobalt exposure and lung disease in tungsten carbide production. Am Rev Respir Dis, 138: 1220-6. |
| 46376 | Migliori M, Mosconi G, Michetti G, Belotti L, et al (1994). Hard metal disease: eight workers with interstitial lung fibrosis due to cobalt exposure. The Science of the Total Environment, 150: 187-96. |
| 46377 | Kawai K, Akaza H (2003). Belomycin-induced pulmonary toxicity in chemotherapy for testicular cancer. Expert Opin Drug Saf, 2(6): 587-96. |
| 46378 | Unknown (2007). Beryllium. Relevance to Public Health. . Retrieved 18 December 2007, from http://www.atsdr.cdc.gov/toxprofiles/tp4-c2.pdf |
| 46379 | Yoon HK, Moon HS, Park SH, Song JS, et al (2005). Dendriform pulmonary ossification in patient with rare earth pneumoconiosis. Thorax, 60: 701-3. |
| 46380 | Vocaturo G, Colombo F, Zanoni M, Rodi F, et al (1983). Human exposure to heavy metals. Rare earth pneumoconiosis in occupational workers. Chest, 83(5): 780-3. |
| 46477 | Masse S, Begin R, Cantin A (1988). Pathology of silicon carbide pneumoconiosis. Modern Pathology, 1(2): 104-8. |
| 46478 | Meyer-Bisch C, Pham QT, Mur J-M, Massin N, et al (1989). Respiratory hazards in hard metal workers: a cross sectional study. British Journal of Industrial Medicine, 46: 302-9. |
| 46479 | Selden AI, Persson B, Bornberger-Dankvardt SI, et al (1995). Exposure to cobalt chromium dust and lung disorders in dental technicians. Thorax, 50: 769-72. |
| 46480 | Safirstein BH, Klukowicz A, Miller R, Teirstein A (2003). Granulomatous pneumonitis following exposure to the World Trade Center collapse. Chest, 123: 301-4. |
| 46504 | Wells AU, Nicholson AG, Hansell DM (2007). Smoking-induced diffuse interstitial lung diseases. Thorax, 62: 904-10. |
| 46505 | Panos RJ, Mortenson RL, Niccoli SA, King TE Jr (1990). Clinical deterioration in patients with idiopathic pulmonary fibrosis: causes and assessment. Am J Med, 88: 396-404. |
| 46506 | Levin JL, Frank AL, Williams MG, McConnell W, et al (1996). Kaolinosis in a cotton mill worker. Am J Ind Med, 29: 215-21. |
| 46624 | Sprince NL, Chamberlin RI, Hales CA, Weber AL, Kazemi H (1984). Respiratory disease in tungsten carbide production workers. Chest, 86(4): 549-57. |
| 46676 | Ruiz-Casado A, Garcia MD, Racionero MA (2006). Pulmonary toxicity of 5-fluoracil and oxaliplatin. Clin Transl Oncol, 8(8): 624. |
| 46677 | Lai CK, Wallace WD, Fishbein MC (2006). Histopathology of pulmonary fibrotic disorders. Semin Respir Crit Care Med, 27(6): 613-22. |
| 46852 | Gilks B, Churg A (1987). Aluminium-induced pulmonary fibrosis: do fibers play a role? Am Rev Respir Dis, 136: 176-9. |
| 46853 | Wickman R (1993). Spanish paint disaster causes lung fibrosis. BMJ, 306: 416-7. |
| 46871 | National Research Council (2006). Health risks from exposure to low levels of ionizing radiation. Beir VII Phase 2, . The National Academies Press, Washington D.C. |
| 46966 | Lacasse Y, Selman M, Costabel U, Dalphin JC, et al (2003). Clinical diagnosis of hypersensitivity pneumonitis. Am J Respir Crit Care Med, 168: 952-58. |
| 46967 | Holbert JM, Costello P, Li W, Hoffman RM, Rogers RM (2001). CT features of pulmonary alveolar proteinosis. AJR, 176: 1287-94. |
| 46968 | Bourke SJ (2006). Interstitial lung disease: progress and problems. Postgrad Med J, 82: 494-499. |
| 46969 | Emad A, Rezaian GR (1997). The diversity of the effects of sulfur mustard gas inhalation on respiratory system 10 years after a single, heavy exposure. Analysis of 197 cases. Chest, 112: 734-38. |
| 46970 | Hidalgo A, Franquet T, Gimenez A, Bordes R, et al (2006). Smoking-related interstitial lung diseases: radiologic-pathologic correlation. Eur Radiol, 16: 2463-70. |
| 46979 | Buechner HA, Ansari A (1969). Acute silico-proteinosis. A new pathologic variant of acute silicosis in sandblasters, characterized by histologic features resembling alveolar proteinosis. Chest, 55(4): 274-84. |
| 46980 | Vincent M, Arthaud Y, Crettet G, Gerard F, et al (1995). Fatal acute silicosis caused by voluntary inhalation of scouring powder [Article in French]. Rev Mal Respir, 12(5): 499-502. |
| 46981 | Hudson AR, Halprin GM, Miller JA, Kilburn KH (1974). Pulmonary interstitial fibrosis following alveolar proteinosis. Chest, 65(6): 700-3. |
| 46982 | Seet RCS, Johan A, Teo CES, Gan SL, Lee KH (2005). Inhalation nickel carbonyl poisoning in waste processing workers. Chest, 128: 424-9. |
| 46983 | Barchowsky A, Soucy NV, O'Hara KA, Hwa J (2002). A novel pathway for nickel-induced interleukin-8 expression. The Journal of Biological Chemistry, 277(27): 24225-31. |
| 46984 | Peall AF, Hodges A (2007). Concomitant pulmonary and hepatic toxicity secondary to nitrofurantoin: a case report. Journal of Medical Case Reports, 1: 59. |
| 46985 | Ginzburg VE (2006). [Letter] Chest pain, dyspnea, and cough. Canadian Family Physician, 52: 1166. |
| 46998 | Marcus RL, Turner S, Cherry NM (1996). A study of lung function and chest radiographs in men exposed to zirconium compounds. Occup Med, 46(2): 109-13. |
| 46999 | Hoet PHM, Gilissen LPL, Leyva M, Nemery B (1999). In vitro cytotoxicity of textile paint components linked to the "Ardystil Syndrome". Toxicological Sciences, 52: 209-16. |
| 47000 | Jedynak AR, et al (2007). Silicosis and coal worker pneumoconiosis. . Retrieved 30 January 2008, from http://www.emedicine.com/Radio/topic637.htm |
| 47001 | Summerhill EM, et al (2006). Pulmonary fibrosis, interstitial (nonidiopathic). . Retrieved 30 January 2008, from http://www.emedicine.com/med/TOPIC1961.HTM |
| 47002 | Holmberg L, Boman G, Bottiger LE, Eriksson B, et al (1980). Adverse reactions to nitrofurantoin. Analysis of 921 reports. The American Journal of Medicine, 69: 733-38. |
| 47003 | Turuguet D, Pou R (1994). Outbreak of organising pneumonia in textile sprayers. The Lancet, 344: 1168. |
| 47004 | Moya C, Anto JM, Taylor AJ, et al (1994). Outbreak of organising pneumonia in textile priniting sprayers. The Lancet, 344: 498-502. |
| 47005 | Hoet PHM, Gilissen L, Nemery B (2001). Polyanions protect against the in vitro pulmonary toxicity of polycationic paint components associated with the ardystil syndrome. Toxicity and Applied Pharmacology, 175: 184-90. |
| 47006 | Honma K, Abraham JL, Chiyotani K, De Vuyst P, et al (2004). Proposed criteria for mixed-dust pneumoconiosis: definition, descriptions, and guidelines for pathologic diagnosis and clinical correlation. Hum Pathol, 35: 1515-23. |
| 47044 | Shimabukuro DW, Sawa T, Gropper MA (2003). Injury and repair in lung and airways. Crit Care Med, 31(8): S524-31. |
| 47045 | Arbiser ZK, Guidot DM, Pine JR, Giltman LI, Gal AA (2003). Pulmonary alveolar proteinosis mimicking idiopathic pulmonary fibrosis. Annals of Diagnostic Pathology, 7(2): 82-6. |
| 47046 | Agarwal PP, Seely JM, Perkins DG, Matzinger FR, Alikhan Q (2005). Pulmonary alveolar proteinosis and end-stage pulmonary fibrosis. A rare association. J Thorac Imaging, 20: 242-4. |
| 47047 | Park CH, Kim K-I, Park SK, Lee CH (2000). Carbamate poisoning: high resolution CT and pathologic findings. Journal of Computer Assisted Tomography, 24(1): 52-4. |
| 47048 | Nicholson AG (2002). Classification of idiopathic interstitial pneumonias: making sense of the alphabet soup. Histopathology, 41: 381-91. |
| 47049 | Tomashefski JF Jr (2000). Pulmonary pathology of acute respiratory distress syndrome. Clinics in Chest Medicine, 21(3): 435-66. |
| 47050 | Clottens FL, Verbeken EK, Demedts M, Nemery B (1997). Pulmonary toxicity of components of textile paint linked to the Ardystil syndrome: intratracheal administration in hamsters. Occup Environ Med, 54: 376-87. |
| 47051 | Cordier J-F (2007). Challenges in pulmonary fibrosis. 2: Bronchiolocentric fibrosis. Thorax, 62: 638-49. |
| 47052 | Monteiller C, Train L, MacNee W, Faux S, et al (2007). The pro-inflammatory effects of low-toxicity low-solubility particles, nanoparticles and fine particles, on epithelial cells in vitro: the role of surface area. Occup Environ Med, 64: 609-15. |
| 47073 | Arakawa H, Honma K, Saito Y, Morikubo H, Shida H (2005). Delayed development of silicoproteinosis with diffuse interstitial fibrosis: 16-year follow-up with autopsy sorrelation. Eur Radiol, 15: 2210-1. |
| 47074 | Asano S, Eto K, Kurisaki E, Gunji H, Hiraiwa K, et al (2000). Acute inorganic mercury vapor inhalation poisoning. Pathology International, 50: 169-74. |
| 47075 | Morrison RJ, Bidani A (2002). Acute respiratory distress syndrome epidemiology and pathophysiology. Chest Surg Clin N Am, 12: 301-23. |
| 47205 | Lo Sasso AA, Osterhoudt K, Meier FA, Costarino AT Jr, Cullen EJ Jr (2002). A 16-year-old boy with rapidly progressing pulmonary fibrosis. J Pediatr, 140(2): 270-5. |
| 47206 | Smith P, Heath D (1975). The pathology of the lung in paraquat poisoning. J Clin Pathol, s3-9(1): 81-93. |
| 47207 | Romero S, Hernandez L, Gil J, Aranda I, Martin C, Sanchez-Paya J (1998). Organizing pneumonia in textile printing workers: a clinical description. Eur Respir J, 11(2): 265-71. |
| 47208 | Camus P, Nemery B (1998). A novel cause for bronchiolitis obliterans organizing pneumonia: exposure to paint aerosols in textile workshops. Eur Respir J, 11(2): 259-62. |
| 47209 | Ould Kadi F, Abdesslam T, Nemery B (1999). Five-year follow-up of Algerian victims of the "Ardystil syndrome". Eur Respir J, 13(4): 940-1. |
| 47210 | Kishimoto T, Fujioka H, Yamadori I, Ohke M, Ozaki S, Kawabata Y (1998). Lethal paraquat poisoning caused by spraying in a vinyl greenhouse of causing pulmonary fibrosis with a hepatorenal dysfunction [Article in Japanese]. Nihon Kokyuki Gakkai Zasshi, 36(4): 347-52. [Abstract] Retrieved 18 February 2008, from Article in Japanese |
| 47211 | Hartman TE, Primack SL, Kang E-Y, Swensen SJ, Hansell DM, McGuinness G, Muller NL (1996). Disease progression in usual interstitial pneumonia compared with desquamative interstitial pneumonia. Chest, 110(2): 378-82. |
| 47212 | Lynch DA (1996). Ground glass attenuation on CT in patients with idiopathic pulmonary fibrosis. Chest, 110(2): 312-3. |
| 47226 | Conrad S (2005). Respiratory distress syndrome, adult. Obtained from. . Retrieved 30 January 2008, from http://www.emedicine.com/emerg/topic503.htm |
| 47227 | Rothenhaus T (2005). Acute respiratory distress syndrome. . Retrieved 30 January 2008, from http://www.emedicine.com/emerg/topic15.htm |
| 47230 | Chapman S, Robinson G, Stradling J, West S (2005). Idiopathic interstitial pneumonias. Oxford Handbook of Respiratory Medicine, 35: 439-56. . |
| 47231 | Chapman S, Robinson G, Stradling J, West S (2005). Hypersensitivity pneumonitis. Oxford Handbook of Respiratory Medicine, 36: 457-62. . |
| 47232 | Chapman S, Robinson G, Stradling J, West S (2005). Pneumoconioses. Oxford Handbook of Respiratory Medicine, 39: 477-85. . |
| 47233 | Chapman S, Robinson G, Stradling J, West S (2005). Toxic agents. Oxford Handbook of Respiratory Medicine, 48: 575-87. . |
| 47234 | Peros-Golubicic T, Sharma OP (2006). Respiratory bronchiolitis associated interstitial lung disease and desquamative interstitial pneumonia. Clinical Atlas of Interstitial Lung Disease, 7: 47-50. . |
| 47235 | Peros-Golubicic T, Sharma OP (2006). Drug addict's lung. Clinical Atlas of Interstitial Lung Disease, 15: 85-9. . |
| 47236 | Peros-Golubicic T, Sharma OP (2006). Pneumoconioses. Clinical Atlas of Interstitial Lung Disease, 17: 97-101. . |
| 47237 | Peros-Golubicic T, Sharma OP (2006). Inhalation fever and chemical pneumonitis. Clinical Atlas of Interstitial Lung Disease, 18: 103-6. . |
| 47238 | Brieva J (2007). Cyclophosphamide-induced acute respiratory distress syndrome. Respirology, 12: 769-73. |
| 47239 | Blanc PD, Golden JA (1992). Unusual occupationally related disorders of the lung: case reports and review of the literature. Occupational Medicine, 7(3): 403-22. |
| 47271 | Jaeger A, Tempe JD, Haegy JM, Leroy M, et al (1979). Accidental acute mercury vapor poisoning. Veterinary and Human Toxicology, 21(Suppl): 62-3. |
| 47297 | Harber P, Saechao K, Boomus C (2006). Diacetyl-induced lung disease. Toxicol Rev, 25(4): 261-72. |
| 47298 | Ujita M, Renzoni EA, Veeraraghavan S, Wells AU, Hansell DM (2004). Organizing pneumonia: perilobular pattern at thin-section CT. Radiology, 232: 757-61. |
| 47299 | Olade R (2007). Pulmonary alveolar proteinosis. . Retrieved 26 February 2008, from http://www.emedicine.com/MED/topic1927.htm |
| 47321 | Gamble JF (1993). A nested case control study of lung cancer among New York talc workers. Int Arch Occup Environ Health, 10: 449-56. |
| 47322 | Akira M, Yamamoto S, Hara H, Sakatani M, Ueda E (1997). Serial computed tomographic evaluation in desquamative interstitial pneumonia. Thorax, 52: 333-7. |
| 47323 | Ishii Y, Hirano K, Morishima Y, Masuyama K, et al (2000). Early molecular and cellular events of oxidant-induced pulmonary fibrosis in rats. Toxicology and Applied Pharmacology, 167: 173-81. |
| 47324 | Churg A, Muller NL (2006). Cellular vs Fibrosing interstitial pneumonias and prognosis. Chest, 130: 1566-70. |
| 47325 | Roberts WC (2002). Pulmonary talc granulomas, pulmonary fibrosis, and pulmonary hypertension resulting from intravenous injection of talc-containing drugs intended for oral use. BUMC Proceedings, 15(3): 260-1. |
| 47326 | Buerke U, Schneider J, Muller KM, Woitowitz HJ (2003). Interstitial pulmonary siderofibrosis: requirements for acceptance as new occupational disease [Article in German]. Pneumologie, 57(1): 9-14. |
| 47327 | Park JS, Brown KK, Tuder RM, Hale VAE, et al (2002). Respiratory bronchiolitis-associated interstitial lung disease: radiologic features with clinical and pathologic correlation. Journal of Computer Assisted Tomography, 26(1): 13-20. |
| 47369 | Schwartz DA (2007). Occupational and environment lung disease. ACP Medicine, 18,14. . |
| 47370 | Maier LA, Martyny JW, Liang J, Rossman MD (2008). Recent chronic beryllium disease in residents surrounding a beryllium facility. Am J Respir Crit Care Med, 177(9): 1012-7. |
| 47371 | Craig PJ, Wells AU, Doffman S, Rassl D, et al (2004). Desquamative interstitial pneumonia, respiratory bronchiolitis and their relationship to smoking. Histopathology, 45: 275-82. |
| 47372 | Bellot SM, Schade van Westrum JAFM, Wagenvoort CA, Meijer AEFH (1984). Deposition of bauxite dust and pulmonary fibrosis. Path Res Pract, 179: 225-9. |
| 47373 | Musk AW, Greville HW, Tribe AE (1980). Pulmonary disease from occupational exposure to an artificial aluminium silicate used for cat litter. Br J Ind Med, 37: 367-72. |
| 47374 | Mossman BT, Churg A (1998). Mechanisms in the pathogenesis of asbestosis and silicosis. Am J Respir Crit Care Med, 157: 1666-80. |
| 47375 | Yamamoto K, Ueda M, Kikuchi H, Hattori H, Hiraoka Y (1983). An acute fatal occupational cadmium poisoning by inhalation. Z Rechtsmed, 91: 139-43. |
| 47376 | Suratt PM, Winn WC, Brody AR, Bolton WK, Giles RD (1977). Acute silicosis in tombstone sandblasters. Am Rev Respir Dis, 115: 521-9. |
| 47377 | Smith TJ, Petty TL, Reading JC, Lakshminarayan S (1976). Pulmonary effects of chronic exposure to airborne cadmium. Am Rev Respir Dis, 114: 161-9. |
| 47378 | Mapel D, Coultas D (2002). Disorders due to minerals other than silica, coal, and asbestos, and to metals. Occupational Disorders of the Lung: Recognition, Management, and Prevention, 10: 163-90. . |
| 47379 | Utell MJ, Lockey JE (2002). Disorders due to manmade vitreous fibers. Occupational Disorders of the Lung: Recognition, Management, and Prevention, 11: 191-9. . |
| 47380 | Nemery B (2002). Toxic pneumonitis: chemical agents. Occupational Disorders of the Lung: Recognition, Management, and Prevention, 12: 201-19. . |
| 47381 | Churg A (2002). Mineralogic analysis of lung tissue. Occupational Disorders of the Lung: Recognition, Management, and Prevention. (Eds: Hendrick DJ, Sherwood Burge P, Beckett WS, Churg A), 34: 535-42. . |
| 47382 | McMillan G (2002). Welding. Occupational Disorders of the Lung. Recognition, Management, and Prevention,, 30: 467-79. . |
| 47383 | Chan-Yeung M, Dimich-Ward H (1999). Natural history of occupational lung diseases. Eur Respir Mon, 11: 46-63. |
| 47384 | Brichet A, Salez F, Lamblin C, Wallaert B (1999). Coal workers' pneumoconiosis and silicosis. Eur Respir Mon, 11: 136-57. |
| 47385 | Begin R (1999). Asbestos-related diseases. Eur Respir Mon, 11: 158-77. |
| 47386 | De Raeve H, Nemery B (1999). Lung diseases induced by metals and organic solvents. Eur Respir Mon, 11: 178-213. |
| 47387 | Viegi G, Annesi-Maesano I (1999). Lung diseases induced by indoor and outdoor pollutants. Eur Respir Mon, 11: 214-41. |
| 47492 | Wesseling C, Hogstedt C, Picado A, Johansson L (1997). Unintentional fatal paraquat poisonings among agricultural workers in Costa Rica: report of 15 cases. Am J Ind Med, 32: 433-41. |
| 47493 | Hoffman S, Jedeikin R, Korzets Z, Shapiro A-L, Kaplan R, Bernheim J (1983). Successful management of severe paraquat poisoning. Chest, 84(1): 107-9. |
| 47494 | Voloudaki A, Ergazakis N, Gourtsoyiannis N (2003). Late changes in barium sulfate aspiration: HRCT features. Eur Radiol, 13: 2226-9. |
| 47495 | Davies D, Cotton R (1983). Mica pneumoconiosis. Br J Ind Med, 40: 22-7. |
| 47496 | Damiano VV, Cherian PV, Frankel FR, Steeger JR, Sohn M, Oppenheim D, Weinbaum G (1990). Intraluminal fibrosis induced unilaterally by lobar instillation of CdCI2 into the rat lung. Am J Pathol, 137(4): 883-94. |
| 47497 | Antoniou KM, Hansell DM, Rubens MB, Marten K, et al (2008). Idiopathic pulmonary fibrosis. Outcome in relation to smoking status. Am J Respir Crit Care Med, 177: 190-4. |
| 47498 | Conen D, Schilter D, Bubendorf L, Brutsche MH, Leuppi JD (2003). Interstitial lung disease in an intravenous drug user. Respiration, 70: 101-3. |
| 47499 | Xu H, Verbeken E, Vanhooren HM, Nemery B, Hoet PHM (2004). Pulmonary toxicity of polyvinyl chloride particles after a single intratracheal instillation in rats. Time course and comparison with silica. Toxicology and Applied Pharmacology, 194: 111-21. |
| 47500 | Soutar CA, Gauld S (1983). Clinical studies of workers exposed to polyvinylchloride dust. Thorax, 38: 834-9. |
| 47501 | Soutar CA, Copland LH, Thornley PE, Hurley JF, Ottery J, Adams WGF, Bennett B (1980). Epidemiological study of respiratory disease in workers exposed to polyvinylchloride dust. Thorax, 35: 644-52. |
| 47502 | Groth DH, Lynch DW, Moorman WJ, Stettler LE, Lewis TR, Wagner WD, Kommineni C (1981). Pneumoconiosis in animals exposed to poly(vinyl chloride) dust. Environmental Health Perspectives, 41: 73-81. |
| 47503 | Epler GR (2001). Bronchiolitis obliterans organizing pneumonia. Arch Intern Med, 161: 158-64. |
| 47504 | Oymak FS, Demirbas HM, Mavili E, Akgun H, Gulmez I, Demir R, Ozesmi M (2005). Bronchiolitis obliterans organizing pneumonia. Clinical and roentgenological features in 26 cases. Respiration, 72: 254-62. |
| 47505 | Ioachimescu OC, Kavuru MS (2006). Pulmonary alveolar proteinosis. Chronic Respiratory Disease, 3: 149-59. |
| 47506 | Seymour JF, Presneill JJ (2002). Pulmonary alveolar Proteinosis. Progress in the first 44 years. Am J Respir Crit Care Med, 166: 215-35. |
| 47507 | Kavuru MS, Bonfield TL, Thomassen MJ (2003). [Comment] Plasmapheresis, GM-CSF, and alveolar proteinosis. Am J Respir Crit Care Med, 167(7): 1036. Author's reply: 1036-7. |
| 47508 | Sieniewicz DJ, Nidecker AC (1980). Conglomerate pulmonary disease: A form of talcosis in intravenous methadone abusers. AJR, 135: 697-702. |
| 47509 | De Vuyst P, Van Weyer R, De Coster A, Marchandise FX, et al (1986). Dental technician's pneumoconiosis. A report of two cases. Am Rev Respir Dis, 133: 316-20. |
| 47510 | Vale JA, Meredith TJ, Buckley BM (1987). Paraquat poisoning: clinical features and immediate general management. Human Toxicol, 6: 41-7. |
| 47511 | Dzau VJ, Szabo S, Chang YC (1977). Aspiration of metallic mercury. A 22-year follow-up. JAMA, 238(14): 1531-2. |
| 47512 | Nakanishi M, Demura Y, Mizuno S, Ameshima S, et al (2007). Changes in HRCT findings in patients with respiratory bronchiolitis-associated interstitial lung disease after smoking cessation. Eur Respir J, 29(3): 453-61. |
| 47513 | Noth I, Martinez FJ (2007). Recent advances in idiopathic pulmonary fibrosis. Chest, 132(2): 637-50. |
| 47514 | Davies G, Wells AU, du Bois R (2004). Respiratory bronchiolitis associated with interstitial lung disease and desquamative interstitial pneumonia. Clin Chest Med, 25: 717-26. |
| 47515 | Glazer CS, Newman LS (2004). Occupational interstitial lung disease. Clin Chest Med, : 467-78. |
| 47583 | Brune D, Kjerheim A, Paulsen G, Beltesbrekke H (1980). Pulmonary deposition following inhalation of chromium-cobalt grinding dust in rats and distribution in other tissues. Scand J Dent Res, 88: 543-51. |
| 47615 | Gomez AD, King TE Jr (2007). Classification of diffuse parenchymal lung disease. Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, 36: 2-10. Karger, Basel. |
| 47616 | Desai SR, Wells AU (2007). Imaging. Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, 36: 29-43. Karger, Basel. |
| 47617 | Collard HR (2007). Diseases: other entities of the idiopathic interstitial pneumonias. Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, 36: 175-84. Karger, Basel. |
| 47618 | Camus P (2007). Drug-induced and iatrogenic infiltrative lung disease. Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, 36: 212-37. Karger, Basel. |
| 47619 | Olson AL, Schwarz MI (2007). Diffuse alveolar hemorrhage. Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, 36: 250-63. Karger, Basel. |
| 47664 | Ward E, Rog J (1998). Bronchiolitis obliterans organizing pneumonia mimicking community-acquired pneumonia. J Am Board Fam Pract, 11(1): 41-5. |
| 47695 | Unknown (2008). Hypersensitivity Pneumonitis. . Retrieved 9 April 2008, from http://proxy14.use.hcn.com.au/popup.aspx?aID=2869483&print=yes\_chapter |
| 47696 | Jawa A (2006). Eosinophilic pneumonia. . Retrieved 9 April 2008, from Obtained from http://www.emedicine.com/med/topic695.html |
| 47697 | Senju R, Fukushima K, Kadota J, Hiratani K, et al (1990). A case of idiopathic pulmonary fibrosis with chronic eosinophilic pneumonia. Nihon Kyobu Shikkan Gakkai Zasshi, 28(1): 172-7. [Abstract] |
| 47698 | Pare JP, Cote G, Fraser RS (1989). Long-term follow-up of drug abusers with intravenous talcosis. Am Rev Respir Dis, 139: 233-41. |
| 47699 | Padley SPG, Adler BD, Stales CA, Miller RR, Muller NL (1993). Pulmonary talcosis: CT findings in three cases. Radiology, 186: 125-7. |
| 47700 | Buschman DL, Ballard R (1993). Progressive massive fibrosis associated with idiopathic pulmonary hemosiderosis. Chest, 104: 293-5. |
| 47701 | Yoshida K, Shijubo N, Koba H, Mori Y, et al (1994). Chronic eosinophilic pneumonia progressing to lung fibrosis. Eur Respir J, 7: 1541-4. |
| 47737 | Balmes JR (2005). Chronic beryllium disease and cobalt-related interstitial lung disease (hard-metal disease and diamond polisher's lung disease). Textbook of Clinical Occupational and Environmental Medicine, 19,7: 357-63. . |
| 47738 | Banks DE (2005). Silicosis. Textbook of Clinical Occupational and Environmental Medicine, 19.9: 380-92. . |
| 47739 | Petsonk EL, Attfield MD (2005). Respiratory diseases of coal miners. Textbook of Clinical Occupational and Environmental Medicine, 19.10: 394-407. . |
| 47740 | Donovan JR Jr, Lockey JE (2005). Other pneumoconiosis. Textbook of Clinical Occupational and Environmental Medicine, 19.11: 408-17. . |
| 47764 | Mochimaru H, Kawamoto M, Fukuda Y, Kudoh S (2005). Clinicopathological differences between acute and chronic eosinophilic pneumonia. Respirology, 10: 76-85. |
| 47765 | Bishay A, Amchentsev A, Saheh A, Patel N, Travis W, Raoof S (2008). A hitherto unreported pulmonary complication in an IV heroin user. Chest, 133(2): 549-51. |
| 47883 | Pujol JL, Barneon G, Bousquet J, Michel FB, Godard P (1990). Interstitial pulmonary disease induced by occupational exposure to paraffin. Chest, 97(1): 234-6. |
| 47884 | Gondouin A, Manzoni P, Ranfaing E, Brun J, et al (1996). Exogenous lipid pneumonia: a retrospective multicentre study of 44 cases in France. Eur Respir J, 9: 1463-9. |
| 47885 | Ohwada A, Yoshioka Y, Shimanuki Y, Mitani K, et al (2002). Exogenous lipoid pneumonia following ingestion of liquid paraffin. Intern Med, 41(6): 483-6. |
| 47886 | Schwarz MI, Brown KK (2000). Small vessel vasculitis of the lung. Thorax, 55: 502-10. |
| 47887 | Lauque D, Dongay G, Levade T, Caratero C, Carles P (1990). Bronchoalveolar lavage in liquid paraffin pneumonitis. Chest, 98(5): 49-55. |
| 47920 | Baron SE, Haramati LB, Rivera VT (2003). Radiological and clinical findings in acute and chronic exogenous lipoid pneumonia. J Thorac Imaging, 18(4): 217-24. |
| 47921 | Miller GJ, Ashcroft MT, Beadnell HM, Wagner JC, Pepys J (1971). The lipoid pneumonia of blackfat tobacco smokers in Guyana. Q J Med, 40(160): 457-70. |
| 47922 | Skyberg K, Ronneberg A, Kamoy JI, Dale K, Borgersen A (1986). Pulmonary fibrosis in cable plant workers exposed to mist and vapor of petroleum distillates. Environ Res, 40(2): 261-73. |
| 47923 | Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for radon, pp 1-20. . Retrieved 1 May 2008, from http://www.atsdr.cdc.gov/toxprofiles/tp145-p.pdf |
| 47948 | Mundt P, Mochmann H-C, Ebhardt H, Zeitz M, et al (2007). Pulmonary fibrosis after chemotherapy with oxaliplatin and 5-fluorouracil for colorectal cancer. Oncology, 73: 270-2. |
| 47949 | Duek A, Feldberg E, Haran M, Berrebi A (2007). Pulmonary fibrosis in a myeloma patient on bortezomib treatment. A new severe adverse effect of a new drug. Am J Hematol, 82(6): 502-3. |
| 47950 | Ostoros G, Pretz A, Fillinger J, Soltesz I, Dome B (2006). Fatal pulmonary fibrosis induced by paclitaxel: a case report and review of the literature. Int J Gynecol Cancer, 16(Suppl 1): 391-3. |
| 47951 | Bechard DE, Fairman RP, DeBlois GG, Via CT (1987). Fatal pulmonary fibrosis from low-dose bleomycin therapy. South Med J, 80(5): 646-9. |
| 47952 | Cordier JF (2006). Cryptogenic organising pneumonia. Eur Respir J, 28(2): 422-46. |
| 47953 | Hirosako S, Fujii K, Kashiwabara K, Kohrogi H (2008). Insidious pulmonary fibrosis occurring at the hypoperfusion area in a patient with chronic pulmonary thromboembolism. Intern Med, 47: 769-72. |
| 47954 | Makris D, Scherpereel A, Copin MC, Colin G, et al (2007). Fatal interstitial lung disease associated with oral erlotinib therapy for lung disease. BMC Cancer, 7: 150. |
| 47955 | Miller PA, Ravin CE, Walker Smith GJ, Osborne DRS (1981). Pulmonary alveolar proteinosis with interstitial involvement. AJR, 137: 1069-71. |
| 47956 | Laurent F, Philippe JC, Vergier B, Granger- Veron B, et al (1999). Exogenous lipoid pneumonia: HRCT, MR, and pathological findings. Eur Radiol, 9: 1190-6. |
| 47957 | Ikehara K, Suzuki M, Tsuburai T, Ishigatsubo Y (2002). Lipoid pneumonia. The Lancet, 359(9314): 1300. |
| 47958 | Maygarden SJ, Iacocca MV, Funkhouser WK, Novotny DB (2001). Pulmonary alveolar proteinosis: A spectrum of cytologic, histochemical, and ultrastructural findings in bronchoalveolar lavage fluid. Diagn Cytopathol, 24: 389-95. |
| 47959 | Leimgruber K, Negro R, Baier S, Moser B, et al (2006). Fatal interstitial pneumonitis associated with docetaxel administration in a patient with hormone-refractory prostate cancer. Tumori, 92: 542-4. |
| 48013 | Clague HW, Wallace AC, Morgan WKC (1983). Pulmonary interstitial fibrosis associated with alveolar proteinosis. Thorax, 38: 865-6. |
| 48014 | Iliopoulou A, Pagou H, Giannakopoulos G, Spiropoulos T (2000). Amiodarone-induced pulmonary interstitial fibrosis. Intensive Care Med, 26: 1585. |
| 48015 | Soboi SM, Rakita L (1982). Pneumonitis and pulmonary fibrosis associated with amiodarone treatment: A possible complication of a new antiarrhythmic drug. Circulation, 65(4): 819-24. |
| 48016 | Dusman RE, Stanton MS, Miles WM, Klein LS, et al (1990). Clinical features of amiodarone-induced pulmonary toxicity. Circulation, 82: 51-9. |
| 48017 | Yao TC, Hung IJ, Wong KS, Huang JL, Niu CK (2003). Idiopathic pulmonary haemosiderosis: An oriental experience. J Paediatr Child Health, 39: 27-30. |
| 48018 | Marsaudon E, Castet D, Barrault MF, Allais C (1997). Diffuse interstitial lung diseases without pleural involvement and high-dose bromocriptine. Rev Mal Respir, 14(5): 405-7. [Abstract] |
| 48019 | Skyberg K, Ronneberg A, Christensen CC, Naess-Andresen CF, Borgersen A, Refsum HE (1992). Lung function and radiographic signs of pulmonary fibrosis in oil exposed workers in a cable manufacturing company: a follow up study. Br J Ind Med, 49: 309-15. Retrieved 14 May 2008, from 309-15 |
| 48020 | Chroneou A, Zias N, Tronic BS, Gonzalez AV, Beamis JF Jr (2007). A case of uncomplicated pulmonary alveolar proteinosis evolving to pulmonary fibrosis. Monaldi Arch Chest Dis, 67(4): 234-7. |
| 48021 | Poll LW, May P, Koch JA, Hetzel G, Heering P, Modder U (2001). HRCT findings of amiodarone pulmonary toxicity: Clinical and radiologic regression. J Cardiovasc Pharmacol Ther, 6(3): 307-11. |
| 48027 | Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE (2001). Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child, 85: 330-4. |
| 48105 | Bleumink GS, van der Molen-Eijgenraam M, Strijbos JH, et al (2002). Pergolide-induced pleuropulmonary fibrosis. Clinical Neuropharmacology, 25(5): 290-3. |
| 48106 | Fielding JWL, Crocker J, Stockley RA, Brookes VS (1979). [Comment] Interstitial fibrosis in a patient treated with 5-fluorouracil and mitomycin C. BMJ, 2(6189): 551-2. |
| 48107 | Yamada Y, Shiga T, Matsuda N, Hagiwara N, Kasanuki H (2007). Incidence and predictors of pulmonary toxicity in Japanese patients receiving low-dose amiodarone. Circ J, 71: 1610-6. |
| 48108 | Kanji Z, Sunderji R, Gin K (2008). Amiodarone-induced pulmonary toxicity. Retrieved 6 May 2008, from www.medscape.com/viewarticle/418090\_print |
| 48109 | MIMS Online (2008). Prescribing Information. Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48110 | MIMS Online (2008). Blenamax Injection. Prescribing Information. Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48111 | MIMS Online (2008). Parlodel Capsules Tablets. Prescribing Information. . Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48112 | MIMS Online (2008). Leukeran Tablets. Prescribing Information. . Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48113 | MIMS Online (2008). Anzatax Injection Concentrate Infusion. Prescribing Information. . Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48114 | MIMS Online (2008). Taxotere Concentrate for Infusion. Prescribing Information. . Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48115 | MIMS Online (2008). Hydrea Capsules. Prescribing Information. . Retrieved 6 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48116 | MIMS Online (2008). CeeNU Capsules. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 48117 | MIMS Online (2008). ViCNU Injection. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48118 | MIMS Online (2008). Methoblastin Tablets. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48119 | MIMS Online (2008). DBL Oxaliplatin for Injection. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48120 | MIMS Online (2008). DBL Fluorouracil Injection BP Solution for Injection. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48121 | MIMS Online (2008). Salazopyrin Tablets. Prescribing Information. Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48122 | MIMS Online (2008). Alkeran Coated Tablets. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48123 | MIMS Online (2008). Cycloblastin Injection Tablets. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48124 | MIMS Online (2008). Macrodantin. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48125 | MIMS Online (2008). Mitomycin C Kyowa Injection. Prescribing Information. . Retrieved 15 May 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&product |
| 48126 | Dawson JK, Fewins HE, Desmond J, Lynch MP, Graham DR (2008). Fibrosing alveolitis in patients with rheumatoid arthritis as assessed by high resolution computed tomography, chest radiography, and pulmonary function tests. Thorax, 56: 622-7. |
| 48127 | Saravanan V, Kelly CA; Dawson JK, Desmond J et al (2002). [Comment] Fibrosing alveolitis in patients with RA. Thorax, 57(4): 375-6. |
| 48128 | Provenzano G (2002). [Comment] Asymptomatic pulmonary involvement in RA. Thorax, 57(2): 187-8. |
| 48129 | Tintner R, Manian P, Gauthier P, Jankovic J (2005). Pleuropulmonary fibrosis after long-term treatment with the dopamine agonist pergolide for Parkinson Disease. Arch Neurol, 62(8): 1290-5. |
| 48130 | Buzdar AU, Legha SS, Luna MA, Tashima CK, et al (1980). Pulmonary toxicity of mitomycin. Cancer, 45: 236-44. |
| 48131 | Akerley W, Safran H, Zaner K, Ready N, Mega T, Kennedy T (2006). Phase II trial of weekly paclitaxel and gemcitabine for previously untreated, stage IIIB-IV nonsmall cell lung cancer. Cancer, 107: 1050-4. |
| 48132 | Boyd O, Gibbs AR, Smith AP (1990). Fibrosing alveolitis due to sulphasalazine in a patient with rheumatoid arthritis. Br J Rheumatol, 29: 222-4. |
| 48133 | Castro M, Veeder MH, Mailliard JA, Tazelaar HD, Jett JR (1996). A prospective study of pulmonary function in patients receiving mitomycin. Chest, 109(4): 939-44. |
| 48134 | Parry SD, Baratzas C, Peel ET, Barton JR (2002). Sulphasalazine and lung toxicity. Eur Respir J, 19: 756-64. |
| 48135 | Imokawa S, Colby TV, Leslie KO, Helmers RA (2000). Methotrexate pneumonitis: review of the literature and histopathological findings in nine patients. Eur Respir J, 15: 373-81. |
| 48136 | Hubbard R, Venn A, Britton J (2000). Exposure to antidepressants and the risk of cryptogenic fibrosing alveolitis: a case-control study. Eur Respir J, 16: 409-13. |
| 48137 | Tisdale JE, Follin SL, Ordelova A, Webb CR (1995). Risk factors for the development of specific noncardiovascular adverse effects associated with amiodarone. J Clin Pharmacol, 35: 351-6. |
| 48138 | Todman DH, Oliver WA, Edwards RL (1990). Pleuropulmonary fibrosis due to broocriptine treatment for Parkinson's Disease. Clinical and Experimental Neurology, 27: 79-82. |
| 48139 | Oldenburger D, Maurer WJ, Beltaos E, Magnin GE (1972). Inhalation lipoid pneumonia from burning fats. JAMA, 222(10): 1288-9. |
| 48140 | Napchan GD, Talmaciu I (2007). Hemosiderosis. Retrieved 21 May 2008, from http://www.emedicine.com/ped/TOPIC970.htm |
| 48141 | Ayyala US (2007). Sarcoidosis and Immunologic Lung Disease. ACP Medicine, 13,14. . |
| 48189 | Garcia JGN, Munim A, Nugent KM, Bishop M, et al (1987). Alveolar macrophage gold retention in rheumatoid arthritis. J Rheumatol, 14: 435-8. |
| 48190 | Goucher G, Rowland V, Hawkins J (1980). Melphalan-induced pulmonary interstitial fibrosis. Chest, 77(6): 805-6. |
| 48191 | Codling BW, Chakera TMH (1972). Pulmonary fibrosis following therapy with Melphalan for multiple myeloma. J Clin Path, 25: 668-73. |
| 48192 | Scott DL, Bradby GV, Aitman TJ, Zaphiropoulos GC, Hawkins CF (1981). Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Ann Rheum Dis, 40: 136-41. |
| 48193 | Anaya JM, Diethelm L, Ortiz LA, Gutierrez M, et al (1995). Pulmonary involvement in rheumatoid arthritis. Semin Arthritis Rheum, 24(4): 242-54. |
| 48194 | Kim DS (2006). Interstitial lung disease in rheumatoid arthritis: recent advances. Curr Opin Pulm Med, 12: 346-53. |
| 48195 | Winterbauer RH, Wilske KR, Wheelis RF (1976). Diffuse pulmonary injury associated with gold treatment. N Engl J Med, 294: 919-21. |
| 48196 | Tanaka N, Kim JS, Newell JD, Brown KK, et al (2004). Rheumatoid arthritis-related lung diseases: CT findings. Radiology, 232: 81-91. |
| 48197 | Phillips TJ, Jones DH, Baker H (1987). Pulmonary complications following methotrexate therapy. J Am Acad Dermatol, 16: 373-5. |
| 48198 | Cottin V, Tebib J, Massonnet B, Souquet PJ, Bernard JP (1996). Pulmonary function in patients receiving long-term low-dose methotrexate. Chest, 109: 933-8. |
| 48199 | Hargreaves MR, Mowat AG, Benson MK (1992). Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports. Thorax, 47: 628-33. |
| 48200 | Music E, Tomsic M, Logar D (1995). Gold salt alveolitis in 3 patients with rheumatoid arthritis. Pneumologie, 49(6): 367-72. [Abstract] |
| 48201 | Crittenden D, Tranum BL, Haut A (1977). Pulmonary fibrosis after prolonged therapy with 1,3-Bis (2-chloroethyl)-1-nitrosourea. Chest, 72: 372-3. |
| 48202 | Major PP, Laurin S, Bettez P (1980). Pulmonary fibrosis following therapy with melphalan: report of two cases. CMA, 123: 197-202. |
| 48203 | Taetle R, Dickman PS, Feldman PS (1978). Pulmonary histopathologic changes associated with melphalan therapy. Cancer, 42: 1239-45. |
| 48204 | Grande C, Villaneuva MJ, Huidobro G, Casal J (2007). Docetaxel-induced interstitial pneumonitis following non-small-cell lung cancer treatment. Clin Transl Oncol, 9: 578-81. |
| 48205 | Zisman DA, McCune WJ, Tino G, Lynch JP (2001). Drug-induced pneumonitis: the role of methotrexate. Sarcoidosis. Vasc Diffuse Lung Dis, 18: 243-52. |
| 48206 | Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y (2003). Methotrexate-induced pulmonary injury: Serial CT findings. J Thorac Imaging, 18(4): 231-6. |
| 48207 | Reiners C, Demidchik YE (2003). Differentiated thyroid cancer in childhood: Pathology, diagnosis, therapy. Ped Endocrinol Rev, 1(Suppl 2): 230-6. |
| 48208 | Cutolo M, Seriolo B, Pizzorni C, Craviotto C, Sulli A (2002). Methotrexate in psoriasis arthritis. Clin Exp Rheumatol, 20(Suppl 28): S76-S80. |
| 48264 | Cavallaro R, Cocchi F, Angelone SM, Lattuada E, Smeraldi E (2004). Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study. J Clin Psychiatry, 65(2): 187-90. |
| 48265 | Rack MJ, Baran AS, et al; Cavallaro R, Cocchi F, et al (2004). [Comments] Cardiopulmonary complications of ergot-derivative dopamine agonists. J Clin Psychiatry, 65(10): 1429-30. |
| 48266 | Kuzela L, Vavrecka A, Prikazska M, Drugda B, et al (1999). Pulmonary complications in patients with inflammatory bowel disease. Hepato-Gastroenterology, 46: 1714-9. |
| 48267 | Leino R, Liippo K, Ekfors T (1991). Sulphasalazine-induced reversible hypersensitivity pneumonitis and fatal fibrosing alveolitis: report of two cases. J Ind Med, 229: 553-6. |
| 48309 | Collin B, Srinathan SK, Finch TM (2008). Methotrexate: prescribing and monitoring practices among the consultant membership of the British Association of Dermatologists. British Journal of Dermatology, 158: 793-800. |
| 48454 | Yague XH, Soy E, Merino BQ, Puig J, et al (2005). Interstitial pneumonitis after oxaliplatin treatment in colorectal cancer. Clin Transl Oncol, 7(11): 515-7. |
| 48455 | Ruiz-Casado A, Garcia MD, Racionero MA (2006). [Comment] Pulmonary toxicity of 5-fluoracil and oxaliplatin. Clin Transl Oncol, 8(8): 624. |
| 49014 | Lee J, Sogutlu G, Leard L, Zarnegar R, et al (2007). Lung transplantation for pulmonary metastases and radiation-induced pulmonary fibrosis after radioactive iodine ablation of extensive lung metastases from papillary thyroid carcinoma. Thyroid, 17(4): 367-9. |
| 49015 | De Vuyst P, Dumortier P, Ketelbant P, Flament-Durant J, Henderson J, Yernault JC (1990). Lung fibrosis induced by Thorotrast. Thorax, 45: 899-901. |
| 49016 | Fathi M, Lundberg IE (2005). Interstitial lung disease in polymyositis and dermatomyositis. Curr Opin Rheum, 17: 701-6. |
| 49017 | Seo P, Min YI, Holbrook JT, Hoffman GS, et al (2005). Damage caused by Wegener's granulomatosis and its treatment. Arthritis & Rheumatism, 52(7): 2168-78. |
| 49018 | Myers JL, Tazelaar HD (2008). Challenges in pulmonary fibrosis: 6 - Problematic granulomatous lung disease. Thorax, 63: 78-84. |
| 49019 | Mori T, Fukutomi K, Kato Y, Hatakeyama S, et al (1999). 1998 results of the first series of follow-up studies on Japanese Thorotrast patients and their relationships to an autopsy series. Radiat Res, 152: S72-80. |
| 49020 | Mark EJ, Flieder DB, Matsubara O (1997). Treated Wegener's granulomatosis: distinctive pathological findings in the lungs of 20 patients and what they tell us about the natural history of the disease. Hum Pathol, 28(4): 450-8. |
| 49021 | Nagaria NC, Cogswell J, Choe JK, Kasimis B (2005). Side effects and good effects from new chemotherapeutic agents. J Clin Oncol, 23(10): 2423-4. |
| 49022 | Marder VJ, Mellinghoff IK (2000). Cocaine and Buerger disease. Is there a pathogenetic association? Arch Intern Med, 160: 2057-60. |
| 49114 | Sgouros G, Song J, Ladenson PW, & Wahl RL (2006). Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med, 47(12): 1977-84. |
| 49115 | Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, Brans B (2007). Targeted therapy in nuclear medicine - current status and future prospects. Annals of Oncology, 18: 1782-92. |
| 49116 | Song J, He B, Prideaux A, Du Y, et al (2006). Lung dosimetry for radiodine treatment planning in the case of diffuse lung metastases. J Nucl Med, 47: 1985-94. |
| 49117 | Ju JH, Kim SI, Lee JH, Lee SI, et al (2007). Risk of interstitial lung disease associated with leflunomide treatment in Korean patients with rheumatoid arthritis. Arthritis Rheum, 56(6): 2094-6. |
| 49118 | Lantuejoul S, Brambilla E, Brambilla C, Devouassoux G (2002). Statin-induced fibrotic nonspecific interstitial pneumonia. Eur Respir J, 19(3): 577-80. |
| 49119 | Lee H-K, Kim DS, Yoo B, Seo JB, Rho J-Y, Colby TV & Kitaichi M (2005). Histopathologic pattern and clinical features of rheumatoid arthritis-associated interstitial lung disease. Chest, 127: 2019-27. |
| 49120 | Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006). Interstitial lung disease in Primary Sjogren Syndrome. Chest, 130: 1489-95. |
| 49121 | Ichikado K, Suga M, Muller NL, Taniguchi H, Kondoh Y, Akira M et al (2002). Acute interstitial pneumonia: comparison of high-resolution computed tomography findings between survivors and nonsurvivors. Am J Respir Crit Care Med, 165: 1551-6. |
| 49122 | Hansell DM (2002). Acute interstitial pneumonia: clues from the white stuff. Am J Respir Crit Care Med, 165(11): 1465-6. |
| 49123 | Joynt GM, Antonio GE, Larn P, Wong KT, Li T, Gomersall CD, Ahuja AT (2004). Late-stage adult respiratory distress syndrome caused by severe acute respiratory syndrome: abnormal findings at thin-section CT. Radiology, 230: 339-46. |
| 49124 | Desai SR, Wells AU, Rubens MB, Evans TW, Hansell DM (1999). Acute respiratory distress syndrome: CT abnormalities at long-term follow-up. Radiology, 210: 29-35. |
| 49125 | Jeong YJ, Kim KI, Seo IJ, Lee CH, et al (2007). Eosinophilic lung diseases: a clinical, radiologic, and pathologic overview. RadioGraphics, 27: 617-39. |
| 49126 | Ryu JH, Parambil JG, McGrann PS, Aughenbaugh GL (2005). Lack of evidence for an association between neurofibromatosis and pulmonary fibrosis. Chest, 128: 2381-6. |
| 49127 | Hirsch NP, Murphy A, Radcliffe JJ (2001). Neurofibromatosis: clinical presentations and anaesthetic implications. British Journal of Anaesthesia, 86: 555-64. |
| 49128 | Camus P, Bonniaud P, Fanton A, Camus C, Baudaun N, Foucher P (2004). Drug-induced and iatrogenic infiltrative lung disease. Clin Chest Med, 25: 479-519. |
| 49129 | Seo P, Min YI, Holbrook JT, Hoffman GS, et al (2005). Damage caused by Wegener's granulomatosis and its treatment. Arthritis & Rheumatism, 52: 2168-78. |
| 49130 | Yokoyama T, Miyazama K, Kurakawa E, Nagate A, et al (2004). [Comment] Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia, 18(3): 645-6. |
| 49131 | Huh JW, Kim DS, Lee CK, Yoo B, Seo JB, Kitaichi M, Colby TV (2007). Two distinct clinical types of interstitial lung disease associated with polymyositis-dermatomyositis. Respiratory Medicine, 101: 1761-9. |
| 49132 | Ohnishi K, Sakai F, Kudoh S, Ohno R (2006). [Comment] Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia, 20(6): 1162-4. |
| 49133 | Leung TW, Lau WY, Ho SK, Ward SC, Chow JH, Chan MS, et al (1995). Radiation pneumonitis after selective internal radiation treatment with intraarterial 90yttrium-microspheres for inoperable hepatic tumors. Int J Radiat Oncol Biol Phys, 33(4): 919-24. |
| 49134 | Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, Atassi B, Ryu RK, et al (2008). Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 47: 71-81. |
| 49135 | Forner A, Bruix J (2008). Locoregional treatment for hepatocellular carcinoma: from clinical exploration to robust clinical data, changing standards of care. Hepatology, 47: 5-7. |
| 49136 | Ott MC, Khoor A, Leventhal JP, Paterick TE, Burger CD (2003). Pulmonary toxicity in patients receiving low-dose amiodarone. Chest, 123: 646-51. |
| 49137 | Mendez JL, Nadrous HF, Hartman TE, Ryu JH (2005). Chronic nitrofurantoin-induced lung disease. Mayo Clin Proc, 80: 1298-1302. |
| 49138 | Yokoyama T, Miyazawa K, Kurakawa E, Nagate A, Shimamoto T, Iwaya K, et al (2004). [Comment] Interstitial pneumonia induced by imatinib mesylate: pathologic study demonstrates alveolar destruction and fibrosis with eosinophilic infiltration. Leukemia, 18: 645-6. |
| 49139 | Anonymous (2004). Pulmonary toxicity with long-term nitrofurantoin. Aust Adv Drug Reactions Bull, 23: 15. |
| 49140 | Scott DL (2004). [Comment] Interstitial lung disease and disease modifying antirheumatic drugs. Lancet, 363: 1239-40. |
| 49141 | McCurry J (2004). Japan deaths spark concerns over arthritis drug. Lancet, 363: 461. |
| 49167 | Khan AN, Irion KL, Nagarajaiah CP (2008). Imaging in drug-induced lung disease. . Retrieved 18 August 2008, from www.emedicine.com/radio/topic401.htm |
| 49233 | Morera J, Vidal R, Morell F, Ruiz J, et al (1983). Amiodarone and pulmonary fibrosis. Eur J Clin Pharmacol, 24: 591-3. |
| 49234 | Ohnishi K, Sakai F, Kudoh S, Ohno R (2006). Twenty-seven cases of drug-induced interstitial lung disease associated with imatinib mesylate. Leukemia, 20: 1162-4. |
| 49235 | Wang KK, Bowyer BA, Fleming CR, Schroeder KW (1984). Pulmonary infiltrates and eosinophilia associated with sulfasalazine. Mayo Clin Proc, 59: 343-6. |
| 49236 | Parish JM, Muhm JR, Leslie KO (2003). Upper lobe pulmonary fibrosis associated with high-dose chemotherapy containing BCNU for bone marrow transplantation. Mayo Clin Proc, 78: 630-4. |
| 49237 | Yamasawa H, Sugiyama Y, Bando M, Ohno S (2008). Drug-induced pneumonitis associated with imatinib mesylate in a patient with idiopathic pulmonary fibrosis. Respiration, 75: 350-4. |
| 49238 | Reiners C, Biko J, Demidchik YE, Drozd VM (2007). Benefit and side effects of radioiodine therapy in radiation-induced childhood thyroid carcinoma. International Congress Series, 1299: 174-82. |
| 49239 | Sgouros G, Song H, Ladenson PW, Wahl RL (1984). Lung toxicity in radioiodine therapy of thyroid carcinoma: development of a dose-rate method and dosimetric implications of the 80-mCi rule. J Nucl Med, 47: 1977-84. |
| 49240 | Woodhead F, Wells AU, Desai SR (2008). Pulmonary complications of connective tissue diseases. Clin Chest Med, 29: 149-64. |
| 49241 | Appelbaum FR (2006). Hematopoietic cell transplantation. ACP Medicine, Section 5 Chapter 11: 1-13. WebMd Inc. |
| 49242 | Hopkin RJ, Grabowski GA (2008). Lysomal storage diseases. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 355: 2452-6. . |
| 49243 | Wolff D, Reichenberger F, Steiner B, Kahl C, et al (2002). Progressive interstitial fibrosis of the lung in sclerodermoid chronic graft-versus-host disease. Bone Marrow Transplantation, 29: 357-60. |
| 49244 | du Bois RM (2007). Mechanisms of scleroderma-induced lung disease. Proc Am Thorac Soc, 4: 434-438. |
| 49245 | Tammaro KA, Baldwin PD, Lundberg AS (2005). Interstitial lung disease following erlotinib (Tarceva) in a patient who previously tolerated gefitinib (Iressa). J Oncol Pharm Pract, 11: 127-30. |
| 49246 | Devaraj A, Wells AU, Hansell DM (2007). Computed tomographic imaging in connective tissue diseases. Semin Respir Crit Care Med, 28(4): 389-97. |
| 49247 | Koulaouzidis A, Karagiannidis A, Prados S, et al (2006). Lymphocytic interstitial pneumonitis (LIP) - the liver and the lung. Annals of Hepatology, 5(3): 170-71. |
| 49248 | Kaloudi O, Miniati I, Alara S, Matucci-Cerinic M (2007). Interstitial lung disease in systemic sclerosis. Intern Emerg Med, 2: 250-5. |
| 49249 | Stefanova-Petrova DV, Tzvetanska AH, Naumova EJ, et al (2007). Chronic hepatitis C virus infection: prevalence of extrahepatic manifestations and association with cryoglobulinemia in Bulgarian patients. World J Gastroenterol, 13(48): 6518-28. |
| 49250 | Zignego AL, Giannini C, Ferri C (2007). Hepatitis C virus-related lymphoproliferative disorders: an overview. World J Gastroenterol, 13(17): 2467-78. |
| 49251 | Sharma OP (2001). Unusual systemic disorders associated with interstitial lung disease. Current Opinion in Pulmonary Medicine, 7: 291-4. |
| 49252 | Ferri C, La Civita L, Fazzi P, Solfanelli S, et al (1997). Interstitial lung fibrosis and rheumatoic disorders in patients with hepatitis C virus infection. Br J Rheumatol, 36(36): 360-5. |
| 49253 | Shankar G, Cohen DA (2001). Idiopathic pneumonia syndrome after bone marrow transplantation: the role of pre-transplant radiation conditioning and local cytokine dysregulation in promoting lung inflammation and fibrosis. Int J Exp Pathol, 82: 101-13. |
| 49254 | Griese M, Rampf U, Hofmann D, Fuhrer M, et al (2000). Pulmonary complications after bone marrow transplantation in children: twenty-four years of experience in a single pediatric center. Pediatric Pulmonology, 30: 393-401. |
| 49255 | Wang JY, Chang YL, Lee LN, Chen JH, et al (2004). Diffuse pulmonary infiltrates after bone marrow transplantation: the role of open lung biopsy. Ann Thorac Surg, 78: 267-72. |
| 49256 | Kulik LM, Carr BI, Mulcahy MF, Lewandowski RJ, et al (2008). Safety and efficacy of 90Y radiotherapy for hepatocellular carcinoma with and without portal vein thrombosis. Hepatology, 47: 71-81. |
| 49257 | Mark EJ, Ruangchira-urai R (2008). Bronchiolitis interstitial pneumonitis: a pathologic study of 31 lung biopsies with features intermediate between bronchiolitis obliterans organizing pneumonia and usual interstitial pneumonitis, with clinical correlation. Annals of Diagnostic Pathology, 12: 171-80. |
| 49258 | Perez-Calvo J, Bernal M, Giraldo P, Torralha MA, et al (2000). Co-morbidity in Gaucher's disease - results of a nationwide enquiry in Spain. Eur J Med Res, 5: 231-5. |
| 49259 | Kong FM, Haken RT, Eisbruch A, Lawrence TS (2005). Non-small cell lung cancer therapy-related pulmonary toxicity: an update on radiation pneumonitis and fibrosis. Semin Oncol, 32(Suppl 3): S42-54. |
| 49306 | MIMS Online (2008). Tykerb Tablets. Prescribing Information. Retrieved 22 August 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 49307 | MIMS Online (2008). Iressa Tablets. Prescribing Information. Retrieved 22 August 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 49308 | MIMS Online (2008). Tarceva Tablets. Prescribing Information. . Retrieved 22 August 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 49309 | Udwadia FE (1967). Tropical eosinophilia - a correlation of clinical, histopathologic and lung function studies. Chest, 52: 531-8. |
| 49310 | Staton GW Jr, Bhalla S (2008). Imaging of lung disease. Section 14 (Chapter II). Retrieved 18 August 2008, from http://www.acpmedicine.com/acpmedicine/pdf/med1402.pdf |
| 49311 | Appelbaum FR (2008). Hematopoietic cell transplantation. Part 6 (Chapter 108). Retrieved 22 August 2008, from http://proxy14.use.hcn.com.au/content.aspx?aid=2866203 |
| 49312 | Nutman TB, Weller PF (2008). Filarial and related infections. Part 7, Section 19: Chapter 211. Retrieved 22 August 2008, from http://proxy14.use.hcn.com.au/content.aspx?aid=2896783 |
| 49313 | Friedman S, Blumberg RS (2008). Inflammatory bowel disease. Part 13, Section 1: Chapter 289. Retrieved 22 August 2008, from http://proxy14.use.hcn.com.au/content.aspx?aid=2883197 |
| 49314 | Hahn BH (2008). Systemic lupus erythematosus. Part 14, Section 2: Chapter 313. Retrieved 22 August 2008, from http://proxy14.use.hcn.com.au/content.aspx?aid=2858970 |
| 49315 | Lipsky PE (2008). Rheumatoid arthritis. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 314: 2083-91. . |
| 49316 | Varga J (2008). Systemic sclerosis (scleroderma) and related disorders. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 316: 2096-06. . |
| 49317 | Dalakas MC (2008). Polymyositis, dermatomyositis, and inclusion body myositis. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 383: 2696-702. . |
| 49383 | Husain AN, Kumar V (2005). Granulomatous diseases. Robbins and Cotran Pathologic Basis of Disease, 7th edition, Chapter 15, The Lung: 737-41. Saunders Elsevier, Philadelphia. |
| 49384 | Sim M, Abramson M, Forbes A, Ikin J, et al (2003). Respiratory Health. Australian Gulf War Veterans' Health Study, Volume 1 Chapter 4.8. Commonwealth of Australia. |
| 49385 | Lin M (1993). Radiation pneumonitis caused by Yttrium-90 microspheres: radiologic findings. AJR, 162: 1300-2. |
| 49386 | Bodolay E, Szekanecz Z, Devenyi K, Galuska L, et al (2005). Evaluation of interstitial lung disease in mixed connective tissue disease (MCTD). Rheumatology, 44: 656-61. |
| 49387 | Lee CC, Lee SH, Chang IJ, Lu TC, et al (2005). Spontaneous pneumothorax associated with ankylosing spondylitis. Rheumatology, 44: 1538-41. |
| 49388 | Geddes DM, Brostoff J (1976). Pulmonary fibrosis associated with hypersensitivity to gold salts. Br Med J, 1(6023): 1444. |
| 49389 | Hamadeh MA, Atkinson J, Smith LJ (1992). Sulfasalazine-induced pulmonary disease. Chest, 101(4): 1033-7. |
| 49390 | Kelsall HL, Sim MR, Forbes AB et al (2004). Respiratory health status of Australian veterans of the 1991 Gulf War and the effects of exposure to oil fire smoke and dust storms. Thorax, 59(10): 897-903. |
| 49391 | Tsuboi M, Le Chevalier T (2006). Interstitial lung disease in patients with non-small-cell lung cancer treated with epidermal growth factor receptor inhibitors. Medical Oncology, 23(2): 161-70. |
| 49392 | Swigris JJ, Fischer A, et al (2008). Pulmonary and thrombotic manifestations of systemic lupus erythematosus. Chest, 133: 271-80. |
| 49393 | Liu V, White DA, Zakowski MF, Travis W, et al (2007). Pulmonary toxicity associated with erlotinib. Chest, 132: 1042-4. |
| 49394 | Yen KT, Lee AS, Krowka MJ, Burger CD (2004). Pulmonary complications in bone marrow transplantation: a practical approach to diagnosis and treatment. Clin Chest Med, 25: 189-201. |
| 49395 | Brown KK (2007). Rheumatoid lung disease. Proc Am Thorac Soc, 4: 443-8. |
| 49396 | Rowe WA (2008). Inflammatory bowel disease. Retrieved 29 August 2008, from http://www.emedicine.com/med/topic1169.htm |
| 49397 | Pletcher BA (2006). Neurofibromatosis, type 1. Retrieved 29 August 2008, from http://www.emedicine.com/NEURO/topic248.htm |
| 49403 | Carver JR, Shapiro CL, Ng A, Jacobs L, et al (2007). American Society of Clinical Oncology clinical evidence review on the ongoing care of adult cancer survivors: cardiac and pulmonary late effects. J Clin Oncol, 25(25): 3991-4008. |
| 49404 | Earle CC (2007). [Comment] Cancer survivorship research and guidelines: maybe the cart should be beside the horse. J Clin Oncol, 25(25): 3800-1. Comment on ID: 49403. |
| 49405 | Simonelli C, Berretta, Tirelli U, Annunziata MA (2008). [Comment] Clinical management of long-term cancer survivors. J Clin Oncol, 26(1): 161-2; Author reply 162. |
| 49406 | Ottesen EA, Nutman TB (1992). Tropical pulmonary eosinophilia. Annu Rev Med, 43: 417-24. |
| 49407 | Songur N, Songur Y, Tuzun M, Dogan I, et al (2003). Pulmonary function tests and high-resolution CT in the detection of pulmonary involvement in inflammatory bowel disease. J Clin Gastroenterol, 37(4): 292-8. |
| 49408 | Kennedy A, Nag S, Salem R, Murthy R, et al (2007). Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys, 68(1): 13-23. |
| 49409 | Herishanu Y, Polliack A, Leider-Trejo L, et al (2006). Fatal interstitial pneumonitis related to rituximad-containing regimen. Clinical Lymphoma & Myeloma, 6(5): 407-9. |
| 49410 | Haq M, Hyer S, Flux G, Cook G, Harmer C (2007). Differentiated thyroid cancer presenting with thyrotoxicosis due to functioning metastases. The British Journal of Radiology, 80: e38-43. |
| 49411 | Lateef O, Shakoor N, Balk RA (2005). Methotrexate pulmonary toxicity. Expert Opin Drug Saf, 4: 723-30. |
| 49412 | Douglas WW, Tazelaar HD, Harman TE, Hartman RP, et al (2001). Polymyositis-dermatomyositis-associated interstitial lung disease. Am J Respir Crit Care Med, 164: 1182-5. |
| 49413 | Kim EA, Lee KS, Johkoh T, Kim TS, et al (2002). Interstitial lung diseases associated with collagen vascular diseases: radiologic and histopathologic findings. Radiographics, 22: S151-65. |
| 49414 | Newman LS, Wasfi YS (2007). Sarcoidosis. In Diffuse Parenchymal Lung Disease. Progress in Respiratory Research, Vol 36: 128-38. Karger, Basel. |
| 49415 | Hoyles RK, Wells AU (2007). Pulmonary fibrosis in collagen vascular disease. Progress in Respiratory Research, Vol 36: 185-95. Karger, Basel. |
| 49545 | Bester L, Salem R (2007). Reduction of arteriohepatovenous shunting by temporary balloon occlusion in patients undergoing radioembolization. J Vasc Interv Radiol, 18: 1310-4. |
| 49555 | Malagari K, Nikita A, Alexopoulou E, Brountzos E, et al (2005). Cirrhosis-related intrathoracic disease. Imaging features in 1038 patients. Hepato-Gastroenterology, 52: 558-62. |
| 49765 | Camus P, Piard F, Ashcroft T, Gal AA, Colby TV (1993). The lung in inflammatory bowel disease. Medicine (Baltimore), 72(3): 151-83. |
| 49766 | Kotloff RM, Ahya VN, Crawford SW (2004). Pulmonary complications of solid organ and hematopoietic stem cell transportation. Am J Respir Crit Care Med, 170: 22-48. |
| 49767 | Marvisi M, Bassi E, Civardi G (2004). Pulmonary involvement in inflammatory bowel disease. Curr Drug Targets Inflamm Allergy, 3(4): 437-9. |
| 49768 | Mayberry JP, Primack SL, Muller NL (2000). Thoracic manifestations of systemic autoimmune diseases: radiographic and high-resolution CT findings. RadioGraphics, 20: 1623-35. |
| 49769 | Ando M, Okamoto I, Yamamoto N, Takeda K, et al (2006). Predictive factors for interstitial lung disease, antitumor response, and survival in non-small-cell lung cancer patients treated with Gefitinib. J Clin Oncol, 24(16): 2549-56. |
| 49770 | Robbins RJ, Schlumberger MJ (2005). The evolving role of 131I for the treatment of differentiated thyroid carcinoma. J Nucl Med, 46(Suppl 1): 28S-37S. |
| 49771 | Ong RKC, Doyle RL (1998). Tropical pulmonary eosinophilia. Chest, 113(6): 1673-9. |
| 49772 | Vijayan VK (2007). Tropical pulmonary eosinophilia: pathogenesis, diagnosis and management. Curr Opin Pulm Med, 13: 428-33. |
| 50049 | Cohen AJ, King TE Jr, Downey GP (1994). Rapidly progressive bronchiolitis obliterans with organizing pneumonia. Am J Respir Crit Care Med, 149: 1670-5. |
| 50050 | Belzunegui J, Intxausti JJ, De Dios JR, Lopez-Dominguez L, et al (2001). Absence of pulmonary fibrosis in patients with psoriasis arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol, 19: 727-30. |
| 50051 | Robert M, Derbaudrenghien J-P, Blampain J-P, Lamy F, Meyer P (1984). [Comment] Fibrotic processes associated with long-term ergotamine therapy. N Eng J Med, 311(9): 601-2. |
| 50052 | Atkinson K, Bryant D, Delprado W, Biggs J (1989). Widespread pulmonary fibrosis as a major clinical manifestation of chronic graft-versus-host disease. Bone Marrow Transplant, 4: 129-32. |
| 50053 | Afessa B, Litzow MR, Tefferi A (2001). Bronchiolitis obliterans and other late onset non-infectious pulmonary complications in hematopoietic stem cell transplantation. Bone Marrow Transplant, 28: 425-34. |
| 50054 | Arnaud A, Pommier De Santi P, Garbe L, Payan H, Charpin J (1978). Polyvinyl chloride pneumoconiosis. Thorax, 33: 19-25. |
| 50055 | Camus P, Colby TV (2000). The lung in inflammatory bowel disease. Eur Respir J, 15: 5-10. |
| 50056 | Danoff SK, Grasso ME, Terry PB, Flynn JA (2001). Pleuropulmonary disease due to pergolide use for restless leg syndrome. Chest, 120: 313-6. |
| 50057 | Graham JR (1967). Cardiac and pulmonary fibrosis during methysergide therapy for headache. Trans Am Clin Climatol Assoc, 78: 79-92. |
| 50058 | Studnicka MJ, Menzinger G, Drlicek M, Maruna H, Neumann MG (1995). Pneumoconiosis and systemic sclerosis following 10 years of exposure to polyvinyl chloride dust. Thorax, 50: 583-5. |
| 50059 | Taal BG, Spierings ELH, Hilvering C (1983). Pleuropulmonary fibrosis associated with chronic and excessive intake of ergotamine. Thorax, 38: 396-8. |
| 50060 | Vallyathan NV, Craighead JE (1981). Pulmonary pathology in workers exposed to nonasbestiform talc. Hum Pathol, 12(1): 28-35. |
| 50062 | Varkey B, Varkey AB (2008). Silicosis. Retrieved 13 October 2008, from http://www.emedicine.com/MED/topic2127.htm |
| 50063 | Horlander KT, Gruden J (2008). Acute respiratory distress syndrome. . Retrieved 13 October 2008, from Obtained from: http:///www.emedicine.com/radio/topic770.htm |
| 50064 | Chilosi M, Murer B, Poletti V (2007). Diffuse parenchymal lung diseases - histopathologic patterns. Progress in Respiratory Research, 36: 44-57. S Kar, Basel, Switzerland. |
| 50095 | Rossi S (2008). Immunosuppression. Australian Medicines Handbook 2008 (Electronic Edition). Retrieved 22 October 2008, from http://proxy7.use.hcn.com.au/chapter14/treatimmunosuppression.t.html |
| 50096 | Rossi S (2008). Azathioprine. Australian Medicines Handbook 2008 (Electronic Edition). Retrieved 22 October 2008, from http://proxy7.use.hcn.com.au/chapter14/monographazathioprine.html |
| 50097 | MIMS Online (2008). Cafergot Suppositories Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50098 | MIMS Online (2008). Dihydergot Solution for Injection Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50099 | MIMS Online (2008). Deseril Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50100 | MIMS Online (2008). Cabaser Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50101 | MIMS Online (2008). Permax Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50102 | MIMS Online (2008). Rapamune Oral Solution Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50103 | MIMS Online (2008). Azamun Tablets. Prescribing Information. Retrieved 22 October 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?MIval=2MIMS\_abbr\_pi&product |
| 50104 | Langford CA, Fauci AS (2008). The vasculitis syndromes. Wegener's granulomatosis. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 319: 2121-4. . |
| 50105 | Anonymous (2006). Deaths with galantamine in mild cognitive impairment studies. Fluoroquinolone antibiotics. Ergot derivatives and fibrotic reactions. Australian Adverse Drug Reactions Bulletin, 25(1): . |
| 50106 | Carmichael DJS, Hamilton DV, Evans DB, et al (1983). Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax, 38: 951-2. |
| 50141 | De Vuyst P, Dumortier P, Rickaert F, Van de Weyer R, et al (1986). Occupational lung fibrosis in an aluminium polisher. Eur J Respir Dis, 68(68): 131-40. |
| 50142 | Frank W, Moritz R, Becke B, Pauli R (1999). Low dose cabergoline induced interstitial pneumonitis. Eur Respir J, 14: 968-70. |
| 50143 | Bedrossian CW, Sussman J, Conklin RH, Kahan B (1984). Azathioprine-associated interstitial pneumonitis. Am J Clin Pathol, 82: 148-54. |
| 50144 | Howard L, Gopalan D, Griffiths M, Mahadeva R (2006). Sirolimus-induced pulmonary hypersensitivity associated with a CD4 T-cell infiltrate. Chest, 129(6): 1718-21. |
| 50145 | Kinnunen E, Viljanen A (1988). Pleuropulmonary involvement during bromocriptine treatment. Chest, 94(5): 1034-6. |
| 50146 | Manito N, Kaplinsky EJ, Bernat R, Roca J, et al (2004). Fatal interstitial pneumonitis associated with sirolimus therapy in a heart transplant recipient. J Heart Lung Transplant, 23: 780-2. |
| 50147 | Gross DC, Sasaki TM, Buick MK, Light JA (1997). Acute respiratory failure and pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation, 64(11): 1607-9. |
| 50148 | Morrissey P, Gohh R, Madras P, Monaco AP (1998). Pulmonary fibrosis secondary to administration of mycophenolate mofetil. Transplantation, 65(10): 1414. |
| 50149 | Pham PT, Pham PC, Danovitch GM, Ross DJ, et al (2004). Sirolimus-associated pulmonary toxicity. Transplantation, 77(8): 1215-20. |
| 50150 | Walker T, McCaffery J, Steinfort C (2007). Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. MJA, 186(2): 91-4. |
| 50151 | Golomb BA, Evans MA (2007). [Comment] Potential link between HMG-CoA reductase inhibitor (statin) use and interstitial lung disease. MJA, 187(4): 253. |
| 50152 | Pfitzenmeyer P, Foucher P, Dennewald G, Chevalon B, et al (1996). Pleuropulmonary changes induced by ergoline drugs. Eur Respir J, 9: 1013-9. |
| 50153 | Townsend M, MacIver DH (2004). Constrictive pericarditis and pleuropulmonary fibrosis secondary to cabergoline treatment for Parkinson's disease. Heart, 90: e47. |
| 50323 | Kiuru A, Yue Q-Y, Meyboom RH (2008). Pulmonary fibrosis reported with statins. . Retrieved 30 October 2008, from Obtained from http://www.who-umc.org/graphics/9720.pdf |
| 50324 | Australian Gulf War Veterans' Health Study (2003). Respiratory Health. Section 4.8. Retrieved 30 October 2008, from Obtained from http://www.dva.gov.au/media/publicat/2003/gulfwarhs/html/ch4.htm#4\_8 |
| 50325 | Chhajed PN, Dickenmann M, Bubendorf L, et al (2006). Patterns of pulmonary complications associated with sirolimus. Respiration, 73: 367-74. |
| 50326 | National Research Council of the National Academies (2007). Health Effects of Beryllium Exposure. A Literature Review, . National Academy Press - Washington, DC. |
| 50381 | Brown AL, Corris PA, Ashcroft T, et al (1992). Azathioprine-related interstitial pneumonitis in a renal transplant recipient. Nephrol Dial Transplant, 7(4): 362-4. |
| 50382 | Murnaghan DJ (1992). [Comment] Azathioprine-related inter-stitial pneumonitis in a renal transplant recipient. Nephrol Dial Transplant, 7(11): 1166. |
| 50383 | Ananthakrishnan AN, Attila T, Otterson MF, et al (2007). Severe pulmonary toxicity after azathioprine/6-mercaptopurine initiation for the treatment of inflammatory bowel disease. J Clin Gastroenterol, 41: 682-8. |
| 50384 | Haydar AA, Denton M, West A, et al (2003). Sirolimus-induced pneumonitis: three cases and a review of the literature. American Journal of Transplantation, 4: 137-9. |
| 50385 | Morcos SK, Thomsen HS (2008). Nephrogenic systemic fibrosis: more questions and some answers. Nephron Clin Pract, 110: c24-c32. |
| 50386 | Nainani N, Panesar M (2009). Nephrogenic systemic fibrosis. Am J Nephrol, 29: 1-9. |
| 50387 | Pakhale SS, Hadjiliadis D, Howell DN, et al (2004). Upper lobe fibrosis: a novel manifestation of chronic allograft dysfunction in lung transplantation. J Heart Lung Transplant, 24(9): 1260-8. |
| 50388 | Burton CM, Iversen M, Carlsen J, Anderson C (2008). Interstitial inflammatory lesions of the pulmonary allograft: a retrospective analysis of 2697 transbronchial biopsies. Transplantation, 86(6): 811-9. |
| 50389 | Katzenstein A-L A, Mukhopadhyay S, Myers JL (2008). Diagnosis of usual interstitial pneumonia and distinction ofrom other fibrosing interstitial lung diseases. Human Pathology, 39: 1275-94. |
| 50390 | Shabana WM, Cohan RH, Ellis JH, et al (2007). Nephrogenic systemic fibrosis: a report of 29 cases. Am J Roentgenol, 190(3): 736-41. |
| 50391 | McElvaney NG, Wilcox PG, Churg A, et al (1988). Pleuropulmonary disease during promocriptine treatment of Parkinson's disease. Arch Intern Med, 148: 2231-6. |
| 50392 | Champion L, Stern M, Israel-Biet D, et al (2006). Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med, 144(7): 505-9. |
| 50393 | MIMS online (2008). Prescribing Information - CellCept, infusion capsules powder for oral suspension tablets. Section 10C, 1361-5. Retrieved 4 November 2008, from http://www.mimsonline.com.au |
| 50394 | Thomson Healthcare Online (2008). Drugdex Evaluations: Tocainide. Micromedex Healthcare Series. . Retrieved 4 November 2005, from http://www.thomsonhc.com/ |
| 50395 | Leewohl M (2008). Cutaneous manifestations of systemic diseases. Section 1 Dermatology. Retrieved 4 November 2008, from http://www.acpmedicine.com/ |
| 50396 | Trulock, EP (2007). Lung transplantation. Respiratory Medicine: XVIII Lung Transplantation 1. . Retrieved 4 November 2008, from http://www.acpmedicine.com/ |
| 50397 | Krishnam MS, Suh RD, Tomasian A, et al (2007). Postoperative complications of lung transplantation: radiologic findings along a time continuum. RadioGraphics, 27: 957-74. |
| 50398 | Konen E, Weisbrod GL, Pakhale S, et al (2003). Fibrosis of the upper lobes: a newly identified late-onset complication after lung transplantation? AJR, 181: 1539-43. |
| 50399 | Rossi S (2008). Imatinib. AMH, Chapter 14 - Immunomodulators and antineoplastics. . Retrieved 4 November 2008, from http://www.amh.net.au/ |
| 50400 | MIMS online (2008). Prescribing information - Sprycel. Section 9(f). , : . Retrieved 4 November 2008, from www.mimsonline.com.au |
| 50401 | Carmichael D, Hamilton DV, Evans DB, et al (1983). Interstitial pneumonitis secondary to azathioprine in a renal transplant patient. Thorax, 38: 951-2. |
| 50402 | Bergeron A, Rea D, Levy V, et al (2007). Lung abnormalities after dasatinib treatment for chronic myeloid leukemia. Am J Respir Crit Care Med, 176: 814-8. |
| 50403 | Camus P, Degat OR, Justrabo E, Jeannin L (1982). D-Penicillamine-induced severe pneumonitis. Chest, 81: 376-8. |
| 50404 | Thomsen HS (2006). Nephrogenic systemic fibrosis: a serious late adverse reaction to gadodiamide. Eur Radiol, 16: 2619-21. |
| 50405 | Chhajed PN, Dickenmann M, Bubendorf L, et al (2006). Patterns of pulmonary complications associated with sirolimus. Respiration, 73: 367-74. |
| 50406 | Champion L, Stern M, Israel-Biet D, et al (2006). Brief communication: sirolimus-associated pneumonitis: 24 cases in renal transplant recipients. Ann Intern Med, 144: 505-9. |
| 50407 | Kobashi Y, Yoshida K, Miyashita N, et al (2005). Hermansky-Pudlak syndrome with interstitial pneumonia without mutation of HSPI gene. Internal Medicine, 44(6): 616-21. |
| 50408 | Rodriguez-Roisin R, Pares A, Bruguera M (1981). Pulmonary involvement in primary biliary cirrhosis. Thorax, 36: 208-12. |
| 50409 | Scot DL, Bradby GVH, Aitman TJ (1980). Relationship of gold and penicillamine therapy to diffuse interstitial lung disease. Annals of the Rheumatic Diseases, 40: 136-41. |
| 50410 | Seki N, Ito A, Watanabe K, et al (2007). Irreversible Imatinib-induced pneumonitis following long-term Imatinib administration. Intern Med, 46(23): 1941-2. |
| 50411 | Vlahakis NE (2006). Sirolimus: friend or foe? Respiration, 73: 283-4. |
| 50412 | Yousem SA (2006). Respiratory bronchiolitis-associated interstitial lung disease with bibrosis is a lesion distinct from fibrotic nonspecific interstitial pneumonia: a proposal. Modern Pathology, 19: 1474-9. |
| 50438 | National Research Council (2005). Assessment of the scientific information for the radiation exposure screening and education program. . Retrieved 28 October 2008, from http://www.nap.edu/catalog/11279.html |
| 50783 | Fernandez AB, Karas RH, Alsheikh-Ali AA, Thompson PD (2008). Statins and interstitial lung disease. Chest, 134: 824-30. |
| 50784 | Attili AK, Kazerooni EA, Gross BH, Flaherty KR, et al (2008). Smoking-related interstitial lung disease: radiologic-clinical-pathologic correlation. RadioGraphics, 28: 1383-98. |
| 50785 | Todd EJ, Kay J (2008). Nephrogenic systemic fibrosis: an epidemic of gadolinium toxicity. Current Rheumatology Reports, 10: 195-204. |
| 50786 | Mendoza FA, Artlett DM, Sandorfi N, Latinis K, et al (2006). Description of twelve cases of nephrogenic fibrosing dermopathy and review of the literature. Semin Arthritis Rheum, 35(4): 238-49. |
| 50787 | MIMS Online (2008). Prescribing Information. Lipex Tablets. . Retrieved 21 November 2008, from http://proxy8.use.hcn.com.au/ifmx-nsapi/mims-data/?Mival=2MIMS\_abbr\_pi&prod |
| 50788 | Rossi S (2008). Imatinib. Australian Medicines Handbook. . Retrieved 21 November 2008, from http://proxy7.use.hcn.com.au/chapter14/monographimatinib.html |
| 50789 | Kaufman JM, Cuvelier CA, van der Straeten M (1980). Mycoplasma pneumonia with fulminant evolution into diffuse interstitial fibrosis. Thorax, 35: 140-4. |
| 50864 | Levy BD, Shapiro SD (2008). Acute respiratory distress syndrome. Introduction. Harrison's Principles of Internal Medicine, 17th Edition, Chapter 262: 1680. . |
| 50865 | Kissane JM (1990). Anderson's Pathology, 9th Edition, 1: 930-48. The C.V. Mosby Company. |
| 50926 | Tablan OC, Reyes MP (1985). Chronic interstitial pulmonary fibrosis following mycoplasma pneumoniae pneumonia. Am J Med, 79: 266-70. |
| 51218 | McKee AL, Rajapaksa A, Kalish PE, Pitchumoni CS (1983). Severe interstitial pulmonary fibrosis in a patient with chronic ulcerative colitis. Am J Gastroenterol, 78(2): 86-9. |
| 51501 | Arakawa H, Johkoh T, Honma K, Saito Y, et al (2007). Chronic interstitial pneumonia in silicosis and mix-dust pneumoconiosis. Chest, 131: 1870-6. |
| 51502 | Selman M (2003). The spectrum of smoking-related interstitial lung disorders. Chest, 124: 1185-7. |
| 51503 | Benfield TL, Prento P, Junge J, Bestbo J, Lundgren JD (1997). Alveolar damage in AIDS-related pneumocystis carinii pneumonia. Chest, 111: 1193-9. |
| 51504 | Wassermann K, Pothoff G, Kirn E, Fatkenheuer G, Krueger GRF (1993). Chronic pneumocystis carinii pneumonia in AIDS. Chest, 104(3): 667-72. |
| 51505 | Saldana MJ, Mones JM (1994). Pulmonary pathology in AIDS: atypical pneumocystis carinii infection and lymphoid interstitial pneumonia. Thorax, 49(Suppl): S46-55. |
| 51506 | Boiselle PM, Crans CA Jr, Kaplan MA (1999). The changing face of pneumocystis carinii pneumonia in AIDS patients. AJR, 172: 1301-9. |
| 51507 | King TE, Tooze JA, Schwarz MI, Brown KR, Cherniack RM (2001). Predicting survival in idiopathic pulmonary fibrosis. Scoring system and survival model. Am J Respir Crit Care Med, 164: 1171-81. |
| 51508 | Vehmas T, Kivisaari L, Huuskonen MS, Jaakkola MS (2003). Effects of tobacco smoking on findings in chest computed tomography among asbestos-exposed workers. Eur Respir J, 21: 866-71. |
| 51509 | Sumikawa H, Johkoh T, Ichikado K, Taniguchi H, et al (2006). Usual interstitial pneumonia and chronic idiopathic interstitial pneumonia: analysis of CT appearance in 92 patients. Radiology, 241(1): 258-66. |
| 51548 | Research Advisory Committee on Gulf War Veterans' Illnesses (2008). Scientific Findings and Recommendations. Gulf War Illness and the Health of Gulf War Veterans, : 264-5. U.S. Government Printing Office, Washington, D.C. |
| 51549 | The University of Newcastle Research Associates (TUNRA) Ltd and Hunter Medical Research Institute (HMRI) (2004). Study of Health Outcomes in Aircraft Maintenance Personnel (SHOAMP). Phase III. Report on the General Health and Medical Study, 11: 199-216. . |
| 51851 | Monash University (2003). Australian Gulf War Veterans' Health Study, Volume 2: 389-402. . |
| 55306 | Lim TK (1993). Respiratory failure from combined emphysema and pulmonary fibrosis. Singapore Med J, 34: 169-71. |
| 55307 | Bringardner BD, Baran CP, Eubank TD, Marsh CB (2008). The role of inflammation in the pathogenesis of idiopathic pulmonary fibrosis. Antioxidants & Redox Signaling, 10(2): 287-301. |
| 55308 | Cisneros-Lira J, Gaxiola M, Ramos C, Selman M, Pardo A (2003). Cigarette smoke exposure potentiates bleomycin-induced lung fibrosis in guinea pigs. Am J Physiol Lung Cell Mol Physiol, 285: L949-56. |
| 55309 | Jankowich MD, Polsky M, Klein M, Rounds S (2008). Heterogeneity in combines pulmonary fibrosis and emphysema. Respiration, 75: 411-7. |
| 55310 | Galvin JR, Franks TJ (2009). Smoking-related lung disease. J Thorac Imaging, 24: 274-84. |
| 55311 | Rogliani P, Mura M, Mattia P, Ferlosio A, et al (2008). HRCT and histopathological evaluation of fibrosis and tissue destruction in IPF associated with pulmonary emphysema. Respiratory Medicine, 102: 1753-61. |
| 55312 | Gribbin J, Hubbard R, Smith C (2009). Role of diabetes mellitus and gastro-oesophageal reflux in the aetiology of idiopathic pulmonary fibrosis. Respiratory Medicine, 103: 927-31. |
| 55313 | du Bois RM (2009). [Comment] Idiopathic pulmonary fibrosis: now less idiopathic? Respiratory Medicine, 103: 791-2. Comment on ID: 55312. |
| 55314 | Garcia-Sancho Figueroa MC, Carillo G, Perez-Padilla R, et al (2010). Risk factors for idiopathic pulmonary fibrosis in a Mexican population. A case-control study. Respiratory Medicine, 104: 305-9. |
| 55315 | Frankel SK, Schwarz MI (2009). Update in idiopathic pulmonary fibrosis. Curr Opin Pulm Med, 15: 463-9. |
| 55316 | Liu Y, Gao W, Zhang D (2009). Effects of cigarette smoke extract on A549 cells and human lung fibroblasts treated with transforming growth factor-B1 in a coculture system. Clin Exp Med, : [Epub ahead of print]. |
| 55317 | Patel RR, Ryu JH, Vassallo R (2008). Cigarette smoking and diffuse lung disease. Drugs, 68(11): 1511-27. |
| 55384 | Mortaz E, Redegeld FA, Sarir H, Karimi K, et al (2008). Cigarette smoke stimulates the production of chemokines in mast cells. Journal of Leukocyte Biology, 83: 575-80. |
| 55385 | Taskar V, Coultas D (2008). Exposures and idiopathic lung disease. Semin Respir Crit Care Med, 29(6): 670-9. |
| 55386 | Vassallo R, Ryu JH (2008). Tobacco smoke-related diffuse lung diseases. Semin Respir Crit Care Med, 29(6): 643-50. |
| 55537 | Prasse A, Stahl M, Schulz G, Kayser G, et al (2009). Essential role of osteopontin in smoking-related interstitial lung disease. Am J Pathol, 174(5): 1683-91. |
| 55632 | Schmidt SL, Sundaram B, Flaherty KR (2009). Diagnosing fibrotic lung disease: when is high-resolution computed tomography sufficient to make a diagnosis of idiopathic pulmonary fibrosis? Respirology, 14: 934-9. |
| 55633 | Choudhary C, Ashton RW (2009). Smoking-associated interstitial lung diseases. Southern Medical Journal, 102(2): 125-6. |
| 55634 | Altayeh A, Alkhankan F, Triest W, Badin S (2009). Concurrent smoking-related interstitial lung diseases in a single patient. Southern Medical Journal, 102(2): 180-3. |
| 55635 | CDC (2004). 2004 Surgeon General's Report - the health consequences of smoking. Executive Summary. . Retrieved 24 February 2010, from http://www.cdc.gov/tobacco/data\_statistics/sgr/2004/pdfs/executivesummary.pdf |
| 55636 | Marten K, Milne D, Antoniou KM, Nicholson AG, et al (2009). Non-specific interstitial pneumonia in cigarette smokers: a CT study. Eur Radiol, 19: 1679-85. |
| 55637 | Katzenstein AL, Mukhopadhyay S, Zanardi C, Dexter E (2010). Clinically occult interstitial fibrosis in smokers: classification and significance of a surprisingly common finding in lobectomy specimens. Human Pathology, 41: 316-25. |
| 55638 | Chung JH, Kanne JP (2010). Smoking-related interstitial lung diseases. Seminars in Roentgenology, 45(1): 29-35. |
| 55639 | Churg A, Muller NL, Wright JL (2010). Respiratory bronchiolitis/interstitial lung disease. Fibrosis, pulmonary function, and evolving concepts. Arch Pathol Lab Med, 134: 27-32. |
| 55640 | Rosas IO, Ren P, Avila NA, Chow CK, Franks TJ, et al (2007). Early interstitial lung disease in familial pulmonary fibrosis. Am J Respir Crit Care Med, 176: 698-705. |
| 55641 | Lundblad LKA, Thompson-Figueroa J, Leclair T, et al (2005). Tumor necrosis factor-a overexpression in lung disease. A single cause behind complex phenotype. Am J Respir Crit Care Med, 171: 1363-70. |
| 55642 | Cottin V, Cordier J-F; Lundblad LKA, Thompson-Figueroa J, et al (2005). [Comments] Combined pulmonary fibrosis and emphysema: an experimental and clinically relevant phenotype. Am J Respir Crit Care Med, 172: 1605-6. Comments on ID: 55641. |
| 55643 | Dalvie MA, London L, Myers JE; Schenker MB, Stoecklin MT (2005). [Comments] Respiratory health effects due to long-term low-level paraquat exposure. Am J Respir Crit Care Med, 172: 646-7. Comments on ID: 43843. |
| 55644 | Lederer DJ, Enright PL, Kawut SM, Hoffman EA, et al (2009). Cigarette smoking is associated with subclinical parenchymal lung disease. Am J Respir Crit Care Med, 180: 407-14. |
| 55645 | Zeid NA, Muller HK (1995). Tobacco smoke induced lung granulomas and tumors: association with pulmonary langerhans cells. Pathology, 27: 247-54. |
| 55967 | Vierikko T, Jarvenpaa R, Uitti J, Virtema P, et al (2008). The effects of secondhand smoke exposure on HRCT findings among asbestos-exposed workers. Respiratory Medicine, 102: 658-64. |
| 55968 | Saketkoo LA, Espinoza LR (2008). Rheumatoid arthritis interstitial lung disease: mycophenolate mofetil as an antifibrotic and disease-modifying antirheumatic drug. Arch Intern Med, 168(15): 1718-9. |
| 55969 | Gochuico BR, Avila NA, Chow CK, Novero LJ, et al (2008). Progressive preclinical interstitial lung disease in rheumatoid arthritis. Arch Intern Med, 168(2): 159-66. |
| 56063 | Zeki AA, Schivo M, Chan AL, Hardin KA, et al (2010). Geoepidemiology of COPD and idiopathic pulmonary fibrosis. J Autoimmun, 34: J327-38. |
| 56139 | Dinis-Oliveira RJ, Duarte JA, Sanchez-Navarro A, et al (2008). Paraquat poisonings: mechanisms of lunch toxicity, clinical features, and treatment. Clin Rev Toxicol, 38: 13-71. |
| 56220 | Osanai K, Takahashi K, Suwabe A, Takada K, et al (1988). The effect of cigarette smoke on bleomycin-induced pulmonary fibrosis in hamsters. Am Rev Respir Dis, 138: 1276-81. |
| 56221 | Im J-G, Lee KS, Han MC, Kim SJ, Kim IO (1991). Paraquat poisoning: findings on chest radiography and CT in 42 patients. AJR, 157: 697-701. |
| 56472 | Lee K-H, Gil H-W, Kim Y-T, Yang J-O, Lee E-Y, Hong S-Y (2009). Marked recovery from paraquat-induced lung injury during long-term follow-up. Korean J Intern Med, 24(2): 95-100 E-pub. |
| 57389 | Blecher CM (2010). [Comment] Alarm about computed tomography scans is unjustified. MJA, 192(12): 723-4. |
| 58622 | Holmes EB, White GL, Gaffney DK (2010). Ionizing radiation exposure, medical imaging. . Retrieved 27 September 2010, from http://emedicine.medscape.com/article/1464228-print |
| 58626 | Fazel R, Krumholz HM, Wang Y, Ross JC, et al (2009). Exposure to low-dose ionizing radiation from medical imaging procedures. N Eng J Med, 361(9): 849-57. |
| 59324 | Berrington de Gonzalez A, Darby S (2004). Risk of cancer from diagnostic x-rays: estimates for the UK and 14 other countries. The Lancet, 363(9406): 345-51. |
| 59477 | Hahn FF, Romanov SA, Guilmette RA, Nifatov AP, et al (2003). Distribution of plutonium particles in the lungs of mayak workers. Radiation Protection Dosimetry, 105(1-4): 81-4. |
| 59485 | Agency for Toxic Substances and Disease Registry (ATSDR) (2008). Draft Toxicological Profile for Radon. US Department of Health and Human Services, : . |
| 59532 | Wilson DA, Diel JH, Hoel DG (2009). Lung fibrosis and lung cancer incidence in beagle dogs that inhaled 238PuO2 or 239PuO2. Health Phys, 96(4): 493-503. |
| 59653 | Brenner DJ, Hall EJ (2007). Computed tomography - an increasing source of radiation exposure. N Eng J Med, 357(22): 2277-84. |
| 59654 | Australian Radiation Protection and Nuclear Safety Agency (ARPANSA) (2002). Recommendations for limiting exposure to ionizing radiation (1995) (Guidance note [NOHSC:3022(1995)]) and National standard for limiting occupational exposure to ionizing radiation [NOHSC:1013(1995)]. . Retrieved 7 February 2011, from http://www.arpansa.gov.au/pubs/rps/rpsl.pdf |
| 60109 | Flors L, Domingo ML, Leiva-Salinas C, Mazon M, Rosello-Sastre E, Vilar J (2010). Uncommon occupational lung diseases: high-resolution CT findings. AJR, 194: W20-6. |
| 60235 | Fahim A, Crooks M, Hart SP (2011). Gastroesophageal reflux and idiopathic pulmonary fibrosis: a review. : 634613. Retrieved 16 March 2011, from http://www.hindawi.com/journals/pm/2011/634613.html |
| 60236 | Raghu G, Fredudenberer TD, Yang S, Curtis JR, et al (2006). High prevalence of abnormal acid gastro-oesophageal reflux in idiopathic pulmonary fibrosis. Eur Respir J, 27: 136-42. |
| 60237 | American Thoracic Society, European Respiratory Society (2000). Idiopathic pulmonary fibrosis: diagnosis and treatment. Am J Respir Crit Care Med, 161: 646-64. |
| 60238 | Tobin RW, Pope CE II, Pellegrini A, Emond MJ, et al (1998). Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 158: 1804-8. |
| 61675 | King TE Jr (2011). Smoking and subclinical interstitial lung disease. NEJM, 364(10): 968-70. |
| 61676 | Washko GR, Hunninghake GM, Fernandez IE, et al (2011). Lung volumes and emphysema in smokers with interstitial lung abnormalities. NEJM, 364(10): 897-906. |
| 61677 | Boucher RC (2011). Idiopathic pulmonary fibrosis - a sticky business. NEJM, 364(16): 1560-1. |
| 61678 | Ward J, McDonald C (2010). Interstitial lung disease. An approach to diagnosis and management. Aust Fam Physician, 39(3): 106-10. |
| 61680 | Meltzer EB, Noble PW (2008). Idiopathic pulmonary fibrosis. Orphanet J Rare Dis, 3: 8. |
| 61681 | King TE Jr, Pardo A, Selman M (2011). Idiopathic pulmonary fibrosis. The Lancet, 6736(11): 60052-4. |
| 61755 | Caminati A, Graziano P, Sverzellati N, Harari S (2010). Smoking-related interstitial lung diseases. Pathologica, 102: 525-36. |
| 61838 | Raghu G, Collard HR, Egan JJ, Martinez FJ, et al on behalf of the ATS/ERS/JRS/ALAT Committee on Idiopathic Pulmonary Fibrosis (2011). An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med, 183: 788-824. |
| 62885 | Havemann BD, Henderson CA, El-Serag HB (2007). The association between gastro-oesophageal reflux disease and asthma: a systematic review. Gut, 56: 1654-64. |
| 63035 | Cottin V, Nunes H, Mouthon L, Gamondes D, et al (2011). Combined pulmonary fibrosis and emphysema syndrome in connective tissue disease. Arthritis & Rheumatism, 63(1): 295-304. |
| 63036 | Samara KD, Margaritopoulos G, Wells AU, Siafakas NM, Antoniou KM (2011). Smoking and pulmonary fibrosis: novel insights. Pulm Med, 2011: 461439. |
| 63123 | Arnson Y, Shoenfeld Y, Amital H (2010). Effects of tobacco smoke on immunity, inflammation and autoimmunity. J Autoimmun, 34: J258-65. |
| 63358 | Butler MW, Fabre A, Dodd JD (2011). Smokers with interstitial lung abnormalities. The New Eng J Med, 364: 2465-66. |
| 63359 | El-Serag H, Hill C, Jones R (2009). Systematic review: the epidemiology of gastro-oesophageal reflux disease in primary care, using the UK General Practice Research Database. Aliment Pharmacol Ther, 29(5): 470-80. |
| 63360 | Galmiche JP, Zerbib F, Des Varannes SB (2008). Review article: respiratory manifestations of gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 27(6): 449-64. |
| 63361 | Garcia-Sancho C, Buendia-Roldan I, Fernandez-Plata R, Navarro C, et al (2011). Familial pulmonary fibrosis is the strongest risk factor for idiopathic pulmonary fibrosis. Respir Med, 105: 1902-7. |
| 63362 | Jaspersen D, Labenz J, Willich SN, Kulig M, Nocon M, et al (2006). Long-term clinical course of extra-oesophageal manifestations in patients with gastro-oesophageal reflux disease. A prospective follow-up analysis based on the ProGERD study. Dig Liver Dis, 38: 233-8. |
| 63363 | Penagini R (2006). [Comment] Extra oesophageal manifestations of gastro-oesophageal reflux disease: Good news ...in the long term! Dig Liver Dis, 38: 238-9. Comment on ID: 63362. |
| 63364 | Lee JS, Collard HR, Raghu G, Sweet MP et al (2010). Does chronic microaspiration cause idiopathic pulmonary fibrosis? Am J Med, 123: 304-11. |
| 63365 | Sangani RG, Ghio AJ (2011). Lung injury after cigarette smoking is particle related. International J COPD, 6: 191-8. |
| 63366 | Tcherakian C, Cottin V, Brillet PY, Freynet O, et al (2011). Progression of idiopathic pulmonary fibrosis: lessons from asymmetrical disease. Thorax, 66: 226-31. |
| 63367 | Maher TM, Wells AU (2011). If it was good enough for Aristotle..... Thorax, 66(3): 183-4. |
| 63368 | Tsushima K, Sone S, Yoshikawa S, Yokoyama T, Suzuki T, Kubo K (2010). The radiological patterns of interstitial change at an early phase: Over a 4-year follow-up. Respir Med, 104: 1712-21. |
| 63370 | Balbi B, Cottin V, Singh S, Wever WD, Herth FJ, Cordeiro CR (2010). Smoking-related lung diseases: a clinical perspective. Eur Respir J, 35: 231-3. |
| 63371 | Sverzellati N, Guerci L, Randi G, Calabro E et al (2011). Interstitial lung disease in a lung cancer screening trial. Eur Respir J, 38: 392-400. |
| 63372 | Jankowich MD, Rounds S (2010). Combined pulmonary fibrosis and emphysema alters physiology but has similar mortality to pulmonary fibrosis without emphysema. Lung, 188: 365-73. |
| 63417 | Bhatt SP, Nanda S, Kintzer JS (2011). Combined pulmonary fibrosis and emphysema. Asian Cardiol & Thoracic Annals, 19(1): 77. |
| 63418 | Morehead RS (2009). Gastro-oesophageal reflux disease and non-asthma lung disease. Eur Respir Rev, 18(114): 233-43. |
| 63419 | Soares RV, Forsythe A, Hograth K, Sweiss NJ, Noth I, Patti MG (2011). Interstitial lung disease and gastroesophageal reflux disease: Key role of esophageal function tests in the diagnosis and treatment. Arq Gastroenterol, 48(2): 91-7. |
| 63420 | Fahim A, Dettmar PW, Morice AH, Hart SP (2011). Gastroesophageal reflux and idiopathic pulmonary fibrosis: A prospective study. Medicina (Kaunas), 47(4): 200-5. |
| 63467 | Lee JS, Ryu JH, Elicker BM, Lydell CP et al (2011). Gastroesophageal reflux therapy is associated with longer survival in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med, 184: 1390-4. |
| 63468 | Raghu G (2011). Idiopathic pulmonary fibrosis: Increased survival with "Gastroesophageal reflux therapy." Fact or fallacy? Am J Respir Crit Care Med, 184: 1330-2. |
| 63834 | Sweet MP, Patti MG, Leard LE, Golden JA et al (2007). Gastroesophageal reflux in patients with idiopathic pulmonary fibrosis referred for lung transplantation. J Thorac Cardiovasc Surg, 133(4): 1078-84. |
| 63835 | Downing TE, Sporn TA, Bollinger RR, Davis RD, Parker W, Lin SS (2008). Pulmonary histopathology in an experimental model of chronic aspiration is independent of acidity. Biol Med, 233: 1202-12. |
| 63836 | King TE (2012). Interstitial lung disease. . |
| 63837 | Venkatraman B, Rehman HA, Abdul-Wahab A (2005). High resolution computed tomography appearances of late sequelae of barium aspiration in an asymptomatic young child. Saudi Med J, 26(4): 665-7. |
| 63838 | Raghu G, Meye KC (2012). Silent gastro-oesophageal reflux and microaspiration in IPF: mounting evidence for anti-reflux therapy. Eur Respir J, 39: 242-5. |
| 63839 | Lee SH, Shim HS, Cho SH, Kim SY et al (2011). Prognostic factors for idiopathic pulmonary fibrosis: clinical, physiologic, pathologic, and molecular aspects. Sarcoidosis Vasculitis and Diffuse Lung Diseases, 28: 102-12. |
| 63862 | Linden PA, Gilbert RJ, Yeap BY, et al (2006). Laparoscopic fundoplication in patients with end-stage lung disease awaiting transplantation. J Thorac Cardiovasc Surg, 131: 438-6. |
| 63863 | Raghu G, Yang ST, Spada C, Hayes J, Pellegrini CA (2006). Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis. Chest, 129: 794-800. |
| 63864 | Fimognari FL, Pastorelli R (2007). [Comment] Corticosteroids may worsen gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Chest, 132(5): 1719-20. |
| 63865 | Oh CK, Murray LA, Molfino NA (2012). Smoking and idiopathic pulmonary fibrosis. Pulm Med, : Epub ahead of print. |
| 63866 | Portillo K, Morera J (2010). Combined Pulmonary Fibrosis and Emphysema Syndrome: A New Phenotype within the Spectrum of Smoking-Related Interstitial Lung Disease. Pulm Med, : Epub 2012 Feb 9. |
| 63867 | Savarino E, Bazzica M, Zentilin P, Pohl D et al (2009). Gastroesophageal reflux and pulmonary fibrosis in scleroderma: A study using pH-Impedance monitoring. Am J Respir Crit Care Med, 179: 408-13. |
| 63868 | Marie I, Dominique S, Levesque H, Ducrotte P, et al (2001). Esophageal involvement and pulmonary manifestations in systemic sclerosis. Arthritis Care and Research, 45: 346-54. |
| 63869 | Noth I, Zangan SM, Soares RV, Forsythe A et al (2012). Prevalence of hiatal hernia by blinded multidetector CT in patients with idiopathic pulmonary fibrosis. Eur Respir J, 39(2): 344-51. |
| 63870 | Lee JS, Song JW, Wolters PJ, Elicker BM et al (2012). Bronchoalveolar lavage pepsin in acute exacerbation of idiopathic pulmonary fibrosis. Eur Respir J, 39: 352-8. |
| 63871 | Wright CL, Werner JD, Tran JM, et al (2012). Radiation pneumonitis following yttrium-90 radioembolization: case report and literature review. J Vasc Interv Radiol, 23(5): 669-74. |
| 63872 | Patti MG, Tedesco P, Golden J, Hays S et al (2005). Idiopathic pulmonary fibrosis: how often is it really idiopathic? J Gastrointest Surg, 9: 1053-8. |
| 63873 | Hershcovici T, Jha LK, Johnson T, Gerson L, et al (2011). Systematic review: the relationship between interstitial lung diseases and gastro-oesophageal reflux disease. Aliment Pharmacol Ther, 34: 1295-305. |
| 63874 | Kaira K, Takise A, Goto T, Hories T, Mori M (2004). Barium sulphate aspiration. The Lancet, 364: 2220. |
| 63875 | Katzenstein AL (2012). Smoking-related interstitial fibrosis (SRIF) pathogenesis and treatment of usual interstitial pneumonia (UIP), and transbronchial biopsy in UIP. Modern Pathology, 25(suppl.1): s68-78. |
| 63977 | Salvioli B, Belmonte G, Stanghellini V, Baldi E et al (2006). Gastro-oesophageal reflux and interstitial lung disease. Dig Liver Dis, 38: 879-84. |
| 63988 | Tazelaar HD, Wright JL, Churg A (2011). Desquamative interstitial pneumonia. Histopathology, 58: 509-16. |
| 63989 | Vassallo R, Ryu JH (2012). Smoking-related interstitial lung diseases. Clin Chest Med, 33: 165-78. |
| 63990 | Johkoh T, Muller NL, Cartier Y, Kavanagh PV et al (1999). Idiopathic interstitial pneumonias: Diagnostic accuracy of thin-section CT in 129 patients. Radiology, 211(2): 555-60. |
| 64121 | Lynch JP (2009). Idiopathic pulmonary fibrosis, nonspecific interstitial pneumonia/fibrosis, and sarcoidosis. ACCP Pulmonary Medicine Board Review, 25th Edition,: 635-86. American College of Physicians, Northbrook. |
| 64600 | Jankowich MD, Rounds SIS (2012). Combined pulmonary fibrosis and emphysema syndrome. A review. Chest, 141(1): 222-31. |
| 66225 | Wuyts WA, Agostini C, Antoniou KM, Bouros D et al (2012). The pathogenesis of pulmonary fibrosis: a moving target. Eur Respir J, : Epub ahead of print. |
| 67466 | Papiris SA, Triantafillidou C, Kolilekas L, Markoulaki D, et al (2010). Amiodarone. A review of pulmonary effects and toxicity. Drug Saf, 33(7): 539-58. |
| 67467 | Ioachimescu OC, Stoller JK (2008). Diffuse alveolar hemorrhage: diagnosing it and finding the cause. Cleveland Clinic Journal of Medicine, 75(4): 258-80. |
| 67468 | Marchiori E, Zanetti G, Mano CM, Hochhegger B (2011). Exogenous lipoid pneumonia. Clinical and radiological manifestations. Respir Med, 105: 659-66. |
| 67469 | Caminati A, Cavazza A, Sverzellati N, Harari S (2012). An integrated approach in the diagnosis of smoking-related interstitial lung diseases. Eur Respir Rev, 21(125): 207-17. |
| 67470 | Sakamoto K, Taniguchi H, Kondoh Y, Wakai K et al (2012). Acute exacerbation of IPF following diagnostic bronchoalveolar lavage procedures. Respir Med, 106: 436-42. |
| 67471 | Naik PK, Moore BB (2010). Viral infection and aging as cofactors for the development of pulmonary fibrosis. Expert Rev Respir Med, 4(6): 759-71. |
| 67472 | Kropski JA, Lawson WE, Blackwell TS (2012). Right place, right time: the evolving role of herpesvirus infections as a "second hit" in idiopathic pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol, 302: L441-4. |
| 67473 | Leung CC, Yu IT, Chen W (2012). Silicosis. Lancet, 379: 2008-18. |
| 67474 | Marchiori E, Lourenco S, Gasparetto TD, Zanetti G et al (2010). Pulmonary talcosis: Imaging findings. Lung, 188: 165-71. |
| 67475 | McCunney RJ, Morfeld P, Payne S (2009). What component of coal causes coal workers' pneumocconiosis? JOEM, 51(4): 462-71. |
| 67503 | Borchers AT, Chang C, Keen CL, Gershwin ME (2011). Idiopathic pulmonary fibrosis- an epidemiological and pathological review. Clin Rev Allerg Immunol, 40: 117-34. |
| 67504 | Popper HH (2013). Interstitial lung diseases - can pathologists arrive at an etiology-based diagnosis? A critical update. Virchows Arch, 462: 1-26. |
| 67505 | Larsen BT, Colby TV (2012). Update for pathologists on idiopathic interstitial pneumonias. Arch Pathol Lab Med, 136: 1234-41. |
| 67506 | Vassallo R (2012). Diffuse lung diseases in cigarette smokers. Semin Respir Crit Care Med, 33: 533-42. |
| 67507 | Noble PW, Barkauskas CE, Jiang D (2012). Pulmonary fibrosis: patterns and perpetrators. J Clin Invest, 122(8): 2756-62. |
| 67508 | Tang FR, Loke WK (2012). Sulfur mustard and respiratory diseases. Crit Rev Toxicol, 42(8): 688-702. |
| 67509 | Prochilo T, Abeni C, Bertocchi P, Zaniboni A (2012). Oxaliplatin-induced lung toxicity. Case report and review of the literature. Current Drug Safety, 7(2): 179-82. |
| 67510 | Oikonomou A, Prassopoulos P (2013). Mimics in chest disease: interstitial opacities. Insights Imaging, 4: 9-27. |
| 67511 | Park KJ, Chung JY, Chun MS, Suh JH (2000). Radiation-induced lung disease and the impact of radiation methods on imaging features. Radiographics, 20: 83-98. |
| 67512 | Khasnis AA, Calabrese LH (2010). Tumor necrosis factor inhibitors and lung disease: a paradox of efficacy and risk. Semin Arthritis Rheum, 40: 147-63. |
| 67513 | Millar A, Mckew J, Taggart A (2012). [Comment] Fatal fibrosing alveolitis with certolizumba. Rheumatology (Oxford)., 51(5): 953-5. |
| 67514 | Schwaiblmair M, Behr W, Haeckel T, Markl B et al (2012). Drug induced interstitial lung disease. Open Respir Med J, 6: 63-74. |
| 67515 | Xu JF, Washko GR, Nakahira K, Hatabu H et al (2012). Statins and pulmonary fibrosis. Potential role of NLRP3 inflammasome activation. Am J Respir Crit Care Med, 185(5): 547-56. |
| 67516 | Grange MJ, Dombret MC, Fantin B, Gougerot-Pocidalo M (1996). Fatal acute pulmonary fibrosis in a patient treated by danazol for thrombocytopenia. Am J Hematol., 53: 149. |
| 67517 | Antonini A, Tolosa E, Mizuno Y, Yamamoto M et al (2009). A reassessment of risks and benefits of dopamine agonist in Parkinson's disease. Lancet, 8: 929-37. |
| 67518 | Muller T, Fritze J (2003). Fibrosis associated with dopamine agonist therapy in Parkinson's disease. Clinical Neuropharmacology, 26(3): 109-11. |
| 67519 | Barber NA, Ganti AK (2011). Pulmonary toxicities from targeted therapies: a review. Targ Oncol, 6: 235-43. |
| 67520 | ter Heine R, van den Bosch RT, Schaefer-Prokop CM et al (2012). Fatal interstitial lung disease associated with high erlotinib and metabolite levels. A case report and a review of the literature. Lung Cancer, 75: 391-7. |
| 67521 | Andersohn F, Garbe E (2008). Cardiac and noncardiac fibrotic reactions caused by ergot-and nonergot-derived dopamine agonists. Movement Disorders, 24(1): 129-33. |
| 67522 | Oberdoster G (2009). Safety assessment for nanotechnology and nanomedicine: concepts of nanotoxicology. Intern Med, 267: 89-105. |
| 67523 | Balali-Mood M, Mousavi SH, Balali-Mood B (2008). Chronic health effects of sulphur mustard exposure with special reference to Iranian veterans. Emerging Health Threats Journal, 1: e7. |
| 67524 | Webb WR, Higgins CB (2011). Talcosis. Thoracic Imaging: Pulmonary and Cardiovascular Radiology, 2nd Edition, Chapter 18. Lippincott Williams & Wilkins (Baltimore). |
| 67525 | Bezerra PN, Vasconcelos AG, Cavalcante LL, Marques VB et al (2009). Hard metal lung disease in an oil industry worker. J Bras Pneumol, 35(12): 1254-8. |
| 67526 | Boggild AK, Keystone JS, Kain KC (2004). Tropical pulmonary eosinophilia: A case series in a setting of nonendemicity. Clinical Infectious Diseases, 39: 1123-8. |
| 67527 | Chitkara RK, Krishna G (2006). Parasitic pulmonary esoinophilia. Semin Respir Crit Care Med, 27(2): 171-84. |
| 67528 | Ferreira AJ, Cemlyn-Jones J, Cordeiro CR (2013). Nanoparticles, nanotechnology and pulmonary nanotoxicology. Rev Port Pneumol, 19(1): 28-37. |
| 67529 | Fontenot AP, Amicosante M (2008). Metal-induced diffuse lung disease. Semin Respir Crit Care Med, 29(6): 662-69. |
| 67530 | Griffith CC, Raval JS, Nichols L (2012). Intravascular talcosis due to intravenous drug use is an underrecognized cause of pulmonary hypertension. Pulm Med, : 617531. |
| 67531 | Huang LK, Tsai MJ, Tsai HC, Chao HS et al (2012). Statin-induced lung injury: diagnostic clue and outcome. Postgrad Med J, 89: 14-9. |
| 67532 | Kahraman H, Koksal N, Ozkan F (2012). Eight years follow-up of a case with idiopathic pulmonary hemosiderosis after corticosteroid therapy. N Am J Med Sci, 4(1): 49-51. |
| 67533 | Memon K, Lewandowski RJ, Kilik L, Riaz A et al (2011). Radioembolization for primary and metastatic liver cancer. Semin Radiat Oncol, 21(4): 294-302. |
| 67534 | Mineo G, Ciccarese F, Modolon C, Landini MP et al (2012). Post-ARDS pulmonary fibrosis in patients with H1N1 pneumonia: role of follow-up CT. Radiol Med, 117: 185-200. |
| 67535 | Naqvi AH, Hunt A, Burnett BR, Abraham JL (2008). Pathologic spectrum and lung dust burden in giant cell interstitial pneumonia (hard metal disease/cobalt pneumonitis). Review of 100 cases. Arch Environ Occup Health, 63(2): 51-70. |
| 67536 | Webb WR, Higgins CB (2011). The idiopathic interstitial pneumonias. Thoracic Imaging, 2nd Edition, Chapter 13. Lippincott Williams & Wilkins (Baltimore). |
| 67537 | Pakhale S, Moltyaner Y, Chamberlain D, Lazar N (2004). Rapidly progressive pulmonary fibrosis in a patient treated with danazol for idiopathic thrombocytopenic purpura. Can Respir J, 11(1): 55-7. |
| 67538 | Rathi M, Ramachandran R, Gundlapalli S, Agarwal R, et al (2012). Rituximab induced pulmonary fibrosis in a patient with lupus nephritis. Lupus, 21: 1131-4. |
| 67539 | Rocco PR, Dos Santos C, Pelosi P (2009). Lung parenchyma remodeling in acute respiratory distress syndrome. Minerva Anestesiol, 75: 730-40. |
| 67540 | Sood A (2009). Current treatment of chronic beryllium disease. J Occup Environ Hyg, 6: 762-5. |
| 67541 | Sun Y, Bochmann F, Morfeld P, Ulm K et al (2011). Change of exposure response over time and long-term risk of silicosis among a cohort of Chinese pottery workers. Int J Environ Res Public Health, 8: 2923-39. |
| 67542 | Williams JP, Johnston CJ, Finkelstein JN (2010). Treatment for radiation-induced pulmonary late effects: spoiled for choice or looking in the wrong direction? Curr Drug Targets, 11(11): 1386-94. |
| 67543 | Yoshida T, Ohnuma A, Horiuchi H, Harada T (2011). Pulmonary fibrosis in response to environmental cues and molecular targets involved in its pathogenesis. J Toxicol Pathol, 24: 9-24. |
| 67544 | Zayen A, Rais H, Rifi H, Ouarda M et al (2011). Rituximab-induced interstitial lung disease: case report and literature review. Pharmacology, 87: 318-20. |
| 67545 | Zhang M, Zheng YD, Lu Y, Li WJ et al (2010). Silicosis in automobile foundry workers: A 29-year cohort study. Biomedical and Environmental Sciences, 23: 121-9. |
| 67548 | Roggli VL, Gibbs AR, Attanoos R, Chung A et al (2010). Pathology of asbestosis - An update of the diagnostic criteria. Arch Path Lab Med, 134: 462-80. |
| 67558 | Ali A (2011). Drug-induced pulmonary toxicity. . Retrieved 6 May 2013, from http://emedicine.medscape.com/article/1343451-overview#showall |
| 67559 | Baylor PA, Sobenes JR, Vallyathan V (2013). Interstitial pulmonary fibrosis and progressive massive fibrosis related to smoking methamphetamine with talc as filler. Respir Care, 58(5): e53-5. |
| 67560 | King TE (2012). Interstitial lung diseases. Harrison's Principles of Internal Medicine, 18th Edition, Chapter 261: 2160-5. . |
| 67561 | King TE (2012). Chapter 261.Interstitial Lung Diseases: Individual forms of ILD. . Retrieved 6 May 2013, from http://www.accessmedicine.com/content.aspx?aID=9128624 |
| 67562 | Godfrey A (2012). Idiopathic pulmonary fibrosis. . Retrieved 6 May 2013, from http://emedicine.medscape.com/article/301226-overview |
| 67563 | Harman EM (2012). Acute respiratory distress syndrome. . Retrieved 6 May 2013, from http://emedicine.medscape.com/article/165139-overview#showall |
| 67564 | Hoppo T, Komatsu Y, Jobe BA (2012). Gastroesophageal reflux disease and patterns of reflux in patients with idiopathic pulmonary fibrosis using hypopharyngeal multichannel intraluminal impedance. Diseases of the Esophagus, : [e-pub ahead of print]. |
| 67565 | Balmes JR, Speizer FE (2013). Occupational and environmental lung disease. Occupational exposures and pulmonary disease. Harrison's Principles of Internal Medicine, 18th Edition, Chapter 256: 2122-8. . |
| 67566 | Kawabata Y, Takemura T, Hebisawa A et al (2012). Desquamative interstitial pneumonia may progress to lung fibrosis as characterized radiologically. Respirology, 17(8): 1214-21. |
| 67567 | Khilnani GC, Hadda V (2009). Lipoid pneumonia: an uncommon entity. Indian J Med Sci, 63(10): 474-80. |
| 67568 | Koike T, Harigai M, Inokuma S, Ishiguro N et al (2011). Postmarking surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol, 21(4): 343-51. |
| 67569 | Morgenthau AS, Padilla ML (2009). Spectrum of fibrosing diffuse parenchymal lung disease. Mt Sinai J Med, 76(1): 2-23. |
| 67570 | Perez-Alvarez R, Perez-de-Lis M, Diaz-Lagares C, Pego-Reigosa JM et al (2011). Interstitial lung disease induced or exacerbated by TNF-targeted therapies: Analysis of 122 cases. Semin Arthritis Rheum, 41: 256-64. |
| 67571 | Takeuchi T, Tanaka Y, Kaneko Y, Tanaka E et al (2012). Effectiveness and safety of adalimumab in Japanese patients with rheumatoid arthritis: retrospective analyses of data collected during the first year of adalimumab treatment in routine clinical practice (HARMONY study). Mod Rheumatol, 22(3): 327-38. |
| 67572 | Wang Y, Xu SQ, Xu J, Ding C (2011). Treatment with etanercept in a patient with rheumatoid arthritis-associated interstitial lung disease. Clinical Medicine Insights, 4: 49-52. |
| 67573 | King TE (2012). Drug-induced pulmonary disease. . Retrieved 6 May 2013, from http://www.merckmanuals.com/professional/pulmonary\_disorders/interstitial\_lung\_diseases/drug-induced\_pulmonary\_disease.html |
| 67574 | King TE (2012). Lymphoid interstitial pneumonia. . Retrieved 6 May 2013, from http://www.merckmanuals.com/professional/pulmonary\_disorders/interstitial\_lung\_diseases/lymphoid\_interstitial\_pneumonia.html |
| 67575 | Summerhill EM (2011). Interstitial (nonidiopathic) pulmonary fibrosis. . Retrieved 6 May 2013, from http://emedicine.medscape.com/article/301337-overview#a0199 |
| 67589 | Newman LS (2012). Coal worker's pneumoconiosis. . Retrieved 7 May 2013, from http://www.merckmanuals.com/professional/print/pulmonary\_disorders/environmental\_pulmonary\_diseases/coal\_workers\_pneumoconiosis.html |
| 67590 | Newman LS (2012). Silicosis. . Retrieved 7 May 2013, from http://www.merckmanuals.com/professional/print/pulmonary\_disorders/environmental\_pulmonary\_diseases/silicosis.html |
| 67591 | Newman LS (2012). Irritant gas inhalation injury. . Retrieved 7 May 2013, from http://www.merckmanuals.com/professional/print/pulmonary\_disorders/environmental\_pulmonary\_diseases/irritant\_gas\_inhalation\_injury.html |
| 67592 | Li LR, Syndenham E, Chaudhary B, You C (2010). Glucocorticoid with cyclophosphamide for paraquat-induced lung fibrosis. The Cochrane Collaboration, (6): CD008084. |
| 67593 | Merrill WW (2013). Radiation-induced lung injury. . Retrieved 7 May 2013, from http://www.uptodate.com/contents/radiation-induced-lung-injury |
| 67594 | American Thoracic society documents (2004). Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med, 170: 691-715. |
| 67598 | Larson TC, Antao VC, Bove FJ (2010). Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. JOEM, 52(5): 555-60. |
| 67601 | Paris C, Thierry S, Brochard P, Letourneux M, et al (2009). Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Respir J, 34: 72-9. |
| 67992 | Hadjinicolaou AV, Nisar MK, Parfrey H, et al (2012). Non-infectious pulmonary toxicity of rituximab: a systematic review. Rheumatology, 51: 653-62. |
| 67993 | Krimsky WS, Dhand S (2008). Pulmonary talc granulomatosis mimicking malignant disease 30 years after last exposure: a case report. J Med Case Rep, 2: 225. |
| 67994 | Macneal K, Schwartz DA (2012). The genetic and environmental causes of pulmonary fibrosis. Proc Am Thorac Soc, 9(3): 120-5. |
| 67995 | Rohs AM, Lockey JE, Dunning KK et al (2008). Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med, 177: 630-7. |
| 67996 | Scheel AH, Krause D, Haars H, et al (2012). Talcum induced pneumoconiosis following inhalation of adulterated marijuana, a case report. Diagnostic Pathology, 7: 26. |
| 67997 | U.S. Department of Health and Human Services, ATSDR and Disease Registry Division of Health Assessment and Consultation (2008). Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United States. . |
| 68171 | Koksal N, Kahraman H (2011). Acute silicosis in teflon-coated pan manufacturing due to metal sandblasting. Int J Occup Environ Health, 17: 210-3. |
| 68172 | Croft PR, Racz MI, Bloch JD, et al (2005). Autopsy confirmation of severe pulmonary interstitial fibrosis secondary to Munchausen syndrome presenting as cystic fibrosis. J Forensic Sci, 50(5): 1194-8. |
| 68173 | Chan AK, Choo BA, Glaholm J (2011). Pulmonary toxicity with oxaliplatin and capecitabine/5-fluorouracil chemotherapy: a case report and review of the literature. Onkologie, 34: 443-6. |
| 68174 | Lee SL (2010). Complications of radioactive iodine treatment of thyroid carcinoma. J Natl Compr Canc Netw, 8: 1277-87. |
| 68237 | Webb WR, Higgins CB (2011). Hard metal pneumoconisis. Thoracic Imaging: Pulmonary and Cardiovascular Radiology, 2nd Edition, Chapter 18. Lippincott Williams & Wilkins (Baltimore). |
| 68445 | Neumann V, Schulz F, Theile A et al (2011). Case report of a rare occupational disease: A during life non-recognised occupational disease - talcosis. Pneumologie, 65(8): 471-6. [Abstract] |
| 68461 | Camus P (2012). Pulmonary fibrosis: causative drugs. . Retrieved 3 July 2013, from http://pneumotox.com/pattern/view/8/I.g/pulmonary-fibrosis/ |
| 68675 | Webb WR, Higgins CB (2011). Drug-induced lung disease. Thoracic Imaging: Pulmonary and Cardiovascular Radiology, 2nd Edition, Chapter 17: 493-98. Lippincott Williams & Wilkins (Baltimore). |
| 68750 | Rose C (2013). Silicosis. . Retrieved 29 July 2013, from http://www.uptodate.com/contents/silicosis?topicKey=PULM%2F4321&elapsedTimeMs=4&view=print&displayedView=full |
| 68751 | El-Kersh K, Perez RL, Smith JS, et al (2013). Smoking-related interstitial fibrosis (SRIF) and pulmonary hypertension. BMJ Care Rep, pii: bcr2013008970. |



Appendix A2

Information received in relation to

investigation 048-02 concerning asbestosis as at 7 August 2013

**1. Submissions**

* 1. Repatriation Commission, 15 November 1995 ‘Asbestosis’ (submission for consideration of the Authority prior to the initial determination of SOPs concerning asbestosis Numbers 11 and 12 of 1996, including draft SOPs and reference list) (1385760R);
  2. Bushe-Jones, Theo, Naval Association of Australia, 27 May 1996 (1385759R);
  3. RMA medical researcher letter, 26 August 1996 (1385758R);
  4. Collins, F., email, 8 August 2002 (1385767R);
  5. Smith, Ted, 20 August 2002 (1385773R);
  6. Holmes, Ron, 23 August 2002 (1385769R);
  7. Holmes, Ron, 18 October 2002 (1385768R);
  8. RMA medical researcher discussion paper ‘Asbestosis’, 6 February 2003 (143755R);
  9. Dean, Kevin, 21 April 2003 (request for investigation) (143753R);
  10. Laidler, P., RSL Victorian Branch, 21 May 2003 (143753R);
  11. Herrett, Bruce, 31 August 2004 (143752R);
  12. Lathlean, Peter, 31 January 2005 (143754R)
  13. RMA medical researcher letter, 16 May 2005 (13103785R);
  14. RMA medical researcher briefing paper ‘Asbestosis’, May 2005 (13103804R);
  15. Department of Veterans’ Affairs (Decision Support Unit), 25 May 2005 (13103791R);
  16. Department of Veterans’ Affairs (Decision Support Unit), 21 June 2005 (13103790R);
  17. Department of Veterans’ Affairs (Decision Support Unit), 6 July 2005 (13103789R);
  18. Fitz, R, 27 September 2005 (1385762R);
  19. Gardner, Dr Ian, Department of Defence, email, 3 May 2010 (1385761R);
  20. Wills, Ian, Chairman Legacy National Pensions Committee, 18 May 2012 (1385552R);
  21. Wills, Ian, Chairman Legacy National Pensions Committee, 12 June 2012 (141487R);
  22. Wills, Ian, Chairman Legacy National Pensions Committee, 18 June 2012 (141688R);
  23. Wills, Ian, Chairman Legacy National Pensions Committee, 5 September 2012 (141486R).



Appendix A1

Information received in relation to investigation 285-09

concerning fibrosing interstitial lung disease as at 7 August 2013

**1. Submissions**

* 1. Humphries, J.G., 24 June 1997 (request for investigation concerning crytogenic fibrosing alveolitis) (143709R);
  2. Repatriation Commission, October 1997 (submission for consideration of the Authority prior to determination of SOPs concerning idiopathic fibrosing alveolitis, Numbers 15 and 16 of 1998, including reference list) (13114006R and 131140086R);
  3. RMA medical researcher briefing paper, 19 January 1998 (143710R);
  4. Everts, Anna, Sydney Legacy, 21 July 1998 (143713R);
  5. Everts, Anna, Sydney Legacy, 27 August 1998 (143714R);
  6. Aust, C.E., Narooma Legacy Group, 17 June 1999 (143712R);
  7. Mr Sam Heys, East Malvern RSL Sub-Branch, 8 October 2002 (143715R);
  8. Mr Ray McMurrich, East Malvern RSL Sub-Branch, 10 February 2003 (request for investigation) (143726R);
  9. RMA medical researcher discussion paper ‘Idiopathic fibrosing alveolitis and request for investigation regarding smoking’, 24 June 2003 (143727R);
  10. Dr Iven Young, 11 November 2005 (143721R);
  11. Mr Gregory Jones, 26 July 2006 (143722R);
  12. RMA medical researcher summary of email interactions with Chris Zappala, November 2008 (143723R);
  13. RMA medical researcher summary of issues ‘Fibrosing alveolitis’, April 2009 (13105361R);
  14. RMA medical researcher briefing paper ‘Fibrosing alveolitis’, Volumes 1-3 April 2009 (13105362R), (13105363R) & (13105364R);
  15. RMA medical researcher additional briefing paper ‘Fibrosing alveolitis’, April 2009 (13105360R);
  16. Chalk, David, FNQVESSC, 16 September 2009 (request for investigation) (143724R);
  17. Glyde, Brian, emails, 5 & 6 February 2010 (143725R);
  18. RMA medical researcher summary of issues ‘Fibrosing interstitial lung disease – focussed review concerning smoking and paraquat’, June 2010 (13105412R);
  19. RMA medical researcher briefing paper ‘Fibrosing interstitial lung disease – focussed review concerning smoking and paraquat’, June 2010 (13105413R);
  20. RMA medical researcher discusion paper ‘Diagnostic radiation’, August 2010 (1396573R);
  21. RMA medical researcher summary of issues ‘Fibrosing interstitial lung disease and ionising radiation’, April 2011 (13105447R);
  22. RMA medical researcher briefing paper ‘Fibrosing interstitial lung disease and ionising radiation’, April 2011 (13105448R);
  23. Cook OAM, Brian, RSL Woden Valley Sub-Branch, 7 March 2011 (request for investigation) (143716R);
  24. Wills, Ian, Chairman Legacy National Pensions Committee, 27 June 2011 (143711R);
  25. Cook OAM, Brian, RSL Woden Valley Sub-Branch, 27 July 2011 (request for investigation) (143718R);
  26. Thomson, Dr Jennifer, 27 November 2011 (143720R);
  27. Bovill, Kevin, 12 December 2011 (request for investigation) (143717R);
  28. Wills, Ian, Chairman Legacy National Pensions Committee, 18 May 2012 (1385552R);
  29. Wills, Ian, Chairman Legacy National Pensions Committee, 12 June 2012 (141487R);
  30. Wills, Ian, Chairman Legacy National Pensions Committee, 18 June 2012 (141688R);
  31. RMA medical researcher summary of issues ‘Fibrosing interstitial lung disease’, August 2012 (13105469R);
  32. RMA medical researcher briefing paper ‘Gastro-oesophageal reflux disease and smoking, and fibrosing interstitial lung disease’, August 2012 (13105471R);
  33. RMA medical researcher summary of studies table ‘Fibrosing interstitial lung disease and smoking’, August 2012 (13105470R);
  34. Wills, Ian, Chairman Legacy National Pensions Committee, 5 September 2012 (141486R).

1. The SMSE is a subset of the available information. It comprises those articles which the Council considers:

   a) are relevant to the matters within the proposed scope of review, and

   b) satisfy the definition in the VEA of 'sound medical-scientific evidence'.

   Sound medical-scientific evidence is defined in section 5AB(2) of the VEA as follows:

   “Information about a particular kind of injury, disease or death is taken to be sound medical-scientific evidence if:

   a) the information:

   (i) is consistent with material relating to medical-science that has been published in a medical or scientific publication and has been, in the opinion of the Repatriation Medical Authority, subjected to a peer review process; or

   (ii) in accordance with generally accepted medical practice, would serve as the basis for the diagnosis and management of a medical condition; and

   b) in the case of information about how that kind of injury, disease or death may be caused – meets the applicable criteria for assessing causation currently applied in the field of epidemiology.

   The later requirement is held to mean ‘appropriate to be taken into account by epidemiologists’. [↑](#footnote-ref-1)
2. See the full Federal Court decision in Repatriation Commission v Bey (1997) 79 FCR 364 which cited with approval these comments from Veterans’ Review Board in Stacey (unreported 26 June 1985), all of which were in turn cited with approval in the Moore J decision at [33]. [↑](#footnote-ref-2)
3. Relevant service in balance of probabilities statements of principles refers to non-operational service having regard to the various definitions applying to types of ‘service’ as defined in the VEA and the MRCA. [↑](#footnote-ref-3)
4. RMA. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-4)
5. RMA. Statements of Principles No. 53 and 54 of 2013 for Fibrosing Interstitial Lung Disease. Brisbane, Australia: 2013. [↑](#footnote-ref-5)
6. RMA. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-6)
7. RMA. Statements of Principles No. 53 and 54 of 2013 for Fibrosing Interstitial Lung Disease. Brisbane, Australia: 2013. [↑](#footnote-ref-7)
8. RMA. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-8)
9. Repatriation Commission and the Military Rehabilitation and Compensation Commission. Submission by the Commission to the Specialist Medical Review Council on Asbestosis & Fibrosing Interstitial Lung Disease. Canberra, Australia: Australian Government Department of Veteran Affairs; 2014 April. [↑](#footnote-ref-9)
10. Repatriation Commission and the Military Rehabilitation and Compensation Commission. 2014 April. *ibid.* [↑](#footnote-ref-10)
11. Repatriation Commission and the Military Rehabilitation and Compensation Commission. 2014 April. *ibid.* [↑](#footnote-ref-11)
12. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-12)
13. Prazakova S, Thomas PS, Sandrini A, Yates DH. Asbestos and the lung in the 21st century: an update. Clin Respir J. 2014;8(1):1-10. (New Information). [↑](#footnote-ref-13)
14. Wagner JC, Moncrieff CB, Coles R, Griffiths DM, Munday DE. Correlation between fibre content of the lungs and disease in naval dockyard workers. Br J Ind Med. 1986;43(6):391-95. Cited by: Roggli VL, Gibbs AR, Attanoos R, Chung A, Popper H, Cagle P, et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#footnote-ref-14)
15. Roggli VL. Scanning electron microscopic analysis of mineral fiber content of lung tissue in the evaluation of diffuse pulmonary fibrosis. Scanning Microsc Suppl. 1991;5(1):71-83. Cited by: Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#footnote-ref-15)
16. Industrial Injuries Advisory Council. Position Paper #23. Pleural plaques. London, UK. 2009. Available from: <https://www.gov.uk/government/uploads/system/uploads/attachment_data/file/328553/iiac-pp23.pdf> (New Information). [↑](#footnote-ref-16)
17. Industrial Injuries Advisory Council. Position Paper #23. London, UK. 2009. (New Information). *ibid.* [↑](#footnote-ref-17)
18. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-18)
19. Schwartz DA. New developments in asbestos-induced pleural disease. Chest 1991;99(1):191-98. Cited by: American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-19)
20. Roach HD, Davies GJ, Attanoos R, Crane M, Adams H, Phillips S. Asbestos: when the dust settles an imaging review of asbestos-related disease. RadioGraphics. 2002;22(Suppl 1):S167-84. (New Information). [↑](#footnote-ref-20)
21. Roach et al. 2002. (New Information). *ibid.* [↑](#footnote-ref-21)
22. Henderson DW, Jones ML, De Lerk N, Leigh J, Musk AW, Shilkin KB, et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide Workshop on Asbestos-related Diseases October 6-7, 2000. Int J Occup Med Environ Health. 2004;10(1):40-6. (RMA ID: 035222). [↑](#footnote-ref-22)
23. Chapman SJ, Cookson WOC, Musk AW, Lee YCG. Benign asbestos pleural diseases. Curr Opin Pulm Med. 2003;9(4):1-5. (New Information). [↑](#footnote-ref-23)
24. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-24)
25. Prazakova et al. Asbestos and the lung in the 21st century: an update. Clin Respir J. 2014;8(1):1-10. (New Information). [↑](#footnote-ref-25)
26. Epler GR, McLoud TC, Gaensler EA. Prevalence and incidence of benign asbestos pleural effusion in a working population. J Am Med Assoc. 1982;247(5):617-22. Cited by: American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-26)
27. Chapman et al. Benign asbestos pleural diseases. Curr Opin Pulm Med. 2003;9(4):1-5. (New Information). [↑](#footnote-ref-27)
28. Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#footnote-ref-28)
29. Asbestos-Related Lung Diseases [Internet]. National Heart, Lung, and Blood Institute, NIH (US) 2014 [cited 2015]. [Figure 1]. Available from: http://www.nhlbi.nih.gov/health/health-topics/topics/asb (New Information). [↑](#footnote-ref-29)
30. Asbestos Victim Advice. Pleural Thickening. Asbestos related pleural thickening. [Internet]. WE Solicitors LLP - Asbestos compensation and claim lawyers and Mesothelioma compensations and claims [cited 2015]. [Figure 1]. Available from: http://asbestosvictimadvice.com/pleural-thickening/ (New Information). [↑](#footnote-ref-30)
31. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-31)
32. Roggli VL. Fiber Analysis. In: Rom WN, editor. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p. 335-45. (RMA ID: 033719). [↑](#footnote-ref-32)
33. Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#footnote-ref-33)
34. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-34)
35. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-35)
36. American Thoracic Society. 2004. (RMA ID: 067594). *ibid.* [↑](#footnote-ref-36)
37. Miles SE, Sandrini A, Johnson AR, Yates DH. Clinical consequences of asbestos-related diffuse pleural thickening: A review. J Occup Med Toxicol. 2008;3:20. (New Information). [↑](#footnote-ref-37)
38. Miles et al. 2008. (New Information). *ibid.* [↑](#footnote-ref-38)
39. Miles et al. 2008. (New Information). *ibid.* [↑](#footnote-ref-39)
40. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-40)
41. American Thoracic Society. 2004. (RMA ID: 067594). *ibid.* [↑](#footnote-ref-41)
42. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-42)
43. International Labour Office. Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses. Occupational Safety and Health Series, No 22 Revised edition 2000. Cited by: American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715 (RMA ID: 067594). [↑](#footnote-ref-43)
44. American Thoracic Society. 2004. (RMA ID: 067594). *ibid.* [↑](#footnote-ref-44)
45. American Thoracic Society. 2004. (RMA ID: 067594). *ibid.* [↑](#footnote-ref-45)
46. Anonymous (International Expert Meeting). 1997. (RMA ID: 026517). *ibid.* [↑](#footnote-ref-46)
47. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-47)
48. Anonymous (International Expert Meeting). 1997. (RMA ID: 026517). *ibid.* [↑](#footnote-ref-48)
49. Fischer M, Günther S, Müller KM. Fibre-years, pulmonary asbestos burden and asbestosis. Int J Hyg Environ Health. 2002;205(3):245-48. (RMA ID: 026590). [↑](#footnote-ref-49)
50. Fischer et al. 2002. (RMA ID: 026590). *ibid.* [↑](#footnote-ref-50)
51. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-51)
52. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-52)
53. Agency for Toxic Substances and Disease Registry (ATSDR). 2001. (RMA: 035227). *ibid.* [↑](#footnote-ref-53)
54. Agency for Toxic Substances and Disease Registry (ATSDR). 2001. (RMA: 035227). *ibid.* [↑](#footnote-ref-54)
55. Ehrlich R, Lilis R, Chan E, Nicholson WJ, Selikoff IJ. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-55)
56. Amosite (sometimes referred to as brown asbestos) is amphibole asbestos. Amphibole asbestos has crystalline fibres that are long, thin, straight and generally brittle. Cited by: Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-56)
57. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-57)
58. Ehrlich et al. 1992. (RMA ID: 034901). *ibid.* [↑](#footnote-ref-58)
59. Shepherd JR, Hillerdal G, McLarty J. Progression of pleural and parenchymal disease on chest radiographs of workers exposed to amosite asbestos. J Occup Environ Med. 1997; 54(6):410-15. (RMA ID: 035757). [↑](#footnote-ref-59)
60. Koskinen K, Zitting A, Tossavainen A, Rinne JP, Roto P, Kivekäs J, et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ Health. 1998;24(2):109-17. (RMA ID: 026513). [↑](#footnote-ref-60)
61. Koskinen et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scand J Work Environ Health. 1998;24(2):109-17. (RMA ID: 026513). [↑](#footnote-ref-61)
62. Schaeffner ES, Miller DP, Wain JC, Christiani DC. Use of an asbestos exposure score and the presence of pleural and parenchymal abnormalities in a lung cancer case series. Int J Occup Med Environ Health. 2001; 7(1):14-18. (RMA ID: 026602). [↑](#footnote-ref-62)
63. Rohs AM, Lockey JE, Dunning KK, Shukla R, Fan H, Hilbert T, et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008; 177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-63)
64. Raw vermiculite is a mica-like mineral that expands rapidly upon heating, producing a lightweight, bulky material that is used in fireproofing, insulation, packaging, and in horticultural/agricultural products (as a soil conditioner, fertilizer carrier). Vermiculite can contain large amounts of tremolite, which is amphibole asbestos. One of the largest vermiculite deposits in the United States is in Libby, Montana, where raw vermiculite was mined and milled from 1923 until 1990. Cited by: Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-64)
65. There are two groups of asbestos minerals; serpentine asbestos (chrysotile) and amphibole asbestos (amosite, crocidolite, and fibrous forms of tremolite, anthophyllite, and actinolite). Amphiboles are cleared less readily and are more persistent in the lungs than chrysotile serpentine asbestos. Cited by: Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service - ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-65)
66. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008; 177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-66)
67. Kishimoto T, Morinaga K, Kira S. The prevalence of pleural plagues and/or pulmonary changes among construction workers in Okayama, Japan. Am J Ind Med. 2000;37(3):291-95. (RMA ID: 026494). [↑](#footnote-ref-67)
68. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 11 and 12 of 1996 for Asbestosis. Brisbane, Australia: 1996. [↑](#footnote-ref-68)
69. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 138 and 139 of 1996 for Asbestosis. Brisbane, Australia: 1996. [↑](#footnote-ref-69)
70. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-70)
71. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 138 and 139 for Asbestosis. Brisbane, Australia: 1996. [↑](#footnote-ref-71)
72. See Appendix A. Table A3 for 1996: Speizer 1994 [2005] (RMA ID: 46975); Roggli [1992] 1998 (RMA ID: 033719); Rom [1992] 1998 (RMA ID: 33719); Becklake & Case 1994 (RMA ID: 430); Churg & Vedal 1994 (RMA ID: 431); Murai et al 1994 (RMA ID: 437); Klass 1993 (RMA ID: 435); Gaensler 1992 (RMA ID: 434); Becklake 1991 (RMA ID: 429); de Klerk et al 1991 (RMA ID: 432); Sluis-Cremer 1991 (RMA ID: 440); Sluis-Cremer & Hnizdo 1989 (RMA ID: 035796); Cookson et al 1986 (RMA ID: 455); Finkelstein & Vingilis 1984 (RMA ID: 454); and Murphy et al 1971 Cited by: Gaensler 1992 (RMA ID: 434). [↑](#footnote-ref-72)
73. de Klerk NH, Musk AW, Armstrong BK, Hobbs MS. Smoking, exposure to crocidolite, and the incidence of lung cancer and asbestosis. Br J Ind Med. 1991;48(6):412-17. (RMA ID: 000432). [↑](#footnote-ref-73)
74. Cookson WO, de Klerk N, Musk W, Glancy JJ, Armstrong B, Hobbs M. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-98. (RMA ID: 000445). [↑](#footnote-ref-74)
75. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-75)
76. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-76)
77. See Appendix A. Table A3 for 1996: Speizer 1994 [2005] (RMA ID: 46975); Roggli [1992] 1998 (RMA ID: 033719); Rom [1992] 1998 (RMA ID: 33719); Becklake & Case 1994 (RMA ID: 430); Churg & Vedal 1994 (RMA ID: 431); Murai et al 1994 (RMA ID: 437); Klass 1993 (RMA ID: 435); Gaensler 1992 (RMA ID: 434); Becklake 1991 (RMA ID: 429); de Klerk et al 1991 (RMA ID: 432); Sluis-Cremer 1991 (RMA ID: 440); Sluis-Cremer & Hnizdo 1989 (RMA ID: 035796); Cookson et al 1986 (RMA ID: 455); Finkelstein & Vingilis 1984 (RMA ID: 454); and Murphy et al 1971 Cited by: Gaensler 1992 (RMA ID: 434). [↑](#footnote-ref-77)
78. See Appendix A. Table A3 for 2005: Henderson et al 2004 (RMA ID: 035222); Burdorf et al 2003 (RMA ID: 035752); Fischer et al 2002 (RMA ID: 026590); Szeszenia-Dabrowska et al 2002 (RMA ID: 028160); Wright et al 2002 (RMA ID: 026507); ATSDR 2001 (RMA ID: 035227); Schaeffner et al. 2001 (RMA ID: 026602); Kurumatani et al 1999 (RMA ID: 026552); Boffetta 1998 (RMA ID: 026600); Levin et al 1998 (RMA ID: 026470); Shepherd et al 1997 (RMA ID: 035757); Ehrlich et al 1992 (RMA ID: 034901); and Selikoff et al 1990 (RMA ID: 035792). [↑](#footnote-ref-78)
79. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-79)
80. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-80)
81. Wright RS, Abraham J, Harber P, Burnett BR, Morris P, West P. Fatal asbestosis 50 years after brief high intensity exposure in a Vermiculite expansion plant. Am J Respir Crit Care Medi. 2002;165(8):1145-49. (RMA ID: 026507). [↑](#footnote-ref-81)
82. Fischer et al. Fibre-years, pulmonary asbestos burden and asbestosis. Int J Hyg Environ Health. 2002; 205(3):245-48. (RMA ID: 026590). [↑](#footnote-ref-82)
83. Roggli VL. Fiber Analysis. In: Rom WN, ed. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p. 335-45. (RMA ID: 033719). [↑](#footnote-ref-83)
84. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service -ATSDR, 2001. (RMA: 035227). [↑](#footnote-ref-84)
85. Henderson et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide Workshop on Asbestos-related Diseases October 6-7, 2000. Int J Occup Med Environ Health. 2004;10(1):40-6. (RMA ID: 035222). [↑](#footnote-ref-85)
86. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-86)
87. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-87)
88. See Appendix A. Table A3 for 2013: Balmes & Speizer 2013 (RMA ID: 67565); Popper 2013 (RMA ID: 67504); Varkey et al [2012] 2013 (RMA ID: 73946); Webb & Higgins 2011 (RMA ID: 68770); Larson et al. 2010 (RMA ID: 67598); Roggli et al 2010 (RMA ID: 67548); and Cited by: Roggli 2010 (RMA ID: 67548) - Browne (2001), Browne (1996), Burdorf & Swuste (1999), Churg (1998), Dement et al. (1983), Fischer et al. (2002), Gibbs et al. (1998), Green et al. (1997), and Sluis-Cremer (1991); Paris et al. 2009 (RMA ID: 67601); Rohs et al. 2008 (RMA ID: 67995); U.S. Department of Health and Human Services, ATSDR, Disease Registry Division of Health Assessment & Consultation 2008 (RMA ID: 67997); Sullivan 2007 (RMA ID: 45641); American Thoracic Society 2004 (RMA ID: 67594); and Wright et al 2002 (RMA ID: 26507). [↑](#footnote-ref-88)
89. Boffetta P. Health effects of asbestos exposure in humans: a quantitative assessment. Medicina del Lavoro. 1998;89(6):471-80. (RMA ID: 026600). [↑](#footnote-ref-89)
90. Doll R, Peto J. Asbestos. Effects on health of exposure to asbestos. London: Health & Safety Commission: H.M.S.O; 1985. Cited by: Boffetta P. Health effects of asbestos exposure in humans: a quantitative assessment. Medicina del Lavoro. 1998;89(6):471-80. (RMA ID: 026600). [↑](#footnote-ref-90)
91. Boffetta P. 1998. (RMA ID: 026600). *ibid.* [↑](#footnote-ref-91)
92. Boffetta P. 1998. (RMA ID: 026600). *ibid.* [↑](#footnote-ref-92)
93. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-93)
94. Finnish Institute of Occupational Health. Asbestos, Asbestosis, and Cancer. Helsinki Criteria for Diagnosis and Attribution 2014. Helsinki. (New Information). [↑](#footnote-ref-94)
95. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-95)
96. Anonymous (International Expert Meeting). 1997. (RMA ID: 026517). *ibid.* [↑](#footnote-ref-96)
97. Henderson et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide Workshop on Asbestos-related Diseases October 6-7, 2000. Int J Occup Med Environ Health. 2004;10(1):40-6. (RMA ID: 035222). [↑](#footnote-ref-97)
98. Anonymous (International Expert Meeting). 1997. (RMA ID: 026517). *ibid.* [↑](#footnote-ref-98)
99. Henderson et al. 2004. (RMA ID: 035222). *ibid.* [↑](#footnote-ref-99)
100. Henderson et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide Workshop on Asbestos-related Diseases October 6-7, 2000. Int J Occup Med Environ Health. 2004;10(1):40-6. (RMA ID: 035222). [↑](#footnote-ref-100)
101. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 23 and 24 of 2005 for Asbestosis. Brisbane, Australia: 2005. [↑](#footnote-ref-101)
102. Henderson et al. 2004. (RMA ID: 035222). *ibid*. [↑](#footnote-ref-102)
103. Henderson et al. 2004. (RMA ID: 035222). *ibid*. [↑](#footnote-ref-103)
104. Fischer et al. Fibre-years, pulmonary asbestos burden and asbestosis. Int J Hyg Environ Health. 2002; 205(3):245-48. (RMA ID: 026590). [↑](#footnote-ref-104)
105. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-105)
106. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-106)
107. RMA. Statements of Principles No. 53 and 54 of 2013 for Fibrosing Interstitial Lung Disease. Brisbane, Australia: 2013. Available from: [www.rma.gov.au](http://www.rma.gov.au) [↑](#footnote-ref-107)
108. RMA. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. Available from: [www.rma.gov.au](http://www.rma.gov.au) [↑](#footnote-ref-108)
109. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-109)
110. RMA Secretariat. Briefing paper - Investigation into Asbestosis. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. [↑](#footnote-ref-110)
111. RMA. Statements of Principles No. 53 and 54 of 2013 for Fibrosing Interstitial Lung Disease. Brisbane, Australia: 2013. Available from: [www.rma.gov.au](http://www.rma.gov.au) [↑](#footnote-ref-111)
112. RMA. Statements of Principles No. 55 and 56 of 2013 for Asbestosis. Brisbane, Australia: 2013. Available from: [www.rma.gov.au](http://www.rma.gov.au) [↑](#footnote-ref-112)
113. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-113)
114. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-114)
115. Paris C, Benichou J, Raffaelli C, Genevois A, Fournier L, Menard C, et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-115)
116. Berry G, Gilson JC, Holmes S, Lewinsohn HC, Roach SA. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-116)
117. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-117)
118. International Labour Office. Guidelines for the use of the ILO International Classification of Radiographs of Pneumoconioses. Occupational Safety and Health Series, No 22 Revised edition 2000. Cited by: American Thoracic Society Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715 (RMA ID: 067594). [↑](#footnote-ref-118)
119. Sluis-Cremer GK, Hnizdo E, du Toit RS. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-119)
120. Hein MJ, Stayner LT, Lehman E, Dement JM. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-120)
121. Larson TC, Antao VC, Bove FJ. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-121)
122. Green FH, Harley R, Vallyathan V, Althouse R, Fick G, Dement J, et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-122)
123. McDonald JC, Harris J, Armstrong B. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-123)
124. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4): 579-85. (RMA ID: 045641). [↑](#footnote-ref-124)
125. Seidman H, Selikoff IJ, Gelb SK. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-125)
126. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-126)
127. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-127)
128. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-128)
129. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-129)
130. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-130)
131. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-131)
132. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4):579-85. (RMA ID: 045641). [↑](#footnote-ref-132)
133. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-133)
134. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-134)
135. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-135)
136. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-136)
137. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-137)
138. Sluis-Cremer et al. 1990. Cited by: Sluis-Cremer GK. 1991. (RMA ID: 000440). *ibid*. [↑](#footnote-ref-138)
139. Hein et al. 2007. (RMA ID: 067597). *ibid*. [↑](#footnote-ref-139)
140. Green et al. 1997. (RMA ID: 026469). *ibid*. [↑](#footnote-ref-140)
141. Ehrlich et al. 1992. (RMA ID: 034901). *ibid*. [↑](#footnote-ref-141)
142. Seidman et al. 1986. (RMA ID: 020152). *ibid*. [↑](#footnote-ref-142)
143. Larson et al. 2010. (RMA ID: 067598). *ibid*. [↑](#footnote-ref-143)
144. McDonald et al. 2004. Cited by: Antao et al. 2012. (RMA ID: 068460). *ibid*. [↑](#footnote-ref-144)
145. Rohs et al. 2008. (RMA ID: 067995). *ibid*. [↑](#footnote-ref-145)
146. Sullivan PA. 2007. (RMA ID: 045641). *ibid*. [↑](#footnote-ref-146)
147. Paris et al. 2004. (RMA ID: 067600). *ibid*. [↑](#footnote-ref-147)
148. Berry et al. 1979. Cited by: Becklake MR.1991. (RMA ID: 000429). *ibid*. [↑](#footnote-ref-148)
149. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-149)
150. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-150)
151. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-151)
152. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-152)
153. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-153)
154. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-154)
155. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-155)
156. Finkelstein MM, Vingilis JJ.1984. (RMA ID: 000454). *ibid*. [↑](#footnote-ref-156)
157. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-157)
158. Ehrlich et al. 1992. (RMA ID: 034901). *ibid*. [↑](#footnote-ref-158)
159. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-159)
160. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-160)
161. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-161)
162. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-162)
163. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-163)
164. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4):579-85. (RMA ID: 045641). [↑](#footnote-ref-164)
165. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#footnote-ref-165)
166. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-166)
167. Larson et al. 2010. (RMA ID: 067598). *ibid.* [↑](#footnote-ref-167)
168. Rohs et al. 2008. (RMA ID: 067995). *ibid.* [↑](#footnote-ref-168)
169. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-169)
170. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-170)
171. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-171)
172. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-172)
173. Finkelstein MM. Asbestosis in long-term employees of an Ontario asbestos-cement factory. Am Rev Respir Dis. 1982;125(5):496-501. Cited by: Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-173)
174. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-174)
175. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-175)
176. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-176)
177. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4):579-85. (RMA ID: 045641). [↑](#footnote-ref-177)
178. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-178)
179. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-179)
180. Hein et al. 2007. (RMA ID: 067597). *ibid*. [↑](#footnote-ref-180)
181. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-181)
182. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-182)
183. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-183)
184. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-184)
185. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-185)
186. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-186)
187. Sullivan PA. 2007. (RMA ID: 045641). *ibid*. [↑](#footnote-ref-187)
188. McDonald et al. 2004. Cited by: Antao et al. 2012. (RMA ID: 068460). *ibid*. [↑](#footnote-ref-188)
189. Berry et al. 1979. Cited by: Becklake MR.1991. (RMA ID: 000429). *ibid*. [↑](#footnote-ref-189)
190. Paris et al. 2004. (RMA ID: 067600). *ibid*. [↑](#footnote-ref-190)
191. Sluis-Cremer et al. 1990. Cited by: Sluis-Cremer GK.1991. (RMA ID: 000440). *ibid*. [↑](#footnote-ref-191)
192. Ehrlich et al. 1992. (RMA ID: 034901). *ibid*. [↑](#footnote-ref-192)
193. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-193)
194. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-194)
195. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-195)
196. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-196)
197. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-197)
198. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-198)
199. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-199)
200. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-200)
201. Ehrlich et al. 1992. (RMA ID: 034901). *ibid*. [↑](#footnote-ref-201)
202. Rohs et al. 2008. (RMA ID: 067995). *ibid*. [↑](#footnote-ref-202)
203. Paris et al. 2004. (RMA ID: 067600). *ibid.* [↑](#footnote-ref-203)
204. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-204)
205. Finkelstein MM, Vingilis JJ. 1984. (RMA ID: 000454). *ibid*. [↑](#footnote-ref-205)
206. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-206)
207. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-207)
208. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-208)
209. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-209)
210. Sluis- Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-210)
211. Sluis-Cremer et al.1990. Cited by: Sluis-Cremer GK. 1991. (RMA ID: 000440). *ibid*. [↑](#footnote-ref-211)
212. Hein et al. 2007. (RMA ID: 067597). *ibid*. [↑](#footnote-ref-212)
213. Larson et al. 2010. (RMA ID: 067598). *ibid*. [↑](#footnote-ref-213)
214. Green et al. 1997. (RMA ID: 026469). *ibid*. [↑](#footnote-ref-214)
215. McDonald et al. 2004. Cited by: Antao et al. 2012. (RMA ID: 068460). *ibid*. [↑](#footnote-ref-215)
216. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4): 579-85. (RMA ID: 045641). [↑](#footnote-ref-216)
217. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-217)
218. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-218)
219. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-219)
220. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3):206-14. (RMA ID: 067600). [↑](#footnote-ref-220)
221. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-221)
222. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-222)
223. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-223)
224. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-224)
225. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-225)
226. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517). [↑](#footnote-ref-226)
227. Barnhart S, Thornquist M, Omenn GS, Goodman G, Feigl P, Rosen-stock LT. The degree of roentgenographic parenchymal opacities attributable to smoking among asbestos-exposed subjects. Am Rev Respir Dis. 1990;141:1102-06. Cited by: American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#footnote-ref-227)
228. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-228)
229. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-229)
230. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#footnote-ref-230)
231. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#footnote-ref-231)
232. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-232)
233. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#footnote-ref-233)
234. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-234)
235. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-235)
236. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-236)
237. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-237)
238. Green et al. 1997. (RMA ID: 026469). *ibid*. [↑](#footnote-ref-238)
239. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-239)
240. Seidman et al. 1986. (RMA ID: 020152). *ibid*. [↑](#footnote-ref-240)
241. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4):579-85. (RMA ID: 045641). [↑](#footnote-ref-241)
242. A single company operated the Wittenoom crocidolite mine and mill in the Pilbara region of Western Australia between 1943 and 1966. The mine and mill at Wittenoom exposed workers to high concentrations of asbestos fibres in inhaled air and the employment records of the company identifying nearly 7000 workers have been retained and form the basis of a continuing study of the workforce. Cited by: Cookson et al. Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med. 1986;43(7):450-57. (RMA ID: 000444). [↑](#footnote-ref-242)
243. Cookson WO, De Klerk NH, Musk AW, Armstrong BK, Glancy JJ, Hobbs MS. Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med. 1986;43(7):450-57. (RMA ID: 000444). [↑](#footnote-ref-243)
244. Cookson et al. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-98. (RMA ID: 000445). [↑](#footnote-ref-244)
245. Reid A, de Klerk N, Ambrosini GL, Olsen N, Pang SC, Berry G, et al. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. J Occup Environ Med. 2005;62(12):885-89. (RMA ID: 037507). [↑](#footnote-ref-245)
246. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#footnote-ref-246)
247. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-247)
248. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-248)
249. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#footnote-ref-249)
250. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-250)
251. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#footnote-ref-251)
252. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#footnote-ref-252)
253. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-253)
254. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#footnote-ref-254)
255. Cookson et al. Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med. 1986;43(7):450-57. (RMA ID: 000444). [↑](#footnote-ref-255)
256. Cookson et al. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-98. (RMA ID: 000445). [↑](#footnote-ref-256)
257. Reid et al. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. J Occup Environ Med. 2005;62(12):885-89. (RMA ID: 037507). [↑](#footnote-ref-257)
258. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#footnote-ref-258)
259. Cookson et al. Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med. 1986;43(7):450-57. (RMA ID: 000444). [↑](#footnote-ref-259)
260. Cookson et al. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-98. (RMA ID: 000445). [↑](#footnote-ref-260)
261. Reid et al. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. J Occup Environ Med. 2005;62(12):885-89. (RMA ID: 037507). [↑](#footnote-ref-261)
262. Harries PG. A comparison of mass and fibre concentrations of asbestos dust in shipyards insulation processes. Ann Occup Hyg. 1971;14(3):235-40. (New Information). [↑](#footnote-ref-262)
263. Harries PG. Asbestos dust concentrations in ship repairing: a practical approach to improving asbestos hygiene in naval dockyards. Ann Occup Hyg. 1971:14(3):241-54. (New Information). [↑](#footnote-ref-263)
264. Van Oyen et al. Development of a job matrix (AsbJEM) to estimate occupational exposure to asbestos in Australia. Ann Ocup Hyg. 2015;59(6):737-48 and supplement tables S1 & S2 pp1-9. (New Information). [↑](#footnote-ref-264)
265. Harries PG. A comparison of mass and fibre concentrations of asbestos dust in shipyards insulation processes. Ann Occup Hyg. 1971;14(3):235-40. (New Information). [↑](#footnote-ref-265)
266. Harries PG. Asbestos dust concentrations in ship repairing: a practical approach to improving asbestos hygiene in naval dockyards. Ann Occup Hyg. 1971:14(3):241-54. (New Information). [↑](#footnote-ref-266)
267. Murbach DM, Madi AK, Unice KM, Knutsen JS, Chapman PS, Brown JL, et al. Airborne concentrations of asbestos onboard maritime shipping vessels (1978-1992). Ann Occup Hyg. 2008;52(4):267-79. (New Information). [↑](#footnote-ref-267)
268. Van Oyen et al. 2015. (New Information). *ibid.* [↑](#footnote-ref-268)
269. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#footnote-ref-269)
270. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#footnote-ref-270)
271. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#footnote-ref-271)
272. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#footnote-ref-272)
273. Larson et al. 2010. (RMA ID: 067598). *ibid.* [↑](#footnote-ref-273)
274. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#footnote-ref-274)
275. Gaensler EA, Jederlinic PJ, Churg A. Idiopathic pulmonary fibrosis in asbestos-exposed workers. Am Rev Respir Dis 1991;144(3 Pt 1):689-96. Abstract. (New Information). [↑](#footnote-ref-275)
276. Roggli et al. Pathology of asbestosis - An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol & Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#footnote-ref-276)
277. Tossavainen A. Consensus report. International expert meeting on new advances in the radiology and screening of asbestos-related diseases. Scand J Work Environ Health. 2000;26(5):449-54. (New Information). [↑](#footnote-ref-277)
278. Selikoff IJ, Churg J, Hammond EC. The occurrence of asbestosis among insulation workers in the United State. Ann N Y Acad Sci.1965;132(1):139-55. (New Information). [↑](#footnote-ref-278)
279. Miles et al. Clinical consequences of asbestos-related diffuse pleural thickening: A review. Journal of Occupational Medicine and Toxicology. 2008;3:20. (New Information). [↑](#footnote-ref-279)
280. IIAC: The Industrial Injuries Advisory Council. Pleural plaques: IIAC Position Paper 23. 1-58. 2009. (New Information). [↑](#footnote-ref-280)
281. Park EK, Yates DH, Wilson, D. Lung function profiles among subjects with non-malignant asbestos-related disorders. Saf Health Work. 2014 Dec;5(4):234-37. (New Information). [↑](#footnote-ref-281)
282. Harries PG. A comparison of mass and fibre concentrations of asbestos dust in shipyards insulation processes. Ann Occup Hyg. 1971;14(3):235-40. (New Information). [↑](#footnote-ref-282)
283. Harries PG. Asbestos dust concentrations in ship repairing: a practical approach to improving asbestos hygiene in naval dockyards. Ann Occup Hyg. 1971:14(3):241-54. (New Information). [↑](#footnote-ref-283)
284. Kawabata Y, Shimizu Y, Hoshi E, Murai K, Kanauchi T, Kurashima K, et al. Asbestos exposure increases the incidence of histologically confirmed usual interstitial pneumonia. Histopathology. 2015; Published Online 22 July 2015. (New Information). [↑](#footnote-ref-284)
285. Copley SJ, Wells AU, Sivakumaran P, Rubens MB, Lee YC, Desai SR, et al. Asbestosis and idiopathic pulmonary fibrosis: comparison of thin-section CT feature. Radiol. 2003;229(3):731-36. (New Information). [↑](#footnote-ref-285)
286. Van Oyen et al. Development of a job matrix (AsbJEM) to estimate occupational exposure to asbestos in Australia. Ann Ocup Hyg. 2015;59(6):737-48 and supplement tables S1 & S2 pp1-9. (New Information). [↑](#footnote-ref-286)
287. Occupations in the armed forces included driver; police officer; rigger; shipwright; welder; pilot navy; aircraft handler; communications officer; cook (army/air force); engineer (aircraft/civil/mechanical); engineer (military)/sapper; machine operator; officer; steward; storeman (non-marine); weapons technician (air force); cook (navy); coxswain; officer (navy); petty officer radio operator; radar operator; seaman; steward (navy); fireman; weapons technician (army); (ship’s refitting, weapons technician (navy) electrical maintenance; electrician; engineer (navy);demolition (building) mechanic builder; fitter, shipyard labourer/worker); carpenter/joiner) boiler; and engine driver; boiler attendant; blacksmith (navy); shipwright (asbestos exposed); artificer; engine room attendant, marine engineer, stoker; insulation/lagging. [↑](#footnote-ref-287)
288. Hyland RA, Yates DH, Benke G, Sim M, Johnson AR. Occupational exposure to asbestos in New South Wales, Australia (1970-1989): development of an asbestos task exposure matrix. Occup Environ Med. 2010;67(3):201-6. (New Information). [↑](#footnote-ref-288)
289. Macfarlane E, Benke G, Sim MR, Fritschi L. OccIDEAS: An Innovative Tool to Assess Past Asbestos Exposure in the Australian Mesothelioma Registry. Saf Health Work. 2012;3(1):71-6. (New Information). [↑](#footnote-ref-289)
290. Van Oyen et al. Development of a job matrix (AsbJEM) to estimate occupational exposure to asbestos in Australia. Ann Occup Hyg. 2015;59(6):737-48 and supplement tables S1 & S2 pp1-9. (New Information). [↑](#footnote-ref-290)
291. Hyland et al. 2010. (New Information). *ibid.* [↑](#footnote-ref-291)
292. Macfarlane et al. 2012. (New Information). *ibid.* [↑](#footnote-ref-292)
293. Sluis-Cremer et al. Evidence for an amphibole asbestos threshold exposure for asbestosis assessed by autopsy in South African asbestos miners. Ann Occup Hyg. 1990;34(5):443-51. Cited by: Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#endnote-ref-1)
294. Sluis-Cremer GK. Asbestos disease at low exposures after long residence times. Ann N Y Acad Sci. 1991;643:182-93. (RMA ID: 000440). [↑](#endnote-ref-2)
295. Hein et al. Follow-up study of chrysotile textile workers: cohort mortality and exposure-response. J Occup Environ Med. 2007;64:616-25. (RMA ID: 067597). [↑](#endnote-ref-3)
296. Ehrlich et al. Long term radiological effects of short term exposure to amosite asbestos among factory workers. Br J Ind Med. 1992;49(4):268-72. (RMA ID: 034901). [↑](#endnote-ref-4)
297. Larson et al. Vermiculite worker mortality: estimated effects of occupational exposure to Libby amphibole. J Occup Environ Med. 2010;52(5):555-60. (RMA ID: 067598). [↑](#endnote-ref-5)
298. Green et al. Exposure and mineralogical correlates of pulmonary fibrosis in chrysotile asbestos workers. J Occup Environ Med. 1997;54(8):549-59. (RMA ID: 026469). [↑](#endnote-ref-6)
299. McDonald et al. Mortality in a cohort of vermiculite miners exposed to fibrous amphibole in Libby, Montana. J Occup Environ Med. 2004;61(4):363-66. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med Medicine. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-7)
300. Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med Medicine. 2012; 18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-8)
301. Rohs et al. Low-level fiber-induced radiographic changes caused by Libby Vermiculite. A 25-year follow-up study. Am J Respir Crit Care Med. 2008;177(6):630-37. (RMA ID: 067995). [↑](#endnote-ref-9)
302. Paris et al. Factors associated with early-stage pulmonary fibrosis as determined by high-resolution computed tomography among persons occupationally exposed to asbestos. Scand J Work Environ Health. 2004;30(3): 206-14. (RMA ID: 067600). [↑](#endnote-ref-10)
303. Sullivan PA. Vermiculite, respiratory disease, and asbestos exposure in Libby, Montana: update of a cohort mortality study. Environ Health Perspect. 2007;115(4): 579-85. (RMA ID: 045641). [↑](#endnote-ref-11)
304. Berry et al. Asbestosis: a study of dose-response relationships in an asbestos textile factory. Br J Ind Med. 1979;36(2):98-112. Cited by: Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#endnote-ref-12)
305. Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#endnote-ref-13)
306. Seidman et al. Mortality experience of amosite asbestos factory workers: dose-response relationships 5 to 40 years after onset of short-term work exposures. Am J Ind Med. 1986;10(5-6):479-514. (RMA ID: 020152). [↑](#endnote-ref-14)
307. Finkelstein MM, Vingilis JJ. Radiographic abnormalities among asbestos-cement workers: an exposure-response study. Am Rev Respir Dis. 1984;129(1):17-22. (RMA ID: 000454). [↑](#endnote-ref-15)
308. Paris C, Thierry S, Brochard P, Letourneux M, Schorle E, Stoufflet A, Ameille J, Conso F, Palron JC, and the National APEXS Members. Pleural plaques and asbestosis: dose- and time-response relationships based on HRCT data. Eur Resp J. 2009;34(1):72-79. (RMA ID: 067601). [↑](#endnote-ref-16)
309. Reid et al. The effect of asbestosis on lung cancer risk beyond the dose related effect of asbestos alone. Occup Environ Med. 2005;62(12):885-89. (RMA ID: 037507). [↑](#endnote-ref-17)
310. Peipins LA, Lewin M, Campolucci S, Lybarger JA, Miller A, Middleton D, Weis C, Spence M, Black B, Kapil V. Radiographic abnormalities and exposure to asbestos-contaminated vermiculite in the community of Libby, Montana, USA. Environ Health Persp. 2003;111(14):1753-59. (RMA ID: 046972). [↑](#endnote-ref-18)
311. Fischer et al. Fibre-years, pulmonary asbestos burden and asbestosis. Int J Hyg Environ Health. 2002;205(3):245-48. (RMA ID: 026590). [↑](#endnote-ref-19)
312. Koskinen et al. Radiographic abnormalities among Finnish construction, shipyard and asbestos industry workers. Scan J Work, Environ Health. 1998;24(2):109-117. (RMA ID: 026513). [↑](#endnote-ref-20)
313. Klaas VE. A diagnostic approach to asbestosis, utilizing clinical criteria, high resolution computed tomography, and gallium scanning. Am J Ind Med. 1993;23(5):801-09. (RMA ID: 000435). [↑](#endnote-ref-21)
314. Jarvholm B. Pleural plaques and exposure to asbestos: A mathematical model. Int J Epi. 1992;21(6):1180-84. (RMA ID: 035335). [↑](#endnote-ref-22)
315. Lilis R, Miller A, Godbold J, Chan E, Selikoff IJ. Radiographic abnormalities in asbestos insulators: effects of duration from onset of exposure and smoking. Relationships of dyspnea with parenchymal and pleural fibrosis. Am J Ind Med. 1991;20(1):1-15. (RMA ID: 046916). [↑](#endnote-ref-23)
316. Selikoff IJ, Lilis R. Radiological abnormalities among sheet-metal workers in the construction industry in the United States and Canada: relationship to asbestos exposure. Arch Environ Health. 1991;46(1):418-20. (RMA ID: 035756). [↑](#endnote-ref-24)
317. Selikoff IJ, Lilis R, Levin G. Asbestotic radiological abnormalities among United States merchant marine seamen. Br J Ind Med. 1990;47(5):292-297. (RMA ID: 035792). [↑](#endnote-ref-25)
318. Sluis-Cremer GK, Hnizdo E. Progression of irregular opacities in asbestos miners. British Journal of Industrial Medicine. 1989;46:846-852. (RMA ID: 035796). [↑](#endnote-ref-26)
319. Cookson et al. Prevalence of radiographic asbestosis in crocidolite miners and millers at Wittenoom, Western Australia. Br J Ind Med. 1986;43(7):450-57. (RMA ID: 000444). [↑](#endnote-ref-27)
320. Cookson et al. The Natural history of asbestosis in former crocidolite workers in Wittenoom Gorge. Am Rev Respir Dis. 1986; 133(6):994-98. (RMA ID: 000445). [↑](#endnote-ref-28)
321. Irwig LM, du Toit RS, Sluis-Cremer GK, Solomon A, Thomas RG, Hamel PP, Webster I, Hastie T. Risk of asbestosis in crocidolite and amosite mines in South Africa. Ann N Y Acad Sci. 1979;330(12):35-52. Cited by Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#endnote-ref-29)
322. Irwig LM, du Toit RS, Sluis-Cremer GK, Thomas RG. Risk of asbestosis in crocidolite and amosite mines in South Africa: an erratum. Am J Ind Med. 1984;5(6):479-83. Cited by Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#endnote-ref-30)
323. Becklake MR. Asbestos and other fiber-related diseases of the lungs and pleura. Distribution and determinants in exposed populations. Chest. 1991;100(1):248-54. (RMA ID: 000429). [↑](#endnote-ref-31)
324. Deng Q, Wang X, Wang M, Lan Y. Exposure-response relationship between chryostile exposure and mortality from lung cancer and asbestosis. Occup Environ Med. 2012; 69(2):81-86. (RMA ID: 067596). [↑](#endnote-ref-32)
325. Moolgavkar SH, Turim J, Alexander DD, Lau EC, Cushing CA. Potency factors for risk assessment at Libby, Montana. Risk Anal. 2010;30(8):1240-48. Cited by Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-33)
326. Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-34)
327. Agency for Toxic Substances and Disease Registry (ATSDR). Health consultation: mortality in Libby, Montana (1979-1998). Atlanta: US Department of Health and Human Services, 2002. Cited by U.S. Department of Health and Human Services, ATSDR, Disease Registry Division of Health Assessment and Consultation. Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United States. 2008. (RMA ID: 067997). [↑](#endnote-ref-35)
328. U.S. Department of Health and Human Services, ATSDR, Disease Registry Division of Health Assessment and Consultation. Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United States. 2008. (RMA ID: 067997). [↑](#endnote-ref-36)
329. Liddell FD, McDonald AD, McDonald JC. The 1891-1920 birth cohort of Quebec chrysotile miners and millers: development from 1904 and mortality to 1992. Ann Occup Hyg. 1997;41(1):13-36. (RMA ID: 026465). [↑](#endnote-ref-37)
330. British Occupational Hygiene Society. Hygiene standards for chrysotile asbestos dust. Ann Occup Hyg. 1968;11(1):47-69. Cited by Agency for Toxic Substances and Disease Registry (ATSDR). Toxicological profile for asbestos. 035227. Atlanta, GA: U.S. Department of Health and Human Services. Public Health Service -ATSDR, 032001. (RMA: 035227) [↑](#endnote-ref-38)
331. Albin M, Pooley FD, Stromberg U, Attenwell R, Mitha R, Johnasson L, et al. Retention patterns of asbestos fibres in lung tissue among asbestos cement workers. J Occup Environ Med. 1994;51(3):205-11. (RMA ID: 034864). [↑](#endnote-ref-39)
332. Amandus HE, Wheeler R. The morbidity and mortality of vermiculite miner and millers exposed to tremolite-actinolite: Part ll. Mortality. Am J Ind Med. 1987;11(1):15-26. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-40)
333. Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-41)
334. McDonald JC, McDonald AD, Armstrong B, Sebastien P. Cohort study of mortality of vermiculite miners exposed to tremolite. Br J Ind Med. 1986;43(7):436-44. Cited by: Antao et al. Libby vermiculite exposure and risk of developing asbestos-related lung and pleural diseases. Curr Opin Pulm Med. 2012;18(2):161-67. (RMA ID: 068460). [↑](#endnote-ref-42)
335. Antao et al. 2012. (RMA ID: 068460). *ibid*. [↑](#endnote-ref-43)
336. Antao et al. 2012. (RMA ID: 068460). *ibid*. [↑](#endnote-ref-44)
337. Mossman et al. Pulmonary endpoints (lung carcinoma and asbestosis) following the inhalation exposures to asbestos. J Toxicol Environ Health B Crit Rev; 2011 Part B(14):76-121. (RMA ID: 067547). [↑](#endnote-ref-45)
338. Roggli VL. Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#endnote-ref-46)
339. US Department of Health & Human Services, ATSDR, Disease Registry Division of Health Assessment and Consultation. Summary report. Exposure to asbestos-containing vermiculite from Libby, Montana, at 28 processing sites in the United Sates. 2008. (RMA ID: 067997). [↑](#endnote-ref-47)
340. American Thoracic Society. Diagnosis and initial management of non-malignant disease related to asbestos. AM J Resir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594). [↑](#endnote-ref-48)
341. Henderson et al. The diagnosis and attribution of asbestos-related diseases in an Australian context. Report of the Adelaide workshop on asbestos-related diseases October6-7, 2000. Int J Occup Med Environ Health. 2004;10(1):40-46. (RMA ID: 035222). [↑](#endnote-ref-49)
342. Agency for Toxic Substances and Disease Registry (ATSDR). Toxicology profile for asbestos. 035227. Atlanta, GA: US. Department of Health and Human Services. Public Health Service – ATSDR, 2001. (RMA ID: 035227). [↑](#endnote-ref-50)
343. Burdorf A, Swuste P. An expert system for the evaluation of historical asbestos exposure as diagnostic criterion in asbestos-related diseases. Ann Occup Hyg. 1999;43(1):57-66. Cited by: Roggli et al. Pathology of asbestosis- An update of the diagnostic criteria: Report of the asbestosis committee of the College of American Pathologists and Pulmonary Pathology Society. Arch Pathol Lab Med. 2010;134(3):462-80. (RMA ID: 067548). [↑](#endnote-ref-51)
344. Roggli et al. 2010. (RMA ID: 067548). *ibid*. [↑](#endnote-ref-52)
345. Roggli VL. Fiber analysis. In: Rom WN, editor. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p 349-77. (RMA ID: 033719). [↑](#endnote-ref-53)
346. Rom WN. Chapter 24: Asbestos related diseases. In: Rom WN, editor. Environmental & Occupational Medicine. 3rd ed. Philadelphia: Lippincott-Raven; 1998. p.349-75. (RMA ID: 033719). [↑](#endnote-ref-54)
347. Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID:026517). [↑](#endnote-ref-55)
348. Becklake MR, Case BW. Fiber burden and asbestos-related lung disease: Determinants of dose response relationships. Am J Respir Crit Care Med. 1994;150(6Pt 1):1488-92. (RMA ID: 000430). [↑](#endnote-ref-56)
349. Churg A. deposition and clearance of chrysotile asbestos. Ann Occup Hyg. 1994;38(4):625-33. Cited by: Mossman et al. Pulmonary endpoints (lung carcinoma and asbestosis) following the inhalation exposures to asbestos. J Toxicol Environ Health B Crit Rev; 2011 Part B(14):76-121. (RMA ID: 067547). [↑](#endnote-ref-57)
350. Mossman et al. 2011. (RMA ID: 067547). *ibid*. [↑](#endnote-ref-58)
351. Becklake MR. Asbestos and other fiber-related diseases of the lung and peura. Distribution and determinants in exposed populations. Chest. 1991;100(1);248-54. (RMA ID: 000429). [↑](#endnote-ref-59)
352. Sluis-Cremer GK. Asbestos disease at low exposure after long residence times. Ann N Y Acad Sci. 1991;643:182-193. (RMA ID: 000440). [↑](#endnote-ref-60)
353. The reasonable hypothesis test is set out in section 196B(2) of the VEA which provides;

     If the Authority is of the view that there is sound medical‑scientific evidence that indicates that a particular kind of injury, disease or death can be related to:

     (a) operational service rendered by veterans; or

     (b) peacekeeping service rendered by members of Peacekeeping Forces; or

     (c) hazardous service rendered by members of the Forces; or

     (caa) British nuclear test defence service rendered by members of the Forces; or

     (ca) warlike or non‑warlike service rendered by members;

     the Authority must determine a Statement of Principles in respect of that kind of injury, disease or death setting out:

     (d) the factors that must as a minimum exist; and

     (e) which of those factors must be related to service rendered by a person;

     before it can be said that a reasonable hypothesis has been raised connecting an injury, disease or death of that kind with the circumstances of that service. [↑](#footnote-ref-293)
354. The balance of probabilities test is set out in section 196B(3) of the VEA which provides:

     If the Authority is of the view that on the sound medical‑scientific evidence available it is more probable than not that a particular kind of injury, disease or death can be related to:

     (a) eligible war service (other than operational service) rendered by veterans; or

     (b) defence service (other than hazardous service and British nuclear test defence service) rendered by members of the Forces; or

     (ba) peacetime service rendered by members;

     the Authority must determine a Statement of Principles in respect of that kind of injury, disease or death setting out:

     (c) the factors that must exist; and

     (d) which of those factors must be related to service rendered by a person;

     before it can be said that, on the balance of probabilities, an injury, disease or death of that kind is connected with the circumstances of that service. [↑](#footnote-ref-294)
355. See sections 120, 120A and 120B of the VEA and sections 335, 338 and 339 of the MRCA. [↑](#footnote-ref-295)
356. American Thoracic Society. Diagnosis and initial management of nonmalignant diseases related to asbestos. Am J Respir Crit Care Med. 2004;170(6):691-715. (RMA ID: 067594).

     Anonymous (International Expert Meeting). Asbestos, asbestosis, and cancer: the Helsinki criteria for diagnosis and attribution. Scand J Work Environ Health. 1997;23(4):311-16. (RMA ID: 026517).

     Greenberg M. The British approach to asbestos standard setting: 1898-2000. Am J Indust Med. 2004;46(5):534-41. (RMA ID: 034865). [↑](#footnote-ref-296)
357. The medical science articles cited by the Commissions - see **Appendix C** [↑](#footnote-ref-297)
358. Selikoff et al. Asbestotic radiological abnormalities among United States merchant marine seamen. British Journal of Industrial Medicine. 1990;47(5):292-297. (RMA ID: 035792). [↑](#footnote-ref-298)